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Mechanical Plasticity: Skeletal Muscle Adaptations
By Naomi Broker

Naomi Broker graduated in June, 2015 with a BS degree in biology and is attending the DPT program at Hunter College.

Abstract
The purpose of this paper is to investigate the adaptations that occur in human skeletal muscle in response to endurance and resistance exercises. The advances made in science over the past several decades increased the number of
methods available for the classification of muscle fibers, resulting in many fiber type classes and their corresponding
characteristics. This allows for the tracking of changes that occur within the muscle fibers. The heterogeneous collection of fiber types found within a muscle allows for its dynamic nature. Myosin form expression varies according to the
muscle’s changing functional demands. In response to endurance training, muscle fibers adapt by changing in composition, converting between type IIB and type IIA (i.e. the fast to slow direction). In response to resistance training, muscle
fibers undergo both fiber-type shifting and hypertrophy. This muscle plasticity allows for the physiologic changes that
take place in athletes and in physical therapy patients. The research available allows for the designing of interventions
specific to increasing one’s endurance or power.
Introduction: Muscle fiber and motor unit typing
Muscle fiber types can be described using morphological, histochemical, immunohistochemical and biochemical characteristics.
Clear morphological differences were seen in birds, with fast
muscles appearing white and slow muscles appearing red. The
redness of the slow muscle is due to the greater myoglobin
and capillary content that permits a greater oxidative capacity
of the muscle (Staron, 1997). Research has long shown that
there is a clear correlation between myosin ATPase activity and
muscle contraction speed. Studies in rats, measuring isolated
muscle units, lead to initial classification of muscle fibers based
on their isometric twitch contraction speed as fast, intermediate and slow (Pette et. al., 1999). Presently, muscle fibers are
classified by means of 3 different techniques: histochemical myosin ATPase staining, immunohistochemical myosin heavy chain
isoform identification, and biochemical identification of metabolic enzymes.
Acronyms:
Myosin ATPase

MATPase

Myosin Heavy Chain

MHC

Sodium Dodecyl Sulfate-Polyacrylamide
Gel Electrophoretic

SDS-PAGE

Fast-Twitch Glycolytic

FG

Fast-Twitch Oxidative

FOG

Slow-Twitch Oxidative

SO

Slow-Twitch

S

Fast-Twitch Fatigue-Resistant

FR

Fast-Twitch Fatigue-Intermediate

Fint

Fast-Twitch Fatigable

FF

Histochemical Classification
Myosin ATPase histochemical staining confirmed the diversity
of muscle fibers. The stain’s intensity differs based on the myofibrillar differences in pH sensitivity. Type I fibers were found
to be alkali labile (lighter stain, low ATPase activity) and acid
stable (intense stain, high activity), while type II fibers were alkali

stable and acid labile (Staron, 1997, Sieck, Prakash, 1997). At
first, fibers were identified as slow type I, and fast types IIA and
IIB (Pette et. al., 1999). However, advances in the histochemical
staining technique has led to the identification of a total of 7
human muscle fiber types (Staron, 1997). The newly identified
fibers, types IC, IIC, IIAC, and IIAB, have intermediate myosin
ATPase staining characteristics. Type IC, the slowest fiber, stains
most similarly to type I fibers, while type IIAB fibers have intermediate staining characteristics between type IIA and IIB fibers.
Thus, the 7 human muscle fiber types (from slowest to fastest),
as identified by myosin ATPase histochemical staining are: types
I, IC, IIC, IIAC, IIA, IIAB, and IIB (Pette et. al., 1999). As seen in
the literature, some researchers do not use all 7 fiber types,
but rather place all fibers into the original 3 categories (Staron,
1997).

Immunohistochemical Classification
A second fiber type classification is based on the identification
of different myosin heavy chain (MHC) isoforms (Pette et. al.,
1999). Immunohistochemical analysis of human muscle began
after scientists discovered antigenic differences between the
myosin types of different human muscle (Staron, 1997). Isoforms
were identified using antimyosin antibodies or by sodium dodecyl sulfate-polyacrylamide gel electrophoretic (SDS-PAGE)
separation (Pette et. al., 1999). A general correlation was discovered between the histochemically classified fiber types and
the MHC isoforms they express (Sieck, Prakash, 1997, Fry et. al.,
1994). The original 3 myosin isoforms identified were MHCI,
MHCIIa, and MHCIIb, corresponding to those identified by myosin ATPase staining as pure types I, IIA, and IIB, respectively.
However, each muscle fiber can contain more than one myosin
heavy chain isoform, forming hybrid fibers. This phenomenon
explains the existence of more muscle fiber types than the
amount of pure isoforms. These mixed fibers almost always
contain “neighboring” myosin heavy chain isoforms (i.e., MHCI
and MHCIIa or MHCIIa and MHCIIb) (Pette et. al., 1999). Type
IIAB fibers that have a predominance of the MHCIIa isoform
stains more like type IIA fibers, but fibers that have a predominance of the MHCIIb isoform stains more like type IIB fibers
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(Staron, 1997). Consequently, the histochemical myosin ATPase
types express their isoform genes to varying degrees, according
to the variable ratio of isoforms present in the fiber. Due to
its quantitative nature, the SDS-PAGE technique is perhaps the
best method for muscle fiber typing, as electrophoretic separation permits the recognition of the relative concentrations of
different myosin heavy chain isoforms in mixed muscle fibers
(Pette et. al., 1999, Fry et. al., 1994).
A fourth myosin heavy chain isoform, MHCIIx or MHCIId, and
its corresponding fiber type IIX, is present in small mammals.
Evidence shows that MHCIIb in humans in homologous to
MHCIIx/d of small mammals (Pette et. al., 1999, Hilber et. al.,
1999). In actuality, MHCIIb in humans is really MHCIIx/d, as humans do not express MHCIIb, the fastest myosin heavy chain
isoform (Pette et. al., 1999). In fact, recent data shows that
fibers that were histochemically identified as type IIB in humans
contain low amounts of MHCIIa, and therefore, in reality, are
hybrid type IIAB fibers (Staron, 1997). Therefore, the 3 myosin
heavy chain isoforms present in human limb muscles are (from
slowest to fastest): MHCI, MHCIIa, and MHCIIx/d (previously
incorrectly known as MHCIIb).

Biochemical Classification
A third classification technique reflects the energy metabolism
of the muscle fibers. Histochemical myosin ATPase fiber typing of type I or type II corresponds to slow and fast muscle
fibers, respectively, and the enzymes involved reflect the metabolic pathways that are either aerobic/oxidative or anaerobic/
glycolytic (Pette et. al., 1999). This classification scheme leads to
3 fiber types: fast-twitch glycolytic (FG), fast-twitch oxidative

(FOG), and slow-twitch oxidative (SO) (Pette, Staron, 1997).
Type I and IIA fibers have a greater mitochondrial density and
oxidative capacity than type IIB and IIX fibers (Sieck, Prakash,
1997). Accordingly, there is a good correlation between type I
and SO fibers, but correlations between type IIA and FOG and
type IIB and IIX and FG fibers are more diverse (Hamalainen,
Pette, 1995). This can be explained by the fact that changes
in oxidative capacity can take place without changes in MHC
isoforms (Staron, 1997). Generally, type I fibers rely primarily
on aerobic/oxidative energy metabolism and type II fibers rely
primarily on anaerobic/glycolytic metabolism, but as it cannot
be assumed, the terms type IIB and FG or type IIA and FOG
cannot be used interchangeably (Pette et. al., 1999).

Myosin Light Chains
The myosin light chains also exist in different isoforms, slow
and fast, and affect the contractile speed of the fiber (Talmadge,
Pette, 1995). A homogeneous/pure myosin heavy chain isoform
can be heterogeneous in regard to its myosin light chain isoform. Usually, however, fast heavy chain isoforms fuse with fast
light chain isoforms, and slow heavy chain isoforms fuse with
slow light chain isoforms (Pette et. al., 1999, Jostarndt-Fogen et.
al., 1998).

Motor Unit Classification
The proper functional unit of the neuromuscular system, the
motor unit, reflects the characteristics of its individual fibers.
Motor units are categorized based on their contractile speeds
and fatigue characteristics. Contractile speed classifies motor
units into slow-twitch (S), usually comprised of type I fibers, or
fast-twitch (F), usually comprised of type II (Burke, 1999). The

Table 1: Summary of fiber types and their corresponding characteristics
Type I fibers
(I, IC)

Type IIA fibers
(IIC, IIAC, IIA, IIAB)

Type IIX fibers

Type IIB fibers
(not present in humans)

MHC isoforms

MHCI

MHCIIa

MHCIIx/d

MHCIIb

Contraction time

Slow

Moderately Fast

Fast

Very Fast

Oxidative Capacity

High

High

Intermediate

Low

Glycolytic Capacity

Low

High

High

High

Biochemical Fiber
Type (generally)

SO
(slow oxidative)

FOG
(fast-twitch oxidative)

FG
(fast-twitch glycolytic)

FG
(fast-twitch glycolytic)

Resistance to Fatigue High

Fairly High

Intermediate

Low

Motor Unit Class
(generally)

S
(slow twitch)

FR
(fast-twitch
fatigue-resistant)

Fint
(fast-twitch
fatigue-intermediate)

FF
(fast-twitch fatigable)

Activity used for

Aerobic

Long-term anaerobic

Short-term anaerobic

Short-term anaerobic

Mitochondrial
Density

High

High

Intermediate

Low

Capillary Density

High

Intermediate

Low

Low

2

Mechanical Plasticity: Skeletal Muscle Adaptations

F motor units are additionally classified by their type II fiber
subdivisions. Fast-twitch fatigue-resistant (FR) are comprised of
type IIA fibers, fast-twitch fatigue-intermediate (Fint) are comprised of type IIX, and fast-twitch fatigable (FF) are comprised
of type IIB (Burke, 1993). The fatigue resistance of the muscle
unit is explained by the mitochondrial density and oxidative capacity of the muscle fibers. The motor unit typically reflects
the function of the muscle. The diaphragm muscle employs its
fatigue-resistant S and FR units to produce normal breathing,
but must recruit its Fint and FF units for actions that require
greater force, such as gagging or sneezing. Contrariwise, the
extensor digitorum longus muscle of the limb, which is used for
motor activities demanding short periods of greater force production, is composed mostly of FF type IIB fibers. Consequently,
type I and IIA fibers are intended to sustain longer periods of
activation, while type IIX and IIB fibers are intended to produce
shorter bursts of activation (Sieck, Prakash, 1997).

regimes is evident in the vastus lateralis. In untrained, physically
active subjects, the vastus lateralis is made up of roughly 50%
of slow type I fibers and 50% type II fibers (40% type IIA and
10% IIX). Power athletes, such as sprinters, power weight lifters
and throwers, are constituted chiefly of IIA and IIX fibers, with
a percentage of type I as little as 20%. Ultra-endurance athletes,
such as long-distance runners, have a 95% constitution of type
I fibers. The variability of the composition of the vastus lateralis muscle is due to fiber type shifting. Long-term endurance
training induces a substantial transformation from fast muscle
fibers to slow muscle fibers. Slow muscle fibers rely mainly on
aerobic metabolism and, for that reason, are vital for endurance
activities such as swimming, cycling and marathon running. The
shift in MHC isoform type depends on changes at the molecular
level. New slow MHC polypeptides, which are still categorized
as type IIA fibers, are produced, marking the start of their transition towards the slow type I fibers (Zawadowska et. al., 2004).

Therefore, the overall properties of a muscle reflects the properties of its heterogeneous collection of fiber types and their
overall proportions. It is this range of fiber types that allows for
the wide range of muscle function a single muscle can display.
Muscle fibers adapt to their motor unit’s changing stimuli not
only by changing their size, but by converting their fiber type
composition to suit the functional demands. This muscle plasticity serves as the physiologic basis for the adaptions of skeletal
muscle to resistance and endurance exercises.

In response to training, the most common fiber conversions are
between type IIB and type IIA. Slow to fast/ type I to type II
conversions are possible in response to the loss of function related to deconditioning, as shown in studies on humans with spinal cord injury and microgravity exposure during their time in
space. Detraining in humans (i.e., decreased use of skeletal muscle following a formerly high activity level) leads to shifts MHCIIa
to MHCIIx/d and possibly MHCI to MHCIIa. Additionally, there
is a related decrease in aerobic-oxidative metabolic enzymes
(Pette, Staron, 1997). In short, immobilization of skeletal muscle
may cause conversions in the slow to fast direction. Scientists
assumed that power training may also cause the transformation
in slow to fast direction.This was a logical assumption, since fast
muscle fibers depend mainly on anaerobic metabolism and are
consequently essential for power training, such as sprinting and
weight lifting. Additionally, IIX fibers produce a greater maximal
power output than IIA fibers and are therefore essential for
such activities. However, studies have proven that all methods
of training (both endurance and power/resistance) cause a conversion toward the slow direction (Zawadowska et. al., 2004).

Methods
EBSCO multi-search, ProQuest Medical Library, Wiley Library,
Journal of Applied Physiology, MEDLINE, and PubMed databases
were used to find material for this paper. Access was gained to
these databases through the Touro College Online Library and
Einstein Online Library websites. Key words, such as “muscle
fiber types” and “effects of exercise on muscle” were used to
search for scientific articles.After reading through these articles,
other key words were identified, such as “fiber-type shifting”,
and “resistance vs endurance”. Additionally, sources listed as
references for review articles on the APTA website (American
Physical Therapy Association) were searched for to find the
original papers.

Discussion
The plasticity of the heterogeneous composition of muscle
fibers allows for adaptations in the contractile and metabolic
properties of skeletal muscle. Various phenotypes are therefore possible in response to different workloads. This plasticity
has practical implications, both for athletes and rehabilitation
patients alike.
This range of myosin form expression in response to exercise

Endurance
Many studies have proven that endurance exercises (low-resistance, repeated contractions that require the muscle to produce
a high aerobic metabolic rate) lead to several adaptations within
the muscle to augment aerobic metabolism and resistance to fatigue (Staron et. al., 1990). Firstly, the oxidative capacity of all fiber
types will increase by increasing the amount of mitochondria, oxidative/aerobic enzymes and capillaries in the muscles being trained
(Holloszy, Booth, 1976, Fitts, Widrick 1996). Based on metabolic
classification scheme, there is a transition from the FG fiber type
to the FOG fiber type without, necessarily causing a change in the
myosin heavy chain composition (Pette, Staron, 1997).
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Secondly, there are alterations in myosin heavy chain isoform.
It has been suggested that there is an increase in the percentage of type I fibers following aerobic training, and a subsequent
decrease following detraining in elite endurance athletes.
Additionally, within type II fibers, MHCIIx/d (IIB) are converted
to MHCIIa (IIA). In other words, there is a decrease in the
population of pure type IIB fibers and an associated increase in
the population of pure type IIA fibers. It also seems that there
is an increase in the hybrid population of type I and type II fibers, known as type IIC (Staron et. al., 1990). Evidence as to
the conversion of type II to type I fibers, as stated previously,
is lacking (Ricoy et. al., 1998). The transformation of type IIB
fibers to type IIA in response to endurance training is fairly
logical. Although there are variations on the oxidative capacities
within a muscle type, as a class, type IIA fibers generally have a
greater oxidative capacity than type IIB fibers. Therefore, an
increase in the population of type IIA fibers makes the muscle
more oxidative. In fact, there is a negative correlation between
the percentage of type IIB fibers and maximum oxygen intake.
Therefore, as stated previously, detraining and immobilization
cause a conversion in the slow to fast direction, from type IIA
to type IIB (Staron et. al., 1990).
Thirdly, there can be a transformation in myosin light chain isoforms. Type I fibers show an increase in contractile speed in
response to endurance exercises, but show a decrease following
deconditioning in humans. Logically, this change cannot be explained by a conversion of fiber type, but rather, by a conversion
in the myosin light chain isoforms from slow to fast and from fast
to slow, respectively (Larsson et. al., 1996, Widrick et. al., 1996).
The conversion from slow to fast allows the fibers to maintain
their properties of efficient energy usage while increasing their
contractile speed to keep up with the demands of the exercise
(Fitts,Widrick, 1996). Such a conversion would not be detected
by the histochemical technique, as there is no change in the myosin ATPase (Pette, Staron, 1997). To summarize, muscle fiber
adaptations to endurance exercise varies based on fiber type.
In all types, the oxidative capacity of the fibers increases. Type
II fibers shift in the type I direction, leading to slower, oxidative
types. Type I fibers convert their myosin light chains to increase
their contractile speeds.

by neural factors, rather than hypertrophy of the actual muscle fibers. However, adaptations may also be occurring in the
contractile proteins of skeletal muscle within a short duration
of training, even two weeks, with sufficient intensity (McArdle
et. al., 1994). Visible hypertrophy is not evident until later in
the training period (>8 weeks) (Kraemer et. al., 1996), around
the same time researchers found a shift in muscle fiber type
composition from MHCIIx/d to MHCIIa (Staron et. al., 1994,
Kraemer et. al., 1995, Staron et. al., 1990).
To explore this plasticity, twenty four male subjects were categorized into three groups according to their sports/physical
activity. Group A was made up of untrained students, group
B of national and sub-national level endurance athletes (7.8+/2.9 years of specialized training) and group C of sprint-power
athletes (12.8+/-8.7 years of specialized training). Biopsies of
the vastus lateralis muscle were obtained and immunohistochemically analyzed for fast/slow MHC composition. This muscle is easily accessible and easily trained. Most importantly, it
expresses all three myosin isoform types at specific amounts,
and so its phenotype visibly mirrors any adaptive modifications
that occur after different forms of exercises. Unpredictably,
group C sprint-power athletes (such as ice hockey, volleyball,
karate, soccer players and modern dancers), who were expected to display the highest percentage of MHCIIX, were no
different in this aspect from group B endurance athletes (such
as marathon runners, cyclists and cross country skiers). The
muscle phenotypes of both groups were similar, containing a
small proportion of the MHCIIX isoform and a predominance
of slow MHCI isoform. Clearly, the muscle phenotype was
adapted for long lasting, sustainable activities (similar to what
happens in endurance athletes), rather than activities that require a maximum power output in minimal time. Moreover,
the fastest isoform, MHCIIX, was relatively lower in group C
athletes than in group A students. This myosin profile in group
C athletes is unfavorable to their sport. Muscles that contain
a higher percentage of type IIX fibers have a greater maximum shortening velocity, which is the most important factor
in maximum power output and therefore vital for their sports
regime. This is a possible explanation for why, despite years
of training, these athletes could not reach international level
(Zawadowska et. al., 2004).

Resistance/Power
High-intensity resistance strength training involves short, maximal contractions that require the muscle to produce a large
amount of anaerobic energy (Staron et. al., 1990). Resistance
training, such as high-load–low-repetition exercises, leads both
to the fiber type shifting seen with endurance training and to
muscle hypertrophy, which plays a significant role in increasing force production (Kraemer et. al., 1996). Initial strength
gains made with high-intensity resistance training are caused
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A study performed on women proved similar to the results
shown by men. To examine the adaptations that take place
following a high-intensity resistance strength training program
(i.e. hypertrophy and fiber type shift), twenty-four women
participated in a 20- week program for the lower extremity. Biopsies were obtained both before and after the training
program from the superficial part of the vastus lateralis. Once
again, this muscle was chosen due to its easy accessibility, broad
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fiber type composition, and potential for training (Staron et. al.,
1990).
Based on staining intensities using MATPase histochemistry,
six fiber types (I, IC, IIC, IIA, IIAB, and IIB) were distinguished,
and three groups were determined based on fiber type (I, IIA
and IIA+IIB) . Dramatic hypertrophy of all three groups (I=
15%, IIA= 45%, and IIAB +IIB= 57%) following a high- intensity strength training regime showed that fast twitch fibers are
not the only fibers affected. There appears to be an increase
in contractile elements within the muscle fibers, leading to
an increase in both muscle strength and size, similar to the
adaptations found in men following strength exercises (Staron
et. al., 1990).
Additionally, the data shows that strength training causes muscle fiber-type conversions. In the pre-training biopsy sample,
group 1 (type I) had the largest cross-sectional area (4253±949
µm2), group 2 (type IIA) had intermediate (3370±1048 µm2),
and group 3 (type IIAB+IIB) had the smallest (2697±931 µm2).
Despite a hypertrophy of all three groups, the “hierarchy of
fiber sizes” was changed following training. The areas of group
1 and 2 were not significantly different from each other (type I
= 4893±770 µm2, type IIA = 4888±967 µm2), and the area of

Figure 1: Cross sections of pre (left) and post (right) biopsies examined
for MATPase activity from three different women. The dark staining
type IIB fibers have visibly disappeared in the post-biopsy biopsy
(Staron et. al., 1990).
group 3 was still significantly smaller (4233±1433 µm2) than
the areas of both group 1 and 2. Therefore, despite the fact
that the total area of type IIB fibers increased, the percentage
of IIB fibers (MHCIIx/d) significantly decreased, with a concomitant increase in the percentage of IIA (MHCIIa) fibers
(Staron et. al., 1990, Figure 1).

It is assumed that the recruitment of the infrequently activated
IIB fibers caused their transformation to type IIA fibers. This
increases the oxidative capacity of strength-trained muscle, as
supported by the findings of significantly greater volumes of
mitochondria in weightlifters’ muscles compared to untrained
subjects. This also explains the observation of an increase in
short-term endurance following an intense-resistance training
routine (Staron et. al., 1990). As a result of this shifting, reductions in myosin heavy chain “coexpression” has been reported
both after endurance and resistance training, with a corresponding increase in pure fibers (Williamson et. al., 2000).

Conclusion
The study of muscle fiber types has constantly been evolving
over the past several decades. New systems of classification
that categorize the fibers into more specific groups enables
researchers to accurately track the changes that occur within
a muscle’s fibers. Endurance training is known to increase the
muscle’s endurance by increasing the oxidative capacity of its
fibers, as supported by the increase in type I fibers. Resistance/
power training is known to increase the volume of the contractile proteins in the muscle fibers, promoting hypertrophy of the
muscles. However, research shows that rather than increasing
the percentage of fast muscle fibers, as expected, resistance exercises leads to fiber type shifting in the slow direction, increasing the oxidative capacity of the muscle.
While research has proven that resistance exercises leads to
hypertrophy and muscle type shifting in both men and women,
such studies are fairly new. Research conducted on the effects
of endurance exercises far exceeds the research conducted on
the effects of resistance exercises. As such, studies pertaining to
resistance exercises do not always agree, and the pool of available research is not large enough to evaluate which studies are
most accurate. For example, some papers claim that fiber type
shifting causes type IIB to convert to type I fibers, while other
papers say that type IIA is the farthest it can go. Therefore, additional research must be conducted to shed light on this topic
and determine which theory is correct. However, it is clear
that just like endurance exercises, resistance exercises lead to
conversions in the fast to slow direction, and not in the slow to
fast direction (as was originally assumed).
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Abstract
Noise-induced hearing loss (NIHL) is a pervasive disability that affects millions of people across the world. It is characterized by a decrease in hearing sensitivity to sounds that fall between 3000–6000 Hz(known as the “notch”). NIHL
is caused by either a sudden acoustic trauma or long-term exposure to noise levels above 85 dB. The noise exposure
induces overproduction of free radicals within the cells of the cochlea, overpowering of the ear’s antioxidant defense
systems. The free radicals then destroy cell membranes and hair cell nuclei, causing necrosis and apoptosis, leading to
hair cell death. This upsets the mechanical structure and the metabolic homeostasis within the ear, impeding hearing
function. Studies have shown that some people are more susceptible to NIHL, either due to environmental factors or
genetic factors. NIHL is preventable; OSHA and the EPA have sought to regulate sound levels on job sites and encourage
the use of hearing protective devices at work, and researchers are developing new imaging tests to accurately diagnose
NIHL before severe hearing loss sets in. There are also ongoing studies regarding the prophylactic and therapeutic use
of pharmacological agents (antioxidants and glucocorticoids) and vitamins in the prevention and treatment of NIHL.
This paper is a review of the literature available on NIHL and the ongoing studies related to diagnosis, treatment, and
genetic factors in the disorder. The literature was found on a number of research databases, with most of the source
material coming from the Academic Search Complete (EBSCO) database.
Introduction

Methods

Millions of people across the globe are exposed each day to acoustic overstimulation – noise – in their daily activities, whether at
their jobs or during their leisure activities. Noise is one of the
most common sources of environmental stress, and it can cause
both mechanical and metabolic damage to an individual’s ear. As a
result, noise-induced hearing loss (NIHL) is a disability that is widespread among individuals exposed to either prolonged loud noise
or excessively loud noise. More than 600 million people around the
world endure excessive noise at their jobs and are thus at risk for
NIHL. Millions more expose themselves to excessive noise during
leisure activities, particularly when listening to or playing music, and
they too place themselves at risk to developing NIHL.

The information in this paper was synthesized from literature
reviews and studies published in peer-reviewed journals. The
articles were selected using databases, primarily the Academic
Search Complete (EBSCO) database made available through the
Touro College virtual library. Data was extracted according to
relevance, with special attention given to NIHL statistical data;
mechanical and metabolic disruption in the ear as a result of
noise trauma; and the diagnosis, treatment, and genetic factors
related to NIHL.

The susceptibility to NIHL has been shown to have both environmental and genetic factors. Environmental variables that increase
a person’s likelihood of developing NIHL include noise exposure
that is combined with extreme temperatures, chemical solvents,
and prolonged vibration. Individual environmental factors including
smoking, high blood pressure, and high cholesterol levels, have also
been shown to increase an individual’s risk of developing NIHL.
Currently, the genetic factors that increase a person’s susceptibility
to NIHL are largely unknown. Many animal studies are currently
ongoing to identify genetic polymorphisms linked with NIHL.
This paper will explore how noise impacts both the mechanical
structure of the ear and the metabolic processes within the ear.
Additionally, it will examine recent and ongoing studies regarding
the genetic factors that increase a person’s susceptibility to developing NIHL, as well as the preventative and therapeutic interventions that are currently in use or being tested in experimental
stages.

Discussion
The word noise is derived from the Latin word nausea, which
means “impulsive, unwanted, and unpleasant” (Taneja, 2014).
In medical terms, noise has been defined as a “physical agent
capable of causing damage to the human body with the short
and medium term effects” (Metidieri et al., 2013). Sound is
measured in units known as decibels (dB), and normal sounds
are generally less than 75 dB and are unlikely to cause any
damage to the ear or cause hearing loss. However, sounds
that are higher than 85 dB can cause physical damage to the
structures of the ear. This includes excessively loud noises
that are short and sudden, such as gunshots or explosions.
Moreover, an individual who is frequently exposed to noises
that are continuously and moderately loud can experience
damage to hearing structures that results in NIHL.NIHL can
involve functional limitations for a number of hearing processes, including “changes in frequency selectivity, temporal and
spatial resolution, recruitment, and tinnitus as well as changes
in hearing sensitivity” (Metidieri et al., 2013). NIHL is the second most common hearing loss after age-related hearing loss
(Levey et al., 2012).
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Excessive noise in public areas has been called noise pollution,
and it is considered an environmental problem along with other
forms of pollution, such as smog or water pollution. In fact, noise
pollution affects the largest number of people worldwide,according to the World Health Organization (WHO) (Metidieri
et al., 2013). In research on NIHL, noise is classified in three
categories: (i) continuous noise, which is noise that persists for
minutes or hours at about the same level of intensity; (ii) impact
noise, which is a high level but short duration noise that occurs
when two objects collide; and (iii) impulse noise, which is a high
level but short duration noise that results from an explosion or
gunfire(Bielefeld, 2015).NIHL can be diagnosed as either acoustic trauma or chronic NIHL. Acoustic trauma is defined as a sudden but permanent hearing loss caused by a one-time exposure
to a forceful sound, with sound pressure levels of approximately
130-140 dB. The extent of damage after an acoustic trauma will
vary from mild to profound. In contrast, chronic NIHL results
from gradual exposure to less forceful noise over an extended
period of time, and this to can result in either mild or profound
hearing loss (Rajguru 2012).
Approximately 25% of workers across the globe are exposed
to noise levels that can induce NIHL. It is the most common
work injury (Metidieri et al., 2013). Noise exposure is often experienced with other causal agents of NIHL, including chemical
exposure. For example, when an individual is exposed to carbon monoxide and noise simultaneously, he has a higher risk of
developing NIHL, even though exposure to carbon monoxide
alone rarely induces hearing loss (Kashani et al., 2011). Smoking
cigarettes while being exposed to noise both raises the risk of
NIHL and increases the extent of the hearing damage. This may
be due in part to the carbon monoxide exposure related to
cigarette smoke (Liuyan et al., 2013). Other causal agents include vibrations, medications, and one’s individual susceptibility
to hearing loss (Metidieri et al., 2013).
The National Institute for Occupational Safety and Health
(NIOSH) estimates that in the United States alone, there are
5–30 million workers who are exposed to dangerous noise levels
each year (Bielefeld, 2015).NIHL is an insidious condition, as those
exposed to loud noise are generally unaware that damage is occurring until it is too late (Levey et al., 2012). It is characterized
by a decrease in hearing sensitivity to sounds that fall between
3000–6000 Hz (known as the “notch”). The decrease in hearing
sensitivity is often asymmetric. Typically, there is greater hearing
loss in the left ear than in the right ear (Phillips et al., 2010).
Individuals from all segments of the population are at risk for
NIHL, though there is a higher prevalence among men (Pelosi,
2014). Among Americans aged 20-69, there are 23 million people (12.8% of this demographic) who have NIHL (Bielefeld,
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2015).However, the risk of developing NIHL is unrelated to
age (Phillips et al., 2010).In fact, the pervasiveness of NIHL rises
steadily over childhood and adolescence (Pelosi, 2014).The
American Academy of Audiology estimated in 2008 that one in
eight children has sustained NIHL. In 2010, a similar estimate
was made in which 16% of teenagers were thought to have sustained NIHL.Among younger demographics, NIHL is typically
caused by exposure to excessively loud music over an extended
period of time, particularly on personal listening devices such
as iPods, MP3 players, or CDs. Children’s toys that emit loud
sounds have also been found to cause NIHL. A study conducted
with 329 student musicians between the ages of 18 to 25 years
found that 45% of the students had sustained NIHL, with 78%
of the hearing loss happening at 6000 Hz (Levey et al., 2012).
Noise exposure at work is often associated with factory workers who spend their working hours in cramped spaces with
loud, industrial machinery. However, there are less conventional
occupations that have high risk of NIHL as well. As many as
60 percent of military personnel involved in active duty return home with NIHL or tinnitus, and have both (Pelosi, 2014).
This is likely due to their excessive gun use (Berg et al., 2014).
Firefighters, too, are at high risk for NIHL, as the noise they are
exposed to regularly is usually high in intensity and short in
duration (Hong et al., 2013).
Individuals who do not work in noisy environments or listen
to loud music can also be at risk for NIHL in their daily lives.
Neitzel et al. found that New York City subway riders are exposed to noise louder than the limits recommended by WHO
and the United States Environmental Protection Agency (EPA).
This presents a heightened risk for NIHL to those who use
mass transit often, especially those who remain on the subways
for a longer period of time (Nietzel et al., 2009).

Mechanical Structure and Metabolic
Processes of the Ear
The prevalence of NIHL demonstrates how the ear is a complex
and vulnerable organ. The cochlea is the inner ear organ that converts sound for the process of hearing.The cochlea holds the organ
of Corti, which is comprised of hair cells that serve as the sensory
receptors of sound.There are two types of hair cells: inner hair cells
and outer hair cells. The inner hair cells use the auditory nerve to
communicate with the brain to create sound perception.The outer
hair cells amplify sound, increasing hearing sensitivity by ∼40 dB.The
organ of Corti also contains a number of supporting cells that form
the physical structure of the ear that is necessary for the mechanical movement that occurs when sound waves reach the ear.
The organ of Corti requires metabolic homeostasis to properly
convert sound waves and auditory signals. Noise exposure can
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Figure 1

ear, bones (also known as “ossicles”) called the malleus, incus,
and stapes, amplify the sounds. The vibrations are then sent to
the inner ear, known as the cochlea, which is a fluid-filled organ
with an elastic membrane known as the basilar membrane.
Attached to the basilar membrane, there are sensory cells,
known as outer and inner hair cells. The vibrations that reach
the inner ear generate a traveling wave that runs along the basilar membrane as a result of the electromotility of the outer

Figure 2

Figure 1: Diagram of the cochlea cut through along the modiolus.
Arrows demonstrate the pathway of pressure waves that originate
in the oval window.
(Curtis et al., 1970)

Figure 3:
Movements of the basilar membrane and the deflection of the
stereocili:
A. Upward movement of the basilar membrane (arrow) deflects
hairs away from the modiolus.
B.The basilar membrane is at rest is
C. Downward movement (arrow) deflects hairs toward the modiolus.
(Klinke, 1978)

damage the cochlea both metabolically and mechanically, and NIHL
can occur from either metabolic or mechanical deterioration, as
well as from a combination of both (Bielefeld, 2015). (Figures 1
and 2)

hair cells. The movement induces stereocilia, spiky structures
on the apical surface of the inner hair cells, to rub up against
the tectorial membrane and thus release neurotransmitters
that travel across the synapse between the inner hair cell and
the auditory nerve. Figure three depicts these movements. This
process allows for sound waves to change into electrical signals
that are carried to the brain by the auditory nerve, and the
brain allows the individual to perceive the sound he is hearing
(Levey et al., 2012).

Normal Ear Function

Development of NIHL

The hearing process is a complex series of steps that occurs
when a sound is emitted. Sound waves travel to an individual’s
ear, where the hair cells act as receptors for the energy from
sound waves and then convert the sound waves into nerve
signals that reach the brain (Pelosi, 2014). Sound waves first
enter the outer ear and then traverse the ear canal to reach the
eardrum. When the sound waves strike the eardrum, it begins
to vibrate, and the vibrations reach the middle ear. In the middle

Most cell populations in the cochlea are vulnerable to noise
damage. Noise can impair or kill: the pillar cells, which provide
the structural support for the organ of Corti; thefibrocytes of
the lateral wall, which allow potassium recycling necessary for
the depolarization of the hair cells; and the outer and inner
hair cells, which are vital for reducing hearing thresholds, discriminating between sound frequencies, and delivering auditory
information to the brain. The synapses between the inner hair

Figure 2: Cochlear partition and the organ of Corti.
(Curtis et al., 1970)
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cells and afferent auditory nerve neurons are also susceptible
to noise damage, and damage to these synapses can result in
long-term auditory nerve neuropathy (Bielefeld, 2015). An individual with NIHL will experience deterioration of the ciliated cells of the organ of Corti (Metidieri et al., 2013). Figure 4
shows the destruction of a region of the organ of Corti. The
noise exposure induces overproduction of free radicals. While
free radicals are often present in cells, they can be destructive
when they are overproduced, resulting in an overpowering of
the ear’s antioxidant defense systems. These free radicals are
made up of reactive oxygen species (ROS) (Levey et al., 2012).
ROS are molecules with an odd number of electrons and thus
highly reactive and destructive to the body. The accumulation of
ROS causes damage to the mitochondria, which is the driving
force of the cell and produces more than 98% of the energy
used in our bodies. When ROS impair the mitochondria, they
lose their capacity to produce energy. Ultimately, this reduces
the amount of energy available for normal inner ear function,
causing hearing loss(Seidman, 1999).
When the ear is exposed to excessive noise, the outer hair
cells in the cochlea require high levels of energy and consume
more oxygen. This generates a number of byproducts that mix
with other molecules in the cochlea to generate high levels of
ROS. This upsets the metabolic homeostasis of the cochlea.
Additionally, the ROS then destroy cell membranes and hair cell
nuclei, which causes tissue death (necrosis) and apoptosis (cell
self-destruction), ultimately leading to hair cell death. Once it
is dead, the hair cell will break into pieces, and this upsets the
mechanical structure of the ear. Eventually, the hair cells are
replaced with scar tissue. While the scar tissue ensures that the
basilar membrane of the ear remains intact, it cannot play a role
in the hearing process, and thus the individual with NIHL will
experience hearing loss (Levey et al., 2012).
Cochlear microcirculation is vital for hearing transduction.
Sensory hair cells of the cochlea are at risk of ischemia during
noise exposure, and studies have shown that inadequate blood
flow is associated with the development of NIHL. An important
component of cochlear microcirculation is the diameter of the
spiral modiolar artery, a branch of the anterior inferior cerebellar artery, which meets the lateral cochlear wall to form the
striavascularis. The spiral modiolar artery has been shown to
constrict during and after noise exposure (Arpornchayanon et
al., 2013), and this is an additional cause of NIHL.
Another contributing factor in the development of NIHL is
calcium homeostasis in the cochlea. Calcium plays the role of
second messenger in a cell’s physiological activities, and an upset
calcium homeostasis has been linked to trauma-induced neuronal injury(Bao et al., 2013).In the cochlea, calcium participates
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in a number of functions, including mechano-electric transduction, hair cells’ voluntary contractions, the inner ear’s frequency
selection, basal membrane vibration, and the release of neurotransmitters (Liu et al., 2012). Calcium homeostasis is sustained through a number of different calcium channels, including
voltage-gated calcium channels (VGCCs).VGCCs are comprised
of two groups: high-voltage-activated (L-type) and low-voltage-activated calcium channels (T-type) (Bao et al., 2013).L-type
VGCCs provide access for calcium to enter hair cells and are
essential for the regulation of calcium homeostasis. After noise
exposure, the levels of calcium in hair cells have been shown to
increase, and an excessive amount of calcium in a cell has been
linked to cell injury and cell death. Thus, too much calcium in
the cochlea, brought on by excessive noise, has been linked to
NIHL (Liu et al., 2012).

Genetic link
Although there is much research about the link between environmental agents and NIHL, less is known about the genetic
basis for the impairment. Various animal studies have provided significant evidence of a genetic predisposition for NIHL.
Mitochondrial dysfunction and ROS production have been
shown to play significant roles in neurodegenerative conditions.
As ROS overproduction is a result of noise exposure, mitochondrial genes and endogenous antioxidant defense-related
genes have been thought to be the genes associated with NIHL.
There are a number of antioxidant enzymes at work in the cochlea. Glutathione-S-transferase (GST) enzymes catalyze the
conjugation of glutathione with xenobiotics and are vital for
antioxidant protection. GST is comprised of a number of gene
classes (GSTA, GSTM, GSTP, GSTT, GSTZ, GSTS, GSTK, GSTO).
Humans have genetic variability of GSTM1 and GSTT1. For example, approximately half of the European population has null
genotypes for GSTM1, and 25–40% of Europeans do not have
GSTT1. A person with a null genotype is unable to conjugate
certain metabolites for these enzymes, and this makes him or
her more susceptible to damage from oxidation. Therefore, it
has been suggested that an individual with a null genotype is
more likely than his peers to develop NIHL when exposed to
excessive noise (Liu et al., 2012).
There are also genetic mutations that reduce susceptibility
to NIHL. A1555G in MTRNR1 is the mitochondrial mutation
most frequently linked to hearing loss, typically with aminoglycoside-induced deafness and non-syndromic deafness. MTTS1
is another mitochondrial gene with a number of mutations.
A1555G or other mitochondrial variants in the MTRNR1 and
MTTS1 have been suggested as factors that lessensusceptibility
to NIHL.
Abreu-Silva et al. conducted a study to evaluate genetic factors
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in susceptibility to NIHL. The researchers compared persons
with NIHL and persons without NIHL, as well as their family
history of hearing loss and whether they had genetic mutations
that have been linked with hearing loss (including deletions in
GSTM1 and GSTT1, A1555G in the MTRNR1 gene. Their sample was comprised of 255 bus drivers and workers at a printing
facility in Sa˜o Paulo, Brazil. Both groups were regularly exposed
to excessive noise. The subjects of the study included 107
people whose audiograms showed NIHL, 44 people with hearing impairment and audiograms that did not show NIHL, and
104 people with normal hearing. Data was collected regarding
each subject’s age, regularity of noise exposure, family history
of hearing loss, alcohol consumption, smoking habits, and geographic origin of their ancestors. Subjects also provided blood
samples for DNA screening and genotyping. The researchers
found that family history of hearing loss is significantly associated with NIHL, which supports a genetic susceptibility to the impairment. Moreover, the researchers found that the existence of
at least one allele in both genes (GSTM1 = 1/? and GSTT1 = 1/?)
increases the risk of NIHL, and that individuals of mitochondrial haplogroup L1 were disproportionately affected byNIHL.
However, no significant findings were made regarding variants in
the MTRNR1 and MTTS1 genes(Abreu-Silva et al., 2011).
Additional research on the genetic susceptibility to NIHL has
focused on Human 8-oxoG DNA glycosylase1 (hOGG1), a key
enzyme in the human base excision repair pathway. NIHL occurs
as a result of DNA damage to cochlear hair cells, causing necrosis
and apoptosis. At the same time, a number of DNA repair pathways, including base excision repair, help to maintain the integrity
of the cell and stave off cell death. This DNA repair has been
shown to be essential in maintaining hearing after noise exposure.
The 8-oxoguanine (8-oxoG) DNA lesion, which is caused by
the overproduction of ROS, is a common cause of oxidative
damage associated with NIHL. HOGG1 in the base excision
repair pathway eliminates 8-oxoG. Reseach has suggested
that the Ser326Cys polymorphism (rs1052133) in exon 7 of
hOGG1 gene can impact the activity of hOGG1 enzyme and
thus may be useful as a genetic marker for vulnerability to different diseases. Shen et al. conducted a study to evaluate whether
there is a link between the hOGG1 Ser326Cys polymorphism
in the human base excision repair pathway and susceptibility
to NIHL. The researchers genotyped 615 workers with NIHL
and 615 normal hearing workers in China.The workers had not
been regularly exposed to any other causal agents of NIHL, like
chemical solvents, heat, or vibrations, and they had no other
medical conditions that could have impacted their hearing.
The researchers found that the hOGG1 Cys/Cys genotype was
statistically associated with NIHL. Therewas a higher number

of persons with the hOGG1 Cys/Cys genotype among NIHL
workers than among normal hearing work, suggesting the
hOGG1 Cys/Cys genotype may have a lesser capacity for restoring 8-oxoG damage, and thus a higher susceptibility for
NIHL. The researchers also found that the hOGG1 Ser326Cys
polymorphism had a synergistic effect when combined with
noise exposure time, noise exposure level, whether the individual is a smoker, and whether the individual drinks alcohol
regularly (Shen et al., 2014).

Diagnosis
Early detection of NIHL would help decrease the social and
economic burdens related to the condition (Meinkeet al., 2013).
Moreover, early detection can help stop the progression of
hearing loss and prevent damage to speech frequencies (i.e.,
500, 1000, 2000 and 3000 Hz) (Mehrparvar, 2011). NIHL is
diagnosed when an individual is found to have a hearing level
change, compared to a baseline audiogram, of an average of 10
dB or more at 2000, 3000, and 4000 Hz in either ear (Levey et
al., 2012). Generally, NIHL results in hearing loss in the higher
frequencies (3000-6000 Hz), so during hearing tests, hearing
loss is observed at 4000 Hz with improvement in hearing at
8000 Hz. However, among elderly patients, the improvement at
8000 Hz is often lost, and this presents difficulty in determining
whether the hearing loss is from NIHL, age, or another cause.
Tympanometry is used to test the condition of the middle ear.
Asymmetric hearing losses are evaluated using a brainstem auditory evoked response or a high resolution CT scan of the
inner ear and internal auditorycanal (Seidman, 1999).
Researchers are currently evaluating a potential new means of
diagnosing and monitoring NIHL known as distortion product otoacoustic emission (DPOAE) level mapping. The goal of
DPOAE is to detect early signs of cochlear damage and then
track changes in cochlear function, but the maps have mostly
been used in trials with animals.A study was conducted in which
they performed DPOAE level mapping on 17 individuals without a history of noise exposure and then compared the results
to maps created with 19 individuals with mild moderate NIHL.
The DPOAE maps presented accurate data in a color pattern, a
“visual snapshot” of cochlear function between the frequencies
of 0.5 kHz and 6.0 kHz. This graphic form of data presentation
enables for more detailed data collection and supports rapid
comparison of maps for an individual. With further research,
DPOAE maps may become the standard tool for detecting and
monitoring NIHL (Meinke et al., 2013).

Prevention
NIHL is not a new phenomenon. Reports from as early as 600
B.C. tell of the Sybarites, who prohibited metal-working or the
possession of roosters within their city limits due to the dangers
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of excessive noise. Other historical documents show that individuals living near the waterfalls of the Nile River experienced
more hearing loss than those at a greater distance from the waterfalls’ noise (Seidman, 1999).NIHL is an impairment that is both
avoidable and foreseeable (Metidieri et al., 2013).The implications
of NIHL can extend beyond hearing loss; it can result in the development of a range of secondary diseases, including hyperacusis (over-sensitivity to certain frequency and volume ranges of
sound), tinnitus, or depression related to social isolation (Tziridis
et al., 2014).
The federal government has long sought to regulate noise exposure and prevent NIHL. In 1936, theWalsh-Healey Public Contracts
Act was instituted to oversee workplace noise exposure, though
it was not properly enforced. In 1970, the Occupational Safety
and Health Administration (OSHA) wasfounded to both monitor
and regulate workplace noise exposure. Currently, OSHA allows
for exposure to 90 dB for 8 hours a day, while the EPA allows
for a level of 85 dB. However, on-the-job inspections are typically
infrequent, and fines for noise-level violations are often low.

effectively when workers received training about the reasons for
HPD use, as well how they can be properly fitted in the ear.
In addition to HPD use, scientists continue to investigate a number of less conventional approaches to reducing the damage
from noise exposure. Experimental methods for preventing
NIHL include reducingbody temperature, stimulating a number
of neural structures, treatment of the ear with a number of
compounds, increasing oxygenation, interfering with ROM activity, and sound conditioning. In some cases, these alternative
approaches have achieved partial protection. In particular, the
concept of sound conditioning has received a lot of attention
from scientists. Conditioning allows for the toughening of the
cochlea through exposure to non-damaging levels of sound
before being exposed to noise trauma. Resistance can develop
after the exposure to stimuli that varies in duration, frequency,
and continuity.This is due to brain and nerve adaptability; during
sound conditioning, the cochlea’s outer hair cells perform similarly to a muscle (Seidman, 1999).

Treatment
The key to preventing NIHL is avoiding damaging noise exposure (Seidman, 1999), beginningwith an assessment of risk of an
environment. It is advisable to have workers rotate tasks to ensure that no individual is exposed to continuous hazardous noise
over an extended period of time (Singh et al., 2012).Additionally,
acoustic attenuation devices or engineering controls can be
used to reduce the noise dose to which an individual is exposed
(Bielefeld, 2015). If sounds often go above 85 dB, hearing protection is essential to preventing damage. OSHA mandates the
distribution of free hearing protective devices (HPDs) in work
places such as these. Protective devices may include ear plugs or
ear muffs (Pelosi, 2014). Earplugs can reduce between 10 dB and
22 dB of sound diminution, and protective earmuffs can reduce
sound by 20-55 dB. When earplugs are used together with earmuffs, the benefit is additive (Seidman, 1999).
However, there are a number of barriers to the use of HPDs.
First, many work sites require ongoing communication with
colleagues, and this is hindered by the use of ear protectors.
Additionally, Reddy et al. (2012)conducted surveys with workers in high-noise environments, and their findings suggest that
there is a “fatalist belief among workers that noise is an acceptable and unavoidable part of the job.” This perception often leads
workers to avoid using HPDs, not recognizing that these devices
can prevent permanent hearing loss (Reddy et al., 2012).Hong
et al. (2013) explain that the perceptual factors involved in HPD
use include perceived self-efficacy, perceived benefits, perceived
barriers, perceived susceptibility to hearing loss, and perceived
severity of hearing loss. In a study conducted by Nodoushan et al.
(2014), HPDs were found to be used more frequently and more
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Research has also focused on the use of pharmacological
agents in the prevention and treatment of NIHL. While there
is no widely-accepted protocol for pharmacological treatment
of NIHL, there are a number of ongoing research studies that
are testing substances on both animals and humans, including
antioxidants that decrease oxidative stress byeliminating ROS;
glucocorticoids; and agents that improve cochlear blood flow,
stimulate inhibitory transmitter systems, or obstruct apoptosis pathways in hair cells (Tziridis et al., 2014).
There are a number of antioxidants currently being tested for
their efficacy in both preventing and treating NIHL. The antioxidant α-tocopherol has been shown to reduce the noise-induced damage in guinea pigs (Kashani et al., 2011).N-AcetylL-Cysteine (NAC), an antioxidant which has been shown to
inhibit lipid peroxidation and destroy ROS by increasing levels
of glutathione within the cell, has been found in a number of
animal studies to be effective in treating NIHL if given immediately after noise exposure (Rajguru, 2012).
Antiepileptic drugs and glucocorticoids are also being tested
in the treatment of NIHL. Bao et al. conducted a study regarding prophylactic treatment of NIHL. Their study sought
to reduce the risk of NIHL by administering anticonvulsant
drugs to block T-type calcium channels in the organ of Corti,
and thus prevent an injurious disturbance to calcium homeostasis that may occur after exposure to noise. This approach
had been found to be effective in protecting neurons after a
stroke. The researchers administered to mice two anticonvulsant drugs - ethosuximide and zonisamide – to block T-type
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calcium channels, and then exposed them to high levels of
noise. The mice were also administered synthetic glucocorticoids, dexamethasone and methylprednisolone (Bao et al.,
2013). Glucocorticoids were used because they activate the
enzyme Na, K-ATPase, which has been linked to restoring
cellular osmolarity and neuronal conduction. Additionally, glucocorticoids have been found to be effective in both cells and
dendrites (Rajguru, 2012).
In Baoet al.’s (2013) study, the anticonvulsant drugs and the
glucocorticoids were administered after the noise exposure as
well to assess whether the drugs had any therapeutic effect after
noise-induced trauma. The researchers found that anticonvulsant
and glucocorticoid drugs could have both a prophylactic and
therapeutic effect, and that there was a synergistic prophylactic
effect when the drug families were used together (Bao et al.,
2013). Further studies are necessary to ascertain whether the
drugs would have the same effect in preventing and treating NIHL
in humans.

homocysteine synthesis in the cochlea, increase concentration of
nitric oxide, and thus cause the blood vessels to dilate. As such,
the B12 may be able to induce increased vascular perfusion and
cellular metabolism within the cochlea. In a study Kibar et al.
(2013) conducted with guinea pigs, they were not able to show
a significant decrease in hearing loss when the guinea pigs were
treated with B12. However, studies are ongoing to determine the
efficacy of B12 treatments in preventing and minimizing the damage of NIHL (Kibar et al., 2013).
Hyperbaric oxygen therapy (HBOT) is also being considered for its
use in treating NIHL. HBOT can be used to improve oxygenation
in the inner air, and thus improve microcirculation and attenuate
injured cochlear hair cells. HBOT can infuse hypoxic areas of the
cochlea with oxygen, which can work to speed up cellular mechanisms necessary for recovery. There are ongoing studies that are
evaluating the impact of HBOT on NIHL, as well as the combined
use of HBOT and glucocorticoids (Rajguru, 2013).

Conclusion
Vitamins and minerals are also being tested in the prevention
and treatment of NIHL. Studies show that magnesium has both
a prophylactic and therapeutic effect on noise-induced injuries.
In the cochlea, levels of magnesium are essential for preventing
disruption in cochlear microcirculation and oxygenation and for
protecting against free radicals. Clinical trials are ongoing to assess whether application of magnesium to the inner ear, together
with the administration of an antioxidant, can prevent and reduce
hearing damage after a noise-related trauma (Rajguru, 2012).
Tziridis et al (2014) conducted a study on the use of ginkgo biloba extract EGb 761 to prophylactically treat NIHL and tinnitus
in the Mongolian gerbil. Their study results demonstrate the
neuroplastic effects of EGb 761 on central and peripheral levels
of auditory processing when given prophylactically to gerbils exposed to noise. The researchers posit that the antioxidant effect
of EGb 761 provides protection against NIHL. Additionally, EGb
761 was shown to increase blood flow, so it provides a protective
effect against noise exposure, which can decrease blood flow in
the cochlea. While EGb 761 has not yet been tested on humans,
the results of the gerbil study are promising (Tziridis et al., 2014).
Another agent being tested in the prevention and treatment of
NIHL is vitamin B12.Vitamin B12 is an essential cofactor in methylation of myelin basic protein and cell membrane phospholipids
and also important in methionine synthesis from homocysteine.
There have been studies that have shown that individuals who
have low levels of vitamin B12 and folic acid are more susceptible
to hearing loss caused by noise exposure. When there is a B12
deficiency, there can be axon degeneration and neuronal loss.
Kibar et al. (2013) theorize that supplementary B12 can decrease

Though the effects of noise exposure have been known within
the medical community since the 1960s, the general public remains largely unaware of the long-term effects of both sudden
and gradual noise trauma. In a study conducted with American
respondents, only 16% of those surveyed reported that they
had read about or heard about NIHL in newspapers or other
media forums. In another American-based study, 72% of respondents admitted that they never wear hearing protection when
they are exposed to loud noises, even though they are aware
that noise exposure can be harmful (Ramma, 2011).
It has been said that an ounce of prevention is worth a pound of
cure, and this maxim is especially relevant in regards to NIHL. It
is essential that the general public is made aware of the damaging effects of noise exposure, both on the job and during recreational activities. While studies related to the prophylactic and
therapeutic intervention for NIHL are promising, there is currently no widely-accepted treatment protocol and no known
cure. As such, it is imperative that OSHA and EPA guidelines are
adhered to in all areas of work, and that HPDs are employed
during occupational hazards and leisure activities. Moreover, it
is essential that people recognize that their ears are vulnerable
to injury, and they should be protected from unnecessary – and
often irreversible – damage.

References

Abreu-Silva R, Rincon D, Mingroni-Netto R, et al. The search of
a genetic basis for noise-induced hearing loss (NIHL). Annals
Of Human Biology [serial online]. March 2011;38(2):210-218.
Available from: Academic Search Complete, Ipswich, MA.
Accessed May 3, 2015.

13

Aviva Levihaiem

Arpornchayanon W, Canis M, Ihler F, Settevendemie C, Strieth
S. TNF-α inhibition using etanercept prevents noise-induced hearing loss by improvement of cochlear blood flow
in vivo. International Journal Of Audiology [serial online].
August 2013;52(8):545-552. Available from: Academic Search
Complete, Ipswich, MA. Accessed May 3, 2015.

Levey S, Fligor B, Ginocchi C, KagimbiL.The Effects of
Noise-Induced Hearing Loss onChildren and Young Adults.
Contemporary Issues In Communication Science & Disorders
[serial online]. September 2012;39:76-83. Available from:
CINAHL Plus with Full Text, Ipswich, MA. Accessed April 26,
2015.

Bao J, Hungerford M, Ohlemiller K, et al. Research paper:
Prophylactic and therapeutic functions of drug combinations against noise-induced hearing loss. Hearing Research
[serial online]. October 1, 2013;304:33-40. Available from:
ScienceDirect, Ipswich, MA. Accessed May 20, 2015.

Liu J, Niu Y, Li X, et al. Interaction of a calcium channel blocker
with noise in cochlear function in guinea pig.Acta OtoLaryngologica [serial online]. November 2012;132(11):11401144. Available from: CINAHL Plus with Full Text, Ipswich, MA.
Accessed May 20, 2015.

Berg R, Pickett W, Linneman J, Wood D, Marlenga B. Asymmetry
in noise-induced hearing loss: Evaluation of two competing theories. Noise & Health [serial online]. March 2014;16(69):102107. Available from: Academic Search Complete, Ipswich, MA.
Accessed April 26, 2015.

Liyuan T, Davis R,Yiming Z, et al. Effect of cigarette smoking
on noise-induced hearing loss in workers exposed to occupational noise in China. Noise & Health [serial online]. January
2013;15(62):67-72. Available from: Academic Search Complete,
Ipswich, MA. Accessed May 20, 2015.

Bielefeld E. Review: Protection from noise-induced hearing
loss with Src inhibitors. Drug Discovery Today [serial online].
January 1, 2015; Available from: ScienceDirect, Ipswich, MA.
Accessed April 26, 2015.

Mehrparvar A, Mirmohammadi S, Ghoreyshi A, Mollasadeghi
A, Loukzadeh Z. High-frequency audiometry: A means for
early diagnosis of noise-induced hearing loss. Noise & Health
[serial online]. November 2011;13(55):402-406. Available from:
Academic Search Complete, Ipswich, MA. Accessed May 3,
2015.

Curtis BA, Jacobson, S. Marcus EM: An Introduction to the
Neurosciences. Philadelphia, Saunders, 1972. B. Davis H,
Silverman SR: Hearing and Deafness, 3rd ed. New York, Holt,
Rinehart, Winston, 1970.
Hong O, Chin D, Ronis D. Predictors of Hearing Protection
Behavior Among Firefighters in the United States.
International Journal Of Behavioral Medicine [serial online].
March 2013;20(1):121-130. Available from: Academic Search
Complete, Ipswich, MA. Accessed May 20, 2015.
Kashani M, Mortazavi S, Khavani A, Allameh A, Mirzaee R,
Akbari M. Protective Effects of α-Tocopherol on ABR
Threshold Shift in Rabbits Exposed to Noise and Carbon
Monoxide. Iranian Journal of Pharmaceutical Research [serial
online]. June 2011;10(2):339-346. Available from: Academic
Search Complete, Ipswich, MA. Accessed May 20, 2015.
Kibar S, Aydin S, Sanli A, Paksoy M,Yilmaz H, Sirvanci S.
Evaluation of Effect of Vitamin B12 on Noise-Induced Hearing
Loss by Distortion Product Otoacoustic Emission (Dpoae)
and Scanning Electron Microscopy. Journal Of International
Advanced Otology [serial online]. May 2013;9(2):167-174.
Available from: Academic Search Complete, Ipswich, MA.
Accessed May 3, 2015.
Klinke R: Physiology of hearing. In Schmidt RF [ed}:
Fundamentals of Sensory Physiology. New York, Springer-Verlag,
1978

14

Meinke D, Clavier O, Norris J, Kline-Schoder R, Allen L, Buckey
J. Distortion product otoacoustic emission level maps from
normal and noise-damaged cochleae.Noise& Health [serial
online]. September 2013;15(66):315-325. Available from:
Academic Search Complete, Ipswich, MA. Accessed May 3,
2015.
Metidieri M, Santos Rodrigues H, de Oliveira Filho F, Pereira
Ferraz D, de Almeida Neto A, Torres S. Noise-Induced Hearing
Loss (NIHL): literature review with a focus on occupational
medicine. International Archives Of Otorhinolaryngology [serial online]. April 2013;17(2):208-212. Available from: Academic
Search Complete, Ipswich, MA. Accessed April 26, 2015.
Neitzel, R., Gershon, Robyn R M, Zeltser, M., Canton, A.,Noise
levels associated with New York City’s mass transit systems.
American Journal of Public Health, August 2009. 99(8), 1393-9.
Available from: ProQuest Database. Accessed May 20, 2015.
Nodoushan M, Mehrparvar A, TorabJahromi M, Safaei S,
Mollasadeghi A. Training in Using Earplugs or Using Earplugs
with a Higher than Necessary Noise Reduction Rating?
A Randomized Clinical Trial. International Journal Of
Occupational & Environmental Medicine [serial online].
October 2014;5(4):187-193. Available from: Academic Search
Complete, Ipswich, MA. Accessed May 20, 2015.

The Impact of Acoustic Trauma on the Ear

Pelosi S. HEARING HEALTH. The Harm From Noise. Hearing
Health [serial online]. July 2014;30(3):24-26. Available from:
CINAHL Plus with Full Text, Ipswich, MA. Accessed April 26,
2015.
Phillips S, Henrich V, Mace S. Prevalence of noise-induced
hearing loss in student musicians. International Journal Of
Audiology [serial online]. April 2010;49(4):309-316. Available
from: CINAHL Plus with Full Text, Ipswich, MA. Accessed April
26, 2015.
Rajguru R. Noise-induced hearing loss: Recent advances in
pharmacological management. Indian Journal Of Otology [serial
online]. October 2012;18(4):174-178. Available from: Academic
Search Complete, Ipswich, MA. Accessed May 20, 2015.
Ramma L.Vuvuzela media coverage during the 2010 FIFA
soccer world cup tournament: Impact on raising awareness
of noise-induced hearing loss. Noise & Health [serial online].
November 2011;13(55):415-422. Available from: Academic
Search Complete, Ipswich, MA. Accessed May 20, 2015.
Reddy R, Welch D, Thorne P, Ameratunga S. Hearing protection
use in manufacturing workers: A qualitative study. Noise &
Health [serial online]. July 2012;14(59):202-209. Available from:
Academic Search Complete, Ipswich, MA. Accessed May 20,
2015.
Seidman M. Noise-Induced Hearing Loss (NIHL).Volta Review
[serial online]. Winter99 1999;101(1):29. Available from:
Academic Search Complete, Ipswich, MA. Accessed May 3,
2015.
Shen H, Cao J, Zhu B, et al. A Functional Ser326Cys
Polymorphism in hOGG1 Is Associated with Noise-Induced
Hearing Loss in a Chinese Population. PlosONE[serial
online]. March 2014;9(3):1-7. Available from: Academic Search
Complete, Ipswich, MA. Accessed May 3, 2015.
Singh L, Bhardwaj A, Deepak K. Prevalence of permanent
hearing threshold shift among workers of Indian iron and steel
small and medium enterprises: A study.Noise& Health [serial
online]. May 2012;14(58):119-128. Available from: Academic
Search Complete, Ipswich, MA. Accessed May 3, 2015.
Taneja M. Noise-induced hearing loss. Indian Journal Of
Otology [serial online]. October 2014;20(4):151-154. Available
from: Academic Search Complete, Ipswich, MA. Accessed May
20, 2015.
Tziridis K, Korn S, Ahlf S, Schulze H. Protective Effects of
Ginkgo biloba Extract EGb 761 against Noise Trauma-Induced
Hearing Loss and Tinnitus Development.Neural Plasticity [serial online]. January 2014;:1-27. Available from: Academic Search
Complete, Ipswich, MA. Accessed May 3, 2015.

15

The Mechanisms of Weight Gain in Sleep-Deprived
Individuals
By Chaya Rosen

Chaya Rosen will graduate in January 2016 with a B.S. degree in Biology.

Abstract
The obese population in America has grown during the last century. During these years as well, American’s have been
sleeping less. Cross sectional studies show that there is a correlation of the two factors, and indeed find a greater
number of overweight individuals amongst the sleep-deprived population. Though they are unclear, studies attempt to
establish possible mechanisms through which weight gain occurs. Results of studies show that sleep deprivation may
influence leptin and ghrelin levels, which can cause hunger, and excessive caloric intake. Sleep-deprived individuals also
have an increased opportunity to eat during the wakeful nighttime hours. In the sleep-restricted state, activity levels
may decrease, and though the extra hours spent awake also cause a small increase in energy expenditure, there is overcompensation in energy intake, leading to weight gain. Obstructive Sleep Apnea also plays a role in obese individuals’
sleep patterns, and may lead to further weight gain. Without excessive caloric intake it may be possible to maintain
weight in the sleep-deprived state. This paper will review a number of studies and give an overview of some of the
possible methods though which sleep-deprivation causes obesity.
Introduction
Sleep was once thought of as a process during which the both the
body and brain are at rest and inactive. But in modern times, starting
in approximately 1950, sleep has been studied and discovered to be
an active process, necessary to maintain many of the body’s functions
(National Institute of Neurological Disorders and Stroke, NINDS,
2014).
In 1937, Alfred Loomis, along with E. Newton Harvey, and Garret
Hobart, used the EEG to map out what they considered five stages
of sleep, A-E. In 1953, Eugene Aserinsky and Nethaniel Kleitman
established the REM sleep stage. In 1957 Dement and Kleitman
mapped out the sleep stages as they are known today, dividing
sleep into NREM (non-rapid eye movement) and REM (rapid eye
movement) sleep. NREM sleep consists of four stages, each with
varying brain wave activity, and increasing in depth as the stage
number increases. These stages are cyclical, repeating throughout
the night. Following the four stages, there is a period of REM sleep
(Shepard et al., 2005). REM sleep is associated with rapid eye
movements, increased heart rate, and dreaming (NINDS, 2014).
With vast research and many studies conducted since, the understanding of the roles that sleep plays in the body has been greatly
advanced and its necessity has been studied extensively (Shepard
et al., 2005).
Sleep is both a circadian rhythm and a homeostatic cycle. A circadian rhythm is natural rhythm, approximately twenty-four hours
long, and controlled primarily by the suprachiasmatic nucleus. The
natural timing of the cycle is based on the light-dark cycle (NIGMS,
2012). Though they are naturally occurring, circadian rhythms can
be altered and affected by environmental factors. One of the circadian rhythms is the body’s drive for alertness and wakefulness,
which gets higher throughout the daytime hours and decreases
during the night. The circadian sleep-wake cycle, along with the
body’s homeostatic drive for sleep, which increases based on the
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amount of prior wakeful hours, keep the body in a proper rhythm,
maintaining the appropriate amount of necessary sleep (Dijk and
Lockley, 2002).
The necessary amount of sleep in humans varies with age, ranging from 16–18 hours in infancy to 7-8 hours in the average
adult (NINDS, 2014). In the last century, America has seen an
approximate 20% decrease in the amount of sleep it gets. This
has had economic, social, and health consequences. Sleep deficiency has been associated with numerous health risks such
as hypertension, stroke, obesity, and diabetes. Sleep is necessary to support many vital systems in the body, and adequate
sleep is necessary for optimal cognitive performance, without
which many accidents may occur (Institute of Medicine (US)
Committee on Sleep Medicine and Research, 2006).
Parallel to the decrease in sleep, the incidence of obesity in
America has drastically increased. Studies conducted by the
National Health and Nutrition Examination Survey (NHANES)
show that more than one third or 34.9% of adults over age
20 are considered obese. Additionally, of American children and
adolescents ages 2–19, approximately 16.9% are obese (Ogden
et al., 2014). Obesity is a result of excessive weight gain, which
occurs primarily when the energy expenditure of the body is
less than energy intake, resulting in a net gain. Over time, if the
gain continues, the weight accumulates and results in obesity.
Other factors that may cause obesity are environmental factors,
genetics, illnesses, and medications (CDC 2011).
The correlation between sleep deficiency and weight gain has
been examined and many cross sectional and epidemiological
studies found a relationship of sleep deprivation with obesity.
Studies show an association of a higher body mass index (BMI)
in individuals who generally sleep fewer hours than the recommended sleep time. Over all, the studies point at a relationship
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of sleep deprivation to obesity primarily in the pediatric and
young adult population (Beccuti and Pannain, 2011). Though
these results were most evident in the young and middle-aged
population, one study found that there is a greater likelihood
(3.7 times in men and 2.3 times in women) for obesity in older
individuals who sleep less than 5 hours per night (Patel et al.,
2008). Though the data is evident of a correlation between the
two, there are many factors that may contribute to the obesity
and the findings are not entirely conclusive (Patel and Hu, 2008).
This paper will investigate the mechanisms involved in sleep
deprivation that result in weight gain and obesity?

Methods
Information was obtained online with access to many online
publications through the Touro College library. Key words included sleep-deprivation, obesity, weight gain, leptin, ghrelin,
energy expenditure, OSA. Additionally, references made by literature reviews were helpful in conducting research.

Discussion
Many studies have been performed in an effort to establish
the relationship of decreasing sleep with increasing likelihood
of obesity. The studies examine whether the shortened sleep
times have an effect on weight, and via which mechanisms this
may occur. Three commonly discussed factors that may contribute to the weight gain in sleep-deprived individuals are
energy intake (consumption of food), energy expenditure, and
hormonal leptin and ghrelin levels.

Leptin and ghrelin
Leptin and ghrelin are two essential hormones in the maintenance
of the body’s energy balance. These two hormones have opposite effects on the body. Leptin induces a satiety and fullness, and
ghrelin, hunger and appetite. Leptin is primarily released by adipose
tissue into the bloodstream and send the brain signals regarding
the energy state of the body. Leptin signals receptors at the hypothalamus, which affect hypothalamic neurons and various neuropeptides. Leptin is known to have anorexic (appetite suppressing)
effects. Ghrelin, is released primarily by the stomach and signals
the hypothalamus, which thereafter has orexic (appetite inducing)
effects (Klok et al., 2007). Because of the correlation found between sleep and weight gain, it is presumed that perhaps leptin and
ghrelin, which are closely related to food intake and regulation, are
affected by sleep restriction. Studies examine this detail, and show
inconsistent results.
One study that examined the sleep-weight gain relationship was
performed on 12 average men, 22 +/- 2 years of age, and with
average BMIs 23.6+/- 2 kg/m2. The participants did not smoke or
take any medication.They all regularly slept 7 to 9 hours, and they
had not crossed time zones in the last four weeks before the study.

The study consisted of two randomized periods, six weeks apart.
Weight did not change during the time between the two studies.
For the first night of study, participants were given a restricted
diet, while during the day, they ate their regular diets. During the
second day of study, they received a glucose infusion of 5 g/kg/ 24
hours. After both periods of the study- two nights of 10 hours in
bed, and two nights of 4 hours in bed, blood samples were taken
at 20-minute intervals, from 8 am to 9 pm. Results showed that in
the sleep deprived state, leptin levels were 18% lower and ghrelin
levels 28% higher than in the normal sleep state (Spiegel et al.,
2004). These results accounted for the elevated hunger levels in
the sleep-deprived state. Consequently, increased hunger usually causes increased food intake. However, these studies did not
measure exact food intake of the participants, so there is no clear
evidence of the increased energy intake.
Another study performed on 1,024 volunteers in the Wisconsin
Sleep Cohort Study found a decrease in leptin levels with sleep
deprivation. They underwent polysomnography and answered
questionnaires to measure sleep. In the sleep-deprived state, (5
hours versus 8) a morning blood test showed a 15.5% decrease
in leptin and 14.9% higher ghrelin levels (Taheri et al., 2004).
Consistent with the findings by Spiegel et al. these results can likely
cause increase in hunger and food intake, leading to weight gain.
Though these results show a clear effect of sleep on leptin and
ghrelin, not all studies yielded such results. Numerous reasons
may be responsible for the discrepancy in the results. One
reason might be that in the study by Spiegel et al., the blood
samples were taken after participants underwent constant glucose infusion, which could perhaps yield results that differ from
those of a regular food diet.
Another study was in search of a relationship of partial sleep
deprivation to weight gain and insulin sensitivity in women. It
was performed on 14 healthy women, age 23-38, who were
weight stable, with no recent illness, non- smoking, non-lactating, and not on any medication besides oral contraceptives.
They were all in the follicular phase of the menstrual cycle,
slept 7.5 to 9 hours on an average night, did not cross time
zones in last month, and had no sleep complaints. Participants
were studied after 2 nights of 8 hours of sleep, after 4 nights
of consistent decrease in sleep (minus one additional hour
nightly) and then 2 nights of recovery sleep. Food was not restricted, though alcohol was. Their diet was carefully recorded
using computer software. After performing a glucose tolerance test, blood was collected in 15-minute intervals for 90
minutes. Leptin levels showed a 24% increase after 2 nights of
approximately 5.5 hours in bed versus 9 hours in bed. Ghrelin
levels were stable. This may be due to the extra caloric intake
during those days of study, as will be discussed below. Insulin
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sensitivity did not appear to be affected by sleep restriction
(Bosy-Westphal et al., 2008).
Numerous other studies also yielded results that were inconsistent with each other. Certain studies show increase in leptin, others
show a decrease, while others do not show any significant change.
One study was performed on eleven people, men and women,
with an average BMI of 26.5, for two two-week periods in random order. In the restricted sleep they slept 5.5 hours, compared to 8.5 hours in the habitual sleep. They had an unrestricted diet throughout the study. The results showed that in the
sleep deprived state, leptin and ghrelin levels were not affected
significantly. These results show that perhaps in response to
sleep loss, the body may have an altered response to restricted
food, and the hormonal levels remain more stable than in the
body’s usual state. This would account for the stable leptin and
ghrelin levels across the two periods of study (Nedeltcheva et
al., 2009).
One other study observed that in nine average weight men
after one night of normal sleep, one of partial sleep restriction
and one total sleep deprivation, leptin levels did not show a
significant change, while ghrelin levels were 22% higher in total
sleep deprivation than in normal sleep (Schmid et al., 2008).
Clearly, many studies yield conflicting results on the effect of
sleep on leptin and ghrelin. Two studies we discussed show entirely opposite results (Spiegel et al. 2004 and Bosy-Westphal
et al., 2008). Why are the observations to the various studies
inconsistent?
Perhaps it is the fact that certain factors were sometimes
unaccounted for in these particular studies, such as genetics,
individual’s environment, race, and height (Spiegel et al., 2004).
Additionally not all of the studies measured and accounted for
precise weight of the participants, which is perhaps necessary
to determine the effect of one factor on another. Additionally,
as mentioned above, the diets of the participants in the studies
were not consistent with each other, which may have had an
effect on the body’s endocrine response.
The inconsistent results of the many studies suggest that the
leptin and ghrelin levels may or may not change and contribute to weight gain in response to sleep restriction. However,
even studies that do not show a direct change in leptin and
ghrelin, do show greater caloric intake, likely due to hunger and
increased opportunity to eat.
The effect that sleep has on energy expenditure must also
be taken into account. Intuitively, in the sleep-deprived state,
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because of fatigue, energy expenditure should decrease.
However, studies show that a sleep deprived individual experiences extra wakeful hours during which he/she is burning
more calories than if he/she had been sleeping. However, because during those wakeful hours the individual is likely fatigued,
activity levels are lower than regular wakeful hours. Therefore,
the overall energy expenditure in the sleep-deprived state may
increase only slightly.

Energy intake versus expenditure
To maintain weight one must be in energy balance, when energy consumed is equal to energy expended. Weight gain occurs
when the body is in positive energy balance, when the person
takes in more calories than they burn. Perhaps even without
an observed hormonal change, the body reacts to sleep deprivation with increased hunger, and thus increased caloric intake.
Sleep may also have an effect on metabolism and energy expenditure? Many of the studies mentioned above, searched for
the effect of sleep deficiency on hunger levels, energy intake,
and energy expenditure, in addition to its role in leptin and
ghrelin levels.
According to Spiegel et al. participants recorded their hunger
levels after both periods of the study- restricted and normal
sleep times- by answering how hungry they felt at every hour
from 9 am to 9 pm, after the second night of sleep. They were
also asked to describe their appetite, answering how much
they would like to eat 7 different foods (sweet, salty, starchy,
fruits, vegetables, meat, dairy etc.) Results showed that consistent with the decreased leptin and elevated ghrelin levels
found in this study, 24% higher hunger levels were found, as
well as 23% higher appetite levels, in the sleep deprived state.
The appetite increase was highest for calorie and carbohydrate dense foods. Increased appetite for protein rich foods
was not significantly increased in sleep-deprived state (Spiegel
et al., 2004).The study by Schmid et al. also showed an increase
in average hunger ratings of 3.9 after total sleep deprivation
as opposed to 1.7 after a 7-hour time in bed, consistent with
increased ghrelin (Schmid et al., 2008).
Presumably, the increase in hunger accounts for greater caloric intake in sleep-deprived individuals, causing weight gain.
However, in the studies by Spiegel et al. (2004) and Schmid
et al. (2008), exact caloric intake during the study periods
was not measured, and thus we cannot necessarily assume
that there was extra consumption of calories or how many.
Additionally, during the study periods, activity levels were kept
low (reclining, sitting etc.), and they did not examine whether or not there is a change in energy expenditure or energy
balance. Without this information we cannot determine if
there would be a theoretical net weight gain. To examine these
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details, further study on energy expenditure is needed.
Energy expenditure can be measured using indirect calorimetry,
metabolic chambers, heart rate and other methods. Indirect calorimetry and metabolic chambers measure the level of carbon
dioxide production to assess energy expenditure.
In the study by Bosy-Westphal et al. careful measurement of caloric intake was measured during the entire study via computer.
Resting energy expenditure was measured using indirect calorimetry, and total energy expenditure was measured using 24hour heart rate monitoring. Physical activity was also measured
with pedometers. Energy intake significantly increased from
baseline to sleep deprived state, while energy expenditure did
not show a significant change. The average increase in calories
was 415 +/- 471 kcal/day, and caused a net weight gain (BosyWestphal et al., 2008). Because there was no change in energy expenditure seen, we can assume that in prolonged sleep
deprivation the individuals would experience significant weight
gain. This provides further evidence that sleep deprivation causes an increase in caloric intake and body weight, despite the
fact that there was no significant endocrine response to sleep
deprivation.
However, the study did observe a change in thyroid hormone
levels, so further research is required to examine more specific results of the effect sleep restriction may have on energy expenditure, such as measuring total energy expenditure
using a caloric chamber (Bosy-Westphal et al., 2008).
This leads us to another study that did indeed measure specific total energy expenditure, using a caloric chamber. The
study shows a significant increase in energy expenditure in
the sleep-deprived state due to the extra hours of time spent
awake. Ten women, with average BMIs were studied under
shortened sleep and habitual sleep, 4 and 8 hours, 3 days
of each, while kept on a strictly controlled diet. The results
showed significantly greater energy expenditure of approximately 92 kcal in the shortened sleep period. This study
provides evidence that there may be an increase in energy
expenditure in the sleep deprived state, however, there is an
overcompensation of energy intake, which leads to weight
gain (Shechter et al., 2013).
Another study that measured energy intake versus expenditure found that with unlimited food allowance, the participants did not consume a significant amount of extra calories during meals, however, they did increase their intake of
snack calories between the hours of 7pm-7am, with more
carbohydrates and less protein/fat snacks (Nedeltcheva et al.,
2009). The fact that the increase was only significant between

7pm-7am, not 7am-7pm, highlights the fact that during the
nighttime hours when sleep is restricted participants found
time to consume significantly more snacks, leading to an increase in daily calories.
When one is sleep deprived and awake during nighttime
hours, not only is there elevated hunger during the day, but
there is also increased opportunity to eat during the extra
hours spent awake. More so, the nature of nighttime eating
is snacking, which can cause unintentional excessive caloric
intake.
The total energy intake was 297 kcal more in sleep-deprived
state. Additionally, during both sleep deprived and habitual sleep state, there was a surplus of calories, due to the
participants’ eating habits. Some individuals had a greater
‘propensity’ to eat, while others not .The study also found a
slight change in energy expenditure between the two sleep
states. The difference, which they considered insignificant, was
136 +/- 437 kcal more per day in the restricted sleep period
(Nedeltcheva et al., 2009). Even if the change in total energy
expenditure was considered significant, there is a surplus of
an average 160 kcal per day in the sleep-deprived state. If
we were to apply this information to a general population
one can assume that the overcompensation in calories would
cause weight gain in individuals who are consistently sleep
deprived.
Perhaps if participants were more active, the studies would
find a significant increase in energy expenditure, and there
would no longer be the overcompensation of calories.
However, because of fatigue and sleepiness, activity levels
should presumably be lower when one is sleep-deprived.
Studies show that the activity levels of sleep-deprived individual are indeed lower.
Another study involved 30 men and women, ages 30-49, and
with BMIs between 22-26. No shift workers, or individuals
that had travelled across time zones within 4 weeks of the
study were allowed. Smokers, diabetics, those with excessive
caffeine intake, or neurologic issues were also disqualified.
The study was divided into two stages of 6 days each. In the
shortened and normal sleep stages, the participants were
given 4 hours in bed and 9 hours in bed, respectively, with no
naps during the day. They measured sleep by polysomnography. For the first 4 days of each period, their food intake was
allotted and strictly measured. The last two days were also
carefully measured, but participants were allowed to make
their own food choices. On day 4 they were asked how they
would rate their hunger, how full they felt, how energetic, how
much they could eat, and how much they would like to eat

19

Chaya Rosen

foods that were sweet, salty, savory etc. After measuring the
energy intake and expenditure, results showed that women
consumed 15.3% more in the restricted sleep period, with a
39% increase in fats. Men consumed 9.2% more. Additionally
they ate more often in the sleep-restricted stage. While they
consumed more, no significant change in energy expenditure
was found, though the point of peak activity observed was
higher in the normal sleep period. In the normal sleep period,
participants spent a greater percentage in sedentary activity,
a lesser percentage in light activity, and a significantly greater
percentage of time doing heavy activity, than in the restricted sleep period. Overall the study showed greater feelings
of sluggishness and less energy during the shortened sleep
period and there was no significant change in total energy expenditure over the course of the study (St.-Onge et al., 2011).
This is intuitive, as a sleep-deprived individual is tired and consequently has less energy for intense activity. Low intensity
activity leads to less energy expenditure, and opportunity for
more weight gain.
Surprisingly, there was no net change in energy balance observed, after controlling for phase order and gender. However,
like Nedeltcheva et al., this study showed an increase of approximately 300 kcal per day in the shortened sleep period. Due
to the fact that they are primarily due to the increase in fat
and saturated fat calories, the people would also be at risk for
cardiovascular disease (St-Onge et al., 2011).
Even though, unlike previous studies, this study did not show
a significant effect on participants hunger ratings, there was an
observed increase in energy intake. This suggests that the relationship of sleep deprivation and obesity is one primarily based
on excessive food intake. The continuous surplus of calories in
the sleep-deprived state may eventually lead to obesity, if not
coupled with an increase in energy expenditure (St-Onge et
al., 2011).

Obstructive Sleep Apnea
There is reason to believe that perhaps the relationship of poor
sleep and obesity is a reverse process. The cross sectional data
showing a relationship between obesity and sleep deprivation
may be due to the fact that as a result of being overweight, obese
individuals experience shortened sleep, with poorer quality.This
is indeed true in the case of Obstructive Sleep Apnea (OSA).
Obese people are twice as likely to experience Obstructive
Sleep Apnea, a significantly higher risk, than average weight individuals. OSA occurs in approximately 45% of obese individuals.
Additionally, their risk for OSA is increased six times, if they
gain even 10% of their normal (baseline) weight. On the other
hand, the OSA can show an improvement with weight loss of

20

the same amount. One reason that obesity increases the risk
for OSA is that fat situated in the upper airways can cause an
increase in the collapsibility of the airway, and increase the risk
for apnea. A patient with sleep apnea has interrupted sleep and
decreased sleep quality. This leads to sleep deprivation, and the
sleep deprivation leads to additional weight gain. The process is
cyclical. An obese individual is at risk for OSA. OSA causes sleep
deprivation and an increased risk for weight gain. The weight
gain causes further worsening of OSA symptoms. Studies propose that weight loss can effectively help the obesity, as well as
help improve symptoms of OSA (Romero-Corral et al., 2010).
In light of the above, we can say that the relationship between
sleep deprivation and obesity is indeed cyclical. However, as our
discussion shows, even amongst the average weight population,
individuals who are sleep deprived tend to increase energy intake and gain weight.

Further Research
Though studies have established correlation of the above factors,
further research would be helpful to provide more conclusive
evidence of the mechanisms involved in sleep deprivation that
cause obesity. Discrepancies amongst the studies may be due to
environmental factors, genetic predisposition, and metabolic differences that vary with each individual participant. Additionally
as mentioned above, participants each have varying propensity
to eat more, and gain or lose weight, independent of sleeping
habits. Furthermore, the studies discussed were performed
on relatively small samples of people. Additional studies with a
greater number of participants, and in a broader population of
ages could perhaps provide more conclusive results. Moreover,
perhaps there is a way to study populations in a free-living environment, rather than in a lab setting, and assess under those
circumstances, which mechanisms resulting from sleep deprivation lead to the development of obesity.

Conclusion
Obesity is an epidemic that has many economic, social, and
health costs. The effects it has on health and healthcare costs
are tremendous. Obesity not only requires treatment itself, but
it also leads to many health problems such as cardiovascular
disease, hypertension, type two diabetes, stroke, osteoarthritis,
gallstones, certain types of cancer, fertility problems in women,
as well as other health issues (Kopelman, 2007).
Studies show that if the growing obesity epidemic continues,
86.3% of American adults will be overweight or obese, with
51.1% obesity by year 2030. This could lead to health care
costs projected at 860.7-956.9 billion dollars (Wang et al.,
2008). Obesity also has many social costs, amongst adults and
children alike. Obese people may experience limitations on
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physical activity, and there are stigmas associated with being
heavily overweight that may cause obese people to be treated
differently in the workplace and social forums (Seidell, 1998). In
light of the above, if sleep deprivation has a role in the growing
obese population, not only is intervention necessary to treat
obesity and its side effects, but there must also be intervention
to counsel people regarding positive sleeping habits. Beginning
with school aged children, they must be educated regarding the
benefits of getting enough sleep. Parents should try to assist
children in creating healthy sleeping habits. Adults should be
careful to try to generally maintain a proper sleep schedule,
when social and work responsibilities do not demand late bed
times. Overall, a greater awareness must be made to the public
that sleep deprivation has serious negative side effects.
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Abstract
MDMA (3, 4-methylenedioxymethamphetamine) is an illicit, recreational drug known by many individuals as ‘Ecstasy.’
MDMA has gained popularity over the past decade and has become a drug of choice at dance parties and clubs because
of the stimulating and hallucinogenic effects that it has on the central nervous system. Scientists have determined that
MDMA causes neurotoxic damage to adults by harming the serotonergic system in the adult brain. Researchers discovered that embryos exposed to MDMA while in utero also suffer neurotoxic deficits, although not due to impairments in
the embryos’ serotonergic systems. These deficits arise because of the cortisol increase that is found in adults after ingestion of MDMA, which can be transmitted to a developing fetus and thereby lead to a reprogramming of the hypothalamic-pituitary-adrenal axis in the fetus. In addition, MDMA can ca use changes in the norepinephrine and/or dopamine
systems in a developing fetus and thus create lasting neurological damage. MDMA-induced elevation of Atg5, a protein
involved in autophagy, leads to teratogenesis in a developing fetus by inhibiting neuronal growth and differentiation. In
another vein, 3, 4-Dihydroxymethamphetamine (HHMA) and malondialdehyde (MDA), two main metabolites of MDMA,
have toxic effects on an embryo and are another mechanism via which Ecstasy can cause impairments in the fetal brain.
While these and other hypotheses are currently under much investigation, scientists are approaching this topic with the
understanding that it is most probably an interplay of many biological changes that result from fetal exposure to MDMA
that together create the neurological defects observed in these fetuses. The various aspects of MDMA and the damage
it can have on a fetus have been researched by the author using the Touro database and various links to journals and
articles that this database provided.
Introduction
MDMA, known scientifically as 3, 4-methylenedioxymethamphetamine, is an amphetamine derivative drug increasing in
popularity amongst teenagers and young adults (Broening, et al.,
2001). Amphetamines are a class of molecules that have stimulating effects on the central nervous system (CNS). MDMA is
known by recreational users as ‘Ecstasy’ because it has stimulating and hallucinogenic effects on the CNS while engendering immediate feelings of ecstasy and openness upon ingestion
(Singer, et al., 2012).
Studies show that adults taking MDMA have a decrease in serotonin (5-HT) in the brain, a reduction in 5-hydroxyindoleacetic
acid (5-HIAA), a main metabolite of serotonin, and a reduction
in tryptophan hydroxylase (TPH), an enzyme involved in the
synthesis of serotonin (Broening, et al., 2001). This serotonergic
reduction is harmful to the exposed adult. Interestingly, though
the effects of MDMA on adults have been well researched, few
studies have been conducted on the effects of MDMA on prenatally exposed children and on the reasons for these effects.
Due to its popularity amongst teenagers and young adults, it
has become increasingly prevalent to find developing fetuses
exposed to MDMA while in utero. Scientists are determining
the long term neurological effects of Ecstasy-exposed fetuses by
conducting post parturition studies on both rats and children
that have been prenatally exposed to MDMA. Some long term
neurotoxic effects include sequential and spatial learning delays
(Broening, et al., 2001) milestone delays at 4 months of age, and
poorer mental development index scorings at 12 months of age
(Singer, et al., 2012). The question stands as to why these and

other neurotoxic effects develop in both rats and children that
have been exposed to MDMA in utero. Scientists are hypothesizing numerous reasons for these effects, including serotonin
(5-HT) reduction (Broening, et al., 2001), elevated levels of cortisol (Parrott, et al., 2014), changes in the norepinephrine (NE)
system (Thompson, et al., 2011) and in the dopamine (DA) system (Thompson, et al., 2009), an increase in autophagy protein
5 (Atg5) (Chae, et al., 2009), and embryotoxicity due to MDMA
metabolites (Barenys, et al., 2012). This paper explores various
venues theorized to be the cause of the cognitive and neuronal
impairment observed in Ecstasy-exposed fetuses.

Methods
Research on the topic of the biological reasons for the neurotoxic effects of MDMA on the developing fetus was compiled
from various sources found in the Touro database. Information
was obtained regarding general usage of MDMA as well as
the observations noted in children of women who ingested
MDMA while pregnant. Finally, data about various experiments
performed on rats was obtained in order to gain insight into
possible biological causes for the neurotoxic deficits noted in
MDMA exposed fetuses. The information was arranged into a
comprehensive order and edited by the author.

Discussion
One strong hypothesis as to how Ecstasy induces long term
brain damage in a fetus is that MDMA-exposed fetuses are
harmed due to a decrease in 5-HT in the brain. This hypothesis
is based on the established fact that MDMA causes serotonergic
reductions in the adult brain. In a study done on Sprague-Dawley
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rats, researchers in the University Of Cincinnati College Of
Medicine sought to determine whether the effects of MDMA
on exposed fetuses are indeed caused by a 5-HT reduction.
Sprague Dawley rats were mated and their litters were reduced
to 8 pups, 4 males and 4 females, with parturition day termed P0.
The rats were divided into 2 groups. One group received two
subcutaneous injections of MDMA daily on P1-P10 while the
second group received similar MDMA injections on P11-P20.
These intervals of P1-P10 and P11-P20 correspond to early and
late third trimester development in humans, respectively.
Between P60 and P80, the rats were tested in various assigns.
The results of the tests illustrated that the rats in the P11-P20
group had significant decreases in sequential learning, spatial
learning, and memory abilities, while those in the P1-P10 group
did not show significant decreases in any of these areas. Neither
group showed a significant decrease in cued learning. These
tests demonstrate that the neurotoxic effects that MDMA has
on a developing fetus are more likely to occur when MDMA is
taken during late third trimester development and that these
effects are long term, as seen from the presence of the impairments in rats that had already reached adulthood.
The researchers sought to determine whether these cognitive
impairments in the rats were due to serotonergic decreases
in the rat brains. In order to investigate this hypothesis, the
rats were decapitated on P105 and their brains were dissected.
Reductions in 5-HT in the hippocampus were found for both
the P1-P10 and P11-P20 groups, findings that do not correlate
with the cognitive impairments seen only in the P11-P20 groups.
In addition, the frontal cortex of the rats displayed 5-HT reductions only in the P11-P20 group, but these reductions were insignificant as seen with a correlation coefficient between these
reductions and the spatial learning deficits exhibited by the rats
that did not approach significance. Therefore, while this study
shows that MDMA has long term negative effects on spatial
and sequential learning and memory, it also illustrates that these
cognitive deficits are not due to serotonergic reductions. The
cause of fetal brain damage by MDMA must be via a mechanism
other than the 5-HT reduction that causes MDMA induced
damage in the adult brain (Broening, et al., 2001).
This idea that prenatal MDMA exposure and the long term
damage that it causes is not due to 5-HT reduction can be supported by the mechanism via which MDMA causes 5-HT reduction in the adult brain. Studies indicate that MDMA metabolites
form free radicals upon further metabolism and thereby damage serotonergic neurons. This is supported by the presence
of malondialdehyde in rat brains after exposure to MDMA.
Malondialdehyde is an end product of lipid peroxidation, the
process during which lipids in cell membranes are broken down
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via free radicals. Because free radicals are hard to measure due
to their short half-lives, the by-products of these radicals known
as TBARS (thiobarbituric acid reacting substances) are used to
measure the damage induced by the free radicals. The TBARS
Assay is a test that reacts thiobarbituric acid with malondialdehyde in order to quantify the amount of free radicals found
in a specimen. This reaction yields a florescent product that
indicates the presence of free radicals. Thus, a high yield of
malondialdehyde from a TBARS Assay found in adult rats exposed to MDMA indicates the presence of free radicals in these
rats. Another indication of the presence of free radicals in rats
exposed to MDMA is that 5-HT reduction is prevented from
occurring in MDMA-exposed rats that are injected with alphaphenyl-N-tert-butyl nitrone (PBN), a free radical scavenger. This
indicates that the 5-HT reduction occurring in adult rats may
be happening in part because of free radicals. A study exposing
both neonate and adult rats to MDMA showed no significant
increase in the presence of malondialdehyde in the hippocampus and cortex of the neonate rats while the adults’ brain cortices did demonstrate a significant increase in malondialdehyde
(Figure 1). Free radicals cause the serotonergic reduction in
adult rats, and it can be inferred that cognitive defects found
in adult humans exposed to MDMA are caused by this 5-HT

Figure 1

Figure 1 - Formation of thiobarbituric acid reacting substances
(TBARS) in the hippocampus and cortex of adult rats and cortex of
neonate rats 3 h (hatched columns) and 6 h (cross-hatched columns)
after MDMA (40 mg kg71, i.p.) administration. Results show %
change in brain malondialdehyde (MDA) formation compared to
saline-injected control animals (open columns), as mean+s.e.mean,
n=8± 10. *Significantly different from saline (Colado, et al., 1997).
reduction. In contrast, neonatal rats and, by inference, humans
prenatally exposed to MDMA, have cognitive impairments that
cannot be attributed to 5-HT reductions (Colado, et al., 1997).
Other factors must be explored to lend reason for these long
term neurotoxic effects.
Another possible cause for the cognitive deficits recognized
in children prenatally exposed to MDMA is elevated levels of
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cortisol caused by ingestion of Ecstasy. As noted, MDMA has
been shown to cause impairments in long term memory, learning, and locomotor activity in children exposed to this drug in
utero. Researchers hypothesize that these impairments may be
due to the increase in cortisol that is present. Individuals ingesting Ecstasy display higher levels of cortisol in comparison
to drug-free individuals with baseline cortisol levels. In addition,
increased cortisol levels may be damaging to fetal development.
Therefore, if the Ecstasy user is a pregnant woman, her MDMA
usage may put her fetus at risk (Parrott, et al., 2014).
Cortisol is a glucocorticoid steroid hormone produced by the
adrenal cortex in response to bodily stress and/or low blood
glucose levels. The body releases this hormone in order to provide additional metabolic resources that enable an individual to
function properly while under stress. The hypothalamic- pituitary-adrenal (HPA) axis is a systemic interaction of endocrine
glands that utilize a negative feedback mechanism in order to
control the hormonal activities of the adrenal cortices (Mosby’s
Medical Dictionary, 2009).
In a recent study performed on MDMA users, light usage of
MDMA (ingestion of MDMA 1-4 times within the past 3
months) led to a mean increase of 50% in cortisol levels, in contrast with a control group of MDMA-free individuals. Heavier
Ecstasy users (ingestion of MDMA 5+ times within the past 3
months) were noted to have a mean increase of 400% in their
cortisol levels in comparison with a control group. While these
statistics definitely illustrate radical increases in cortisol levels
in MDMA users, a 10% increase of maternal cortisol leads to a
mere 1% increase in fetal cortisol. This is due to the placental
glucocorticoid barrier that prevents most of the cortisol from
reaching the fetus. However, while a small increase in maternal
cortisol levels may not cause damage to a fetus, a 400% increase
in maternal cortisol can possibly have long term deleterious effects on the child.
According to the scientific review by Parrott, et al.(2014), “…
HPA basal hyperactivation…may represent a complex neuroendocrine dysfunction associated with MDMA use.” They imply
that elevated cortisol levels caused by MDMA ingestion may
lead to HPA axis impairments, specifically in a developing fetus.
This idea is supported by a study on the effects of maternal
stress on a fetus, because researchers have found that similar
to ingestion of MDMA, an increase in a mother’s stress level
causes more cortisol to be produced, and this hormone is then
passed to the fetus via the placenta. As noted, although most
of the cortisol is prevented from reaching the fetus due to the
placental glucocorticoid barrier, about 1/10th of the cortisol
will still reach the fetus. This hormone may then reprogram the
HPA axis activity of the developing fetus which can cause long

term damaging effects on the child. Studies illustrate that the
negative effects of stress on the developing fetus include poorer
attention spans, sleeping, feeding, and activity problems, greater impulsivity, and a higher pervasiveness of Attention Deficit
Hyperactivity Disorder (ADHD). Because ingestion of MDMA
causes an increase in cortisol in the same way that maternal
stress does and because cortisol has been shown to cross the
placental barrier, researchers infer that it is the elevated cortisol
levels found in MDMA users that are responsible for the neurotoxic deficits found in Ecstasy-exposed fetuses and that the
long term effects of MDMA may mirror the effects of maternal
stress on a fetus.
It is interesting to note that increased cortisol levels can be seen
in an individual for up to 3 months after he/she has stopped
using MDMA. Thus, it follows that a woman who stops MDMA
usage prior to pregnancy may still be liable to inflict lasting
damage to her fetus unless she has had several months of drug
abstinence prior to conception (Parrott, et al., 2014).
A study researching the connection between elevated cortisol
levels and memory problems supports the idea that elevated
cortisol levels may be the cause of long term damage in MDMAexposed fetuses, specifically in the area of memory impairment.
Researchers tested healthy individuals with a mean age of 61.8
years to determine if memory problems are linked to elevated
cortisol levels. This study used a special testing method in order
to control for any stress that would develop in the subjects
because of the inherent knowledge of their memory loss. The
study demonstrated that women with memory complaints
had significantly higher levels of cortisol than women without
memory complaints, although no such difference was seen in
men. In addition, individuals who complained of memory issues
also had increased activity of their HPA axes (Wolf, et al., 2004).
Similar to the adults in this study, fetuses exposed to MDMA
also had elevated cortisol levels and hyperactivity of their HPA
axes (Parrott, et al., 2014). In a similar vein, a study performed
on cocaine dependent individuals served to analyze the cause
for the learning and memory dysfunctions observed in these
drug addicts. Researchers determined that cocaine dependent
individuals have higher levels of cortisol than individuals in a
‘cocaine-free’ control group, and this increase was associated
with the poorer learning and memory skills observed in these
individuals (Fox, et al., 2009).Thus, it can be inferred that the
memory impairments noted in children prenatally exposed to
MDMA may be caused by the elevated cortisol levels that these
fetuses are exposed to.
Another hormone that may be linked to the damage induced
by MDMA in the developing fetus is norepinephrine (NE). NE
is a noradrenergic hormone and neurotransmitter made from
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dopamine (DA) by the enzyme dopamine beta hydroxylase
(DBH). It is released from the adrenal medulla into the bloodstream and acts as a systemic hormone, and it is also released
from noradrenergic neurons in the locus ceruleus of the brain
where it acts as a neurotransmitter. Scientists have found that
a correlation exists between prenatal exposure to MDMA in
rats and changes in the structure and function of the NE system in these prenatally exposed rats. NE system dysfunction
has been associated with exaggerated behavioral responses to
new stimuli as well as a decrease in habituation to these stimuli, impairments which are attributed to attentional processing
deficits. Because researchers have observed these behaviors in
prenatally exposed rats, they infer that the damage induced by
MDMA exposure to a developing fetus may be linked to abnormal wiring of the fetus’s NE system (Thompson, et al., 2011).
In order to test this hypothesis, pregnant Sprague-Dawley rats
were randomly assigned to two groups. One group was injected
with 15mg/kg of MDMA twice a day at 8 hour intervals, a dose
consistent with the typical MDMA dosage taken for human
consumption, while the other group received subcutaneous
injections of saline two times a day at corresponding 8 hour
intervals. These injections were administered from embryonic
day 14 (E14) to embryonic day 21 (E21).The pups were born on
E21 and the first day after parturition was termed postnatal day
1 (P1).The litters were reduced to 4 males and 4 females for the
MDMA group and 5 males and 5 females for the saline group.
The pups were anesthetized on P21 and their brains were removed and cut into specific sections for observational analysis.
Among the different areas of the brain that were analyzed, three
sections of the rostral hippocampus, CA1, CA2, and CA3, were
scrutinized for NE abnormalities. This section of the brain was
studied because it is receives noradrenergic innervation from
the locus ceruleus and because it is involved in spatial memory
and responses to novelty, abilities that have been found lacking in MDMA exposed fetuses. The rats prenatally exposed to
MDMA exhibited a 32.1% increase in DBH fiber density in the
CA1 region of the hippocampus in comparison with the control
group. In addition, norepinephrine transporter (NET), a molecule that regulates NE signaling by clearing NE from the synaptic
cleft, increased in MDMA rats by 39.3% in the CA1 region and
32.1% in the CA3 region. In spite of these increases, the rostral
hippocampus displayed no elevation in NE levels and levels of
3-methoxy-4-hydroxyphenolglycol (MHPG), a main metabolite
of NE. The locus ceruleus displayed no increase in DBH fibers,
and NET binding did not increase in this area. However, in the
prelimbic (Cg3) region of the prefrontal cortex, there was a
69.2% increase in DBH neurites. This was accompanied by a
15% increase in NE in the prefrontal cortex as a whole, although
there was no increase in NET binding or MHPG levels in the
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prefrontal cortex.
These findings suggest that MDMA can cause NE system dysfunction in the developing fetus. As an example, the increase
in NET binding observed in the CA1 and CA3 regions of the
hippocampus illustrate that MDMA caused more NE to continue to be present in these areas even after exposure, or that
the high levels of NE found in the hippocampus during MDMA
exposure led to a sustained increase in NET binding in these
areas as a form of systemic regulation. Because NE in the CA1
region of the hippocampus plays a big role in communication
signaling between the hippocampus and entorhinal cortex, NE
abnormalities in this region may lead to communication deficits
which in turn may lead to impairments in spatial learning and
working memory. In fact, as illustrated in other studies previously mentioned, these deficits have been found in rats exposed to MDMA while in utero. Also, as mentioned previously,
NE increases have been related to exaggerated responses to
novelty and attentional processing impairments. These deficits
also correlate with a study that observed that rats exposed to
MDMA while in utero had increased levels of responsivity to a
new cage at P21, an increase that persisted into adulthood as
far as P61-P62. Therefore, it can be theorized that NE system
changes caused by rat embryonic exposure to MDMA, and, by
inference, NE system changes caused by human fetal exposure
to MDMA, lead to many of the impairments observed in children prenatally exposed to MDMA. Changes in the noradrenergic system that develop in the fetus as a result of MDMA exposure have direct links to the deficits noted in these children
post-parturition.
It is worth mentioning that the results of the MDMA exposure
are noted on P21, and that this corresponds to the early teenage years in humans.Thus, NE system changes and the resulting
impairments can be effective in this time period. These systemic deficits may be the cause of the impulsivity and ‘search for
novelty’ that is present amongst many young adults that often
leads to substance abuse or reckless behavior (Thompson, et
al., 2011). Perhaps the mothers ingesting MDMA while pregnant are unknowingly setting the stage for substance abuse in
their children many years down the line.
In a similar study, scientists determined that fetal rat exposure
to MDMA affects the fetus’s dopamine (DA) system. These effects can be seen by a five-fold increase in dopamine neuron
fibers in the prefrontal cortex of the rat brain as well as by
smaller increases in DA fiber density in the striatum and nucleus accumbens of rats exposed to MDMA while in utero.
DA has many pathways in the brain, one of which is the mesocortical tract, a pathway that transports DA from the ventral
tegmentum to the frontal cortex. The pathway is known to
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influence exploratory behaviors, impulsivity, and a search for
novelty. When this system is impaired, the results can cause hyperactivity and are sometimes linked to behavioral issues such
as ADHD. Because changes in the DA system of both humans
and rats is associated with decreased habituation to novelty
and increased locomotor activity, this study sought to discover
whether the changes in the DA system noted in the rats exposed to MDMA could be correlated with significant changes
in these particular behavioral areas (Thompson, et al., 2010).
The study tested Sprague Dawley rats that were injected with
MDMA on embryonic day 14-20, as well as a group of ‘control’
rats, and measured their behavior on postnatal day 21. Many

packaging unneeded cytoplasm and organelles into vesicles
known as autophagosomes in preparation for degradation
so that the cell can recycle these particles. After an isolation
membrane elongates and surrounds unneeded cellular particles, an autophagosome is formed which fuses with a lysosome,
eventually leading to the catalytic breakdown of the extraneous
cellular particles. Seven proteins known as autophagy-related
proteins regulate this process. These proteins are grouped into
two distinct categories – the Atg12 system (comprised of Atg
5, 7, 10, and 12) which involves regulating the elongation of
the autophagosome isolation membrane, and the Atg8 system
(comprised of Atg 3,4,7, and 8), a system involved in regulating
the attachment of the phospholipids in the autophagosome

Figure 2

This diagram illustrates images of fetal brain development of various rat embryos that received specific doses of MDMA on gestational
day 8.5. Note how the teratogenic effects pointed out by the arrows are in concordance with the higher dosages of MDMA (Chae, et
al.,2009)
behavioral areas such as home cage locomotor activity, running
wheel activity, gravitation towards a high fat diet, and cocaine
self-administration levels where tested. However, the only areas
of behavior that had significant results in comparison with the
control group were the rats’ decreased acclimation to new
environments, increased perseverance to find a cued platform,
and increased locomotion in the center of an open field which
served as an indication of the rats’ decreased levels of anxiety. Thus, the researchers hypothesized that the rats exposed
to MDMA in utero had alterations in their dopamine systems,
specifically in the mesocortical pathway. They conjectured that
a possible cause for the decreased habituation to novelty and
increased perseverance seen in the rats was caused by impairments that the MDMA wreaked on the fetal rats’ developing
DA systems (Thompson, et al., 2010).
Another study researching deficits found in fetuses exposed
to MDMA explores impairments in neuronal differentiation
that arise due to an increase in an autophagy-related protein
5 (Atg5). Autophagy is an intracellular process that involves

membrane (Chae, et al., 2009).
Defects in the autophagy system have been linked to various
physiological impairments. In this study, researchers discovered
that rats embryos injected with MDMA had elevated levels of
Atg5.The study explanted rat embryos after 8.5 days of gestation
and administered dos es of 2.5, 5, and 10 micrograms of MDMA
to the embryos.When the embryonic mRNA was sampled, it was
noted that Atg5 expression had doubled after 48 hours of MDMA
exposure and that extreme teratogenesis and fetal brain damage
was observed in the rats (Figure 2). In order to determine if this
brain damage occurred due to impairment of neuronal differentiation, human neuroblastoma SH-SY5Y cells were divided into
two groups, a control group and a group injected with 10 micrograms of MDMA. The group of cells administered with MDMA
illustrated an increase of 1.8 times the amount of Atg5 mRNA
expression after 48 hours. Furthermore, when a sample of SHSY5Y cells was induced with a green florescent protein vector
(GFP), a protein used as a marker of genetic expression, in the
presence of a plasmid encoding for Atg5, the cells did not express
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Figure 3

This figure depicts the SH-SY5Y cells that were induced with GFP
vector and retinoic acid for 5 days.The control group (top row) was
imaged after 5 days while the test group (bottom row) was induced
with Atg5 and also imaged after 5 days. Neurite extension and
arborization is present and can be seen in the control group while no
extension and arborization is present in the test group (Chae, et al.,
2009).
any neurite extensions or arborizations (fine branching at the
end of the neurite fiber). This was in the presence of retinoic
acid, a metabolite of vitamin A that usually aids in growth and
development. In contrast, a control group of SH-SY5Y cells induced with a GFP vector and retinoic acid in the absence of Atg5
exhibited extensive neurite extension and arborization (Figure
3). This demonstrates that an increase in Atg5 impairs neuronal
growth and differentiation.Therefore, because an increase in Atg5
is found to impair the differentiation of SH-SY5Y neuroblastoma
cells, it can be inferred that the teratogenesis observed in rats exposed to MDMA that is accompanied by an increase in Atg5 can
be attributed to a similar mechanism of impairment of neuronal
differentiation (Chae, et al,. 2009).
An additional area that can be explored in order to explain the
neuronal impairments discovered in fetuses exposed to MDMA
is the metabolites that MDMA forms upon ingestion. As stated previously, when MDMA enters the body, it is broken down
into substances that are further metabolized into free radicals.
This is supported by the presence of malondialdehyde (MDA)
in rat brains after exposure to MDMA, because MDA is one of
the end products of lipid peroxidation, a process during which
lipids in cell membranes are broken down via free radicals.
However, MDMA forms other metabolites aside from MDA,
depending on which enzymes are present to break it down.
Therefore, while the formation of the MDA metabolite accounts for the breakdown of 20-90% of MDMA ingested by rats,
3, 4-Dihydroxymethamphetamine (HHMA) is a metabolite of
MDMA that is formed upon human consumption and accounts
for 53-81% of MDMA metabolism in humans. The difference in
MDMA metabolism that results in the formation of MDA or
HHMA is very slight. Ortho-demethylenation of MDMA, which
occurs in humans, leads to the formation of HHMA, while
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Figure 4

Figure 4 - This diagram illustrates the two main metabolic
pathways of MDMA. O-demethylenation produces HHMA and is
the main pathway that occurs in humans while N-demethylation
produces MDA and is the main metabolic pathway that occurs in
rats (Barenys, et al., 2012).
N-demethylation, occurring in rats, leads to the formation of
MDA (Figure 4). MDMA does metabolize into MDA in humans,
as does MDMA metabolize into HHMA in rats, but only trace
amounts of these metabolites are found in humans and rats,
respectively (Barenys, et al., 2012).
Researchers have found that the presence of HHMA or MDA
while a fetus is developing can lead to embryonic defects in the
fetus. Scientists explanted embryos from Sprague Dawley rats
after 9.5 days of gestation and injected various embryos with
MDMA, MDA, and HHMA. The concentrations of the injections
for each substance were 5, 15, 25, and 50 micrograms. They
discovered that the embryos injected with 25 and 50 micrograms of MDMA had a decrease in crown-rump length (CRL), a
measurement of the fetus from the top of the head (crown) to
the bottom of the buttocks (rump). In addition, abnormal tissue
formations, known as dysmorphogeneses, were observed in the
rats injected with 50 micrograms of MDMA. These dysmorphogeneses displayed themselves as an opening in the superior
frontal tissue of the head, termed an open cranial neural pore,
an abnormal prominence in the inferior frontal part of the head,
termed a protuberant nasal placode, and a disproportionately
small forebrain in comparison with the midbrain and hindbrain
(Barenys, et al., 2012).
Similarly, the embryos injected with doses of MDA displayed a
decrease in their CRL after receiving a dose of 50 micrograms
of MDA. These rats also exhibited dysmorphogeneses such as
the posterior part of the embryonic trunk located behind the
embryo instead of in front of it, termed an abnormal flexion,
an abnormal caudal part of the embryo that was marked by a
bend in the distal part of the embryo’s trunk, abnormally shaped
somites, and unusual narrowing of the otic vesicles that represented the formation of irregular ears (Barenys, et al., 2012).
The embryos injected with doses of HHMA also displayed
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similar anomalies. Interestingly, the group of embryos injected
with 50 micrograms of HHMA died upon exposure to this
concentration of metabolite. Therefore, the doses were modified to 10, 20, 30, and 40 micrograms of HHMA per group of
embryos. At both 30 and 40 micrograms of HHMA, the CRL of
the embryos significantly decreased. Additionally, dysmorphogeneses such as abnormal flexion, a protuberant nasal placode,
and an abnormal yolk sac (an anomaly marked by a yolk sac that
was not properly rounded or was missing vasculature) were
noted in the embryos injected with 40 micrograms of HHMA
(Barenys, et al., 2012).
This research indicates that MDMA severely damages a developing fetus due to the toxic metabolites that are formed
upon MDMA ingestion. However, it must be addressed why the
dysmorphogeneses noted in the fetuses exposed to MDMA
differed from those noted in the fetuses exposed to MDA
and HHMA. While some of the abnormalities such as a protuberant nasal placode and decreased CRL were seen in both
the MDMA-exposed embryos and the MDA and/or HHMAexposed embryos, there were anomalies noted in the MDA and
HHMA-exposed embryos that were not found in the MDMAexposed embryos. This presents a problem, because MDA and
HHMA are metabolites of MDMA and therefore, all of the
anomalies found in an embryo exposed to these metabolites
should be found in an embryo exposed to MDMA. Perhaps this
can be explained by the fact that MDMA forms many metabolites upon ingestion, aside from MDA and HHMA. It is possible
that the ‘other’ metabolites of MDMA interact with one another and ‘change’ the irregularities noted in embryos exposed to
MDA or HHMA to represent those seen in embryos exposed
to MDMA.
Additionally, it is worth focusing on the fact that the HHMA
killed the embryos that received injections of 50 micrograms
while this did not occur to the embryos receiving injections
of 50 micrograms of MDA. HHMA is the main metabolite of
MDMA in humans, and this finding suggests that it is more toxic
than MDA, the main metabolite of MDMA that is found in rats.
Because many of the studies available today about MDMA and
its harmful effects have used rats as their method of research,
perhaps humans need to be extra cautious when ingesting
MDMA. This is because the negative effects that MDMA has
been shown to display in rats is probably greater in humans
since HHMA is the main metabolite of MDMA in humans and
appears to be a more toxic metabolite than MDA.

memory, decreased habituation to novelty, poorer mental development index scorings, and other neurological impairments.
While researchers have determined the negative effects that
MDMA has on a fetus, the biological reasons for these effects
are still being researched extensively. Scientists have determined
that these deficits are not due to 5-HT reductions in the brain.
However, these defects may be caused by changes in the fetuses’
cortisol levels, systemic NE or DA changes that are caused by
exposure to MDMA, an increase in Atg5 that leads to inhibition of neuronal growth and differentiation, or the embryotoxic
effects of HHMA and MDA, two main metabolites of MDMA.
These explanations require further research to determine how
they interrelate with one another. Additional studies can investigate the interactions of all of the systemic changes caused by
fetal exposure to MDMA to explore how these interactions
bring about the cognitive deficits noted in MDMA-exposed
fetuses. While this area of research has yet to be explored, individuals should take note that the harmful effects of MDMA have
already been determined with certainty and that consumption
of this drug should be avoided.
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Abstract
Research on humans is limited, therefore human animal chimeras have been used to study human systems. A Human
animal chimera is an animal containing animal and human cell lines. The primary goal of human animal chimera research
is to establish an animal with human cellular characters, which can and should more realistically be able to imitate as
closely as possible the in vivo situations in humans. This research is very important, because it allows scientists to study
human systems in vivo using a humanized animal model. However ethical issues arise when experimenting with humans
and animals being mixed together. Using information found on Touro College’s database, this article reviews studies
done using human animal chimeras, and their potential benefits for therapeutic protocols.
Introduction
A primary goal in biological research is to understand human development, however research on humans in restricted. Although
isolation of human embryonic stem cells (hESCs) and the generation of human induced pluripotent stem cells, have led to more
options in the field of human biology, there is still need to analyze these cells in an in vivo setting. As a result, many researchers
are now turning to human animal chimera research (Hermerén,
2015). The definition of a chimera, suggested by Lensch et al.
(2007), is an organism containing cells from two or more individuals of the same or different species. Behringer (2007) proposed,
that a chimera is an organism with two cell lines, where the individual is “composed of somatic and, in certain cases, germline
tissues derived from more than one zygote.”
There are different types of chimeras, Tetragametic chimeras,
arise in many cases from in vitro fertilization (IVF), a route of
fertilization, in which an egg and sperm are combined in a laboratory dish, and the resulting embryo is then transferred into
the uterus. Because the ensuing embryos were grown in close
contact, Tetragametic chimeras can result (Granzen, R.R, 2014).
Tetragemetic chimeras also occur when twin zygotes fuse together and develop into one body. As a result, the individual’s
tissues are derived from more than one zygote, and contain
two sets of DNA. There have been cases where this happened,
and affected the individual later on in life, when she has her
own child and if a DNA test is done, it might not match up. It
can be her ‘sisters’ genes that she fused with that matches her
children’s. Further testing will prove it’s her child by matching
the same genotype in some parts of her body. A person who has
two different eye colors, can be from the fusion of two zygotes,
among other causes. Consequently, someone born with male
parts and female parts can be male and female early embryos
that merged together (Norton and Zehner, 2008). But here,
chimeras spoken about are human animal chimeras, which are
being studied more by scientists in the hope to discover cures
for diseases, such as Alzheimer’s and Parkinson’s and to develop
vaccines, for example to help fight HIV.
Human animal chimeras have been created by “grafting human
cells and tissues into the embryos, fetuses, or adults of vertebrate
model organisms (Behringer, 2007).” Currently researchers and

scientists are experimenting how the use of chimeras can advance the field of medicine. Scientists are utilizing the unique
ability of stem cells to proliferate and differentiate into various
cells. They are using the idea of stem cell research, but with a
twist. Scientists are injecting human stem cells (hCSs) into animal embryos for the purpose of studying human diseases.When
a fetus is forming, the immune system is not mature enough to
attack anything foreign, therefore modifications can be made
in an embryo. For example, early discovery of an abnormality
can be treated with stem cell administration. The injected cells
can freely proliferate and/or differentiate into new cells, replace
the diseased ones, and regenerate damaged tissue. Although this
concept might sound relatively new, the idea of chimeras are already being practiced today, by using pig heart valves for humans
and using animals for skin grafts (Cooper, 2012).
The study of biological systems in humans is largely regulated to
in vitro models that lack the mechanisms and intricacy of living
organisms. The complexity of a biologic structure can only be
precisely and realistically replicated by an in vivo system. In vivo
studies in laboratory animals are routinely used to model human
biology and disease but they are not human and therefore cannot fully replicate human functioning. Transplanting human cells
into animals provides a way to study human systems in vivo (Sun
et al., 2007). Humanizing an animal, by implanting human blood,
neurons, germ cells and other tissues into it, results in a chimera.
Human animal chimeras, containing animal and human cell lines
have been generated for decades to facilitate human biological
studies and therapeutic strategies for disease (Behringer, 2007).
This paper reviews studies done using human animal chimeras.
Although research with chimeras shows great potential for insight into diseases and medicine, it also raises unique ethical
issues that must be considered. Are the benefits of using human
animal chimeras for therapeutic protocols worth the possible
risks?

Materials and Methods
In order to answer the question proposed above, many research papers and journal articles with relation to this area
have been read. Touro College’s library data base (tourolib.org)
was utilized to search for relevant studies and reviews, with
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databases such as ProQuest, and EBSCO. Further research was
done by looking up references cited from review articles to find
original papers.All research accumulated was used in an attempt
to determine if the benefits of humanized animals outweigh the
possible risks.

Discussion
There have been a number of studies using human animal chimeric mice as an in vivo system to study how stem cells proliferate,
to test diseases, and to study in more detail the biologic systems.
Often mice are used, however fetal sheep and fetal goat, during
the pre-immune stage of development, have also been used as a
surrogate animal model for human stem cells. The pre-immune
stage allows for the transplant of human stem cells, and the
resulting human animal chimera serves as a unique and clinically
relevant xenograft animal model for assessing the differentiation
potential of hSCs in vivo. However from a scientific perspective,
large animals are not a suitable model for mechanistic research
and the experiments reviewed here utilize mice, as a host for
human cells. Small animal models, such as mice and rats according to scientists are ideal models to use.The advantages of using
small animals is that they contain naturally occurring migration
patterns of stem cells, and provide the availability of extending
homing and engraftment sites. Additionally, the presence of tissue and organ specific signals from niche, greatly facilitate the
widespread distribution of human donor cells. It is these reasons that compelled scientists to develop an influential small
animal model, also known as a humanized animal for pursuing
hSC basic research (Sun et al., 2007).

Stem Cells
In one study, a human/rat xenograft animal model was generated by transplanting human low-density mononuclear cells
(hMNC’s) from human umbilical cord blood (hUCB) into fetal
rats to study how the human donor stem cells behave in vivo.
Numerous methods including flow cytometry, Polymerase
Chain Reaction (PCR), and immunohistochemistry (IHC)
assay were used to test the human donor contribution. Flow
cytometry detected that out of 29 recipients, 19 had human
leukocyte common antigen, CD45+ cells in peripheral blood
(PB). PCR analysis on 11 different adult tissues showed that 14
out of 19 CD45+ animals possessed donor derived human engraftment in multiple tissues for example, the liver, spleen and
thymus. The differentiation of human donor cells in the liver
was assessed by IHC with the use of human specific antibody
against the hepatocyte marker; CK18. The recipient liver, and
the human liver had cells that expressed human CK18, while
normal control rats did not. IHC examination revealed that
in the chimeric adult spleen of recipients, many donor derived
human cell populations expressed CD45 marker indicating the
human spleen- specific differentiation of donor derived human
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cells. Differentiation of hMNC’s was evaluated in the rat thymus using IHC with a human specific antibody against CD45.
At 3 weeks, 2 months and 6 months after in utero transplantation, multiple human cells recognized in the recipient thymus
strongly expressed CD45. Human umbilical cord derived cells
expressing CK18 underwent site specific differentiation into
CK18+ human cells in the recipient liver and CD45+ human
cells in the recipient spleen, which demonstrates that after in
utero transplantation of hMNC’s, they successfully engraft into
the liver and spleen of recipients. “Subsequently, the long term
that survive in these organs are then actively influenced by niche
signals to contribute in organogenesis (for example liver and
spleen) recipients in the xenogeneic competitive settings.” This
experiment concluded that a human rat chimera was successfully developed in which xenogeneic human cells exist for up to 6
months. This provides a great in vivo model to study how stem
cells work (Sun et al, 2007).
In another study, hESCs were implanted into the brain ventricles
of embryonic mice, and found to differentiate into functional
neural lineages, generating mature active human neurons that
successfully integrate into the adult mouse forebrain. This study
reveals insights to recognition of common signals for neural
differentiation throughout mammalian evolution. The results
showed that hESCs, when transplanted into the ventricle of the
developing mammalian brain, can give rise to neuronal and glial
lineages, suggesting that they are “responsive to environmental
cues that regulate cell fate determination and differential migration.” This human animal chimera model provides an in vivo approach to study human neural development. An approach which
can be used to study human neurodegenerative and psychiatric
diseases, and a prospective technique to speed up the screening
process for therapeutic drugs in the future (Muotri et al., 2005).

Disease Model
In another experiment, an animal with a humanized immune
system was used to serve as a human disease model for Human
Immunodeficiency Virus type 1 infection (HIV-1). Rag2−/−vc−/−
mice, when neonatally injected with human CD34+, develop a
functional human immune system, with human hematopoietic cells found in the thymuses, PB, spleen, and bone marrow
(BM) of the animals. Rag2−/−v c−/− mice become infected with
HIV-1 when injected with CCR5 tropic HIV-1. HIV-1 infection
is characterized by constant virus replication and a gradual loss
of CD4+ T cells and T-cell function. After being injected with
CCR5 tropic HIV-1, there was a productive infection of human
cells in PB, thymus, spleen tissue, and BM, and ratios of CD4 (+)
T cells to CD8 (+) T cells declined. Infection of the mice with
5000 TCID50 of R5 HIV-1 resulted in a productive infection
in 3/3 animals. HIV replication was detected in PB, thymuses
and spleen and BM was also positive for HIV-1. When a 10 fold
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smaller amount 500 TCID50 was used for infection, only 2/5
were found to be productively infected with HIV 1 in PB and
all lymphoid organs. This study demonstrated that HIV-1 can be
detected in multiple lymphoid tissues of Rag2−/−vc−/− mice,
using low doses of CCR5- tropic HIV-1. This mouse, consisting
of a human hematopoietic system, can serve as a small animal
model for investigating HIV-1 pathogenesis and testing potential
HIV-1 therapies (An et al., 2007).
In the next study, a chimeric mouse, that sufficiently mimics the
pathophysiological micro-environment in human liver, was established as a unique experimental model to study human liver
cancer metastasis (Fujiwara et al., 2012). This was discovered
by expression of an albumin-urokinase plasminogen activator
(Alb-uPA) transgene in the mouse that is hepatotoxic, resulting
in the progressive destruction of the mouse liver. It was found
that when primary healthy normal human hepatocytes were
transplanted into this mouse, the human hepatocytes were capable of reconstituting the host liver, highlighting the generous
capacity of hepatocytes to regenerate. This liver reconstitution
mouse model has led to a mouse with a humanized liver, by the
development of mice with livers that are reconstituted by engrafted human hepatocytes. This model can be useful for in vivo
testing of anti-cancer drugs and for studying the mechanisms of
human cancers (Behringer, 2007). Based on this, scientists theorized that the chimeric mouse can be used as an animal model
to investigate the underlying mechanisms of tumor metastasis
into the liver, where the “parenchyma is composed largely of
normal and healthy human hepatocytes (Fujiwara et al., 2012).”

Human Organs
Human animal chimeras can be used to create complete human
organs by growing organs made exclusively from human cells in
a chimeric animal, such as a pig, that could potentially be used
for organ transplants (Hermerén, 2015). It was shown, that
when a mouse that is deficient in T and B cells was injected with
mouse embryonic stem cells, the T and B cells generated were
the donor derived mouse embyonic stem cells. The donor stem
cells compensated for the lack of T cells by producing T cells. It
was hypothesized that the same may be true for organs. That if
an animal that is deficient in an organ is injected with stem cells,
the stem cells might compensate for what its lacking and grow
into that organ.
A study was done where mouse wild-type pluripotent stem
cells (PSCs) were injected into Pdx1−/− mouse blastocysts,
(pancreatogenesis-disabled) and found that they developmentally compensated vacancy of the pancreatic “developmental
niche,” generating almost entirely PSC-derived pancreas. The
organ generation system described may be useful to treat
organ failure in humans if pigs or other large animals are used.

However, several concerns have to be addressed first to bring
this idea into practice. For example, if interspecific chimeras between mouse and rat were to be generated, their “embryonic
lethality is high and maturation into adulthood is uncommon
(Kobayashi et al., 2010).”
In another study the immune-deficient athymic nude mouse was
used as a recipient of human tissue grafts, to generate human
animal chimeras. Because this mouse lacks T cells, it allows for
many types of xenograft tissues to survive and grow (Behringer,
2007). Four to seven grafting experiments using human fetal
material in the nude mouse have been successful. In 1969 the
first successful transplantation of human malignant tumor tissue
in the nude mouse was reported. Since then, the number of tumors transplanted has increased steadily. The nude mouse with
transplanted malignant tumors is a new alternative model in
oncologic research. It can be applicable to: “basic studies of the
genesis of cancer tissue, immunology, and cell kinetic research
(Spang-Thomsen and Visfeldt, 1976).” The nude mouse was used
as a model for cancer, by grafting pieces of human tumors under
the skin of the nude mice, in that way, providing a “bio incubator” for tumor growth. This bio incubator gives scientists a
glimpse into how to treat diseases in humans. The introduction
of the nude mouse significantly enabled these types of studies
and this in vivo assay is one of the fundamental experimental
models for cancer research (Behringer, 2007).
Other experiments include studying mice with human germ
lines. By subcutaneously transplanting human pre-pubertal and
adult testicular tissue fragments into immune deficient mice, it is
seen that human spermatogonia can survive in mice. Hopefully
with more research, it may be possible to come up with a strategy to preserve the germline of young boys undergoing chemotherapies and radiotherapies that cause sterilization (Behringer,
2007). This study utilized Nude mice and severe combined immunodeficiency- non-obese diabetic mice, (SCID-NOD), two
immunodeficiency recipients to compare the grafting of pre-pubertal and adult murine and adult human testicular tissue. The
survival of pre-pubertal and adult murine testicular tissues, and
of adult human testicular tissue was evaluated after subcutaneous grafting to immune deficient mice. This xenograft model in
an immune deficient mouse with pre-pubertal human testicular
tissue is a theoretical strategy for restoring fertility in childhood
cancer patients, while circumventing the risk of malignant recurrence (Geens et al., 2006).

Ethical issues
These different types of human animal chimeras have provided important insights into fundamental biological mechanisms
and the development of therapeutic protocols for human disease. Chimeras have compensated as human animal models for
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the study of human processes in vivo. However there has been
a lot of ethical debate concerning this research. These experiments reviewed have been approved, because the carefully
transplanted human cells aren’t large enough to make the animal human.They only humanize certain parts, and the resulting
chimeras are euthanized after a number of days. Many boundaries had to be set with this type of research. In these studies,
the human donor contribution is very low compared to the
animal host. Although cells express an evidently higher degree
of activity than genes, they also are intricately dependent on
their surroundings. When hSCs are transplanted into animals,
although they are free to proliferate and differentiate they are
still in an animal body, and are reliant on their environments.
They help to humanize an immune system if the animal is
lacking one, however the host still remains an animal, with a
distinct cell line of human cells, resulting in a chimera. Only
in a receptive host, local niches regulate key developmental
changes for several adult stem cell types, termed as an “inseparable relationship”, besides for bone marrow transplantation,
in which the hematopoietic stem cell is an “agent” in blood
reconstitution (Hyun, et al 2007).
Research with human animal chimeras become a problem
when cognitive capacities of the animal is changed, and when
the germ line is affected. Therefore, boundaries have been put
into place. Precautions in this field of research include, using
progenitors rather than PSCs to avoid germ line contribution,
which pose the risk of producing human embryos in animals.
And treating the humanized mice, as a modified crop, by keeping it isolated to prevent it from mating with other mice, as
well as euthanizing it immediately when research is concluded
(Hermerén, 2015).

Conclusion
The above studies reviewed involved reconstituting animal
models by transplanting human stem cells, HIV, cancer, and
growing human organs in mice. The experiments resulted in a
human animal chimera, an animal with two cell lines. Human animal chimeras, animals carrying human tissues were used as an
alternative model to investigate human specific biological processes without experimentation on human individuals. Although
human animal chimeras provide numerous possibilities, there
is still a lot of controversy and risk associated with it. Since
research is developing rapidly, and people’s values and perception of risk and benefit change, not all issues can be settled.
This approach to studying human pathways in animals concerns
many people, however with the proper care and thought-out
methods, research should be able to proceed without extreme
regulation, and more experiments using human animal chimeras
for therapeutic protocols should be approved.
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Abbreviations

HSCs- Human Stem Cells
HESCs- Human Embryonic Stem Cells
hMNC’s- Human Low-density Mononuclear cells
hUCB- Human Umbilical Cord Blood
PCR- Polymerase Chain Reaction
IHC-Immunohistochemistry
PB- Peripheral Blood
HIV-1-human Immunodeficiency Virus type 1 infection
BM- Bone Marrow
Alb-uPA- Albumin-Urokinase Plasminogen Activator
PSCs- Pluripotent Stem Cells
SCID-NOD- Severe Combined Immunodeficiency- NonObese Diabetic
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Abstract
It would seem that differentiation of stem cells is the remedy of modern times.Yet stem cell research is more complex
that the public may recognize and is still in the developmental stage. Recent breakthroughs show promise; various
guidelines provide structure to this growing field but it is not ready for gross public application. The objective of this
paper is to research various different methods of stem cell production and application. Methods included reviewing
articles and studies to evaluate the process in production of affective stem cells.There are many therapies that illustrate
this research. Upon completing and explaining this phase, further analysis of research presented risk factors such as
negative immune responses, tumor, and teratoma formation are discussed. This paper further examines the different
complications that may be triggered by stem cell therapy. The danger analysis is briefed to describe the risks involved
in stem cell therapy while explaining the ongoing research and discoveries to assist in limiting these risks. This paper
culminated with the success of the most affective form of therapy to date.There are ongoing studies directed to limiting
stem cell therapy for safe and risk-free application. Nevertheless, no definite conclusion can be reached as to how stem
cells can be limited to the point of remaining simultaneously pluripotent and effective.
Introduction
A young woman walks into her doctor’s office complaining of
what seems to be a pimple that does not go away. She initially
treated it with over counter creams, then a facial and many dermatologist visits. Upon a more extensive examination the specialist realized that this was not the average case of adolescent
acne and ordered blood work. The test revealed that this girl
has type-one diabetes. Her plans to go to college were placed
on hold and her life completely changed. What if diabetes didn’t
have to be a life altering disease? What if glucose monitoring
and insulin injections were replaced with a one-time stem cell
therapy that could replace the damaged cells? This example did
occur and the girl is being treated with subcutaneous insulin
infusion therapy. Stem Cell Research has not reached this breakthrough but the hope is that in the future stem cells will be used
to test medical treatments and replace cells lost by devastating
diseases that currently have no sustainable cure.
The first several divisions of the mammalian fertilized oocyte
give rise to totipotent cells. These cells can form cells in the
placenta, embryotic sack, and any cell in the body. Once cells are
designated for the body they are termed pluripotent cells.These
embryotic stem cells have virtually limitless potential and are an
invaluable resource for the biomedical community. Along with
the importance of these cells arises a responsibility of using
them correctly. The process of understanding how these stem
cells work and the services they can provide has not been an
easy feat. This battle has been fought in both the courtrooms
and laboratories. The legal system bears the responsibility of
creating a system in which guidelines are being followed and
ethics upheld. This is an ongoing battle, and there is no undermining this work. Regardless of several ongoing debates and
some legal verdicts, the biomedical community is addressing
stem cell research, cell regeneration, and organ construction
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from two different perspectives. There is ongoing promising
research being done on organ and cell regeneration with the
use of somatic stem cells. Specific mature, undifferentiated, adult
cells are reprogramed to function as stem cells and referred to
as induced pluripotent stem cells (iPSC). These cells, generally
found in the epithelial cells of an adult organ, have already been
assigned a task and are therefore limited to the regeneration of
that particular cell or organ. However, being that they are extracted from the patient, it is assumed, although not tested, that
these cells will face less rejection after implantation because
of the body’s familiarity with the cells. An alternative form of
adult stem cells is activation of somatic stem cells (Stem Cell
Information, n.d.) within the body. These cells reside within a
healthy body and function as a natural maintenance system by
regenerating aged or damaged tissue and replacing lost cells.
Examples of the somatic stem cells are cord blood and bone
marrow. The third of these general stem cell approaches allows
for more potential but at a greater risk; pluripotent embryotic
stem cells (ESC) can be used to create any cell or organ but at
a higher probability for tumor growth.There are several distinct
differences between embryotic and adult stem cells. Adult stem
cells are rare cells that require extraction, isolation, and then in
vivo cell culturing, to multiply. This cell culture process has not
fully developed and is a great deal more complicated than the
growth of ESCs (Herberts et. al. 2011., Shanthly et. al. 2006).
This paper will explore the potential of regenerating tissue by
means of pluripotent stem cells, as well as discuss literature on
growth of these cells to build tissues and replace cells. Upon exploring the processes of in vitro and in vivo differentiation, in
both induced pluripotent stem cells (iPSC) and human embryonic
stem cells (hESC), one can question the technology needed to
operate these cells. Is it possible to limit stem cells to differentiate, as they would in utero, to create a select tissue or organ?

Stem Cells Differentiation into a Specific Organ

Methods
This document was amassed by referencing original research and
peer reviewed scholarly articles. US government websites and
portions of scholarly articles were accessed to gain knowledge
about the background, history, and general methods involved in
stem cells therapies. Specific topic information, regarding the research question, was collected, reviewed, and analyzed. Google
Scholar, and databases that are made accessible through the
Touro College online library, such as Proquest and Ebsco, were
used to search and access documents related to the research
topic.The following are examples of key words were used: stem
cell and apoptosis, c-myc, tumorigenic factors, in vivo growth,
nodal signaling. There was no discrimination made regarding the
date of publication on articles.

History
Initial stem cell research dates back to 1870, with in vitro fertilization of an oocyte. Any form of promising finding were slow
until research intensively propelled in the late nineteen seventies. Notable accomplishments include cloning of mammals in
1997 and development of the first stem cell culture in 1998.
The virtually simultaneous discovery of cloning and stem cells
were the building block of forthcoming research. Stem cells cultured in today’s laboratories are removed from the blastocyst
early in differentiation and frozen in their state until they are
differentiated into the cells required for a specific medical therapy (Shanthly et. al. 2006). Research is ongoing and promising;
the biomedical community has only scratched the surface of
the untapped potential of stem cells. There are various issues
and setbacks that are limiting stem cell potential (Stem Cell
Information, n.d.).
Stem cell research raised sharp scientific, technological, ethical, and political controversies. The United States federal and
state governments enforced laws to enhance and restrict actual
stem cell research. States such as Florida and New York agree
to provide state funding while other states such as Arkansas
and Michigan have placed bans on the creation and use of ESC
for biotech research (Vestal 2008). Some forms of stem cell
research and experimentation are more disputed than others;
stem cells derived from oocytes are more controversial than
induced adult cells. For example, in 2006 the Senate passed a
law allowing federal money to benefit the specific research of
iPSC, umbilical blood and bone marrow treatments but not
ESC. However, in 2011 President Obama removed all bans that
restricted federal funding from being assigned to new lines of
embryotic stem cells. Regardless of the origin of the cell, human
stem cells research raises ethical sensitivities. The ethical policies are continuously evolving and the biomedical community is
attempting to overcome the challenges to ensure that research
is carried out in an appropriate manner (Levin et. al. 2013).

In addition to legal constraints the anatomical components that
comprise stem cells are intrinsically a hindrance. The same factors, enzymes, and transcription that insure the cell’s ability for
self-renewal cause biomedical complications (Li et. al. 2015).

Differentiations
Some mammalian tissues, such as the skin and liver, have the
ability to regenerate yet others cannot. The capability of bioengineering and sustaining all organs, regardless of their regeneration factor, will be invaluable; this can ultimately circumvent the
transplant system ensuring that patients don’t die waiting for an
organ. Regeneration capability is reliant on stem cells. For the
purpose of this paper stem cells are divided into two categories, embryonic stem cells (ESC) and induced pluripotent stem
cells (iPSC). In more recent years, researchers have developed
methods of directly reprograming differentiated cells to produce iPSC. iPSCs are rare and found in only some differentiated
tissues throughout the human body. A common use for iPSC
is bone marrow transplants to fight leukemia. Although only
one in every one hundred thousand cells is stem cell, advanced
techniques allow for harvesting and collecting those cells in
concentration to be donated by injecting the donor with colony-stimulating factor 3 (CSF 3). This glycoprotein stimulated the
bone marrow to produce more stem cells; a necessary tool to
collecting these otherwise dispersed cells. Such techniques can
be used to collect adult stem cells but the process is tedious and
does not allow for the unlimited potential hESC offer (Shanthly
et. al. 2006). Although iPSC involves complications, such as the
complexity of collection, it also provides therapeutic potential
because these cells are harvested from a patient’s own cells.This
can alleviate tissue and cell rejection complications.
Since adult stem cells cannot give rise to all cells and tissues
in the body, the ideal regenerative cell is embryotic stem cell.
There are three different forms of embryonic stem cells used
for medical research. The foremost method, true embryotic
stem cells, is made from fertilized eggs generally donated by
patients undergoing in vitro fertilization. Somatic cell nuclear
transfer (ntES cell) is the process of creating an embryotic cell
by inserting the nucleus of a general human cell into an egg cell.
Although this technology has not been tested on higher mammals, it can be of great use because the nucleus of the cell will be
a genetic match to the patient. The third form of ESC, not ready
for clinical use, is called parthenogenetic embryonic stem cells
(pESC). Through the process of parthenogenesis, an unfertilized
egg is stimulated into differentiating as an embryotic cell would
(Shanthly et. al. 2006).

Stem Cell Links to Tumorigenic Cells
Regardless of the types of ESC, these stem cells are derived from
the core of mammalian blastocysts and can multiply infinitely
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and differentiate into three germ layers: mesoderm, endoderm
and ectoderm. However, there are stem cells that have been
documented to have significantly more genetic mutations as
they grow in vitro. Research performed on zebra fish indicates
that nodal signaling and pathways are found in both metastasized
cancerous cells and embryotic stem cells yet not in healthy skin
cells (Topczewska et. al. 2006). Nodal proteins are growth factors important to pattern formations needed for the embryotic
differentiation, specifically as it relates to the formation of the
mesoderm and endoderm .(Shen 2007). Activation of the nodal
pathways is tightly regulated and prompts self-gene inscription
with positive and negative feedbacks .(Cheng, Sun, 2014). The
similarities between ESC and tumorigenic cells may lead to discoveries that can limit the association between stem cells and
cancer. Nodal signaling pathways are not the only unique link
between stem cells and metastasized tumor cell; telomerase is
an enzyme that facilitates growth and development of DNA in
ESC but also found in upwards of fifteen times more often in
cancer cells than in healthy cells .(Hiyama, Hiyama, 2007).
Nonsense-mediated mRNA decay (NMD) is been known to
clean RNA in order to protect from early termination. At the
PTC site, the location where early termination would commence, the NMD complex is assembled. This complex balances
and regulates the proteins and is essential for homeostasis and
overall survival of not only the embryonic cell, but organisms as
a whole. One factor of the NMD complex is Smg5, this factor
is involved in telomere and telomerase maintenance. Thus this
NMD factor and Telomerase protein are both essential components that regulate cell viability. They may cause cell fatality or
paradoxically, cancer (Li et. al. 2015).
Understanding the similarities between these cells help with
limiting ESC. This process is called clinical transitions; scientific
knowledge is gathered, understood and then turned into medical treatments. Regardless of these setbacks, the utility of these
cells should not be undermined; simple laboratory practices
such as freezing can assist with excess cell growth. Chemicals
have been tested to determine if ESC can be treated to induce
certain forms of apoptosis. Apoptosis is the shrinking of a complete cell and its membrane. Apoptosis differs from the generic
form of cell death by the fact that it does not leave residue.
Excess cell components that did not shrivel; undergo phagocytosis. The purpose of these chemicals would be to generate
cell death and on the specific component of the cell that may
lead to complications, while leaving the remainder of the stem
cell unharmed. Research performed on these compounds and
chemical were published in 2012 and these findings claim to
identify compounds that altered the viability of ESC (Conesa
et. al. 2012).
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Research In Vivo/ In Vitro
A ten-year research program beginning in the late 1980’s studied
soft tissue engineering using totipotent stem cells. The experiment used mouse embryotic stem cells to attempt to build lymphatic tissue, among other structures. Prior to commencement
the researchers set out to establish what would be an ideal
environment for embryogenesis. Building tissues in vivo requires
an environment that mimics all aspects of uterus or in vitro development; components such as nutrient and culture conditions
are key. However, the physical creation of such an environment
is quixotic, at best (Chen et. al. 1997, Shanthly et. al. 2006). A
later study characterizes the complexity of stem cells by explaining the conditions for maintaining undifferentiated status.
This study dictates that FGF2 and conditioned medium (CM)
support hESC in an undifferentiated state. In 2005 undifferentiated hESC were maintained with either FGF2 or CM. These
stem cells remained in undifferentiated colonies apposed to the
hESC that were maintained without these factors. Maintenance
of the undifferentiated cells is an extremely delicate process,
indicating that the steps from that point forward, toward proper
differentiation, is that much more complex (Sumi et. al. 2007,
Umar et. Al. 2014).
Development of any tissue, regardless of its origin requires
three steps: cell differentiation, complex tissue formation, and
the building of a three-dimensional, three-layered germ celled
organ (Chen et. al. 1997). The most complex portion of complete in vitro embryogenesis is the maintenance of a live culture
throughout this process. As it is with a fetus, tissues, and organs
can only function if the fetus is alive. Considerable research has
been completed, and is ongoing, on many different forms of tissue growth.To better understand the processes of building cells
and tissues with stem cells, this paper will only be discussing
two different tissues developed in culture, cardiac myocytes and
lymphoid tissues. The decision to use these specific examples is
based on varied dates of the research and the difference in tissue complexity, due both to function and development of each
cell.

Cardiac Myocytes
The differentiation of stem cells to cardiac myocytes is a rather complex. Cardiac muscle is a prime example of a complex
tissue due to the various forms of specific muscular tissues
and their functions as it relates to an efficiently operating
heart. Cardiac tissue is made up of interlocking, single nuclei,
striated, muscle fibers. The unique and complex aspect of this
tissue includes the intercalated disc, which assist in conduction
speed, and autorythmicity, the ability to set its own contractions. Research published in April of 2011 suggests promising
potential of differentiation of cardiac myocytes from hESC. By
inhibiting Bone Morphogenic Proteins (BMP), a growth factor,
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during cardiac differentiation, cardiogenesis is initiated. This
step is far from the only one that is needed to allow for ESC
to be transplanted for therapeutic uses. Additional research
is required such as the study of the regulation of retinoid sig-

Table 1
ESC:

iPSC:

SSC:

Derived from inner
mass of blastocyst

Derived from somatic
cells

Isolated from postnatal
adult tissue

Allogenic material

Autologous or Allogen- Autologous or
ic material
Allogenic material

Pluripotent

Pluripotent

Multipotent

Can differentiate into Can differentiate into
all three germ cells
all three germ cells

Can differentiate to
limited cell types.

Self-renewal

Self-renewal

Limited Self-renewal

Indefinite Growth
Significant Teratoma
Risk

Indefinite Growth
Significant Teratoma
Risk

Limited Lifespan
No Teratoma Risk

Serious Ethical Issues Serious Ethical Issues

Serious Ethical Issues

Immuno-priviliged

Unpredictable

Not Immuno-priviliged

(Prendergast 1999)
naling, the key that defines the difference between ventricular
and arterial myocytes (Zhang et. al. 2011, Hartman et. al. 2014).

Lymphatic Tissue
The microenvironment needed for embryogenesis is delicate.
Being that lymphoid cells develop toward the end of this process, it was difficult to assume that the microenvironment need
for ES cultures could be sustained until that point. Initiation of
the research began with mice. Through the use of viral vectors,
oncogenes were inserted and developed in vivo to produce B
and T cells. Many attempts and adjustment were made.The generation of B and T cells from lymphatic tissue was rare at the
time publication of this journal but at the end of the research it
was confirmed that lymphoid precursor cells could be derived
from ESC. These years of research, experiments, and analysis of
data only begins to explain the complexity of building tissues,
regardless of their origin (Chen et. al. 1997).

Complications
Regardless of the difficulty of building tissues from stem cells
and the improvements to cell cultures explained in cardiomyocytes formation, there are other complications that require
attention. In fact, some stem cell therapies such as bone marrow
transplants with somatic stem cell, do not involve the intricate
complexities that tissue growth requires. Yet even these therapies must be addressed as it relates to the other risk factors
involved in such a therapy. Risk factors begin in procurement
and linger through the many phases involved, beginning with culturing and injection. Subsequent to any initial success, long-term
affects must be analyzed. There is deficient clinical experience

in embryonic and adult stem cells. This lack of experience is an
inevitable aspect of relatively new, current, and ongoing research
and results in a variety of complications, after stem cell injection
(Herberts et. al. 2011).
General observations of the three most common forms of stem
cells are summarized in Table 1. Improved comprehension of
the differences and characteristics of these cells will assist in
establishing their risk analysis.
An example of a consequence is tumor formation. This is a
known complication that is being investigated from different
standpoints. Understanding cell growth and death is crucial to
such an analysis.The Myc gene family encompassed both factors.
It is for that reason that this paper uses c-Myc as an example
of a protein that may help limit tumor genesis. In addition fifty
percent of tumor formation found in mouse research of iPSC is
attributed to c-Myc.

Tumor Formation
The basic and universal self-renewal factors that assist in
feedback and feed forward loops is Oct4, Sox2 and Noanog.
However, the Myc gene family is additional self-renewal proteins
and factors that affect intrinsic stem cell existence and apoptosis.
Research published in 2007 investigated the function of c-Myc in
stem cells regulation, differentiation, and apoptosis. Initially the
tests were performed on mouse stem cells and later applied to
hESC. It was widely known that that c-Myc is required to regulate normal cell development. However, the application of this
factor in hESC regulation was confirmed and verified as being
expressed as three different factors of the same family (Myc,
Mycn, MycL1). Each of these Myc proteins were tested and found
in the mRNA of hESC. Furthermore, just as c-Myc was present in
regulation of mice cells, it was traced in undifferentiated human
stem cells. Testing of this protein suggests that c-Myc is a factor
of self-renewal.This research further investigated if c-Myc would
also affect apoptosis and differentiation (Sumi et. al. 2007).
The properties of the c-Myc protein are best explained when
looking at cancer cells. The protein factor c-Myc is found to be
uncontrolled in end-stage cancers. This overexpression in tumorigenic cells helps explain the role it plays in normal cell growth,
stem cell proliferation, differentiation, and apoptosis. Even prior
to a complete discovery of the potential of c-Myc, it was known
that increased levels of c-MYC indicated the initiation of cell
death.There are various pathways in which apoptosis is initiated.
The first is by the regulator p53 ultimately activating BAX. The
second is activation of PI3’K-AKT.The third and final pathway to
cell apoptosis is through cell ligations that activate c-Myc. The
activation and increase of this protein then caused apoptosis
(Prendergast 1999).
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Being that this factor plays a role both in the differentiation of
stem cells and the death of tumor cells, it must be assumed
that investigations on regulation of this protein may be vital to
advancements in stem cell therapy. With better control of this
protein a clinical laboratory scientist may be able to use it in
either furthering the differentiation of cells or leaving them in an
undifferentiated state when deemed necessary.The link between
the Myc gene family and oncogenic cells will additionally assist
with the considerable complications facing stem cell therapy,
tumorgenesis.
Aside for the risk of essentially causing tumor formation, stem
cell therapy may also affect the growth and formation of existing
tumor cells. If, for example, a patient has a dormant tumor of
cancerous cells, stem cell therapy may active it. This has not
been proven but is under investigation with the use of mouse
stem cells.

Immune Response
Any donation requires proper human leukocyte antigen matching (HLA); stem cell therapy is no different.Taking care to ensure
that the donor and recipient match decreases the risks of Graft
Verse Host Disease (GVHD). As detailed in table one, some
forms of stem cell therapy are allogeneic.Therapies that are not
recognized by the body risk immune rejection. Even those that
are immune privileged (hESC) may be subject to rejection and/
or an inflammatory response due to the increase in response
stimulus, caused by the actual stem cell therapy induction. For
that reason, stem cell therapy may be administered while the
patient is on immune suppressants. Placing a patient on immune
suppressants runs the risk of adverse drug reactions. There are
ongoing studies investigating different methods of stem cells
growth in vivo that will limit the risk of rejections and GVHD.
Such studies include introduction of mesenchymal stem cells
in vivo. Data from such research indicated that these stem
cells tranquilize the immune system and regulate its responses
(Herberts et. al. 2011).

Teratoma
A teratoma is a benign mass composed of a hazardous mixture of tissues, generally resembling remnants of all three germ
layers. It is established in vivo and assumed to be congenital.
Being that pluripotent stem cells can create all three layers,
this therapy is susceptible to such a risk. In fact the same characteristics that defines stem cell, pluripotency, are the same
trait that creates teratomas. Research produced in 2011
details the comparative affects of tumor formation on both
hESC and iPSC. The research indicates that because iPSC is a
stem cell engineered in vitro and thus a more controlled cell
than hESC, iPSC is less susceptible to tumor genesis. In fact
the reason that teratomas are found less frequently in iPSC is
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because the heterogeneity of this cell causes slower growth
rate (Zhang et. al. 2012).
In addition to cell type effects on teratomas, injection sites may
also influence distinctive increase or decrease levels of formation. Although not enough clinical research and analysis can confidently support this claim, it is reasonable (Zhang et. al. 2012).
More research has been performed on mouse stem cells to
detect the correlation of the environment in which the stem
cells are injected into and malignant tumors. Although tumor
growth differs from teratomas, these discoveries may lead to
additional exploration into the plausible affect of increased teratomas based off of site administration (Herberts et. al. 2011).

Success
Success is a complicated term to define when associating
it with ongoing scientific research. Success can be attributed
to a research breakthrough or a clinical accomplishment; it’s
simply relative. Longevity is fundamental determinate of success. Pluripotent haematopoietic stem-cell transplantation for
cancer therapy has made significant stride since initial investigations over sixty years ago. It progressed from research that
was plagued with complications and hurdles to a standard form
of treatment. This blood forming stem cell is the only therapy
approved for standard use because of sufficient understanding of the cells, possible complications, and long term affects.
Expansion of this therapy for use other than replacement of
blood and immune cells causes similar complications mentioned
throughout this document. There are many trials taking place
and success may be recognized within each trial but a complete
understanding of overcoming challenges and complications can
only be determined by continual research and the test of time
(Stem Cell Information, n.d.).

Conclusion
Research, along with case studies and accounts show there are
far more complications with stem cells than would appear at
first glance; they require numerous forms of adjustments to
insure an innocuous treatment. Limiting stem cell therapies is
a promising prospect, and in some therapies it has been successful. However, there is insufficient research completed at this
time to form a definite universal response for limiting any form
of stem cell for every therapy application.
Researchers are investigating the factors that cause the risks
involved in various therapies and consequently exploring remedies and suggestive solutions. However, stem cell therapies
involve a multitude of complexities, some yet to be ascertained.
The reason for these uncertainties appears to be based on the
varied potential administrations, forms of stem cells (hESC, iPSC,
ntES), their associated risks, and the limitless therapies they can
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produce. This research is a relatively new and revolutionary
field of study. With increase research, funding, and integration
of continual findings, selectively listed in this paper, scientists
are advancing to the goal of utilizing all that stem cells have
to offer. This includes the capability to understand its potential,
related limitations, and safely developing the two in an effort to
advance medicine. Stem cell therapy is the promise for infinite
preventative care and treatment options.
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Abstract
There are many ways to fight cancer using the body’s own immune system. Some methods include the administration of
vaccines while others involve stimulatory factors injected near tumors. One promising method is enlisting the help of T cells.
To fight cancer effectively, T cells must be able to recognize cancerous antigens and the environment in which these T cells
reside must be conducive to their function, survival, and proliferation.This paper discusses a method of providing such an environment called adoptive cell transfer, as well as the elements that effect this protocol and the ways in which the environment
can be manipulated to increase the effectiveness of adoptive cell transfer.
Many factors contribute to the observation that the effectiveness of adoptive cell transfer increases as immunodepletion increases, namely, the depletion of regulatory T cells.Additionally, the existence of natural killer cells during adoptive cell transfer
has been shown to decrease its effectiveness. Also, increased levels of cytokines IL-7 and IL-15 enhance the function, survival
and proliferation of transferred T cells which would increase their effectiveness. Moreover, the results of adoptive cell transfer
are more positive when patients’ own T cells are used.
These findings show that T cells can be used through adoptive cell transfer as an effective treatment for metastatic melanoma
patients, and that there is potential for adoptive cell transfer to be adopted as a widespread effective treatment for cancer.
Introduction
Cancer is a disease characterized by the presence of mutated
cells that continue to divide uncontrollably. Cancerous, or malignant, tumors, can spread to other parts of the body especially
via the lymph system which can act like a cancer highway, and
new tumors can then form in places far from the original tumor
source (What is Cancer 2015).These tumors can have negative
health effects and in many cases can be life threatening.
According to the World Health Organization more than 14 million new cancer cases were diagnosed in 2012 and there were
more than 8 million deaths attributed to cancer. Additionally,
the American Cancer Society projects the number of new cancer cases in the United States in 2015 to exceed 1.5 million and
the number of deaths to exceed a half million.
Radiotherapy, a common cancer treatment, works by directing
high energy beams, including x-rays and gamma rays, at cancer
cells to disrupt their DNA and ultimately result in cell death
(“Radiation Therapy”). Although radiation therapy can be successful at eradicating cancerous cells, relapse is a common
problem because a few cells, or even just one cell, left behind
can continue to divide and pose a serious health risk (Wayteck
et. al., 2014).
To combat the problem of relapse, chemotherapy is commonly prescribed to ensure that all cancerous cells are eradicated. Chemotherapy works by killing all rapidly dividing cells
(“Chemotherapy”). However, chemotherapy has many unwanted
side effects as it does not differentiate between healthy rapidly dividing cells and cancerous rapidly dividing cells. This effects many
different systems within the body and can cause anemia, hair loss,
infection and other unhealthy and unwanted symptoms.
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Another form of treatment, immunotherapy, works by using
immune elements to target cancerous cells through recognition of cancer antigens. There are two different ways of recognizing cancerous cells through antigens. One way is through
tumor specific antigens which are expressed solely in cancerous tumor cells, while the other involves overexpressed antigens which more abundant in cancerous tumor cells than in
healthy cells. This method of treatment aims to avoid the side
effects of chemotherapy by targeting only cancerous cells and
to also thwart the problem of relapse seen in radiation therapy
(Wayteck et. al., 2014).
Passive immunotherapy uses stimulatory factors such IL-2
which is injected into the tumor area to stimulate anti-tumor
T cells to proliferate, activate, and increase effector functions
(Wayteck et. al., 2014). Active immunotherapy, on the other
hand, involves CD 8 and CD4 T cells that are primed to recognize specific cancerous antigens and thereby direct immune
cells to target and kill these cancerous cells. This report discusses the effectiveness of active immunnotherapy in general
and, specifically, a branch of active immunotherapy called adoptive cell transfer.

Methods
To research the effectiveness of active immunotherapy and specifically adoptive cell transfer, relevant information was gathered
from many databases and journals. Those databases included:
the Touro College Library database, Proquest Science Journals,
Pub MEDLINE (EBSCO), and Oxford Journals. The information
gathered was narrowed further and analyzed to glean an understanding of the effectiveness of these treatment protocols.
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Discussion
A recent study indicates that active immunotherapy can be an
effective treatment for cancerous tumors (Raez, et. al. 2003). This
study assessed the impact and response of CD8 T cells to tumorcell-based allogeneic vaccines in patients with advanced non-smallcell carcinoma, commonly known as lung cancer. However, the
selection of patients with advanced stages of non-small-cell carcinoma may have resulted in reduced effectiveness of treatment,
as cancerous cells may have been too numerous for the body’s
immune system to handle. Similarly, as only patients previously
unresponsive to conventional treatments like chemotherapy and
radiation therapy were studied, the results may have been lower
than they might be had the body’s ability to fight off harmful cells
not already been undermined.

Vaccinations were delivered in three courses. After completion of the first course, only patients with stable disease
progression or positive response against non-small-cell carcinoma as determined by CT scan, coupled with low toxicity,
continued to a second course of vaccination. Again, patients
with no tumor progression and non-life threatening levels of
toxicity continued on to a third course of vaccination (Table
1). The patients were evaluated at the beginning and end of
each course to study clinical effects and to determine toxicity
levels (Raez, et. al. 2003).
The results of the above study, as shown in Table 2, indicate an
increase in CD8 T cell response in all but one patient. Clinically,
however, the results were less profound. Only 27% of the patients

Table 1

Course 1
Study entry

1

Weeks on
Study
Pre-entryevaluation

2

4

6

1

2

3

Course 2
7

8

10

12

4

5

6

Course 3
13

14

16

18

7

8

9

19

x

Immunization

Table 2, Clinical and Immunological response

Previous

Survival
(months)

Time to
progression
(months)

Preimmune

First
course

Second
course

Third
course

190

C+R

10

-

0

190

ND

ND

NE

NE

C

15

-

0.2

ND

ND

ND

PD

25

C+S

18

-

0

25

ND

ND

1002 A2

PD

1.6

C+S

22

-

41

65

ND

ND

1009 A2

PD

6.5

C

3

-

2

13

ND

ND

1010 A2

PR

41

S

27+

3

3.8

46

88

157

1011 A2

PD

19

C

11

-

3

30

57

ND

1013 A2

PD

34

C+R+S

2

-

5.2

164

178

ND

1014 A2

SD

19

C+S

13+

3

1.6

30

30

25

1015 A2

PD

0

C+R

7

-

0

0

ND

ND

1003 non

SD

134

S

31+

26+

1

134

113

84

1004 non

SD

424

C+R

23

11

0

424

232

>450

1006 non

PD

9.3

C+S

30+

-

16

150

ND

ND

1007 non

SD

14

C+R+S

29+

23+

1.2

2.8

0.8

0/17

1008 non

PD

32

C

6

-

5.6

178

ND

ND

Patient #
HLA

Response

Fold titer
increase

1005 A1

PD

1012 A1
1001 A2

PD=progressive disease; PR=partial response; SD=stable disease; ND=not determined; C=chemotherapy; R=radiation therapy; S=supportive
care; NE=not evaluable
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showed stable disease progression while another 7% showed a
partial response. This total clinical response of 33% suggests that
immunotherapy may be a viable option but requires further study
to assess clinical effectiveness. (Raez, et. al. 2003)
The vaccine used in this study was developed by Dr. N. Savaraj
through modification of a cell line harnessed from a patient in 1994.
The cells were rendered incapable of colonizing ensuring they
would not cause any harm to study participants. However, perhaps
a more effective albeit more expensive method, demonstrated at
the Johns Hopkins School of Medicine (Perica, et.al. 2015), may be
to extract a patient’s own CD8 T cells from the vicinity of the
tumor and subsequently culture them in vitro. This would ensure
that the T cells would be reactive to the patient’s own cancerous
cells. Using pharmaceuticals to regulate the patient’s regulatory T
cells, the CD8 T cells harnessed in vitro can be reinserted with free
rein to target cancerous cells (Perica, et.al. 2015).

Figure 1

Phan, Rosenberg, 2013
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Adoptive cells transfer is a treatment in which immune cells
harnessed in vitro are transferred to a patient to give him specific immune functions. To treat cancer patients using adoptive
cell transfer, a piece of a tumor is removed from the body, so
that T cells can be removed from the tumor, and stimulated to
grow rapidly in vitro.These T cells are then infused back into the
patient to target and kill cancer cells (Figure 1).
When attempted on patients with metastatic melanoma, adoptive cell transfer showed potential as an effective treatment
although admittedly it had limited clinical results. A trial of 20
metastatic melanoma patients were treated with adoptive cell
transfer and given IL-2 to stimulate the transferred T cells. The
results revealed tumor regression in multiple sites in 11 of the
20 patients studied (Phan, Rosenberg, 2013). However, it should
be noted that although IL-2 promotes the growth and function
of transferred T cells, its addition may also help regulatory T cell
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suppress these transferred T cells thus countering the intended
effect and perhaps limiting the overall effectiveness of the treatment. This indicates that adoptive cell transfer may have a place
in the pursuit of a cure for cancer but it does require some
further fine tuning.
Depletion of immune cells and other immune elements before
adoptive cell transfer of CD 8 T cells in mice has been shown to
increase the effectiveness of transferred T cells (Gattinoni et. al.,
2005). It has been proposed that depleting the immune system
of its natural elements keeps regulatory T cells from turning off
anti-cancer CD 8 T cells transferred during adoptive cell transfer. Additionally, adoptive cell transfer helps lower the immune
system’s tolerance of the cancerous “self-antigens” by selecting
and activating highly specific T cells, mostly CD 8 T cells, and by
changing the body’s internal environment to one that is more
receptive to these cells.

A recent study looked at 13 metastatic melanoma patients who
received immunodepleting chemotherapy specifically targeted
to regulatory T cells. The patients were then injected with in
vitro cultured T cells as well as IL-2. Because the patients first
received immunodepleting chemotherapy, in this study the addition of IL-2 avoided the adverse effect of activating regulatory T
cells.This allowed for highly favorable results (Table 3) that were
significantly more efficient than the results of the study involving
non-small-cell carcinoma patients. Of the 13 patients, 6 showed
positive clinical responses, and 4 showed mixed responses consisting of considerable shrinkage of at least one tumor. Although
the study was relatively small and was limited to melanoma patients, it nevertheless demonstrates the potential of adoptive
cell transfer in treating cancer patients (Dudley et. al., 2002).
In a similar trial, metastatic melanoma patients were treated with
different levels of immunodepletive therapy prior to adoptive cell

Table 3
Patient Demographics, Treatments Received, and Clinical Outcomes.
Treatment

Patient

Age/Sex

Cells
infused
(10^-10)

1

18/M

2.3

11/39

Other

9

Lymph(axillary
nodes mesenteric
pelvic)

PR (24+)

None

2

30/F

3.5

83/15

MART-1
gp100

8

Cutaneous, subcutaneous

PR (8)

Vitiligo

3

43/F

4.0

44/58

gp100

5

Brain, cutaneous,
liver,lung

NR

None

4

57/F

3.4

56/52

gp100

9

Cutaneous, subcutaneous

PR (2)

None

5

53/M

3.0

16/85

Other

7

Brain, lung, lymph
nodes

NR-mixed

None

6

37/F

9.2

65/35

Other

6

Lung, intraperitoneal,
subcutaneous

PR (15+)

None

7

44/M

12.3

61/41

MART-1

7

Lymph nodes, subcutaneous

NR-mixed

Vitiligo

8

48/M

9.5

48/52

gp100

12

Subcutaneous

NR

None

9

57/M

9.6

84/43

MART-1

10

Cutaneous, subcutaneous

PR (10+)

Vitiligo

10

55/M

10.7

96/2

MART-1

12

Lymph nodes, cutaneous, subcutaneous

PR (9+)

Uveitis

11

29/M

13.0

96/3

MART-1

12

Liver, pericardial,
subcutaneous

NR-mixed

Vitiligo

12

37/F

13.7

72/74

MART-1

11

Liver, lung, gallbladder,
lymph nodes

NR-mixed

None

13

41/F

7.7

92/8

MART-1

11

Subcutaneous

NR

None

CD8/CD4
phenotype (%)

Antigen
specificity

IL-2
(doses)

Sites of
evaluable
Metastases

Response
duration
(months)

Autoimmunity

PR = Partial Response, NR = No Response

Dudley et. al., 2002
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transfer in order to establish a level of immunodepletion that would
best enhance this treatment protocol (Rosenberg et. al., 2011). One
group of 43 patients received a nonmyeloablative preparative regimen, a less toxic method of immunodepletion. A second and third
group of 25 patients each, received a more toxic total body irradiation of 2 Gy and 12 Gy (Dept. of Homeland Security 15), respectively, in addition to a non-myeloablative preparative regimen. All
three groups were subsequently treated with adoptive cell transfer
(Rosenberg et. al., 2011).
The results of this study (Table 4) showed that at higher levels of
immunodepletion positive clinical outcomes following adoptive
cell transfer increased. In the group that received only a non-myeloablative preparative regimen, 49% of subjects showed an overall
response while 5% showed complete response. The group that
received 2 Gy of total body irradiation exhibited slightly higher incidence of overall response at 52%, but showed a large increase in
complete response at 20%. The group that received 12 Gy of total
body irradiation showed a marked overall response of 72% with
complete response at 40%, indicating that the greater the immunodepletion the greater the clinical outcome of adoptive cell transfer
(Rosenberg et. al., 2011).

Table 4
Regimen

No. of
Patients

Partial
Response
n (%)

Complete
Response
n (%)

Overall
Response
n (%)

No TBI

43

16 (37)

5 (12)

21 (49)

2 GY TBI

25

8 (32)

5 (20)

13 (52)

12 GY TBI

25

8 (32)

10 (40)

18 (72)

Total

93

32 (34)

20 (22)

52 (56)

TBI=total body irradiation, TIL=tumor-infiltrating lymphocyte

Phan, Rosenberg, 2013
One possible method to increase the overall effectiveness of
adoptive cell transfer and such positive results is to harness
a patient’s own CD 8 T cells to ensure that the T cells are as
specific to the cancer cell antigens as possible to. However, this
is likely a complicated task as it would require development
of a “new drug” for every patient. Another method that may
enhance the results of adoptive cell transfer is to take a sample
of the patients own cancer cells and test CD 8 T cell reactivity
to the cancer antigens thereby ensuring a highly reactive T cell
response. In another experiment, 20 metastatic melanoma patients received a less intense form of immunodepletion called
nonmyeloablative preparative regimen. However, no patient received total body irradiation. In this trial, however, T cells were
taken directly from the actual patients’ tumor and grown quickly in vitro, as opposed to using previously developed anti-tumor
T cells. This may have helped ensure T cells would be highly
specific and highly reactive to the patients’ own cancerous cells.
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Of the 20 patients treated, 10 had an overall response, of
which 2 had a complete remission and 8 had a partial remission. Additionally, 4 patients had stable disease, and 6 had progressive disease for an overall response of 70% (Besser et.
al., 2010). The results show that nonmyeloablative preparative
regimen, coupled with adoptive cell transfer that uses cells
harnessed from patients own tumors can be an effective treatment. Furthermore, analysis of the results may show that the
results are more positive then what is seen on the surface. Of
the 6 patients with progressive disease after treatment, all 6
started with stage M1c melanoma, which represents the stage
in which the tumor has traveled to vital organs (excluding the
lungs) or when the tumor has traveled to other areas and
the patient shows elevated levels of low-density lipoprotein
(“How is Melanoma Staged”). At this stage the cancer cells
may have been too numerous for the transferred T cells.
However, all patients with stages below M1c melanoma and
even some patients with stage M1c melanoma showed at least
some response to adoptive cell transfer, either complete response, partial response, or stable disease. This indicates that
adoptive cell transfer using patient’s own T cells, combined
with nonmyeloablative preparative regimen for immunodepletion is an effective treatment for early stages of metastatic
melanoma patients.
This trial, in which patients received only nonmyeloablative
preparative regimen for immunodepletion prior to adoptive
cell transfer, significantly outperformed the previously mentioned trial in which patients received only nonmyeloablative
preparative regimen for immunodepletion prior to adoptive
cell transfer. One possible explanation may be that this trial
used T cells taken from removed portions of the patients own
tumor, ensuring that the T cells used were highly reactive to
the patients cancerous cells.
As previously stated, immunodepletion prior to adoptive cell
transfer increases the effectiveness of the treatment. However,
immunodepletion effects the entire immune system, which can
have life threatening side effects. Therefore further study to
determine key components that effect the effectiveness of
adoptive cell transfer and how to precisely block them may
be helpful.
The most obvious immune element that would reduce the
effectiveness of adoptive cell transfer is regulatory T cells.
When developing T cells and B cells, the body has mechanisms
through which it ensures than no immune cell is released that
reacts to self-antigens; however, the system is not foolproof.
Regulatory T cells restrain the few immune cells that get
through those mechanisms and suppress them ensuring that
no self-cells are targeted by the immune system.
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It has been shown that regulatory T cells suppress anti-cancer
CD 8 T cells in vitro (Antony et. al., 2005). It would be logical
to hypothesize that regulatory T cells would also effect the T
cells transferred during adoptive cell transfer. To test for a correlation between regulatory T cells and adoptive cell transfer,
tumor bearing mice were treated with adoptive cell transfer.
Some mice were then injected with anti-Thy-1.2 antibody and
complement to suppress function of regulatory T cells, while
others were given active regulatory T cells. The results showed
that when regulatory T cell function was turned off the transferred T cells destroyed the cancerous cells. However, when
active regulatory T cells were added the size of the tumors
continued growing exponentially (North, 1982). This shows
that regulatory T cells have a large impact on the effectiveness
of adoptive cell transfer.
Although regulatory T cells decrease the effectiveness of adoptive cell transfer, simply turning them off while leaving the rest
of the immune system intact would allow surviving immune
cells that recognize self-antigens to attack patients’ healthy
cells causing autoimmune disease.
One method to reduce the effect of regulatory T cells on adoptive cell transfer without effecting the entire immune system
may be to induce apoptosis only in regulatory T cells in close
proximity to the tumor. This would allow the transferred T
cells to operate in an environment conducive to their function,
while allowing regulatory T cells in other areas of the body to
operate freely avoiding autoimmune disease.
Recently, it was suggested that the protein FasL-Fc can be used
to deplete regulatory T cells located only in tumors (Chen et.
al., 2007). To confine the protein FasL-FC to the tumor, a protein is incorporated into cell membranes and acts as a trap
for the Fc portion of FasL-Fc, not allowing it to escape the
confines of the tumor (Chen, Zheng, Tykocinski, 2000). To test
this suggestion, tumor bearing mice were injected with FasL-Fc
in the tumor region. The results showed a significant increase
in apoptosis of regulatory T cells in the tumors treated with
FasL-Fc, indicating this may be a viable option to decrease the
regulatory T cell effect on adoptive cell transfer without effecting the entire immune system (Chen et. al., 2007).
To test the actual effect of the protein FasL-Fc on adoptive cell
transfer, tumor bearing mice were treated with both FasL-Fc
and adoptive cell transfer. The results were a significant retardation of tumor growth in a large portion of mice. Additionally,
complete tumor regression was seen in 53% of the mice (Chen
et. al., 2007). This indicates that using the protein FasL-Fc may
be a viable option to eliminate the effect of regulatory T cells
on adoptive cell transfer while allowing the immune system to

operate regularly and without the risk of autoimmune effects.
To determine the impact of other immune elements on adoptive cell transfer, tumor bearing mice were tested and the results analyzed. In many studies, after irradiation of cancer bearing mice lacking regulatory T cells, effectiveness of adoptive cell
transfer increased. This indicates that regulatory T cells are not
the only elements responsible for decreased effectiveness of
adoptive cell transfer (Gattinoni et. al., 2005).
One hypothesis is that Natural Killer cells act as sinks for cytokines responsible for survival, proliferation, and function of
transferred CD 8 T cells (Gattinoni et. al., 2005). Host Natural
Killer cells, also in need of cytokines, compete for the same
cytokines necessary to support the transferred T cells leading to a limited amount of cytokines available to support the
transferred T cells. To test this hypothesis, tumor bearing mice
lacking endogenous B cells and T cells, including regulatory T
cells, were treated with anti-NK1.1 antibody to decrease the
number of Natural Killer cells to the number found after irradiation of the entire immune system. They were then treated
with adoptive cell transfer and compared to mice not given
the anti-NK1.1 antibody and treated with adoptive cell transfer. The results showed that removal of Natural Killer cells
increased the effectiveness of adoptive cell transfer, indicating
that Natural Killer cells play an important role in the function
of transferred CD 8 T cells (Gattinoni et. al., 2005).
One way to avoid the effects of cytokine sinks may be to precisely determine which cytokines the Natural Killer cells sink,
and stimulate an increase of their production giving the transferred T cells access to those cytokines.
To determine the effects of cytokines on adoptive cell transfer,
different cytokines were removed and added to tumor bearing
mice treated with adoptive cell transfer. Results indicated that
the cytokline IL-7 was needed to maintain survival and continued growth of transferred T cells, but was not necessary to
maintain function of the T cells. Conversely, IL-15 was necessary to maintain function, but did not play a part in survival and
proliferation of transferred T cells. This shows that increasing
both IL-7 and IL-15 at the same time increases the transferred
T cells effectiveness against tumors, while decreasing both IL-7
and IL-15 at the same time would decreases the transferred T
cells effectiveness against tumors (Gattinoni et. al., 2005).
These findings indicate that there may be a path by which regulatory T cells can be eliminated from the area of the tumor
(Chen et. al., 2007), and transferred CD 8 T cells can be stimulated to proliferate and enhance their effector functions without effecting the entire immune system (Gattinoni et. al., 2005).
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Conclusion
In conclusion, increasing CD 8 T cell count alone is not the most
effective way to use T cells to fight cancer. Instead immunodepletion together with an increase in anti-cancer T cells delivered
through adoptive cell transfer is an effective approach that has
been shown to be effective in humans with metastatic melanoma. Other factors besides immunodepletion also effect the
results of adoptive cell transfer such as cytokines, and the origin
of the T cells injected. The key to adoptive cell transfer success
with limited side effects, is the balance of all elements involved
which is a large task and requires further study but does seem
possible in the future.
However, for now, adoptive cell transfer is still a relatively new
method of treatment and still requires immunodepletion for
its effectiveness. This can bring with it its own problems, such
as an increased risk of infection and a limited ability to fight
infection. Additionally, most trials of adoptive cell transfer on
humans have been limited to melanoma patients, making further
research necessary for it to be used to fight other cancers. To
that effect, further studies are currently underway to broaden
this treatment to fight other cancers including, lymphoma, leukemia, and neuroblastoma (Deng et. al., 2014) giving hope to
cancer patients all over the world.
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Abstract
Traumatic brain injury has a devastating effect on millions worldwide each year. As yet, there are no methods which have
been proven to improve recovery from the trauma. Current treatment protocols revolve around reducing secondary
insult, such as hypoxia, hypotension, and cerebral edema, which raises intracranial pressure. The purpose of this study is
to assess the efficacy of three responses to traumatic brain injury. Two of them, the administration of hypertonic saline
and the administration of progesterone, are pharmacologic, while the third, the performance of a decompressive craniectomy, is surgically invasive. A number of original studies have been analyzed to develop an understanding of the topic. It
was concluded that hypertonic saline should only be given to patients in whom surgery is indicated, while progesterone
should be a widespread acute response. For relatively young patients suffering from uncontrollable intracranial pressure,
decompressive craniectomy should be considered as an immediate response as well.
Introduction
Traumatic brain injury serves as a major cause of death and
disability. Over one million people are treated for traumatic
brain injury in emergency rooms in America each year. Fifty
thousand die as a result, while seventy to ninety thousand are
left with debilitating long term neurological impairment. Among
men under the age of 35, traumatic brain injury as a result of
vehicular accident is the leading cause of death and disability
(Shear, et al. 2002). Besides for the direct effects of the primary
injury, outcomes are affected by the onset of secondary insult.
Such insult includes the onset of hypoxia, hypotension, and an
increase in intracranial pressure, which is often due to cranial
edema. Hypotension has been correlated with a mortality rate
which is double that of patients without the condition (Cooper,
et al. 2004; Cooper, et al. 2012; Shackford, et al. 1998). As yet, no
pharmacologic agent has been proven to improve the outcome
of traumatic brain injury, notwithstanding the intense efforts of
many researchers. To date, the management of traumatic brain
injury consists of preventing further neurologic insults, managing intracranial pressure, and instituting surgical procedures to
minimize damage (Shear, et al. 2002; Wright, et al. 2007; Xiao, et
al. 2008).
The severity of a traumatic brain injury is universally measured
according to the Glasgow Coma Scale, which assesses eye, verbal and motor condition following the injury. The scale which is
most often used is the Extended Glasgow Coma Scale, which
ranges from 3 to 15, awarding points for various functions which
can be achieved. A score on the Glasgow Coma Scale of 3 indicates death or a deep coma, while a 15 indicates complete
consciousness.
The outcome of traumatic brain injury is universally assessed
according to the Extended Glasgow Outcome Scale, which is
highly sensitive. It consists of eight diagnoses, which are: Dead,
Vegetative State, Lower Severe Disability, Upper Severe Disability,
Lower Moderate Disability, Upper Moderate Disability, Lower
Good Recovery, and Upper Good Recovery This study aims to
analyze and assess the effectiveness of three of the current acute

Extended Glasgow Outcome Scale
Spontaneous-open with blinking at
baseline
Opens to verbal command, speech,
Eye Opening Response or shout

Verbal Response

Motor Response

4 Points
3 Points

Open to pain, not applied to face

2 Points

None

1 Points

Oriented

5 Points

Confused conversation, but able to
answer questions

4 Points

Inappropriate responses, words
discernable

3 Points

Incomprehensible speech

2 Points

None

1 Points

Obeys commandes for movement

6 Points

Purposeful movement to painful
stimulus

5 Points

withdraws from pain

4 Points

Abnormal (spastic) flexion, decorti3 Points
cate posture
Exterior (rigid) response, decerebrate
2 Points
posture
None

1 Points

responses to traumatic brain injury, including both chemical and
surgical options. Methods used to decrease intracranial pressure
include hypertonic saline resuscitation and the administration of
progesterone, which has been touted as a neuroprotector. The
performance of decompressive craniectomy has also been factored into this study.

Hypertonic Saline
Hypertonic saline is administered intravenously, often en route
to the hospital. The underlying claim to the administration of
hypertonic saline is that it restores systemic blood pressure
and cardiac output to manageable levels with less volume being
necessary than when using the standard Lactated Ringer’s solution. The hypertonic saline extracts water from the intracellular
space in order to restore intravascular losses and it has a positive
inotropic effect on cardiac output. In addition, hypertonic saline
has been shown to improve oxygen transport, mesenteric and
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coronary blood flow, myocardial contractility, and redistribution of extracellular and interstitial fluid (Mattox, et al. 1991;
Shackford, et al. 1998).

hypertonic saline, as compared to a positive trend in the intracranial pressure of patients receiving Lactated Ringer’s solution.
This data was observed on the second day following trauma
(Shackford, et al. 1998).

Progesterone
Progesterone is administered in a similar fashion to hypertonic
saline. The concept of using progesterone to alleviate problems
caused by traumatic brain injury was discovered when researchers noticed a significant sex difference in trauma outcome in
correlation to hormonal cycling. Female rats with elevated
levels of progesterone showed reduced tissue damage and improved behavioral recovery (Shear, et al. 2002). As progesterone
has been used safely on humans for years, it was hoped that
it would have a positive effect on people with traumatic brain
injury (Wright, et al. 2007).While the mechanism is unknown as
of yet, progesterone has been shown to reduce cerebral edema,
prevent neuronal loss, improve functional outcome, and inhibit
oxidative damage in the central nervous system. It might also
promote peripheral remyelination of axons following injury.
Progesterone is lipid soluble, so it rapidly crosses the bloodbrain barrier to reach equilibrium within an hour of administration (Shear, et al. 2002; Wright, et al. 2007; Xiao, et al. 2008).

Decompressive Craniectom
Decompressive craniectomy is a surgical measure which is taken
when patients present with dangerously high intracranial pressure. Part of the skull is removed to allow room for the brain
to swell. Proponents of decompressive craniectomy state that it
can relieve uncontrollable intracranial pressure by increasing the
volumetric capacity of the intracranial cavity. Craniectomies have
been performed since the early nineteenth century, with varying
degrees of success (Akyuz, et al. 2010; Morgalla, et al. 2008).

Methods
This study was performed through analyzation of published original studies on the effects of hypertonic saline, progesterone, and
decompressive craniectomy on traumatic brain injury. Sources
include TouroLib databases, PubMed databases, and the archives
of Lancet.

Discussion
Hypertonic saline was found in all cases to be safe for use.
Shackford, et al. (1998) do caution that solutions that are too
hypertonic are liable to reversibly open the blood-brain barrier, cause cerebral edema, and increase intracranial pressure.
However, great care is taken to assure that proper proportions
are used. Solutions that are 7.5% hypertonic saline have been
shown to be both safe and effective (Bulger, et al. 2010; Cooper,
et al. 2004; Mattox, et al. 1991). Administration of hypertonic saline causes a slight increase in intracranial compliance, as shown
by a decrease in mean intracranial pressure in patients receiving

When administering hypertonic saline, fluid input must be
increased, as the saline decreases the fluid balance. No cases
of renal failure or neurological complications due to hypernatremia or hyperosmolarity have been found, but precautions
should be taken all the same (Shackford, et al. 1998).
Patients receiving hypertonic saline showed a higher rate of nosocomial infection due to the increased rate of the bloodstream.
The increased amount of fluid output also led to a higher incidence of urinary tract infections. In addition, administration
of hypertonic saline might cause regulation of the A3 receptor
on neutrophils, which would cause an increase in susceptibility
to infection (Bulger, et al. 2010). Patients receiving hypertonic
saline required a greater number of interventions to lower intracranial pressure over the course of their hospitalization, but
the difference was not significant (Shackford, et al. 1998).
While many studies have attempted to prove the superiority of
hypertonic saline over other standard protocols, such as mannitol and Lactated Ringer’s solution, most have been unsuccessful.
Out of five studies analyzed, only one study conclusively stated
that hypertonic saline was universally preferable to mannitol. In
that study, Battison, et al. (2005) administered four doses each
to nine patients. Two doses were of hypertonic saline and two
were of mannitol, in no particular order. The minimum intracranial pressure was measured ten minutes before each treatment
and was compared with the minimum intracranial pressure an
hour after each treatment. While hypertonic saline reduced
the intracranial pressure slightly more than mannitol did, there
was no significant difference. The duration of the effect, however, was seen to be significantly longer in hypertonic saline.
This study cannot be seen as conclusive, though, as it was only
done on nine patients. In addition, the patients received both
mannitol and hypertonic saline over a set period of time. As
such, the effect could be due to the presence of both mannitol
and hypertonic saline in their systems, and cannot be attributed
solely to the hypertonic saline.
Hypertonic saline has been shown to work slightly faster than
controls. Cooper reports that patients receiving hypertonic saline had a faster rate of decrease in intracranial pressure than
those in the control group. However, the study also states that
standard protocols are equally effective. All studies concur that
there is no significant difference in favorable outcomes of patients who receive hypertonic saline and those who are treated
with standard measures (Battison, et al. 2005; Bulger, et al. 2010;

51

Shoshana Fireworker

Cooper, et al. 2004; Mattox, et al. 1991; Shackford, et al. 1998).
While it may improve physiologic parameters, the long term
benefit of administering hypertonic saline is negligible. Patients
who received 7.5% hypertonic saline and those who received
Lactated Ringer’s solution showed identical neurologic function
after six months. The percentage of patients who survived to
hospital discharge was similar. Studies found no significant difference in intracranial pressure for the duration of hospital stay,
and there was no discernible difference in Glasgow Outcome
Scale values. (Bulger, et al. 2010; Cooper, et al. 2004; Mattox, et
al. 1991; Shackford, et al. 1998).

was noted, as well as an increase in peripheral remyelination of
axons, an inhibition of oxidative damage in the central nervous
system, and an overall enhanced recovery from cortical, cerebral, and spinal cord injury (Pan, et al. 2007; Shear, et al. 2002;
Wright, et al. 2007; Xiao, et al. 2008).

Progesterone

There has been much speculation as to the mechanism behind
progesterone. It has been ascertained that it works, but not how
it works. Progesterone down-regulates the inflammatory cytokine cascade, which can increase the damage caused by trauma.
Trauma causes a release of amino acids, which cause neuronal
exitotoxicity. Progesterone might act at the GABA receptor to
diminish that exitotoxicity (Shear, et al. 2002). The study by Pan,
et al. (2007) posits that progesterone acts as a sigma-1 receptor
antagonist, which can initiate the opioid-like capabilities of the
receptor. In addition, progesterone inhibits nuclear factor kappa
B, which is known to be a pro-inflammatory transcription factor.
Nuclear factor kappa B is the activator of numerous inflammatory cytokines, including tumor necrosis factor alpha, interleukin-1 beta, C3, and glial fibrillary acidic protein. Thus, inhibition
of nuclear factor kappa B decreases system-wide inflammation
(Pan, et al. 2007).

Aside from its long history of safe use, progesterone has been
proven to be completely safe for use in humans. A study was
performed with the express purpose of determining the safety of progesterone as a response to traumatic brain injury
(Wright, et al. 2007). It was found that administration of progesterone was in no way harmful to patients, and it was indicated that it might be beneficial to their recovery. Furthermore,
endogenously released progesterone causes a 1° F increase
in core body temperature. This deviation from standard basal
temperature might hinder neurologic outcome in a patient with
traumatic brain injury. However, the study found that no such
increase in body temperature manifested in relation to administered progesterone.

The timing and duration of administration are key to the effectivity of progesterone. Most studies found a correlation
between speedy dispensation of progesterone and favorable
outcome. Wright et al. (2007) reports that the greatest benefit
is gleaned when progesterone is administered within two hours
of injury, but that there is still great advantage when it is given
within 24 hours. Pan et al. (2007) and Shear et al. (2002) both
started treatment within an hour of injury. It was noted that
there is a consistent reduction in formation of cerebral edema
when progesterone is given within 24 hours of injury (Shear,
et al. 2002). There is a consensus that much of the success of
progesterone is dependent upon the timing of its initiation.

Multiple studies have found immense short term and long term
benefits from the use of progesterone as an acute response
to traumatic brain injury. Patients receiving progesterone had
significantly fewer deaths due to neurologic causes. At 30 days
postinjury, the mortality rate of patients receiving progesterone was less than half of that of the control group (Wright,
et al. 2007). A significant difference in neurologic outcome was
evident up to six months post-treatment, with the experimental group having a 58% favorable outcome as compared to the
control’s 42% (Xiao, et al. 2008). In addition, treated patients
showed a decrease in cerebral edema, necrotic cavity formation, and neuronal loss as compared to control groups, which
presented with neuronal and glial shrinkage and neutrophil infiltration. For example, necrotic cavity formation decreased by
approximately 20% in treated patients. A decrease in apoptosis

The duration of administration is slightly more controversial.
One study, citing the contradictory effects of inflammatory cytokines, limited the duration of progesterone to 24 hours. The
researchers claimed that while immediately following an injury,
inflammatory cytokines are neurotoxic, they are later neuroprotective. Seeking to block the initial harmful effect of inflammatory
cytokines yet capitalize on their latent neuroprotective abilities,
the study administered progesterone from 30 minutes to 24
hours following injury, at which time they ceased administration
of the treatment (Pan, et al. 2007). However, other studies noted
that the greatest benefit was attained when progesterone was
administered for five days (Shear, et al. 2002; Xiao, et al. 2008). In
the experiment carried out by Shear, et al. (2002) on rodents, one
group received progesterone for three days, while the other received it for five. It was concluded that five days of progesterone

Patients who were to undergo surgery showed a far better outcome when given hypertonic saline in dextran (Mattox, et al.
1991). However, at this time, hypertonic saline in dextran is quite
expensive, as compared to the cost of standard treatments, such
as Lactated Ringer’s solution and mannitol (Battison, et al. 2005).
Therefore, rather than staying as a first tier response to traumatic brain injury, perhaps hypertonic saline should be relegated
to a measure which is used only when surgery is indicated.
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are necessary to achieve the desired results, namely an alleviation
of the neuropathological and behavioral abnormalities which are
caused by traumatic brain injury. This finding seems to contradict
that of Pan’s. However, as harmful consequences of extending
the progesterone treatment have not been found, it might be advantageous to forfeit the possible neuroprotective capabilities of
inflammatory cytokines in favor of the documented benefits of an
extended progesterone treatment.

Decompressive Craniectomy
Craniectomy has long been used as a last resort in the treatment of traumatic brain injury. It is only when indicators of
incredibly high intracranial pressure manifest that craniectomy
is considered. Such indicators include compression of cortical
gyri and basal cisterns, signs of immediate herniation, and cerebral swelling (Morgalla, et al. 2008). In the majority of studies
analyzed, craniectomy was only used after standard protocols
had failed to lower intracranial pressure sufficiently. As such, it
is difficult to assess the efficacy of craniectomy, as it is generally
used only on patients with severe injuries who have already
undergone other treatments. Usually, by the time a craniectomy
is performed, there has been a lapse of time between injury and
the surgery (Morgalla, et al. 2008; Olivecrona, et al. 2007), limiting its benefit. Another hindrance to the study of decompressive
craniectomy is that due to the surgical nature of the procedure,
a blinded study is impossible.
While one study analyzed found decompressive craniectomy
to lower intracranial pressure but hinder favorable outcome
(Cooper, et al. 2012), four other studies found that long term
results justify the surgery (Akyuz, et al. 2010; Morgalla, et al.
2008; Olivecrona, et al. 2007; Qiu, et al. 2009). Cooper, et al.’s
2012 study reports that patients who received a craniectomy
along with standard treatment showed a less favorable outcome
after six months. However, the mortality rate was the same in
patients who had undergone the procedure and those who had
not. In contrast, Olivecrona, et al. (2007) found a 10% difference
in outcome, with those who received a decompressive craniectomy having the more favorable outcomes when compared to
patients who received only standard care.
Patients who had undergone a decompressive craniectomy
needed fewer interventions to lower intracranial pressure.They
required a shorter period of time on mechanical ventilation,
and they spent a shorter amount of time in the intensive care
unit (Cooper, et al. 2012). There was a significant reduction in
intracranial pressure directly after the surgery, which later stabilized to manageable levels (Olivecrona, et al. 2007). One study
found that 40% of patients who were otherwise likely to die had
favorable results after undergoing a decompressive craniectomy
(Morgalla, et al. 2008).

There are a number of caveats in regard to craniectomies.
Firstly, patients who underwent the surgery had a higher incidence of hydrocephalus (Cooper, et al. 2012), which necessitates additional medical or surgical care. Secondly, unilateral
craniectomies have been linked to delayed intracranial hematomas and subdural effusion, both of which must be treated
through surgical intervention (Qiu, et al. 2009). However, success has been seen in bilateral craniectomies. A problem with
all decompressive craniectomies seems to be an increase in
transcapillary leakage. The point of a craniectomy is to allow
room for swelling. The loss of resistance in the brain leads to
transcapillary leakage due to an increase in the transcapillary
hydrostatic pressure gradient. In order to counteract this effect
of a craniectomy, the transcapillary pressure must be lowered
by preventing an increase in arterial pressure and infusing albumin and packed red blood cells (Olivecrona, et al. 2007). These
issues are all collateral damage of decompressive craniectomies,
but the benefit of the surgery seems to outweigh the detriment.
An important factor to consider is the timing of the procedure.
While most craniectomies are performed after standard protocol has been tried and found unsuccessful, thus lengthening the
amount of time between the injury and the surgery, this might
not be the most advantageous use of craniectomies. Akyuz, et al.
(2010) compared the results of craniectomies on patients who
received the surgery following standard procedure to those
who received the surgery immediately. The first group had their
craniectomies around 35.7 hours after trauma, as compared to
the second group, who underwent the procedure approximately 4 hours after trauma. It was found that early decompressive
craniectomy resulted in a 48% decrease in intracranial pressure.
The group which underwent standard protocols before receiving craniectomies yielded a 27.8% favorable outcome as compared to the other group, which had a 50% favorable outcome
after 12 months. While the best results were found when the
procedure was performed within 4 hours of injury, performing
the craniectomy within 48 hours still provides benefit (Qiu, et
al. 2009). Using craniectomy as a second tier response hinders
the positive effects of the procedure, as an extended amount of
time with high intracranial pressure is detrimental to functional
outcome.
The size of the decompressive craniectomy is also significant. If
the craniectomy is too small, it will not allow the brain enough
room to expand. The brain will then swell through the incision,
causing external herniation. Bilateral craniectomies have the advantage of providing more space for the brain to expand (Akyuz,
et al. 2010).
Age is also an integral consideration when determining the outcome of decompressive craneictomy. In fact, the study done by
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Cooper, et al. (2012), which found the least favorable results,
was the study which included the oldest patients. It seems that
the highest recommended age upon which a craniectomy for
traumatic brain injury should be performed is 40, and that it is
detrimental to those over 60 (Akyuz, et al. 2010; Morgalla, et al.
2008; Olivecrona, et al. 2007). The greatest benefit is to younger
patients. This might be due to a stronger immune system or to
an elevated recovery ability in younger patients.

Conclusion
These three responses to traumatic brain injury are still being
researched. From the studies analyzed, it is apparent that due to
the negligible benefit and immense cost of using hypertonic saline, it should be reserved for patients with injuries that indicate
surgery. The status of hypertonic saline as a first tier response
should be reevaluated. Progesterone, on the other hand, should
be initiated into standard protocol. It shows no discernable
harm and has been proven to do much good. It is essential that
it be included in first tier response, as the immediacy of administration bears effect on the amount of good it can do for
the patient. Decompressive craniectomy should be considered
immediately in a case of uncontrollable intracranial pressure in
a relatively young patient, so as to capitalize on the efficacy of a
rapid craniectomy. In such a case, the gains outweigh potential
damage. However, all assessments must be made on an individual basis, as each patient presents a unique set of properties.
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Abstract
Living with a sensory impairment is challenging, and those who have lost the use of one sensory modality need to find
ways to deal with numerous problems encountered in daily life. When vision is lost, these challenges include navigation
through space, finding objects, recognizing people or surroundings, reading or even communicating without access to
nonverbal signs provided by others such as eye gaze or facial expressions. Nevertheless, the blind manage to function
efficiently in their environment, often to a surprisingly high degree. The key to this amazing phenomenon lies in the
plasticity of the brain and the connections it makes after loss of a sensory modality. Based off this theory is the idea
that the brain’s plasticity allows for the effective use of sensory substitution devices (SSD). Sensory substitution refers
to the transformation of the characteristics of one sensory modality into the stimuli of another modality. Primarily,
this paper will attempt to answer the question of whether or not auditory to visual sensory substitution devices have
the potential to be incorporated into long term rehabilitation efforts for the blind. In order to conclusively answer this
question, this paper will discuss how effective these devices are in recreating the lost sense, in terms of acuity, pattern
recognition, depth perception, SSD based movement, and sensory perceptions acquired from long term use of SSD’s by
blind patients.
Introduction: Neuroplasticity following blindness
Neuroplasticity describes the brain’s ability to change its structure and function throughout the course of a lifetime. The
largely differing conditions in the brain following early onset
sensory impairments such as congenital blindness or deafness,
allow for large scale changes that promote a full reorganization
of the brain. This may result in a functional network remarkably
different from the one seen in healthy individuals. Accordingly,
in a congenitally blind person, despite the lack of visual input
to the brain, the visual cortex does not degenerate, but rather
it receives input from non-visual functions such as touch and
audition (Bubic, et. al., 2010). Functional neuroimaging methods
validate these findings by showing that the occipital cortex functionally engages in perceptions such as audition (Gougoux, et al.,
2005; Kujala, et al., 2005) and tactile Braille readings (Gizewski,
et al., 2003). Studies in which auditory (Collingnon, et al., 2006)
and tactile processing (Merabet, et al., 2004) were disrupted via
transcranial magnetic stimulation to the occipital cortex confirm the necessity of occipital engagement in these non-visual
functions. Recently, anatomical studies in primates indicated the
existence of projections from the auditory to the visual cortex
(Chabot, et. al., 2007) Furthermore, it is important to realize
that the involvement of unimodal brain regions (occipital cortex) in cross modal perception (auditory and tactile stimuli processed by the occipital cortex) is not only limited to individuals
with sensory impairments, but can under specific circumstances
be identified in the general population.The difference is that the
cross modal involvement is much more pronounced in those
with sensory impairments, perhaps due to increased neuroplasticity, as sensory areas deprived from their customary sensory
input become integrated into other neural circuits, affecting the
entire system as a whole (Bubic, et. al., 2010).

Sensory substitution devices/ the humanmachine interface:
Sensory substitution refers to the transformation of the characteristics of one sensory modality into the stimuli of another
modality. For example, it is possible to replace vision with touch
or audition, and to replace audition or vestibular sense, with
touch. This paper will focus on sensory substitution devices
(SSD’s) which replace vision with audition, otherwise known
as auditory to visual sensory substitution devices. In general,
auditory to visual SSD’s capture visual information via a video
camera, which then transforms the images into auditory input
that is conveyed to the user using headphones or an earpiece
(Bubic, et. al., 2010). (Figure 1)

Figure 1

The general concept of a sensory substitution device (SSD) and a typical
visual to auditory setup. SSD’s typically include a visual capturing device, a
computational device transforming the visual input into auditory input, and an
output device, transforming this information to the user (Bubic, et. al., 2010).
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Different auditory to visual SSD’s primarily differ in the conversion algorithm the computer utilizes to transform the visual information into auditory input.To formulate an answer regarding
the rehabilitative value of auditory to visual sensory substitution
this paper takes into account the following selection of auditory
to visual SSD’s which are used in the various studies cited later
on. The first auditory SSD developed is the vOICe system. The
capital letters conveniently stand for “Oh I See”. The vOICe
utilizes a conversion algorithm in which for every image picked
up by the camera, the vertical axis is represented by frequency,
the horizontal axis is represented by time and stereo panning,
and the brightness of the image is encoded by the amplitude of
the sound (loudness). The resulting sound encoding the image
is termed a “soundscape” (Bubic, et. al., 2010). (Figure 2) The
voice can theoretically generate a resolution up to 25,344 pixels
(Striem- Amit, et al., 2012).

determined by a set of sensors. So, a receptor is concerned by
a particular area of the captured video frames. Each receptor
produces a signal that can be interpreted as a sound. The signals
of all the receptors are mixed together to produce a stereo
audio output that can be adequately adapted for human perception (Hanneton, et al., 2010). Lastly, Israeli Scientists have come
up with a new device called EyeMusic which uses an algorithm
that is similar to vOICe algorithm in most respects, except that
it also conveys color. It distinguishes color by using different
musical instruments for each of the four colors: white, blue, red,
and green. Black is represented by silence. In order to increase
the pleasantness of the sound the device was created with a relatively low resolution of 24 by 40 pixels, is (Abboud, et. al., 2014)

Figure 2

Recent neuroimaging studies have investigated the neural bases
of sensory substitution, raising questions about the nature of sensory substitution in blind versus blindfolded individuals. (Poirier,
et. al., 2007a) Studies show Occipital activation in both blind and
blindfolded sighted subjects while using auditory SSD’s. Using
Positron Emission Tomography (PET), Arno and colleagues have
shown that pattern recognition using the PSVA induced the recruitment of extra-striate occipital areas (BA 18 and 19) in early
blinded subjects, and to a lesser degree in blindfolded sighted
control subjects (Arno, et. al., 2001). In another study PET was
used to show activation of the visual cortex during depth perception using an auditory SSD. In this study blindfolded sighted
volunteers used the PSVA to determine depth based on the
relative target size, the proximity of the target to the horizon,
and the linear perspective. The exercise was found to involve
the extra-striate area BA 19 (Renier, et. al., 2005). A study using
functional Magnetic Resonance Imaging (fMRI) has shown that
pattern recognition through an auditory to visual device can
induce the recruitment of striate (BA 17) and extra-striate
(BA 18 and 19) areas in blindfolded sighted subjects (Poirier
et al., 2007b). These studies show similar occipital activation in
the blind and sighted when using these devices, however the
basis of the visual activation in each subject group is debated.
In general, the use of SSD’s seems to induce visual brain areas
via two processes: mental imagery and cross modality. Though
cross modality, a function of the brain’s neuroplasticity, seems
to be the primary basis of SSD use, mental imagery may play an
important part in the process, especially for blindfolded sighted
users. Both blind and sighted people can perform mental imagery.The phenomenon of cross modality, though more significant
in the blind, occurs in the sighted too. So, both processes can be
performed by either group. In addition, both mental imagery and
cross modality are known to activate the visual area of the brain.
After reviewing the data a study by Poirier et al proposes that
perhaps mental imagery is predominant in sighted subjects, and
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A schematic summary of the vOICe algorithm.Time and stereo
panning constitute the horizontal axis in the sound representation of
an image, tone frequency makes up the vertical axis, and loudness
corresponds to pixel brightness (Bubic, et. al., 2010).

Another more recently developed device is the Prosthesis for
Substitution of Vision by Audition (PSVA). The algorithm is similar to vOICe, except the PSVA uses a frequency mapping to
map horizontal position as well as vertical position. Thus, the
frequency associated to each pixel increases from left to right
and from bottom to top. Furthermore, in order to enhance the
similarity with the human visual system, the receptor field of
the PSVA has a higher resolution in the center of the picture to
simulate the human fovea (Hanneton, et al., 2010) In contrast,
the PSVA has a maximal theoretical resolution of only 124 pixels
(Striem- Amit, et al., 2012). Another device known as the Vibe
converts a video stream into a stereophonic sound stream. It
uses a virtual retina composed of two levels of “cells”; sensors
and receptors. Each sensor corresponds to a particular pixel.
The activity of the sensor is a function of the coded components of the captured pixel. A receptor has a receptive field
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Occipital Activation through the use of Sensory
Substitution Devices

Auditory to Visual Sensory Substitution Devices for the Blind

The results, analyzed on both a group level and on an individual
basis, showed that group performance differed statistically from
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An important factor regarding the usefulness of SSD’s is the
amount of detail resolvable to the user. To measure this, a study
was conducted using the Snellen E- chart visual acuity test. This
test, generally used by ophthalmologists, was adapted into an
auditory version via the vOICe technology, and used to test the
visual acuity of a group of eight congenitally blind, and one early
onset blind individual. Each participant was trained for several
months in a two hour weekly training session, by a single trainer,
on a one by one basis. The training program was composed of
two features. One part focused on structured two dimensional
training, in which the participants were taught how to process
two dimensional static images such as letters, numbers, faces
and houses using the vOICe. The second part, live view training, focused on visual depth- perception and training in hand
“eye” coordination using the vOICe.The test was conducted by
playing soundscape stimuli in a pseudo randomized order of E
directions. Patients had to state the rotation of the letter E (up,
down, left, right). (Figure 3)

Figure 4
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Discussion: Acuity

chance level, and individual visual acuity scores varied between
20/200 and 20/600. Five of the nine participants had visual acuity that exceeded the visual acuity threshold for blindness of
20/400 as defined by the World Health Organization (WHO).
(Figure 4)
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The information in this paper was obtained from Touro College’s
online database and from various online medical journals. All of
the data is experiment based, collected and analyzed to best
answer the question of how effective SSD’s are and to analyze
their potential to be incorporated into rehabilitation efforts for
the blind.

A blind participant perceiving an image of a large Snellen E and
identifying its direction (Striem-Amit et. al., 2012).

20

Methods:

Figure 3

Performance (% success)

cross-modality is predominant in blind subjects (Poirier, et. al.,
2007a). Both populations may fare better in different respects
following this proposal. The sighted or for practical purposes
late onset blind, who predominantly utilize mental imagery, will
be able to better associate the cross-modal input to the properties of vision as they knew it. On the other hand, the early blind
who lack such understandings of the visual world, and instead
primarily utilize the cross modality of the brain, due to more
highly developed cross modal networks and plasticity, seemingly
have a larger potential in the realm of sensory substitution.(
Bubic, et. al., 2010) In general, this paper will value this proposal, and when analyzing various studies which utilize blind and/
or blindfolded participants, it will acknowledge the discrepancy
in their use of SSDs, and the effect that these differing modes
of use have on the results when applicable, while still focusing
on the broader picture. This approach will help when trying to
determine an answer regarding the rehabilitation potential of
these devices for the blind, as this paper is less concerned with
the effects and potential of these devices in regard to sighted
individuals.

The group performance on the Snellen acuity test, also displayed is
the WHO Blindness Threshold (BT) (Striem-Amit et. al., 2012).

The study also showed that participants were able to identify
and mimic the body posture of a person standing a few meters away and navigate in crowded corridors while avoiding
obstacles. One of the participants was able to identify live three
dimensional emotional facial expressions. Capabilities such as
these provide a basis for the device to be used in natural settings, which are sufficiently more complex than those present
in the study. (Striem-Amit et. al., 2012) Another study also investigated the acuity of users of the vOICe via the Snellen E
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test. This time, however, all the participants were blindfolded
sighted vOICe users who received no training prior to experimentation. In this way the study aimed to provide a benchmark
measure of acuity, because in the previous study it is unclear
whether the acuity levels achieved are due primarily to the
resolution of the device, or rather the compensatory neural
plasticity of the blind participants, combined with their expertise in using the device.The participants included 26 adults all of
whom reported normal vison. The participants completed two
experimental procedures using the Snellen E test. In the first
test scores of 20/2464 and 20/4682 (in comparison with normal
vision: 20/20) were achieved by the highest number of participants. In the second test a score of 20/2464 was achieved by
the highest number of participants, showing a marked improvement from the first test. In general, the acuity results from this
study are much lower than those of the previous. However, the
participants in this study received less than 1% of the training
received by participants of the previous study. In addition, since
all the participants of the previous study were blind this was
probably a factor in their high performance. Nonetheless, these
results are significant, because they show that very little training
or explanation is required to carry out this task using an SSD
(Haigh, et. al., 2013). This study is important because it helps to
define the minimum capability of the device. The participants
were both blindfolded and received no training and still managed to extrapolate results, showing the even greater potential
of the device with blind users who will use the device after
many hours, days or even years of practice, and who may also
have developed compensatory neuroplasticity. In addition, these
studies of acuity along with future studies of acuity using auditory SSD’s, are important in providing a standard measure of acuity for comparing sensory substitution algorithms, and individual
differences in sensory substitution acquisition. Furthermore, a
standard measure of acuity might be helpful to test the resolution and precision of synesthetic experiences described by long
term users of SSD’s as described below.

Pattern Recognition
One of the most important developments in information technology is the graphic user interface (GUI). However, the GUI
has presented a new challenge for blind people given its inherent visual nature, with icons, multi windows, and mouse-based
command structure. Similarly, in the current world of communication, graphics play an increasingly important role. Numerous
graphs, charts, diagrams and other forms of visual communication are included in documents intended to be read by sighted
people. Thus, blind people remain at a great disadvantage for
graphical information access. In a study by conducted pattern
recognition in a computer environment was investigated in six
early blind and six blindfolded sighted subjects using the PSVA.
By comparing performance of both groups, the study aimed to
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investigate the effect of early visual deprivation on recognition
of visual patterns. Subjects were trained during twelve, one hour
sessions. During training the subjects learned how to recognize
patterns displayed on a PC screen by exploring the graphics
tablet with a pen. Subjects heard sounds related to their hand
movements and had to recreate the pattern in a frame using
aluminum dots and strips. At the end of training, learning was
tested by having the subjects recreate patterns which they had
encountered during training. Performance was evaluated on the
basis of response accuracy and processing time needed to answer. Accuracy was assessed by finding the number of common
points between the subject’s recreated pattern and the actual
pattern. The results showed that early blind and blindfolded
sighted subjects are able to recognize patterns from auditory
feedback related to hand movements, but the early blind scored
better in both accuracy and processing time. This suggests that
mental imagery is not a prerequisite for the development of
these representations. The results are encouraging from a rehabilitation point of view by showing that pattern recognition
in a computer environment is possible using a vison to audition
coding scheme without previous visual experience. (Arno, et.
al., 2001)

Depth Perception
Sighted people use depth perception for many applications
such as obstacle avoidance, navigation, object localization, and
grasping. A study investigated how early blind subjects interpret
visual depth cues and use them to locate objects using the PSVA
SSD, and how sensory substitution can contribute to the development of depth perception and visual perspective in early
blind subjects through interactions with the environment. The
participants included twenty blindfolded sighted volunteers and
ten early blind individuals. All received training in recognizing 2D
shapes with the device. None of the participants had previously
used the SSD to localize objects, or to explore a 3D environment. The experiment was divided into a pre-test, a practicing
session, and a post test. Results from the pre and post-test were
compared to see the effect the practicing session had on each
of the subjects groups. During the pre-test subjects explored a
three dimensional set up via a head mounted camera. The set
up consisted of a black table surrounded with six white poles
with twenty preselected positions on the table for a white cube.
(Figure 5).
The cube was placed pseudo randomly at different positions
during the experiment. After exploring a specific set up, the
PSVA was turned off, the cube was removed, and the subjects
had to replace it by hand in its initial location. Scores were calculated by finding the difference between the correct position
and the position the subject placed it in. Each participant completed 20 set ups. In sighted subjects the mean error score was
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Figure 5

View of the 3D display used in the experiment. The perceived size,
height in the field view and the geometrical perspective induced by
the poles can be used as depth cues to estimate the egocentric
distance of the white cube.The arrows indicate the width and depth
axes of the scene. (Renier, et. al., 2010).
about 11 cm for the depth and about 5.5 cm for the width. In
early blind subjects, the error score was about 19 cm for the
depth and 5 cm for the width. These results show better performance in sighted subjects for the depth and little difference
for the width. These results are explained due to the fact that
sighted subjects used their knowledge about visual depth to
perform the task with the PSVA, in other words using a form
of mental imagery, while the early blind subjects were affected
by their lack of visual experience. Then, during three 45 minute
practicing sessions, subjects got to practice with the PSVA in
the 3D display. All subjects had the same number of trials to
practice with the PSVA. The post-test following the practicing
session consisted of the same procedure as the pre-test. When
comparing the scores, significant improvement was seen in the
early blind subjects for determining depth, while on a whole
there was no significant improvement in the sighted subjects.
Only those in the sighted group who were the least accurate
in the pre-test showed an improvement in the post test, seemingly representing a ceiling level for accuracy in sighted subjects.
However, the improvement seen in the early blind was probably
due to enhanced tactile and auditory abilities which contributed to an optimization of the learning process, thus enabling
them to learn how to correctly use visual depth cues. With a
longer practice period it is likely that early blind subjects would
outperform the sighted subjects. These results suggest that visual experiences via an SSD can help blind people learn visual
perspective and pictorial depth cues both of which are key for
depth perception. (Renier, et. al., 2010)

Fast accurate reaching movements with a visual
to auditory SSD:
Previously this paper has discussed acuity, pattern recognition,
and depth perception using auditory SSD’s. A further study discusses SSD’s in regard to sensorimotor integration, which is
critical in the effort to make SSD’s relevant for everyday tasks,
including making accurate reaching movements toward objects,
and interacting with people and objects. The purpose of the
study was to test the use of auditory SSD’s to guide a fast reaching movement. This study utilized the EyeMusic SSD device, and
involved 18 sighted participants who were naïve to the use of
SSD’s. The experiment consisted of a familiarization session and
a test session. During the test session participants used a pen
shaped stylus to perform 2D reaching movements with their
dominant hand on top of a digitizing tablet. Movements were
made from a center location to one of four 2 cm radius targets,
represented by a white square located 6 cm from the center. In
the testing session, participants performed two blocks of trials,
which differed by the type of feedback provided: either auditory
(SSD) or visual (VIS). During the SSD block participants were
blindfolded, while during the VIS block, the participants’ arm was
placed under an opaque cover, such that they did not have direct visual feedback of their hand. (Figure 6)

Figure 6

The experimental setup: A participant performing the SSD block
blindfolded (on left). A participant performing the VIS block, with his
forearm hidden from view by an opaque cover (right) (Levy-Tzedek
et. al., 2012).
Participants did not receive feedback on their movement path,
but received feedback on the location of their hand at the end
of each trial. If the endpoint location was within 2 cm of the
center of the target the trial was considered successful and only
feedback on the location of the endpoint was given in the form
of a blue square. However, if the end location of the hand was
farther than 2 cm away from the center of the target, feedback
on the location of both the target square (white), and endpoint
(blue) was given, such that participants could use their end
position relative to the target to correct future movements.
During the SSD block the participants did not see the squares
when receiving feedback, but could distinguish between the
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target and the endpoint square because of special eye music
algorithm which allows for color incorporation, piano for white
and marimba for blue. The following measures were used to
characterize participants reaching movements under the two
feedback conditions; movement time: the time elapsed from the
movement onset to termination, peak speed: the maximal hand
speed during the movement, path length: the total displacement
of the hand from the beginning to the end of the movement, and
endpoint error: the distance between the hand’s final position
and the target. Surprisingly, there were no significant differences
between movements performed with SSD feedback compared
to those performed with visual feedback in term of movement
time, peak speed and path length. Average endpoint error in
both types of movements was smaller than 0.5 cm. It is likely
that with further practice participants will be able to perform
movements with an even smaller endpoint error using the
EyeMusic SSD. The main limit on the study is the fact that it did
not include any blind subjects. As previously explored, because
the subjects were sighted it is possible that rather than using
auditory information directly to control movement, they “translated” it into a visual image of the target location, and acted
based on this image. However, the study is strengthened by the
fact that there was no visual information given of the target
directly before or during the testing block, so there was no possibility to perform any vision based calibration between trials,
which could help to improve subsequent trials (Levy-Tzedek
et. al., 2012) Furthermore, the use of sighted subjects is auxiliary, because it allows for the movements using an SSD to be
compared to the movements of the same individuals using sight.
This helps to better define this capability using the device. With
blind subjects there would be no comparison point, because the
subjects can only reach out blindly. Nonetheless, a future experiment with blind individuals would reveal the ability the ability
of blind subjects to create a spatial representation, and act on it,
without the possibility of mediation by visual imagery. Still these
results are important since those obtained from the SSD block
can be used in a future study as a comparison point for blind
individuals using an SSD. Furthermore, if the blind can replicate
the accuracy level reached in this study by the sighted subjects,
then performing daily tasks with an SSD is feasible, and thus the
prospects of the rehabilitative use of SSD’s are broadened.

Novel SSD’s what they offer to the world of
rehabilitative techniques: Eye Music and The Vibe
Thus far, various experiments have demonstrated the ability
of blind users to use SSD’s on various levels. However, most
auditory SSD’s generate unpleasant sounds and also lack color
information. For some this provides for a bland and somewhat
irritating experience at times. Eyemusic was created to address
these issues by using natural instruments to convey visual information in a pleasant manner, while also conveying color
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information. Different instruments represent different colors
and the ceiling frequency was limited to 1568 Hz, because high
frequency ranges have been linked with unpleasantness. A study
was conducted to see if the device accomplished these goals.
The study included twelve blind participants, and ten sighted
blindfolded controls. Part of the study included a survey which
asked the participants to compare the pleasantness of EyeMusic
with the pleasantness of the vOICe, the leading algorithm for
many auditory SSD’s. This was done by generating two second
soundscapes using the vOICEe SSD and EyeMusic in their default modes with a two second break between them. All but two
participants scored the soundscapes generated by the EyeMusic
as more pleasant on average. Of these two participants one
scored the vOICe soundscapes as equally pleasant on average,
and the other found the vOICe soundscapes to be slightly more
pleasant on average. On a whole these results are promising
suggesting that EyeMusic could be a step forward in terms of
user experience. Notwithstanding, the increased pleasantness
and potential for prolonged use come at the expense of image
resolution. Therefore, EyeMusic could be useful for tasks that
that require prolonged use or when color is valuable to the
user, while other devices, such as the vOICe, that offer higher
resolution could be used for tasks demanding finer detail. One
device does not have to replace the other; rather, each with
its specific characteristics can be utilized at different points to
augment the rehabilitative process. In addition, since the sounds
generated by the device are relatively pleasant this may encourage users to use the system as pleasant sounds are said to
induce positive emotions ( Abboud et. al., 2014) The Vibe is another SSD developed that offers extra versatility, an important
feature when trying to tailor the device for a specific user. The
mechanism of the device is described above briefly. This unique
format allows for several innovations. The first is pre-filtering
of the video stream. A useful example of this is the application
of a threshold to the captured pictures.The threshold can make
a great number of receptors silent, and consequently can make
the resulting audio signal less complicated and more comfortable for the user. A second example of pre-filtering is the use of
a filter that computes as input to the Vibe a time difference of
successive captured frames.With this kind of filtering, instead of
producing a continuous and complex audio stream, the Vibe will
generate sounds only if there are changes in the video stream.
This functioning can also be more comfortable and less tiresome
for the user than the static solution that continuously produces
a complex sound. One can imagine building filters that combine
thresholds and time differences for an optimal user experience.
Another adaption is sensor distribution which affects the pixels addressed by each sensor of each receptive field. Receptive
fields can thus be large or small, identical or different, overlapping or non- overlapping. The distribution of the sensors on the
2D plane of captured pictures can affect the perceptive abilities
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of the user. Thus, the sensor distribution can be modified for
specific users and in specific situations when different effects
are wanted. Finally, the Vibe also offers the possibility to enhance
the binaural perception and differentiation by the listener of
the sound by adding inter-aural disparity cues to the sound like
inter aural time differences.This can be done by adding delays to
the transfer functions of the receptors (Hanneton, et. al., 2010)
The versatility of the Vibe, allows for extra capabilities, which
enhance the user experience and customization, allowing it in
these respects to serve as a better rehabilitative tool.

Long Term visual experiences in the blind
induced by SSD’s
Ward and Meijer (2010) investigated the phenomenology of
two late onset blind users of the vOICe system. The users both
report detailed visual phenomenology that developed within
months of immersive use and has continued to evolve over a
period of years. In addition, their long term use of the device
seems to have produced an acquired synesthesia. Synesthetic
experiences are percept in nature and are elicited by a stimulus
and occur involuntarily. Furthermore, the experienced sensation co-exists with the induced one rather than replacing it. So,
for a synaesthete a sound is seen, but it is also heard. This effect
may be due to different mechanisms of plasticity that emerge
after long term use of the device. One is unmasking of existing
cross modal connections, and another is a slower reorganization perhaps associated with changes in synaptic connectivity.
The two subjects in the study PF and CC both became blind
at the ages of 21 and 33 respectively. PF currently has a small
amount of light perception in the left eye, while CC has a low
visual acuity that enables her to count fingers in front of her,
and notice large objects in strong contrast. Both were asked a
series of questions to understand their visual experience, how
it developed, and the extent to which it comprises an acquired
synesthesia. Initially, both were asked about perceiving edges,
contrast and acuity. PF reports visual experience in terms of a
non-detailed grey scale sketch. She says, “I cannot tell fine little
tiny details. Rather my vision is based upon black and white and
all the little gradients in between. The best way I try to describe
this to people is : take a large black sheet of paper; now take a
magical piece of white chalk and sketch me here on this stage
in line drawing now make me three dimensional…”. CC, like PF
also claims not to get enough visual detail to identify a person’s
sex or age with the vOICe, but can sometimes differentiate sex
based on clothing. She says, “I could tell whether they had a
long coat on or shorts…” Both PF and CC report being able
to perceive depth, but that the ability occurred gradually, and
only after having flat visual experiences of edges and shading. PF
described the acquiring of depth perception as a sort of eureka
moment that occurred while she was washing dishes as she
looked down at the sink and realized with astonishment, “Oh

I can see down. I can see depth.” In addition, both were asked
about perceiving movement.The vOICe software normally converts one visual image per second into a soundscape and is not
well suited for detecting fast moving objects. However, both PF
and CC no longer report any subjective experience of jerkiness,
nor is their experience a series of snapshots. PF describes it like
using a flip book, “You don’t see the different breaks between
images.” Likewise CC says at first it was like a very jerky movie,
but now she experiences smooth movement. As far as acquired
synesthesia, both PF and CC claim to be able to ‘see sounds’
when not using the vOICe. Their brains have internalized the
vOICe rules for mapping between hearing and vision, and the
rules are applied, both, when the device is worn, and when it is
not. CC describes her synesthetic experience: “Monochrome
artificially induced synesthesia, only in certain frequencies of
sound. A small price to pay for very detailed vision, but the consultant’s music next door sets me off as well (Bach Mass in B
Minor)… It is not triggered by all sounds but by vOICe like
sounds. It is almost as if you had a computer with two monitors running simultaneously different pictures… and sometimes
you switched your attention between both.” PF also gives visual
descriptions, all monochrome, to a number of simple sounds.
In addition, PF also believes her synesthetic experiences are
stable, a hallmark feature of developmental synesthesia. On a
whole, both the sound of human speech and the sound of most
instrumental music do not elicit visual experiences. This study
is enlightening, but also raises further questions. Would congenitally blind users acquire an altered sense of visual like space
as a result of using the device, or is prior vision a prerequisite
for these experiences that go beyond the scope of what the
vOICe SSD delivers in most experiments? Furthermore, are the
particular mappings used by the vOICe special in some way, or
could any consistent mapping between vision and audition lead
to these kinds of experiences? It is noteworthy that for both
their phenomenology has developed over time. The length of
time using the device may be the key to both of these questions,
but further study on a larger sample size would be necessary.

Conclusion
The data from the studies supports the use of SSD devices in
the rehabilitation for the blind. Most studies comparing the use
of blind versus blindfolded volunteers showed increased potential for blind users using these devices. However, more data
should still be collected. The present studies are limited by the
relatively small sample size of volunteers, and the lack of real
data following long term use. Additionally, the testing set up of
the experiments cannot parallel the real world which is fast
paced and demanding, so it would have to be determined if the
clear benefits as demonstrated under testing conditions could
be utilized in a real world setting, when the subject has little
room for error. In the long term, sensory substitution devices
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seem to be both a promising and innovative addition to the
rehabilitation of blind people.
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Abstract
Influenza is a disease that has caused the deaths of tens of millions people in the last century alone. The influenza neuraminidase protein is essential in the mechanism infection. It enables the virus to leave the infected cell and proliferate.
Antiviral neuraminidase inhibitor drugs can be used for treatment. The drug Tamiflu is the standard of care for both
treatment and prophylaxis of influenza. The Cochrane reports of 2009 and 2014 conclude that evidence is lacking to
support this. Numerous bodies disagree. Cochrane also question the accuracy and credibility of many studies and
agencies in support of Tamiflu. This paper explores the issues.
Introduction
Influenza is a viral disease that routinely causes significant morbidity and mortality. Influenza pandemics have been responsible
for the deaths of tens of millions of people in the last century
alone. Science has been desperately searching for any agent to
mitigate the effects of this infectious disease.
Tamiflu (a neuraminidase inhibitor) was brought to market in
the last 20 years with great fanfare and hope. During the 2009
influenza pandemic government agencies and hospitals spent
billions of dollars stockpiling the Tamiflu. It was widely touted
by health professionals and the media as an effective “silver
bullet” for the disease. In 2009 The Cochrane Report created
a tremendous uproar with a British Medical Journal (BMJ) report that concluded that Tamiflu was not effective. Despite the
controversy, Tamiflu continues to be recommended for use at
clinics and hospitals as first line defense for treatment as well as
prophylaxis (Zachary 2015).
Like any medication, use of Tamiflu involves financial and other
costs i.e. side effects. Given that it is not a benign drug, it behooves us to explore the controversy in detail.

Methods
The information for this paper was obtained from many online resources. Many of the databases and journals used were
accessed through the Touro library database and PubMed.gov.
Much of the background information and pictures were accessed through Dr. Vincent Racaniello’s (College of Physicians
and Surgeons of Columbia University) “Virology 101” blog.

Background
Influenza is a viral infection that attacks the respiratory system
(the nose, throat and lungs). It is caused by one of the three
types of influenza viruses A,B and C. Influenza viruses can be
spread by airborne droplets(aerosols) person-to-person contact, or contact with contaminated items (fomites). Airborne
spread appears to be the most important mechanism. A single
sneeze can generate up to 20,000 virus containing aerosol particles. Aerosolized particles produced by these activities are of
different sizes. The largest droplets fall to the ground within a
few meters and will transmit an infection only to those in the

immediate vicinity. Smaller droplets can travel long distances
determined by their size.
Onset of symptoms ranges from 1 to 4 days with an average
of about 48 hours. Symptoms include sudden onset of chills,
fever, cough, and generalized aches and pains. Severe Headache
is common. In mild cases, many symptoms are like those of a
common cold e.g. sore throat, runny nose, and mild conjunctivitis may also occur. After 2 to 3 days, acute symptoms rapidly
subside, although fever may last up to 5 days. Cough, weakness,
sweating, and fatigue may persist for several days or occasionally
for weeks.
Influenza-related pneumonia is an important cause of increased
morbidity or mortality in high-risk patients. Encephalitis, myocarditis, and myoglobinuria, sometimes with renal failure, develop infrequently after influenza A or B infection. Patients at
higher risk are those with: underlying illness, acute respiratory
distress syndrome, primary influenza pneumonia, or secondary
bacterial pneumonia .These include: Children under the age of
4 years; adults over the age of 65 years; people with chronic
medical disorders (e.g., cardiopulmonary disease, diabetes mellitus, renal or hepatic insufficiency, hemoglobinopathies, immuodeficiency); women in the 2nd or 3rd trimester of pregnancy
and patients with disorders that impair handling of respiratory
secretions (e.g., cognitive dysfunction, neuromuscular disorders,
stroke, seizure disorders).
Aside from the use of antivirals such as Tamiflu treatment is
symptomatic. This includes rest, hydration, and antipyretics
as needed. Appropriate antibiotics are necessary for treating
complicating bacterial infections. Antiviral drugs given within 1 to 2 days of symptom onset may decrease the duration
of fever, severity of symptoms, and time to return to normal
activity. The two main drug types are the neuraminidase inhibitors Oseltamivir and Zanamivir, and the adamantane drugs,
Amantadine and Rimantadine. Neuraminidase inhibitors interfere with release of influenza virus from infected cells thereby
halting the spread of infection. These will be discussed at length
in this paper. Adamantanes block the M2 ion channel thereby
interfering with viral uncoating inside the cell. They are effective
only against influenza A viruses (influenza B viruses lack the M2
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protein). Choice of antiviral drug is complicated by resistance
of different influenza types and subtypes to different drugs
(Pringle, 2014).

type 7 is called Influenza H11N7. Only a few types of influenza
are pathogenic to humans. This depends on their ability to bind
to Human sialic acid, as discussed later.

The influenza virus is unique in that it completely experiences changes in the characteristic of the antigens on its surface.
Typically, small changes occur from one year to the next. This
is known as “antigenic drift”. Less frequently, there are significant changes in the surface antigens. This is known as “antigenic
shift.” Hosts who have been previously exposed to influenza
generally have some residual immunity against viruses that have
drifted antigenically. In contrast, there is little/no preexisting immunity against viruses that have shifted antigenically.The former
is responsible for epidemics which tend to be milder in severity.
The latter situation results in influenza pandemics, with high
mortality e.g. The Spanish influenza of 1918 is thought to have
caused 30-50 million deaths worldwide.

Antigenic drifts are minor mutations in preexisting HA and NA
combinations resulting in new strains. This decreases the effectiveness of antibodies to the Influenza. Antigenic Shifts are new
combinations of HA and NA proteins. Such as a change from
H1N1 to H1N2. Antibodies produced against previous influenza
strains are generally ineffective, thereby increasing its ability to
infect and cause illness. These shifts often occur when two different influenza types infect one cell.When the viruses replicate
the RNA can then combine and form a new “reassortant” type
(see picture 3 below (Ranciello, 2013)).
Figure 1

Influenza Type A can cause pandemics and epidemics and is
our main concern. Type B can only cause epidemics. Type C can
cause mild illness but does not cause pandemics nor epidemics.
Influenza is often confused with “Influenza-like- illness” which
may be caused by other factors but has similar symptoms.
Influenza is most common in the winter months.This is because
the winter conditions are optimal for the spread of influenza.
The transmission of infection is most effective at a humidity
level of 20-35 degrees and colder temperatures. At these conditions virion particles are more stable and can travel further
distances in droplets (Mubareka et al., 2009). Increasing levels of
humidity of indoor air during the winter may be an effective way
of decreasing the spread of influenza.

Pathophysiology

HA (bl ue), NA (red), and M2 (purple) proteins
(Ranciello 2013)
Figure 2

Influenza types
As noted above There are three types of Influenza A, B and C.
Type A and type B cause the same spectrums of disease but
type B can only infect humans and seals and therefore limits the
reassortments in contrast to type A which has numerous hosts
and numerous reassortments.
Influenza A Subtypes
Type A has 3 different membrane proteins, surface proteins
hemagglutinin (HA), neuraminidase (NA). Matrix protein 2
(M2) traverses the membrane. As shown in figure 1. (Type B has
the HA and NA proteins but does not have the M2 protein).
(Tscherne and Garcia-Satre, 2011). The subtypes of influenza A
are classified based on the HA and NA proteins. There are 18
HA types and 11 NA types. This means there are 198 possible
combinations. The nomenclature of the virus describes the HA
and NA subtypes for example a virus with HA type 11 and NA
Influenza reassortment (Ranciello, 2013)
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NA Structure
NA is a tetramer of four identical polypeptides each containing approximately 470 Amino Acids. It has four sections: A cytoplasmic sequence, a transmembrane sequence, a stalk and a
globular head. There are two phylogenetic groups of NA, NA
group 1 and NA group 2. Group 1 contains N1, N4, N5 and
N8. Group 2 contains N2, N3, N6, N7 and N9. Group 1 has
an additional cavity “150 loop” that is not present in group
2(Air, 2012).

receptors on the cell membrane as it leaves. This would result
in the virus becoming trapped on the host cell.This is prevented
by the NA protein which cleaves the sialic acid to allow the
virus to escape (Wagner et al, 2002). NA also cleaves sialic acid
molecules in mucus in the human respiratory tract (Cohen, et
al., 2013). This increases viral infectivity.

Neuraminidase inhibitor drugs

Animal respiratory cell membranes contain Sialic acid molecules. These molecules are the binding site receptors of the
influenza virus. (Gamblin, and Skehel, 2010). When viral HA
proteins bind to sialic acid receptors on the host cells a sequence of events is set in motion resulting in the virus entering
the cell.

In order to prevent viral infection the NA protein has been
exploited by developing drugs that act as sialic acid analogs
which bind to the NA active site.These are called NA inhibitors.
These drugs disable the NA protein from cleaving sialic acid,
leaving the virus trapped on the cell (Russel et al., 2006).Tamiflu
(Oseltamivir) and Relenza (Zanamivir) are the two drugs which
dominate the market. These have been stockpiled by governments and public health agencies (Jefferson et al., 2009) for the
treatment of Flu and are recommended by the CDC.

Types of Sialic Acid

Oseltamivir resistant strains

Sialic acid is a glycoprotein. It is typically linked to a galactose
molecule. As stated, Sialic acid is linked to galactose. There are
2 main types of such linkages: 1. Alpha2, 3 linkage (pictured
above), in which the carbon 2 of the acid is linked to the carbon 3 of galactose. 2. Alpha 2, 6 linkage, in which the carbon2
of the acid is linked to carbon 6 of galactose. Humans primarily have a2, 6 receptors. This means that viruses targeting this
structure are more likely to infect these cells. The results of
studies of early influenza virus isolates from the 1918, 1957,
and 1968 pandemics suggest that these viruses preferentially
recognized alpha (2, 6) linked sialic acids. In contrast, viruses
targeting the a2, 3-linked structure are not very pathogenic
for humans. In humans, these linkages are only found in ciliated
epithelial cells, which are a minor population within the human
respiratory tract. Nevertheless, these are the preferred receptors for the avian flu (Matrosovich et al., 2000).

There have emerged strains of flu that are resistant to oseltamivir. This is due to a point mutation of histidine being switched
for tyrosine (H274Y) in NA. This leads to decreased binding of
the drug. Nevertheless this change is also detrimental for the
virus as it leads to a decrease of surface NA reducing the virus
replicating abilities and infectivity.

Cell Invasion

Mechanism of infection
First the viral HA protein binds to the sialic acid receptors
on the cell membrane. The virus is then engulfed by the cell
through endocytosis.This causes the pH of the endosomal vesicle to drop to 5 which activates a conformation change on the
HA protein which exposes a fusion peptide.The fusion peptide
enables the viral envelope to fuse with the vesicle membrane
wall. The viral RNA is then released into the cytoplasm. Viral
RNA travels to the nucleus to initiate protein synthesis and
assemble new viruses. The newly formed viruses travel back to
the cell membrane. The virus interacts with the cell membrane
causing it to bud off. The virus is released to infect other cells.
The mechanism of the virus leaving involves a potential problem.
One would expect the viral HA protein to bind to the sialic acid

During the 2008-09 flu season oseltamivir resistant influenza
H1N1 viruses with the H274Y change became more prevalent,
and within a year they were found in most seasonal isolates.Two
amino acid changes were identified that even in the presence
of H274Y restore surface levels of NA. These are V234M and
R222Q. These secondary mutations seem to balance the deleterious effects of the H274Y mutation, thus enabling it to spread
(Bloom et al., 2010).

Discussion- The Tamiflu Controversy
Cochrane Report
At the height of the 2009 H1N1 influenza pandemic, the British
Medical Journal (BMJ) released a Cochrane update (of a 2005
Cochrane meta-review) which shook the medical world. The
report cast serious doubt on the usefulness of neuraminidase
inhibitors (Nis) in influenza. Specifically concluding that, at best,
NIs reduce symptoms by approximately one day- a moderate
benefit.
They reviewed 1416 titles for neuraminidase inhibitors mostly
on oseltamivir. They discarded all but 20 due to various problems. These included, variously, insufficient information, inaccessibility to data, poor description of methods, and issues of
reliability. For example, some studies used a mixed population
of healthy adults and those with comorbid complications. This
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meant the studies weren’t effective in properly determining
outcome in healthy populations. They noted that, even this data
may not be accurate as up to 80 percent of the studies may have
not been “pure” influenza, rather “influenza like illness”. This is
because influenza was unconfirmed by laboratory tests.

to generate these reports. He criticizes the fact that government
organizations have spent so much money on a drug before ascertaining the reliability of the data of its effectiveness. He notes that
the Centers for Dis¬ease Control and Prevention (CDC) based
their recommendations on the problematic Kaiser report.

Most importantly, according to Cochrane, there is insufficient
data as to whether NIs are effective in reducing complications
of lower respiratory tract infection as indicated by antibiotic
use or hospital admissions. They also note that there is a significant risk of toxicity, especially of psychosis, in prophylactic
treatment. They concluded “because of the moderate effectiveness of neuraminidase inhibitors, we believe they should not be
used in routine control of seasonal influenza.”

The US government also partly based its national pandemic preparedness strategy on similar assumptions. As a result billions of
dollars were spent building drug stockpiles, and oseltamivir was
elevated to the status of a public health drug.

Kaiser et al (2003)published a meta-analysis of 10 studies of
oseltamivir.They concluded that Oseltamivir was effective in reducing lower respiratory tract infections (LRTIs).The Cochrane
2005 report, which relied on this study also concluded that it
was effective in reducing LRTIs.
Hayashi (Jefferson, et al, 2009) pointed out that the 2005
Cochrane report was flawed in that they didn’t actually review the data of the individual studies themselves. In addition,
he questioned the reliability of the Kaiser report as only 2 of
these studies were actually published in peer reviewed journals
(JAMA and Lancet). The other eight were not and were not
available for review. He also notes a conflict of interest in that
the authors of the Kaiser report included four employees and
one paid consultant of F. Hoffman-La Roche (the manufacturer
of oseltamivir). Hayashi also noted that in the two published
studies, there was no significant difference between Oseltamivir
and placebo in the incidence of LRTIs. He suggests that the only
way to rely on the report is by a rigid appraisal of the other
eight trials-which were not released by the drug company La
Roche.

In 2014, Cochrane (published in BMJ 2014) released an update
of a 5 year campaign it launched against Roche to obtain all the
clinical study reports (CSRs)- which are extensive summaries of
RCTs, on Tamiflu. Cochrane managed to pressure Roche into
releasing all their data. They note that this is the first time all
clinical study reports of trials in a manufacturer’s program have
been made available to readers without any restriction. The importance of this is the ability of researchers to assess the clinical
trials for reliability, adherence to protocol, clarity of definitions
and avoided reliance on conclusions of researchers who may
have published biased material. It also allows for considerable
more information on potential harms.

Cochrane was unable to obtain the data of the 8 unpublished
studies for further analysis. This led Cochrane to conclude
in 2009 that “paucity of good data has undermined previous
findings for oseltamivir’s prevention of complications from influenza. Independent randomized trials to resolve these uncertainties are needed.” The question of a publication bias was also
raised by Cochrane due to the fact that these results weren’t
published.

Cochrane notes that many discrepancies, problems and biases
have been found in these trials.These include: Lack of clear definitions. For example there are eight definitions for laboratory
confirmed influenza and no clear definition for influenza-like illness. Lack of reliability of the placebo. In many cases the placebo
capsule had a different colored cap than that of the active capsule. This was not remarked on in the report. Many of the placebo capsules in oseltamivir trials contained dehydrocholic acid
and dibasic calcium phosphate dihydrate. Both can cause gastrointestinal symptoms. Although the substances seemed to be in
low doses, no discussion of their potential effects in people with
fever was reported. Missing documents. This includes missing
study protocols and amendments, study manuals of procedures
and minutes of safety data monitoring committee meetings.
Ghost authorship and lack of accountability. Authorship and accountability for the writing of many of the clinical study reports
remains unclear. Some names on studies were redacted and no
one seemed to claim responsibility for assembling and writing
the reports. Missing data on duration and durability of symptom
relief. Data on relapse after the five day treatment period were
not reported in the clinical study reports.

Doshi (2009), (a Cochrane author) goes so far as to suggest that oseltamivir is no better than NSAIDs, such as aspirin, in the treatment
of influenza. He also notes the numerous contradictory reports in
the clinical studies on the effectiveness of oseltamivir which casts
doubts upon the reliability of the methods and information used

There was also a mix-up with follow-up cards in a few of the
trials which was not even reported in CSRs and only came to
light from the FDA Summary Basis of Approval papers. There
is ambiguity as to whether treatment of the flu shown through
reduction of antibody titers was due to effectiveness of the viral
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fighting activity of the drug or the immunosuppressant activity
of the drug.
Cochrane 2014 concludes that oseltamivir is helpful for prophylaxis and modestly helpful in treatment (though they downplay
its usefulness). In contrast to the assertion of various organizations Cochrane concludes that there is little evidence of
significant benefits with regards to complications caused by
influenza and viral transmission. Due to the above as well as
the side effects, oseltamivir should be used cautiously. Due to all
the discrepancies and poor quality of the studies, they question
governmental sole reliance on this data to stockpile oseltamivir,
its inclusion on the WHO list of essential drugs, and its use
in clinical practice as an anti-influenza drug. This is especially
true due to lack of sizeable benefits, and concerns of toxicity
(Jefferson et al, 2014).

Cochrane study results
For Adults in Treatment trials: oseltamivir reduced the time to
first alleviation of symptoms by 16.8 hours-from seven days to
6.3 days. In treatment trials there was no difference in admissions
to hospital.
For Adults in prophylaxis pre-exposure: oseltamivir reduced
symptomatic influenza in participants by 55%. There was no significant effect on asymptomatic influenza (increase in antibody
titers without symptoms). In post-exposure there are two components to interrupting transmissions of the virus.The reduction
of viral spreading from nasal shedding and the prevention of
onset of influenza in contacts.
Roche claims that it is effective, but there were serious flaws
in the methods of the studies. This includes giving paracetamol
which may have reduced viral shedding, and not checking antibodies in participants with potentially asymptomatic influenza.
This leads to the conclusion that there is “no evidence of a reduction in transmission.”
It is important to note that these studies specifically influenced
WHO’s policy of recommending this drug.
Harms for Treatment: increased the risk of nausea (risk difference 3.66%, 0.90% to 7.39%; number needed to treat to harm
(NNTH) 28.) and vomiting (4.56%, 2.39% to 7.58%; 22, 14 to 42).
For Prophylaxis: oseltamivir increased the risk of psychiatric adverse events during the combined “on-treatment” and “off-treatment” periods (risk difference 1.06%, 0.07% to 2.76%; NNTH 94,
36 to 1538) and there was a dose-response effect on psychiatric
events in two “pivotal” treatment trials of oseltamivir, at 75 mg
(standard dose) and150 mg (high dose) twice daily (P=0.038).

Oseltamivir increased the risk of headaches on-treatment (risk
difference3.15%, 0.88% to 5.78%; NNTH 32, 18 to 115).It increased renal events with treatment (0.67%,−0.01% to 2.93%),
and increased nausea while receiving treatment (4.15%, 0.86% to
9.51%; NNTH 25, 11 to 116).
For child treatment it reduced influenza for otherwise healthy
children by 12 to 47 hours with a mean difference of 29 hours.
There was no effect in children with asthma.There was no significant difference in admissions to hospital.There was no significant
effect on bronchitis, otitis media, sinusitis unverified pneumonia
or any complication classified as serious or that led to study
withdrawal. There was no significant difference in prophylaxis.
In treatment of children, oseltamivir induced vomiting (5.34%,
1.75% to 10.29%; 19, 10 to 57).

Cochrane’s call to governments
Compared with a placebo, taking Tamiflu led to a quicker alleviation of influenza-like symptoms of just half a day (from 7 days to
6.3 days) in adults, but the effect in children was more uncertain.
There was no evidence of a reduction in hospitalizations or serious influenza complications; confirmed pneumonia, bronchitis,
sinusitis or ear infection in either adults or children. Although
when used as a preventative treatment, the drug can reduce the
risk of people suffering symptomatic influenza, it is unproven that
it can stop people carrying the influenza virus from spreading it
to others.
Evidence from treatment trials confirms increased risk of suffering from nausea and vomiting. And when Tamiflu was used in
prevention trials, there was an increased risk of headaches, psychiatric disturbances, and renal events.
Evidence also suggests that Tamiflu prevented some people from producing sufficient numbers of their own antibodies to fight infection.
Claims about the effectiveness of Tamiflu against complications
were a key factor in decisions made by governments around the
world to stockpile these drugs in case of a pandemic. The US
has spent more than $1.3 billion buying a strategic reserve of
antivirals, while in the UK the government has spent almost £424
million for a stockpile of about 40 million doses*.
It was initially believed that it would reduce hospital admissions
and complications of influenza, such as pneumonia, during influenza pandemics. However, the original evidence presented to
government agencies around the world was incomplete.
Along with the evidence of harms from the medication, it raises
the question of whether global stockpiling of the drugs is still justifiable given the lack of reliable evidence to support the original
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claims of its benefits.The BMJ and Cochrane issued a joint call to
government and health policy decision makers the world over
asking, in light of the latest findings from the Cochrane Review,
would you make the same recommendations today, choosing to
stockpile Tamiflu? (Breeze and Burns 2014).

complications and hospitalizations- which are the key outcomes
of interest during a flu pandemic. This is especially true noting
that these small clinical trials were carried out to gain regulatory
approval for Tamiflu as treatment and prophylaxis for seasonal flu.
The trials were not designed to test for the severe outcomes that
are most relevant to pandemics.

Criticisms against the Cochrane reports
There are many that criticized the BMJ/Cochrane reports. The
study was done in collaboration with channel 4 TV station in Britain.
This may have led to a conflict of interests in overdramatizing a
story for viewers. As Revere notes (Revere 2009) “Doing this in
tandem with a media outlet whose objectives are not science but
snagging viewers is unseemly at best and borders on the unethical”.
An article in Nature (Noorden 2014) notes that it seems as
if Cochrane, in their overzealousness to confront the big
Pharmaceutical agencies have been ”cherry-picking” the results
to make them look worse for antivirals. Some of their statements
have contributed to media misinterpretation that the drugs are
‘ineffective’ or ‘useless’.” For example: Cochrane writes ” (oseltamivir) reduces symptoms of influenza by half a day” instead
of the more precisely stating 18 hours for adults and 29 hours
in children. In the 2009 report they also neglect to mention the
prophylactic benefits. The Cochrane article obscures the therapeutic effect on decreased risk of diarrhea and cardiac system
events by sandwiching them among the harms of the drug. A
Cochrane author takes the extreme approach-not supported
by evidence- of suggesting that Oseltamivir is no more effective
than paracetamol.
It is important to note that Cochrane hasn’t shown that antivirals didn’t work for healthy people who got flu and were given
a neuraminidase inhibitor to avoid more serious complications
like pneumonia. It just alleged there was no “Cochrane-requiredlevel-of-evidence” that they did prevent complications.
Cochrane only uses Randomized Controlled Trials (RCTs).
These are studies in which volunteers are randomly assigned to
get a treatment or a placebo and are considered the gold standard of evidence. Observational Studies that observe outcomes
in people who receive a treatment don’t make the cut because
they are “unreliable for establishing treatment effects”. However,
often the observational studies are better at concluding the actual facts on the ground as opposed to the theory. For example,
an observational study (Muthuri, 2014) of 30,000 people hospitalized during the 2009–10 swine-flu pandemic reported that
neuraminidase inhibitors reduced mortality by 25%.

Additionally, The Metro (Branswell 2009) notes, sometimes
it isn’t possible to conduct randomized controlled trials.
Sometimes observational data is the best evidence available.
For instance, it’s unlikely any researchers could get permission
to test Tamiflu against a placebo in people severely ill with
H1N1. It would be considered unethical to withhold the drug
from severely ill H1N1 patients if observational data suggested
the drug might help.
Researchers worry that the Cochranes recommendation “we
believe they should not be used in routine control of seasonal
influenza” and the ensuing media storm of overly negative publicity risks undermining public confidence in this class of drug
which will increase illness. Tamiflu is prescribed as the main
treatment for serious cases of flu. Many experts say based on
the observational data that these drugs work and have beneficial effects on severity of illness and preventing death. They are
worried that we risk losing one of the few weapons we have.
This is especially true based on the timing of the release and the
lack of conclusive evidence that it doesn’t work. “So here we
are in the middle of a pandemic and the Cochrane folks, aided
and abetted by the BMJ and television producers, are saying,
“How do you know for sure that they will prevent pneumonia
in an otherwise healthy person who gets flu?” There is evidence
about this, even if the Cochrane zealots don’t recognize it”.

Evidence supporting the efficacy of Oseltamivir
It is hard to say that Oseltamivir is completely ineffective. One
of the first human studies on the effectiveness of Tamiflu was
published approximately fifteen years ago. In a 1999 study
(Hayden et al) 117 healthy adult volunteers were inoculated
with the influenza A virus. Two studies were conducted, one on
prophylaxis where volunteers were given the drug 26 hours before inoculation and one on therapeutic treatment where they
were given the drug 26 hours after inoculation. Treatment was
continued for 5 days. In these trials, prophylaxis and early treatment with oral oseltamivir were both associated with significant
antiviral and clinical benefits in experimental human influenza.

Prophylactic
Although RCTs are considered the gold standard in of establishing effectiveness of a drug, they lack sufficient statistical power to
allow reliable conclusions to be drawn about the effects on flu
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Among the 12 evaluable placebo recipients, 8 (67%) had laboratory-confirmed infection and 6 (50%) had recovery of the virus
from nasal washings. In contrast, of the 21 receiving oseltamivir

Is Tamiflu Effective in Influenza Treatment?

only 8 (38%) had laboratory confirmed infection and none of
the 21 evaluable oseltamivir recipients had virus isolated.
The total symptom score area under the curve value was lower in
the combined oseltamivir groups (n=21) compared with placebo
(n=12); P=.02. Fourteen symptoms related to influenza were included in the score.

Therapeutic
Of the 69 with laboratory confirmed illness At 24 and 36 hours
after initiating treatment, the median time to cessation of viral
shedding was reduced from 107 hours in the placebo group to 58
hours in the combined oseltamivir group as shown in the graph.
No virus was detected by 60 hours after infection. Effect of Oral
Oseltamivir Treatment on Illness Following Experimental Influenza
A/Texas/36/91(H1N1) Infection The total symptom score area
under the curve value was lower in the combined oseltamivir groups
(n=56) compared with placebo (n=13);
The total symptom score area under the curve value was lower in
the combined oseltamivir groups (n=56) compared with placebo
(n=13);

Dobson et al, 2015
In 2015 the Lancet published a study by Dobson et al. which shows
that oseltamivir in adults with influenza accelerates time to clinical
symptom alleviation, reduces risk of lower respiratory tract complications, and admittance to hospital.
The Cochrane reviews were based on meta-analysis of clinical trial
study reports alone and not on individual patient data. In the Lancet
study, Dobson et al did a meta-analysis of all available randomized
treatment trials of oseltamivir-which includes both published and unpublished data (thereby overcoming previous concerns regarding potential publication bias).This analysis is first of its kind that reviewed
individual patient data.
Nine trial studies were done between 1997 and 2001 involving 4328
participants. Participants were labeled as laboratory confirmed influenza-infected (“intention to treat infected”) and Influenza-like
(“intention to treat non- infected”). Participants were within 36
hours of feeling unwell- with a fever and at least two other influenza
symptoms. They received 5 day regimens of Tamiflu with a 21 day
follow up.
Limitations of these studies are that they weren’t set up to test for
relieving of respiratory complications As such, specific diagnostic
tests were not used. Instead, in order to enhance reliable reporting
of complications they incorporated “antibiotic use” in the definition
of LTRIs.These tests were also not set up to determine prophylactic
effects.

Effectiveness
Included are data from nine trials including 4328 patients. In
the Influenza confirmed population (intention-to-treat infected
population),
Alleviation of all symptoms for oseltamivir versus placebo recipients-21% shorter time of 25·2 h,
(The median times to alleviation were 97·5 h for oseltamivir and
122·7 h for placebo)
An estimated 44% reduction in risk lower respiratory tract complications requiring antibiotics more than 48 h after receiving oseltamivir (65 of 1544 participants given oseltamivir and110 of 1263 participants given placebo. Components were 56 versus 87 bronchitis, nine
versus 21 pneumonia, and one versus four lower respiratory tract
infections, respectively)
An estimated 63% risk reduction of admittances to hospital for any
cause In the intention-to-treat (nine of 1591 participants had to be
admitted to hospital for any cause versus 22 of 1302 participants
given placebo). Participants given Oseltamivir had significantly less
diarrhea, infections and infestations, and respiratory, thoracic and
mediastinal disorders and fewer cardiac disorders. Regarding safety, increased the risk of nausea (9·9% oseltamivir vs 6·2% placebo),
increased vomiting (8·0% oseltamivir vs3·3% placebo). No recorded
effect on neurological or psychiatric disorders (although slightly higher with 150 mg). No serious adverse events.
Non-confirmed
population)

influenza

(intention-to-treat

non-

infected

Oseltamivir was ineffective in non-confirmed influenza. This is
consistent with the fact that Oseltamivir is an anti-viral. In some
studies some researchers haven’t distinguished between confirmed and non-confirmed influenza population. This will skew
the results of efficacy of the drug being that it is not meant to
treat non-confirmed influenza. Nevertheless, these results will
more clearly resemble the effectiveness in real world situations
where there is mix of these populations.
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CDC rejection of Cochrane Report
The CDC (CDC 2015) continues to promote antivirals such as
Oseltamivir for treatment of the flu. The CDC promotes the
“Take 3” campaign to fight the flu. Step 1 is to get vaccinated.
Step 2 is taking preventative action to stop the spread of germs.
Step 3 of the campaign encourages people to “take flu antiviral
drugs if your doctor prescribes them.”
In CDC (2014) an article entitled ““Have You Heard? CDC
Recommendations for Influenza Antiviral Medications Remain
Unchanged.” The CDC addresses their recommendations and
the Cochrane’s criticism. Based on the observational studies
published, the CDC says “treatment with a neuraminidase inhibitor antiviral drug was associated with a 25% reduction in the
likelihood of death compared to no antiviral treatment. Early
treatment with neuraminidase inhibitor antiviral drugs (i.e.,
within 48 hours of development of influenza illness) halved the
risk of death compared to no antiviral treatment. This confirms
findings from previous observational studies in hospitalized influenza patients that the clinical benefit of neuraminidase inhibitor antiviral treatment is greatest when started within two days
of influenza illness onset.”
The CDC states that their disregard for the Cochrane findings
is because Cochrane did not consider any data from observational studies of oral oseltamivir. CDC adds that observational
studies of antiviral treatment of seasonal influenza or influenza
A (H1N1) pdm09 (2009 H1N1) have been conducted among
hospitalized patients, including critically ill children and adults.
Theses have consistently found that early oseltamivir treatment
of influenza patients reduces the duration of hospitalization and
risk of severe outcomes such as intensive care unit admission
or death. CDC states that Cochrane RCT reviews of data on
outpatients with clinically mild influenza-like illness is limited in
by the narrow scope of participants. It is statistically underpowered and not designed to assess the effects of the medications
on more severe influenza illness outcomes, such as hospitalizations, intensive care unit admissions, or deaths. RCT data
is unavailable for those at highest risk for developing severe
complications from influenza: hospitalized patients with severe
influenza illness, the elderly, young children, pregnant women,
and persons with underlying medical conditions such as chronic obstructive pulmonary disease (COPD), asthma, congestive
heart failure and diabetes.
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They conclude “available evidence for seasonal influenza and
2009 pandemic H1N1 virus infections consistently indicates
that antiviral treatment, when initiated as soon as possible, can
have clinical and public health benefits in reducing severe outcomes of influenza. Therefore, neuraminidase inhibitor antiviral
medications continue to be recommended for treatment of
influenza.”

BMJ/Cochrane response to CDC and Lancet
In a response article written by the BMJ’s Jeanne Lenzer “Why
aren’t the US Centers for Disease Control and Food and Drug
Administration speaking with one voice on flu? ” (BMJ 2015)
Lenzer raises allegations regarding the reliability of CDC. She accusing them of being “more emotional than scientific” and notes
that they are at odds with the FDA Who have said oseltamivir “has
not been proven to have a positive impact on the potential consequences (such as hospitalizations, mortality, or economic impact)
of seasonal, avian, or pandemic influenza.” She considers the CDC’s
reliance on the Lancet review as unreliable.This is because the authors have not made their study protocol available for critique nor
have they released an appraisal of the methodological quality of
each study. She concludes by raising the concerns that the policies
of the CDC and Lancet review have been influenced by funding
from the Pharmaceutical companies. The CDC Foundation confirmed to The BMJ that the CDC received a directed donation
from Roche for the campaign, stating, “Roche provided a grant of
$198 000 to CDC Foundation [which] has an administrative fee
of 13.5%, so $174 800 was provided to [the CDC to] support
qualitative research into influenza prevention and treatment messaging.” The CDC Foundation also receives funding from the pharmaceutical industry. A spokesperson said that over the past three
years the foundation has received an average of around $6.3m
annually from the industry, 21% of the foundation’s overall funding.
Some of the companies who have provided funds include Gilead,
which holds the patent on oseltamivir, as well as Genentech and
Roche, the drug’s manufacturers.This greatly discredits the CDC’s
credibility as a nonbiased party.

The Lancet’s Funding
The Lancet study itself was conducted through MUGAS which
was funded by an open grant from Roche- as the study noted.
Lancet asserts that neither they nor the study itself were influenced in any way by Roche. Additionally, neither MUGAS nor
Roche saw the results of the study before publication.
Also two of the researchers note that they have had ties in the
past to Roche. A third researcher, Stuart Pocock didn’t list any
conflict of interest on the research paper, but revealed to The
BMJ that he has received funding from several drug companies for
cardiovascular research, including Gilead and Genentech, but that
none of his funding was related to the study of antivirals for flu.
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Paul Roblin in his BMJ blog notes Although the name Multiparty
Group for Advice in Science ( MUGAS) might lead you to imagine an independent body bringing together representatives of a
number of organizations to consider a range of issues, MUGAS is
funded by Roche and is led by four scientists, three of whom are
advisers to Roche. It appears to have been set up specifically as
part of the attempt to counter the Cochrane’s criticisms. He also
notes that there is a complex set of inter-related organizations
that supported the Lancet study and receive funding from Roche
and Gilead. Also, one the Lancet authors and MUGAS have many
more connections to the CDC, Roche and Gilead than they disclosed. One of the researchers for the Lancet article, Professor
Richard J Whitley joined Gilead’s board of directors in 2008 and
works with/for the CDC.

trustworthiness of decision making by government bodies should
be questioned. In any situation, conflict of interest may be present.
Thirdly, as suggested by their critics, was the Cochrane disingenuous in completely ignoring observational data supporting use of
Tamiflu? And were the Cochrane writers sensationalists in their
conclusions and media communications?
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Abstract
ADHD, attention deficit hyperactive disorder, is a disorder characterized by hyperactivity, inattentiveness, inability to
remain on task, fidgetiness, and impulsivity. An over absorption of dopamine by the dopamine transporters leads to a
lack of dopamine, the inhibiting neurotransmitter in the brain, resulting in the inability for the individual to inhibit their
impulses. The disease is most likely seen in children but may continue into adulthood. The length of the disease across
the individual’s life span, results in expensive treatment, whether it be medication or Cognitive Behavior Therapy, CBT.
Therefore, these medical costs have caused researchers to find the most efficient drugs to provide the ADHD patients
with the most effective, cost effective, and beneficial results. Different individuals require different treatment options,
whether it be due to sex, age of onset, socioeconomic group, and attitude toward medication. This paper will provide
an overview of the different treatment options with their side effects, causes and remedies.
Introduction to ADHD
Attention deficit hyperactivity disorder (ADHD) is a disorder
most commonly seen in children and adolescents, but also may
present or persist into adulthood. It is a neurocognitive behavioral disorder that presents with symptoms of maladaptive behaviors such as impulsivity and or hyperactivity, the inability to
pay attention and remain on task. ADHD is also associated with
other maladies such as, mood disorders and learning disabilities
(Journal of Attention Disorders, 2014). ADHD is costly because
it is usually diagnosed in childhood and may become a lifelong
disorder that causes a wide range of symptoms. In addition, children with ADHD have been shown to be more likely to sustain
major injuries and need both inpatient and outpatient emergency care. Median medical costs for children with ADHD were
double those of children without the disorder when studied
over a nine year period.
Because of its prevalence amongst American children and
adults and its high cost to the health care system, treatment
of ADHD is important. Today, many treatments are available,
these may include, behavioral as well as pharmaceutical therapies. Medications available range from non-stimulant options
to stimulants available in both extended release, long acting or
traditional dosages (Journal of Attention Disorders, 2014). This
paper will attempt to understand the causes of ADHD on a
neurological level and evaluate possible treatment options, analyzing how physicians may be better able to match treatment to
a patient lifestyle and disease.

What is ADHD?
ADHD, attention deficit hyperactivity disorder, is a neurobiological developmental disorder that is characterized by the inability
to remain on task, difficulty to remain focused and the tendency
to be overly energetic with impulsive behaviors. It is most commonly found in school-age children but can frequently continue
into adulthood. ADHD is a widespread disease, having been
found in all countries surveyed with a prevalence of about 7-8%

of youths and 4-5% of adults. Furthermore, interestingly enough,
ethnicity did not seem to be a factor in the frequency, however,
social groups, were found to be most likely to play a role in the
diagnosis (Journal of Attention Disorders, 2014).
ADHD, attention deficit hyperactivity disorder, is broken up
into three different categories, ADHD-I; ADHD, Predominantly
Hyperactive-Impulsive Type; and ADHD, Combined Type:
Inattentive and hyperactive/impulsive. ADD, attention deficit
disorder, is an alternate name for ADHD-I, the first type of
ADHD. ADHD is the broad term for the hyperactive, inattentive
disease and ADD is a classification of ADHD. Firstly, ADHD-I,
also known as ADD or ADHD-Inattentiveness, is diagnosed by
the inability to keep on task or follow and understand instructions. Furthermore, children with ADD tend to make careless
mistakes and use minimal effort in accomplishing difficult tasks.
Additionally, the ADHD Predominantly Hyperactive-Impulsive
Type is categorized by the individual suffering with the symptoms of hyperactivity, such as, fidgeting, squirming, trouble
playing quietly or interrupting constantly. Lastly, the combined
type of ADHD is characterized by a pattern of inattentiveness
and over activity. Meaning, an individual with the combined type
of ADHD will exhibit symptoms of fidgetiness, and inability to
concentrate and remain seated, in addition to, signs of constant
distraction and failure to remain on task (diffen.com).

Causes of ADHD
Attention deficit hyperactive disorder can be triggered by many
matters. For instance,ADHD is mainly prompted by genetics, but,
it can also be the result of the environment or specific brain injuries. Firstly, many studies have proven hereditability to be the most
common cause of ADHD. Genes can have the greatest impact on
one’s children, whether it means passing down an advantageous
trait, or passing down a disease, such as ADHD (myadhd.com).
Family studies were performed in order to find the relationship
between ADHD and genetics. Results have shown that 25% of
closely-related family members with ADHD also have the disease.
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Furthermore, adoption studies and twin studies were done in
order to support the idea that ADHD is genetically related. If
ADHD was not genetic, then adopted children should further
resemble their adopted parents than their biological. However,
reports have shown that adopted children are more similar to
their biological parents, further supporting the point. Twin studies, have shown similar results. Identical twins contain the same
genetic materials as each other, and therefore, if one twin has the
disease, the other twin does as well. The last study that was done
on ADHD patients, was molecular genetic research. Molecular
genetic research focuses on the specific genes related to the
transmission of ADHD. DAT1 and DRD4 are two dopamine
genes that were discovered to have the biggest effect on ADHD
gene transmission (myadhd.com).
Additionally, exposure to toxicity can be another cause of
ADHD. A relationship has been found between mothers who
have smoked tobacco or intoxicated in alcohol during pregnancy, and the probability that learning disabilities and ADHD
will develop in their child. Furthermore, lead exposure or poisoning in early years of childhood can have negative effects on
the child’s progress and advancement. The last, atypical, cause
of ADHD can be a head or brain injury. Although somewhat
unlikely, tumors, traumas, strokes or diseases can also result in
ADHD as well (myadhd.com).

ADHD and the Science of the Brain
Current research has proven that the causes of ADHD are highly related to many dysfunctions of neurotransmitters and of regions in the brain. A highly essential neurotransmitter, dopamine,
has proven to have an effect in ADHD, as well as, the prefrontal
cortex which requires high amounts of dopamine in order to
function. Dopamine is a significant inhibiting neurotransmitter;
meaning, that it plays a major role in preventing certain impulses in the brain, and ultimately, preventing the causes of ADHD
(dnalc.org). Dopamine transporters are found to be responsible
for the lack of dopamine in the brain since they absorb too
much dopamine, disabling it to transfer from one brain cell to
another, thereby causing a dopamine deficiency in the brain.
The basal ganglia, a collection of nuclei located throughout the
brain, also suffer from the lack of dopamine, DA, present in the
brain. The basal ganglia are responsible for motion or normal
voluntary movement and are excited by dopamine transmitters.
Therefore, a lack of dopamine also effects the role of the basal
ganglia, causing ADHD. When the levels of dopamine are low,
there are high risks for attention deficit hyperactivity disorder
because the main neurotransmitter which inhibits impulses is
lacking (dnalc.org).
Therefore, the ADHD drugs are specially designed and intended
to bind to a dopamine transporter with their nitrogen, oxygen
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or carbon atom, enabling it to transfer the dopamine to the
brain. The nitrogen and oxygen atoms are surrounded by at
least one lone pair which assists in the formation of a hydrogen bond to the dopamine transporter. However, although the
carbon atom is lacking such a lone pair, it has interestingly been
discovered that it too can form a bond to the dopamine carriers
(dnalc.org).
The question still remains, however, how do the ADHD drugs
increase the levels of dopamine in the brain by binding to the
dopamine transporters? There are three known mechanisms
that ultimately inhibit the rise of dopamine in the brain. The
dopamine rapidly diffuses into the synapse causing the dopamine transporters to bind to the dopamine and positioning it
throughout the nerve cell membrane. Then, extracellular action
of dopamine on the auto receptors of the neuron, consequently inhibit the further release of dopamine. Thus, the dopamine
stimulating drugs are aimed to prevent the uptake of dopamine
by the neurons so that extracellular action will not occur.
Furthermore, the drugs can promote additional dopamine release. For example, either the drug can bind to the dopamine
transporters hindering it from bringing the dopamine into the
neuron. Or, other forms of the drug can excite the release of
more dopamine (Molecular Psychiatry, 1998).
Additionally, the prefrontal cortex and its association with further brain regions, such as the striatum, cerebellum are found to
be slightly smaller or less active in ADHD victims. Furthermore,
the frontal lobe, basal ganglia, and the caudate nucleus, are also
related to ADHD and they too play a significant role in regulating behavior. Studies of animals have shown that the prefrontal
cortex has a responsibility in regulating behavior and attention,
as well as, understanding representational data (sciencedaily.
com). Researchers were not surprised to find a smaller prefrontal cortex in patients with ADHD due to the fact that the
prefrontal cortex is critical in providing and dividing attention,
and inhibiting distractions. Therefore, it was understood why
the MRI’s of ADHD victims exhibited significantly smaller prefrontal cortexes.

Treatment of ADHD: Stimulant vs.
Non-Stimulant Drugs
Treatments for attention deficit hyperactive disorder include
pharmacological approaches, as well as, non-pharmacological
care.When treated pharmacologically, the patients are cared for
using specific prescriptions of drugs that provide them relief
from their symptoms. Most often, stimulant drugs, drugs that
arouse activity in the brain, are used as pharmacological treatments. However, non-stimulant medications can be used as well
(Journal of Attention Disorders, 2014).
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Psychostimulants are stimulant drugs that are psychoactive,
meaning, they temporarily generate mental and physical functions in the brain such as increased awareness and attentiveness (Molecular Psychiatry, 1998). Current psychostimulants
include D-amphetamine, D, L-amphetamine, Magnesium pemoline, Methylphenidate, dexmethylphenidate, mixed amphetamine
salts and lisdexamfetamine dimesylate (LDX). Surprisingly, the
structural composition of these molecules are all different,
however, share a common backbone of phenyl-ethylamine with
endogenous catecholamines, such as, norepinephrine and dopamine. Uptake of the psychostimulant drugs provide the brain
with significant dopamine, thereby enabling the inhibition of
impulses (Molecular Psychiatry, 1998).
Methylphenidate, is an example of a short acting, central nervous system, stimulant drug for children and adults. They have
an onset of approximately 30-60 minutes and remain in action
for about 2-5 hours. Methylphenidate regularizes certain brain
functions, specifically in the frontal lobe, prefrontal cortex, the
basal ganglia and cerebellum, by stimulating the brain chemicals
dopamine and norepinephrine (Molecular Psychiatry, 1998).
Dopamine and norepinephrine are important neurotransmitters
in the brain, and, a lack of them can cause dysfunction in brain
activity. Drugs that increase the dopamine or norepinephrine
levels will, therefore, provide a short-lasting relief to individuals
with ADHD. Methylphenidate binds to the dopamine transporters, and blocks them from transporting to the neurons. In this
way, the extracellular action in the neurons will not take place
and further production of dopamine will not stop (L.E Arnold).
Methylphenidate also provides a therapeutic effect due to the
slow and steady increases of the stimulants. In addition to the
physical effect, methylphenidate also provides an emotional
relief by increasing the child’s self-esteem and bettering their
interactions with others. Therefore, stimulant medications are
usually given gradually until a beneficial, relaxing effect comes
about (Molecular Psychiatry). Also, when treated with the sustained-release preparations, they can have longer lasting effects of
8-12 hours. Evidence to the efficacy of the drug can come from
functional magnetic resonance imaging tests (fMRI) on ADHD patients, which have shown that after a dosage of methylphenidate,
there was increased activations in the brain, verifying the efficacy
of this drug. The medication has been continuously proven to
positively affect many ADHD victims (L.E Arnold).
Ritalin, Concerta, Quillivant XR, Daytrana, Focalin, Medikinet,
Equasym XL and Methylin are all derivatives of methylphenidate
and all have similar effects. Firstly, the main byproduct of methylphenidate, Ritalin, is a short-lasting drug providing immediate
release of dopamine and norepinephrine in the body (psychcentral.com). Hence, those patients in need of immediate relief will

benefit from Ritalin. On the other hand, Concerta, is a long acting
stimulant which increases dopamine levels gradually. Thus, one
may not need to take more than one dose a day, due to its all-day
symptom relief. Depending on the severity, time and frequency,
different patience may have a preference for either the short-acting Ritalin or the long lasting Concerta (healthline.com).
Furthermore, Quillivant XR may be an option to some ADHD
patients. Quillivant XR is the only liquid long lasting medication,
thereby, attracting young children who cannot swallow pills. In
addition, since it is a liquid, it is easily measurable, and, therefore, those patients who only need a small dosage will tend to
choose Quillivant XR. Daytrana, has an unusual advantage of existing in patch form. Meaning, a specific dosage of medication is
located in a patch that is worn somewhere on the body usually
the hip. Throughout the day, the Daytrana is released into the
blood. Consequently, the effects on the patient will have a longer duration, usually lasting throughout the entire day. Children
typically are the most common ones to use this drug, being that
it makes life simpler (adhd-treatment-options 2009). The next
drug, Focalin, is also a drug that offers extended-release, and is
found to more effective than Concerta. Focalin has proven to
offer immediate relief first thing in the morning, and then provide
continuous effects throughout the day, thereby allowing children
to focus during the day in school. Therefore, Focalin has been a
first choice drug option for school-age children (drugs.com).
Another methylphenidate drug, Medikinet, grants immediate-relief and short lasting results. Therefore, it would need to be
taken several times a day. However, Medikinet XL is a new version of the drug which splits up the dosage, releasing 50% immediately and holding back the other 50% to be released later
on in the day.The latter form of the drug is most probably more
beneficial to most people, not needing to retake the medication multiple times a day (netdoctor.co.uk). Similar to Medikinet
XL, Equasym XL, is also a pill that releases 30% immediately
and stores the other 70% to be released hourly throughout
the course of the day. In this case, as well, one morning capsule
is enough to last the child the whole day. Lastly, Methylin, is
short-lasting pills and requires multiple doses during the course
of the day. Additionally, it has many side effects so it is not the
best option of an ADHD drug (netdoctor.co.uk).
The second most common type of ADHD stimulant drug,
Amphetamine, is similar to Methylphenidate, except that variants of this drug are usually intermediate-acting. For example,
D, L-amphetamine, has a slightly longer duration of 4-6 hours. A
blend of four amphetamine salts, amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine sulfate and
dextroamphetamine saccharate, produce Adderall, which is an
equally effective drug (progressivehealth.com). Being that the
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two main drugs are especially similar, differences between methylphenidate and amphetamine are not so distinct. However, the
chemical activity is different. Ritalin, travels into the brain cells
and prohibits them from continuous absorption of dopamine
(learn.genetics). On the contrary, Adderall, not only stops the
brain cells from absorbing the dopamine, but, also, forces the
cells to drain the already absorbed dopamine, thereby, directly
increasing the dopamine levels in the brain. Furthermore, when
methylphenidate binds to the dopamine transporters, it merely
inhibits the uptake of dopamine by the neurons, thereby stopping the inhibition of dopamine. Amphetamine furtherly differs
from methylphenidate in that along with the immediate release
formulation of the drug, it can provide extensive release as well.
Therefore, less dosages per day are needed of Adderall than of
methylphenidate. Furthermore, even though Adderall is more
powerful than Ritalin, some people react better to Ritalin, some
react better to Adderall and some react equally to both drugs
(LE Arnold).

Strattera, Clonidine, Guanfacine, Intuniv, and Kapvay, are some
of the most popular non-stimulant possibilities. Furthermore,
Bupropion SR and XL,The tricyclic antidepressants,The Selective
Serotonin Reuptake Inhibitors (SSRIs), and Effexor can also be
used as non-stimulant relief (ncpamd.com).

Being that stimulant ADHD drugs are similar to cocaine and morphine, many risks and side effects exist. People think that being
that many children use it, the drug is harmless and mild. However,
being that methylphenidate is highly addictive, many dangers are
present. The FDA requires all Ritalin boxes to contain the following notification, “Ritalin is a federally controlled substance
because it can be abused or lead to dependence. Keep Ritalin
in a safe place to prevent misuse and abuse.” The above warning
states that the effects Ritalin can be abused and harmful if not
used in the correct manner. The use of this drug can also lead to
anxiety, agitation, trouble sleeping, decreased appetite, headaches,
stomachaches etc. More serious side effects include the chance
for seizures, and blurred vision (ritalinsideeffects.net). The main
concern with these stimulant drugs is its potential for physical
and emotional abuse. Addiction to the drugs can be caused by
increasing dosages due to a buildup of tolerance to the drugs.
The higher dosages, may then cause the patient’s body to become
solely dependent on the drug, craving it and eventually being unable to live life without it. Withdrawal from the medication can
lead to panic attacks, depression and hunger. Therefore, limitations to this drug are extremely important to prevent addiction
and abuse (drugabuse.gov). Side effects of both medications include vomiting, nausea, anxiety, insomnia, skin rashes, headaches,
dry mouth and agitation. Furthermore, Adderall has an additional
side effect of increasing the risk of certain heart diseases, such
as, heart palpitations, increased heart rates and increased blood
pressure.

Clonidine and Guanfacine, have been used in adults mainly
to control high blood pressure but has been further used to
control ADHD mainly in adults with impulsivity and aggression.
Due to its painkilling and soothing characteristics, Guanfacine,
is commonly used to help individuals fall asleep. However, due
to the major side effects of these drugs including high blood
pressure and heart rate, it is important to monitor one’s blood
pressure with frequent EKG’s, electrocardiograms, tests that
check the electrical activity of the heart. Guanfacine lasts longer than Clonidine and only one or two dosages are needed
per day. Furthermore, these drugs mainly relieve over activity as
opposed to inattentiveness.

Although stimulant medication is usually the most effective for
treatment of ADHD, these drugs are not for everyone. Whether
it being the intolerable side effects, or the ineffectiveness of stimulants, some patients prefer the non-stimulant option remedy.
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The first approved ADHD non-stimulant medication for children and adults, Strattera, also called Atomoxetine, increases
the amount of norepinephrine in the brain, thereby increasing
a child’s attention span and moderating their impulsive behavior (ncpamd.com). Strattera does not directly influence the
dopamine levels as do the stimulant medications. Strattera is
effective in decreasing the ADHD symptoms, however, it is not
controlled and it is less likely to be abused and cause addiction.
The clinical effects last throughout the day and therefore, more
than one dosage a day is not necessary.Although there are some
side effects, they are minimal and tolerable, such as, fatigue, dizziness and nausea (my.clevelandclinic.org).

Intuniv and Kapvay are other non-stimulating drugs approved
by the FDA in September 2009-2010 for individuals ages 6-17.
Both drugs can be used independently or simultaneously with
a stimulant. They also tend to take longer than stimulants to
show results. It may take up to a month to see their effects.
Furthermore, just like Guanfacine and Clonidine, Kapvay may
cause a rise in blood pressure and it therefore should be monitored (ncpamd.com).
Antidepressant drugs can also be used to cure ADHD that is
linked to depression. Although its results are not as beneficial
to helping children with attentiveness and remaining on task,
children who are depressed due to their disease, commonly
lead towards anti-depressants for help. The first, most popular,
category of anti-depressants are The Tricyclic Antidepressants
which include, Pamelor, Norpremine, Aventyl, and Tofranil. They
are long-lasting so do not require frequent dosages (ncbi.nlm.
nih.gov). Tricyclics, however, can cause dry mouth, blurred vision, constipation, dizziness and sedation. Other antidepressants
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such as Wellbutrin, Effexor, Effexor XR, and MAO inhibitors, are
mainly used as antidepressants but can be used to treat ADHD
by increasing serotonin in the brain, thereby, increasing concentration in the child. MAO inhibitors are usually a last choice
for ADHD patients because of their dangerous side effects
including high blood pressure when taken with certain foods.
Antidepressants are sometimes mixed with stimulant drugs
when the individual is suffering from symptoms of anxiety in
addition to their hyperactivity and inattentiveness (Journal of
Attention Disorders, 2014). In conclusion, the use of antidepressants to relieve the symptoms of ADHD may be beneficial
if monitored by a health professional.

What is Cognitive Behavioral Therapy for
children or adults with ADHD?
Patients diagnosed with ADHD need to manage their symptoms
of hyperactivity, impulsivity and inability to focus their attention. CBT, cognitive behavioral therapy, consists of teaching skills
to control these symptoms. There are two different arms to
this strategy. One is to teach ways of staying focused and organized while the other’s goal is to minimize disruptive behaviors
that interfere with social and academic growth. CBT is used
both alone and in conjunction with pharmaceutical treatment
consisting of stimulant and non-stimulant medication (MillerBehavioral Treatments for Kids with ADHD). CBT is important
as, unlike medication, it teaches life skills that can serve the patient even after medication is stopped.
For children with behavior problems that detracts from their
academic progress and causes conflict both at home and in
school, parent-child interaction therapy, PCIT, may be beneficial.
It involves 14-17 week sessions in which parent-child interaction
is viewed through a one way mirror and the parent is coached
by a phycologist using an ear bud. Parents are encouraged to use
positive reinforcement in conjunction with strict consequences
for inappropriate behaviors. These techniques are meant to be
continued at home and in school. Teacher involvement is encouraged and essential. Goals are set, such as following specific
classroom rules with a prize following each positive behavior.
Over time, he child learns to control behavior and therefore,
have more beneficial interactions with parents, teachers, and
peers (Miller, Child Mind Institute).
Another form of behavior therapy involves the attention aspect
of the disorder. These include techniques to establish routines
to allow the ADHD patient to organize himself, allowing him to
stay on task and accomplish his goals. It also focuses on transitioning techniques to allow for less distraction. Everyday tasks
such as homework or bed time are broken down into smaller
achievable steps (Miller, Child Mind Institute). In general, both
methods of CBT have been shown to be more effective the

younger the child is, and less benefit has been seen by those
children who have reached adolescence.

Cognitive Behavioral Therapy as a viable
treatment for ADHD
Because the use of pharmacological treatments of ADHD may
not be acceptable to some parents of affected children or the
affected individuals themselves, cognitive behavioral therapy,
CBT, has been an alternative to the use of these medications.
CBT has long been used to treat ADHD both in conjunction
with medication or on its own. However, not many studies are
available comparing CBT applied on its own, to medication
alone, to a combination of CBT and pharmaceutical options
(Journal of Attention Disorders, 2014). A study by Susan Young
and J. Myanthi Amarasinghe view these possible treatment options through the lifespan of the ADHD patient uncovering evidence which suggests different approaches to treatment are
more effective during different periods in the patient’s life.
The young preschool child, who is still cognitively immature,
cannot yet put into practice skills that are taught directly. He
responds best to parental training to enforce positive behavior control such as tangible consequences along with positive
support to reinforce good behavior. It has been noted that
preschoolers that do not meet criteria for diagnosis and therefore do not receive early treatment were further affected into
their school years and beyond than those children treated early
(Young and Amarasinghe). In addition, parent-child relationships
are strained during these early years creating stress that lingers
into adulthood. Because the focus of a child’s life at this time
is his home and parents, parent training is the most effective
treatment yielding the most benefits throughout the patient’s
lifetime. Parenting techniques and interventions include teaching
parents about ADHD and addressing and targeting behavioral
problems associated with it. Reward and positive reinforcements for appropriate social behaviors are stressed in conjunction with consequences for negative and socially inappropriate
behaviors. Parents may also be offered support groups to deal
with their own reactions to their child’s difficulties (Young and
Amarasinghe).
Older, school age children, are cognitively capable of learning
skills and techniques to aid in social and academic situations.
They appreciate being involved in their care at this stage in their
development.This type of behavior therapy can be developed to
aid in treatment of older adolescence as well as adult patients.
These patients exist in two basic environments: at home and at
school, therefore treatment must be tailored to these situations.
Home-school connections must be fostered and communication between the two is imperative. Parent training is similar to
that of younger children as described above while teachers are
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coached to set achievable academic and social goals in addition
to positive reinforcement along with tangible consequences for
behavioral issues or impulsivity (Miller, Child Mind Institute).
As children move past their elementary school year, a child is
able to be more involved in his behavioral therapy. He is able to
be involved in role playing to advance social skills and improve
communication with eye contact and body language. An adolescent can be taught how to give compliments, accept constructive criticism, take turns and resolve conflicts. He can be taught
to actively listen to and follow directions and monitor his own
attention All of these will improve the patient’s relationships and
academic achievement improving self-esteem. As an adolescent
enters adulthood, all of these techniques can be furthered, setting direct treatment goals such as dealing with procrastination
and developing strategies to aid in memory and impulsivity control (Miller, Child Mind Institute).
There are ongoing discussions in the medical and psychiatric
communities on which avenues of treatment to choose as the
optimal way to treat ADHD. Depending on the age of the child,
the first line of defense may be different. The ADHD NICE
Clinical Guideline advises that parent training be the initial
treatment in preschool children and young school age children
with behavioral issues. Parent training is not as effective in older
children. Parent training has also been shown to be less effective in cases where the parents themselves exhibit symptoms of
ADHD (Young and Amarasinghe).
In a Multimodal Treatment study, four treatment possibilities
were compared. Firstly, medication, in the form of methylphenidate. Second, CBT including parent training, summer treatment
programs and school based treatment. Third, A combined treatment including medication and behavior therapy. And, lastly, a
control group of community care consisting of children, many of
whom were medicated, but did not receive treatment from the
researchers. Results found that the medication and combined
tracks were more effective than behavioral therapy alone or
the community care. The combined treatment which consisted
of medication and CBT in combination was more effective for
symptoms reported by parents then medication alone. In addition, CBT, with or without medication was very effective for
those patients from poorer socioeconomic groups who were
receiving public assistance. The combination treatment was
more effective and less costly for patients with many comorbid symptoms. In addition, it is important to note that children
in the combination treatment were able to control symptoms
with lower doses of medication (JAMA Psychiatry).
As patients enter adolescence, boys and girls may present with
different symptoms and, therefore, may need different courses
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of treatment. Boys have a tendency to be more aggressive and
the need for behavior control is more pressing while girls may
have more social and emotional symptoms requiring social and
mood altering treatments. It is for this reason that at this stage,
teens must be made an integral part of their own treatments.
Parent training at this stage includes the same basic premise
as younger children with positive reinforcements becoming
more age appropriate. For example, positive reinforcement includes more time with friends or more computer time while
consequences for negative behavior may be losing privileges
(Miller, Child Mind Institute). Working closely with teachers
and counselors at this stage is most important as difficulties
in school is a major concern. It seems that CBT and parent
training alone is not as effective in the adolescent group as in
younger children and a combined regimen including medication
and behavior intervention is more effective than either alone
(JAMA Psychiatry). More studies on adolescents need to be undertaken, however, since most assume that their problems may
be successfully addressed using similar methods as those used
for their younger counterparts.

Conclusion
ADHD is a developmental and neuropsychological disease
caused by low levels of dopamine release that presents with
symptoms including behavioral impulsivity and inability to focus,
along with the possibility of comorbid conditions of depression
and behavioral defiance. It is a disease which may present at any
time throughout a lifespan, but treatment is most effective when
diagnosed and treated earlier in life. There are many treatment
options available to the ADHD patient including stimulant and
non-stimulant medications which may be administered in many
modalities and doses to fit many different lifestyles. Non pharmacological approaches include cognitive behavior therapies,
including parent and teacher training, student workshops and
summer training programs. Individualized approaches to treatments seem to be the most effective based on a patient’s age,
symptoms, socio-economic group, and sex. In general, combined
medication therapy with different forms of CBT tailored to patient lifestyle as he grows is the most effective treatment.
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Abstract
Probiotics have been commonly ascribed many therapeutic powers. The aim of this review is to investigate these claims.
While some of the claims are well supported by research, the effects of probiotics are very specific and depend on the
strains used as well as the disease or condition targeted. Age and racial ethnicity may also be factors impacting the
efficacy of probiotic strains.
Introduction
In recent years, probiotic supplements and probiotic yogurt
have become increasingly popular pharmacy and grocery items.
Proponents posit that these live cultures of beneficial bacteria
counteract the negative effects of antibiotics and decreased microbial exposure of modern life, while others are skeptical of
these relatively new products and claims.
Every human gut contains millions of bacteria from hundreds of
species which aid in digestion and promote health. These bacteria are healthy bacteria and are very important to one’s wellbeing. Western, developed countries successfully controlled infectious diseases during the last century by improving sanitation
and using antibiotics and vaccines.At the same time, a rise in diseases such as allergies, autoimmune disorders, and inflammatory bowel disease has been observed in both adults and children,
and it is hypothesized that improvements in hygiene, decreased
microbial exposure in childhood, and decreased maintenance of
microflora are responsible for this increase. In 1907, the Russian
zoologist Élie Metchnikoff was the first one to suggest that gut
microbes may influence human health (Britannica).
Recent studies show that ingesting oral probiotics can promote
health and counteract some negative effects of antibiotics, but
only in specific ways. It is necessary to understand the mechanisms and limitations of probiotic supplements in order to be
an informed consumer.

Methods
This subject was researched using Touro College’s online library
database as well as Google Scholar. Additionally, ProQuest,
EBSCO, MEDLINE, and PubMed were used to search for articles.The author had free access to these search engines through
the Touro College Library. The method of research entailed
reviewing published articles and studies that have been peer
reviewed. Key words such as “gut bacteria”, “probiotic bacteria”,
“health promoting bacteria”, “probiotic yogurt”, “human microbiome”, and “microbiota” were used to find appropriate articles.

Background: Development of gut microbiome
Babies born via vaginal births are colonized by bacteria as they
pass through the birth canal. The vaginal microbial communities
appear to change during pregnancy to provide newborns with
beneficial microbes; at the time of delivery, the vagina is dominated by Lactobacillus and Prevotella spp (Krajmalnik-Brown et
al 2012). Breast milk also populates the baby’s gut with additional
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health promoting bacteria from the Bifidobacterium family.
According to very recent research, babies acquire stomach bacteria from their mothers even before birth. In healthy human fetuses, bacteria have been detected in umbilical cord blood, fetal
membranes, and amniotic fluid, supporting the notion of bacterial transmission through the placental barrier. Furthermore,
the meconium (ingested amniotic fluid) from newborns has
been shown to be non-sterile, home to a complex community
of microbes, including Enterococci and Escherichia, commonly
found in the adult GI tract. Therefore, even babies born by caesarean section are born with microbiomes, despite lacking the
vaginal exposure (Funkhouser and Bordenstein 2013).

Diversity between ethnic groups
While 90% of all people’s gut biome is similar, the bacteria species and proportions vary between races and ethnic groups. A
study published in 2010 comparing rural children of Burkina
Faso, Africa, with children in the modern and developed city
of Florence, Italy, showed that Bacteroidetes and Spirochaetes
were abundant in the microbiota of the African children and that
the specific types that were increased were well suited to extract nutrition from their herbal-rich diet. These bacteria were
from the genus Prevotella and Xylanibacter (Bacteroidetes) and
Treponema (Spirochaetes), which are known for their skill at
cellulose and xylan hydrolysis. The diet of the rural village in
Burkina Faso is low in animal protein and fat but rich in starch,
fiber, and plant polysaccharides from local herbs and vegetables. These bacteria were completely lacking in the European
children whose diet was high in fat, animal protein, sugars, and
nutrient-rich but thoroughly cleansed foods (De Filippo et al
2010).
A recent study has shown that the Japanese possess unique
bacteria in their intestines which allow them to digest red
algae, commonly used to wrap fish in sushi. Japanese have a seaweed-rich diet, eating on average of 14.2 grams of sushi a day.
Red algae, used in sushi, contain the polysaccharide porphyran
in their cell walls. It is broken down specifically by an enzyme
called porphyranase. This enzymatic activity is unique to select
marine bacteria such as Zobellia galactanivorans, the bacteria
that populate the gut of the Japanese, giving them the machinery
they need to digest these nutritional sea plants (Hehemann et
al 2010).
A similar phenomena has been detected in the guts of rodents.
Desert woodrats (Neotoma lepida) of the Mojave and Great
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Basin deserts have special toxin-degrading gut microbes to digest the toxic creosote and juniper bushes (Kohl et al 2014).
This diversity between ethnic groups adds a dimension of complexity to understanding the workings of the microbiome. This
variation may impact the manner in which the gut responds to
introduced probiotic bacteria and may result in probiotic treatments being beneficial for some people but not others.

How gut microbes affect autrient absorption and
energy regulation
In a way similar to how rhizoidal fungi allow plant roots to absorb soil nutrition, the biofilm structure of the many mucosal
microbiota adhering to gut epithelium facilitates benefits for the
host, including nutrient exchange and stimulation of immunity
(Sonnenburg et al 2004). For example, Bacteroides thetaiotaomicron is a major symbiont of the human adult gut (Hayashi
et al 2013). This organism makes an important contribution
to human digestion by breaking down complex plant material
that innate human enzymes cannot digest. The human body can
produce amylase and sucrase which break down starch, glycogen, and sucrose respectively, yet it cannot independently digest
complex plant material (Microbewiki). Using the plant and fungus
polysaccharides ingested by the human host as its food source,
B. thetaiotaomicron is able create small sugars with its glycoside
hydrolases which hydrolyze glycosidic bonds in complex sugars.
It produces mucus that allows it to attach to the gut epithelial
cells, avoiding washout from the microecosystem. The mucus
sticks to epithelial lining as well as to undigested food particles.
These aggregations serve to promote the assembly of more
microbes and allow their syntrophic relationship with the gut..
Other gut bacterial species such as harmless strains of E. Coli
benefit from the small sugars provided by B. thetaiotaomicron,
which the E. Coli cannot produce independently. Methanogens,
another family of the microbiome, use the short-chain fatty acid
products of the fermentation of carbohydrates.These symbiotic
relationships add productivity to the human gut (Sonnenburg
et al 2004). It is clear that the many interactions between gut
bacteria are extremely complex and to date only a fraction of
this organization is understood. Much research is needed to
fully understand the way in which introduced probiotic bacteria
interrelate and network with the host gut microbiome.

Vitamins
Vitamin B12 is required for metabolism in cells and for the
formation of red blood cells. The human body cannot produce
vitamin B12. Only bacteria and archaea are capable of manufacturing this vitamin. Species of Pseudomonas and Klebsiella,
normal residents of the human small intestine, have been shown
to produce vitamin B12 (Albert et al 1980). E. coli in the large
intestine produce Vitamin K2 (Bentley and Meganathan 1982).

Biotin (vitamin B7), a vitamin required for production of fatty
acids and cell growth, is synthesized in significant quantities by
the intestinal flora (Scheinfeld et al 2015)..

Gut bacteria help prevent pathogenic infections
Lactic acid bacteria are found naturally in acidic foods such as
pickles, olives, and yogurt, preventing spoilage by maintaining a
low pH. In the same way, many pathogenic bacteria are deterred
from growing in the human intestines due to the unfriendly
acidic environment created by members of lactic acid bacteria
family, Lactobacillales. Furthermore, by merely colonizing the
gut, the healthy bacteria leave little real estate for pathogenic
bacteria to occupy (Nester).
Having established the presence and functions of gut microbes,
a question of concern is how the common use of antibiotics
affects this microbiome and the life functions dependent upon it.

What happens to the bacteria when antibiotics
are taken?
Studies on isolated cultured colonies of gut bacteria in a laboratory setting have shown how antibiotics impact them. In one
study, 14 common gut bacterial species from the Clostridium,
Bifidobacterium, and Bacteroides genera were treated in vitro
with ampicillin and metronidazole, clinically prescribed antibiotics. Effects on bacterial physiology and metabolism were
monitored over a 48 hour period. Bacteroides and some
Clostridium species were substantially reduced by Ampicillin.
On bifidobacterial species ampicillin only had a bacteriostatic
effect. Metronidazole strongly affected bacteroides communities, reduced some clostridium species, but had no effect on
bifidobacterial communities. This study showed that the antibiotics ampicillin and metronidazole have a real inhibitory effect
on some intestinal bacteria species but not others (Newton F
et al 2013).
Modeling tests have been conducted on mice as well to better understand the relationship between antibiotics and intestinal bacteria. Mice have similar gut bacterial composition to
humans. Oral intake of antibiotics, streptomycin and vancomycin, was used to agitate the intestinal microbiota of the mice.
Thereafter, the mice were infected with Salmonella enterica serovar Typhimurium to gauge the results of antibiotic treatment.
Analysis showed that the number of intestinal bacteria was not
altered significantly by the antibiotic regimen, but the microbiota composition was affected. Both vancomycin and streptomycin
treatments significantly decreased lactobacilli and enterococci/
group D streptococci populations and promoted the overgrowth of Enterobacteriaceae. These perturbations in the microbiota caused the mice to be more susceptible to Salmonella
serovar Typhimurium intestinal colonization and infection than
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before antibiotic treatment.This study demonstrates the importance of a healthy microbiota in limiting susceptibility to enteric
pathogens. This study showed that the antibiotics vancomycin
and streptomycin can have a detrimental effect on intestinal
bacteria species, limiting host immunity (Sekirov et al 2008).
A leading expert in this field, David Relman M.D., investigated
the gut bacterial communities of three healthy humans before
and after treatment with ciprofloxacin, a commonly prescribed
broad spectrum antibiotic of the fluoroquinolone family, by
comparing stool samples before and after treatment. He monitored them for a period of ten months. Ciprofloxacin treatment eliminated about a third of the bacterial taxa in the gut,
decreasing the diversity of the community. Faecalibacterium,
Lachnospiraceae, Bacteroides and Alistipes are names of several
genera that were reduced by ciprofloxacin. The magnitude of
this effect varied to some degree between individuals. However,
by 4 weeks after the end of treatment, the makeup of the community closely resembled its pretreatment state in all three individuals with the exception of several taxa which failed to recover even 6 months later. During the four week recovery period,
the participants reported normal intestinal function. The rapid
resurgence of the pretreatment community indicates strong
bacterial community resilience. However, the fact that several
bacterial species did not recover tells that even a short course
of antibiotics may cause minor permanent changes to gut community flora. Though the participants did not experience any
immediate obvious stomach problems from the medication, this
cannot predict the possibility of long term impacts such as increased susceptibility to allergies or skin irritations (Modi S et al
2014). Relman found that a second exposure to ciprofloxacin a
half year after the first treatment causes similar effects but was
accompanied by incomplete recovery (Dethlefsen and Relman
2010).
Similar studies using clindamycin showed that the gut Bacteroides
community never returned to its original composition even two
years after antibiotic treatment (Jernberg et al 2010). Clearly
antibiotics impact the bacterial gut population with possible effects on host wellness.

Which diseases result from antibiotic use?
Campylobacteriosis (stomach ulcer) has been linked with intake of antibiotics up to one year before the onset of disease
(Folkhälsomyndigheten 2014). Candida glabrata, an opportunistic pathogen of the urogenital tract and bloodstream in immunocompromised persons, has been associated with taking of
specific antibiotics (Ben-Ami 2012). In one large study, fluoroquinolones were found responsible for over 55% of cases of
Clostridium difficile-associated diarrhea, an often fatal disease
(Pepin et al 2005). Studies have demonstrated using mouse
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models that the two antibiotic-associated pathogens, Salmonella
typhimurium and Clostridium difficile, infect their host by catabolizing mucosal carbohydrates liberated from microbiota by the
antibiotic streptomycin (Katharine et al 2013). Use of antibiotics in children was significantly associated with Crohn’s disease
even if 6 months had elapsed between diagnosis and the latest
intake of antibiotics (Virta et al 2012).
Aside for the infection of Salmonella typhimurium and
Clostridium difficile, the exact biological mechanism for most
of these epidemiological associations is currently unknown.
However, it is logical to assume that killing off good bacteria
is causative because we don’t know of any other lasting effects
of antibiotics, but we did see from the studies of Modi et al
(2014) and Dethlefsen and Relman (2010) that some of the
good bacteria decrease and don’t ever reestablish themselves.

Results: Probiotic theory
To counter the adverse effects of antibiotics many have considered consuming probiotics. The theory behind probiotics is
that swallowing new live bacteria will replenish the lost bacterial
communities diminished by the antibiotics. Because a healthy
gut microbiome is believed to promote and maintain health,
probiotic yogurt and dietary supplements have been suggested
even for individuals who have not taken antibiotics. First, though,
it must be determined that probiotic bacteria are alive and can
reach the gut when consumed orally.

Do probiotic bacteria die in the acidic pH of the
stomach before they reach the intestine?
Critics of probiotics question whether the majority of the bacterial communities housed in a probiotic pill survive the acidic
environment of the stomach on their journey to the intestine. Research has been done to determine the effects of the
stomach’s acidic environment on probiotic bacteria. It is worth
noting that Lactobacilli, which are native gut bacteria and are
included in most probiotic formulations, are acidophilic and are
not adversely affected by stomach acid (Tannock 2004).
De Campo et al (2005) performed a double-blind study with
114 healthy volunteers. After 15 days of yogurt consumption,
the participants’ feces were analyzed by culture, specific PCR,
and DNA hybridization for presence of the yogurt organisms
L. delbrueckii and Streptococcus thermophilus. Detection of
yogurt lactic acid bacteria in total fecal DNA by bacterial culture and PCR assay was consistently negative indicating that
the strong acidic environment of the stomach killed microbes.
However, Marina Elli et al (2006) showed that the De Campo
et al’s analytical detection methods were poorly set up. Elli’s
studies in turn confirmed that yogurt bacteria, especially L. delbrueckii subsp. bulgaricus, can be retrieved from feces of healthy
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individuals after a few days of ingestion of commercial yogurt.
Thus, Marina Elli’s research established that many strains of
probiotic bacteria do indeed survive transit through the gastrointestinal tract. It still is a possibility that though the low pH of
the stomach does not destroy the entire probiotic population,
it may limit the number of live bacteria that reach the intestine,
reducing the effectiveness of the probiotic administration.
To overcome the possibility that a portion of the probiotic bacteria die in the stomach acid, new delivery technology has been
developed to protect the strains from stomach acid. Scientists
have constructed a coating for susceptible probiotics to avoid
this possibility. Bifidobacterium breve, a model probiotic, was
encapsulated into a multilayer alternating alginate-chitosan
coating. This construction improved the endurance of B. breve
during contact with stomach acid. During exposure to in vitro
gastric conditions, a tremendous increase in viability from that
seen in free cells was demonstrated (Cook et al 2013). Other
studies have shown that capsules made of alginate, xanthan gum,
and carrageenan gum increased the survival of probiotic bacteria in acidic stomach conditions (Ding and Shah 2009). Many
probiotic supplements sold today include protective coatings.
Though probiotic bacteria in yogurt has no such coating, the
study of Marina Elli et al (2006) confirms that much of the bacteria do survive the acidic stomach environment.
Ancillary support for the survival of probiotic bacteria comes
from the animal world. Coprophagy is the norm in an overwhelming number of vertebrae. Rodents, rabbits, pigs, foals and
gorillas and chimpanzees all eat their feces regularly (Soave and
Brand 1991). The young of elephants, pandas and hippos eat
their maternal feces and thereby obtain the bacteria required
to properly digest and obtain nutrition from vegetation in their
diet.They are born without these necessary bacteria in their intestines (Zilber-Rosenberg 2013).The idea of sharing gut microbiota via feces has made its way to human medicine. Fecal bacteriotherapy or stool transplants have a well-entrenched place in
the history of medicine of many ancient cultures. Recent studies
have shown that C. difficile can be effectively treated with fecal
transplants (Shultz 2014). The idea behind the consumption of
feces is very similar to the reason to eat probiotics. It replenishes the microbiome with friendly bacteria.

Viability of organisms in capsules
Skeptics have questioned whether probiotic bacteria are alive
and viable in their capsules or whether they die during production or storage. Many studies have been conducted proving
that the bacteria are indeed alive. This is the general manufacturing process of probiotic pills as described by the Lallemand
Health Solutions probiotic producer (2015): Chosen bacteria
are inoculated onto a culture media and multiply. Live bacteria

are then separated from the culture medium by centrifugation;
they are mixed with a cryoprotectant, to help them survive the
freeze-drying process. Alternatively, they are vacuum dried or
spray dried. The dried bacteria form a solid cake which is milled
into a fine homogeneous powder, each grain of which contains
approximately 1 billion bacteria. Bacteria powders are blended
with other carrier and diluent ingredients for the desired bacterial concentrations and then encapsulated and packaged.
Studies into the storage stability of spray-dried (Ananta E et
al 2005), and freeze dried (Kurtmann L et al 2009) probiotics
are positive. The bacteria remain alive, although dormant, and
start to grow again after they reach the moist gut environment.
Even higher storage stability has been found for vacuum-dried
probiotic cells. Vacuum-dried cells show much higher stabilities
than the freeze-dried cells (Foerst P et al 2012).

Effects of temperature on probiotic quality
Temperature has been shown to play a role in the stability of
probiotics. Warmth and moisture are the ideal growing conditions for probiotic and gut bacteria.The growth and reactivation
of these dormant organisms is inhibited in the presence of cold
air, which holds less moisture and is not in the ideal temperature
range for these bacteria to thrive. Cold air is therefore optimal
for storage of probiotics as it keeps the bacteria from activating
and hence dying before they have a chance to reach the human
body. High heat can also degrade the viability of these organisms and care should be taken to keep them away from high
temperatures. A thorough study on the effects of temperature
on vacuum-dried probiotic bacteria revealed that after three
months of storage at 4°C cells remained stable with a survival
rate of 70%. At non-refrigerated temperatures (~37°C) only
54% of the cells survived (Foerst P et al 2012). Similarly, a study
of freeze-dried common probiotic lactobacteria strains showed
that stored at 4°C for three months, the survival rate was 76%,
while storage at 23°C for the same length of time had only a 37%
survival rate (Jalali M et al 2012). Similar effects of temperature
on probiotic bacteria were determined for cells produced by
spray-drying (Corcoran BM et al 2004). Based on this it would
be best to store probiotics at refrigerated temperatures. Ideally,
they should be kept at such temperatures in warehouses, shipment, and stores as well, though this is not currently standard.
It should be noted that as an extra measure, many manufacturers add an overage of bacteria to their probiotic products
to compensate for the expected decline in numbers over time
(NowFoods).

Probiotics and health
To date there has been insufficient research to prove whether
probiotics counteract the many adverse effects of antibiotics
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mentioned above, besides for treating antibiotic-associated diarrhea. However, a large number of studies have demonstrated the
benefits of prophylactic probiotic treatment for general health
benefits, preventing a variety of ailments, and curing other diseases not associated with antibiotics.

Probiotics as treatment for antibiotic-associated
diarrhea
In 2012, researchers (Hempel S et al 2012) conducted an analytical search of hundreds of earlier studies and reviews about
the effects of probiotics on antibiotic-associated diarrhea. This
systematic review found that using the lactic acid-producing
bacteria such as Lactobacillus rhamnosus, or L. casei as well as
Saccharomyces boulardii [cerevisiae] may be helpful in preventing
and curing antibiotic-associated diarrhea.The number-needed-totreat value (NNT) was found to be 13. This means that statistically on average out of thirteen susceptible patients being treated
with probiotics for antibiotic-associated diarrhea, one will benefit. Due to overall poor documentation of the probiotic strains,
it was not clear if the efficacy of treatment was strain specific.
Furthermore, the studies were spread over a vast population so
more research needs to be performed to determine whether
the elderly, middle-aged, or children would benefit most from
adjunct probiotics therapy. Another question that requires clarity
is which specific antibiotics are more likely to cause diarrhea and
which probiotic strains best combat those particular antibiotics.
However, the studies analyzed included patients taking a variety of
antibiotics or did not specify the antibiotics used, limiting any conclusive correlation (Hempel S). Because the overall results from
these studies are promising, many medical experts see no reason
not to suggest probiotics when prescribing antibiotics (Kligler and
Cohrssen 2008).
A more recent (2013) large study targeting 2,941 inpatients over
65 years of age exposed to broad-spectrum antibiotics found no
supporting evidence that multi-strain lactobacilli or bifidobacteria
probiotics were effective in prevention of antibiotic associated
diarrhea in that group (Allen S et al 2013).
Studies on the effects of probiotics on the particularly dangerous
condition, Clostridium difficile colitis, often caused by an impaired
microbiome due to antibiotics, provide insufficient evidence to
recommend probiotic therapy even merely as an adjunct treatment (Pillai A and Nelson R 2008).

Probiotics may shorten the duration of infectious
diarrhea
Infectious diarrhea is often caused by shigella, E. coli, salmonella,
and clostridium bacteria. A meta-analysis of almost 2000 patients
from 23 studies of infectious diarrhea in both adults and children
indicates that the duration of symptoms may be shortened by
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the use of probiotics by a mean of 30 hours (Allen SJ et al 2004).
The majority of the probiotics tested in these studies were lactic
acid bacteria; two studies used Saccharomyces boulardii. Though
infectious diarrhea is not necessarily a result of antibiotic treatment, infectious diarrhea from Salmonella often is associated with
antibiotic use. Thus, in this way probiotics may be considered to
be counteracting the effects of antibiotics.

Bifidobacterium infantis 35624 reduced
symptoms of irritable bowel syndrome (IBS)
In a review analyzing 16 randomized clinical trials of irritable
bowel syndrome (IBS) patients who received either placebo
or probiotic supplements, Bifidobacterium infantis 35624 was
effective in reducing irritable bowel syndrome symptoms, such
as intestinal gas, abdominal pain, bloating, and bowel function
(Brenner DM et al 2009). There was no evidence of adverse
results. No other probiotic, including isolated Lactobacillus species, showed significant improvement in IBS symptoms in appropriately designed randomized clinical trials.
Another systematic review of the literature revealed that probiotics succeeded in reducing irritable bowel syndrome symptoms with a number needed to treat (NNT) of 4 (Moayyedi
P et al 2010). Almost all probiotic combinations contained
Bifidobacteria species (Verna 2010).

Probiotics for constipation
Dr. Mary Morgan, an immunologist and researcher for probiotics companies, conducted a meta-analysis to uncover which
probiotics have the best results for constipation. She found
the following five are best: Bifidobacterium lactis DN-173 010,
VSL#3 formula (a probiotic mix), Bifidobacterium lactis Bb12, Lactobacillus casei Shirota, and Bifidobacterium longum
(Morgan 2013).

Probiotics may prevent hepatic encephalopathy
development from cirrhosis
A recent study shows that probiotics are effective in preventing the progression of liver cirrhosis to hepatic encephalopathy
(Lunia MK et al 2013). Cirrhosis is an advanced liver disease
characterized by replacement of healthy liver tissue with scar
tissue, leading to progressive loss of liver function. It is usually
caused by alcoholism, Hepatitis A or Hepatitis B. As cirrhosis is
irreversible, treatment of cirrhosis focuses on preventing progression. In a progressed state, cirrhosis may lead to hepatic
encephalopathy, in which an over accumulation of toxic ammonia in the blood due to loss of liver function brings the patient
to an altered level of consciousness or coma. Natural members
of gut flora such as Eubacterium aerofa-ciens, E. lentum, and
Peptostreptococcus productus produce urease, which hydrolyzes urea into ammonia (Suzuki K et al 1979). In a healthy body,
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this ammonia is absorbed from the intestine into the bloodstream then filtered out by a functioning healthy liver. Hepatic
encephalopathy, the result of poor liver function, is commonly
treated with the sugar, lactulose, which reduces the absorption
of ammonia from the gut into the bloodstream. The usefulness
of lactulose is limited by side effects such as diarrhea, bloating,
and flatulence. The Lunia MK, et al study found that intake of
a specific set of probiotics will alter the intestinal microbiota,
preventing development of hepatic encephalopathy in patients
with cirrhosis. By recolonizing the gut with non-urease producing bacteria such as those in the supplements used in this study,
a buildup of ammonia is avoided, thus preventing hepatic coma.
The 86 patients in the treatment group received a regimen of
probiotics which contained Bifidobacterium breve, B. longum,
B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei,
L. bulgaricus, and Streptococcus thermophilus, 110 billion colony-forming units in all, in one capsule 3 times per day. The
control group included 74 patients. Patients were told to refrain from eating any commercial probiotic yogurt. The patients
were followed up on each month for six months to ascertain
that they were keeping to their probiotic treatment plan and
to track the development of any hepatic encephalopathy symptoms. The researchers observed that the incidence of hepatic
encephalopathy was significantly lower in patients treated with
probiotics. No adverse effects were detected from the probiotics.These results offer a more comfortable and better-tolerated
alternative to current lactulose treatments (Lunia MK).
A recent study shows that probiotics are effective in preventing the progression of liver cirrhosis to hepatic encephalopathy
(Lunia MK et al 2013). Cirrhosis is an advanced liver disease characterized by replacement of healthy liver tissue with scar tissue,
leading to progressive loss of liver function. It is usually caused by
alcoholism, Hepatitis A or Hepatitis B. As cirrhosis is irreversible,
treatment of cirrhosis focuses on preventing progression. In a
progressed state, cirrhosis may lead to hepatic encephalopathy,
in which an over accumulation of toxic ammonia in the blood
due to loss of liver function brings the patient to an altered level
of consciousness or coma. Natural members of gut flora such
as Eubacterium aerofa-ciens, E. lentum, and Peptostreptococcus
productus produce urease, which hydrolyzes urea into ammonia
(Suzuki K et al 1979). In a healthy body, this ammonia is absorbed
from the intestine into the bloodstream then filtered out by a
functioning healthy liver. Hepatic encephalopathy, the result of
poor liver function, is commonly treated with the sugar, lactulose, which reduces the absorption of ammonia from the gut into
the bloodstream. The usefulness of lactulose is limited by side
effects such as diarrhea, bloating, and flatulence. The Lunia MK,
et al study found that intake of a specific set of probiotics will
alter the intestinal microbiota, preventing development of hepatic

encephalopathy in patients with cirrhosis. By recolonizing the gut
with non-urease producing bacteria such as those in the supplements used in this study, a buildup of ammonia is avoided, thus
preventing hepatic coma.
The 86 patients in the treatment group received a regimen of
probiotics which contained Bifidobacterium breve, B. longum,
B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei,
L. bulgaricus, and Streptococcus thermophilus, 110 billion colony-forming units in all, in one capsule 3 times per day. The
control group included 74 patients. Patients were told to refrain from eating any commercial probiotic yogurt. The patients
were followed up on each month for six months to ascertain
that they were keeping to their probiotic treatment plan and
to track the development of any hepatic encephalopathy symptoms. The researchers observed that the incidence of hepatic
encephalopathy was significantly lower in patients treated with
probiotics. No adverse effects were detected from the probiotics.These results offer a more comfortable and better-tolerated
alternative to current lactulose treatments (Lunia MK).

Probiotics as bowel movement and nutrition
enhancer in the elderly
Hilla Zaharoni et al (2011) conducted a study to determine
the preventive impact of probiotics on problems with bowel
movement and malnutrition in the elderly (Zaharoni H et al
2011). The study included 215 elderly patients at an orthopedic
rehabilitation center (107 as control, 108 as probiotic recipients), age 65 and over. Each participant received a daily dose
of commercially sold probiotic bacteria. The dosage consisted
of four strains of Lactobacillus – L. planturum, L. paracasei, L.
bulgaris, L. acidophilus; three strains of Bifidobacterium – B.
breve, B.longum, B. infantis; and one strain of Streptococcus, S.
thermophiles.The control group received a daily placebo packet
looking exactly like the probiotic complement. After being fed
daily probiotics or placebo pills for 45 consecutive days in a
randomized, double-blind, placebo-controlled trial, the patients
were monitored for 45 follow-up days. The incidences of diarrhea were significantly lower among the study group (HR=0.42,
p=0.04) with a more significant difference among participants
age 80 and older (HR=0.32, p=0.026). The necessity to use laxatives, an indicator of constipation, also showed significant decrease in the probiotic group compared with the control group
(HR=0.74, p=0.032).
Additionally, healthier levels of transthyretin, reflecting a positive nutritional intake status, and increased serum albumin
levels, necessary for proper distribution of body fluids, were detected in the octogenarians of the treatment group compared
with the control group (P=0.047, p=0.07, p=0.03 respectively)
but not in the younger age group (between 65 and 80 years
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of age). This study strongly indicates that the studied bacterial
strains in commercial probiotics have a positive effect on the
bowel movements of elderly patients in orthopedic rehabilitation (Zaharoni H et al 2011).

Bifidobacterium lactis (BB-12), Lactobacillus
reuteri prevents occurrence of infantile fever
and diarrhea, though not respiratory illness
An important study led by Weitzman Z et al (2005) shows excellent results for probiotics’ prophylactic effect against fever
and diarrhea in infants. A placebo-controlled, double-blind
trial was conducted at 14 child care centers on healthy infants four to ten months old. Infants were assigned randomly
to either no probiotics or baby formula supplemented with
Bifidobacterium lactis (BB-12) and Lactobacillus reuteri 55730
for a period of 12 weeks. The infants were not breastfed prior
to the study, and were fed only the assigned formula. The parents agreed not to administer any other probiotic or prebiotic supplements. The number of episodes of fever (>100.5
degrees F), diarrhea, and respiratory illness and the days of
duration were measured for both groups.
Of 201 participating infants who were similar in gestational
age, birth weight, and prior breastfeeding, 60 infants were controls, 73 were fed B. lactis, and 68 were fed L. reuteri. Febrile
outbreaks and diarrheal episodes were nearly double in the
control group compared to the recipients of B. lactis. The duration of diarrhea was also protracted in the control group.
Results from the 68 infants of the L. reuteri group were even
more encouraging. Compared with the controls and even B.
lactis infants, the L. reuteri group had a substantial decrease
in number of days with fever, doctor visits, nursery absences,
and antibiotic medication prescriptions. The probiotic supplements showed no effect on the incidents of respiratory
illnesses between the groups.

Bifidobacteria infantis, Streptococcus
thermophilus, and Bifidobacteria bifidus for
necrotizing enterocolitis
Prophylactic use of the probiotics, Bifidobacteria infantis,
Streptococcus thermophilus, and Bifidobacteria bifidus, were
tested by Alona Bin-Nun et al (2005) to determine their effect on the incidence and severity of necrotizing enterocolitis. Necrotizing Eterocolitis is a postnatal medical condition
where portions of the bowel undergo necrosis. Primarily seen
in premature infants, it is among the most common causes of
mortality in premature infants. Neonates were randomized to
either receive a daily feeding supplementation with a probiotic
mix of 109 colony-forming units per day or to receive no probiotic supplements.
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For 72 study and 73 control infants, respectively, birth weight,
gestational age, and time to reach full feeds were nearly equal.
The incidence of necrotizing enterocolitis was reduced in the
study group (4% vs 16.4%). Additionally, necrotizing enterocolitis was less severe in the probiotic-supplemented infants. Three
of 15 babies who developed necrotizing enterocolitis died, all
three from the control group.

Discussion and future study
Over the past two decades there has been significant advancement in the field of probiotics since it has been first suggested in
1907 by Elie Metchnikoff.These studies have used random undirected criteria for choosing which bacteria from amongst thousands of species and strains to test for potential health benefits.
They often chose strains occurring in various fermenting foods.
Each trial has been like a shot in the dark hoping to find a cure.
The author suggests that future studies focus on the strains
unique to the gut of residents of the rural village in Burkina
Faso in the De Filippo et al (2010) study and of other remote
non-westernized locales for their potential probiotic qualities.
Epidemiological evidence tells that the improved sanitation,
sterile industrial foods, and antibiotics of westernized civilization has controlled infectious diseases but also has increased the
incidence of allergic, autoimmune disorders, and inflammatory
bowel disease (IBD). By selecting gut bacteria unique to isolated
populations living with an environment and diet of the pre-modern era, we may discover probiotic beneficial bacteria which can
restore and implant the health benefits of those primeval and
rustic lifestyles into the modern urbane world. The De Filippo
et al study identified bacteria from the genus Prevotella and
Xylanibacter (Bacteroidetes) and Treponema (Spirochaetes) exclusive to the Burkina Faso population. These results should be
verified and similar investigations should be made into the gut
bacteria of other traditional societies such as remote Tibetan
villages and Northern Okinawa farm towns. New randomized
clinical trials for probiotic efficacy should be designed utilizing
the bacterial findings of these remote searches.

Practical consumer implications; Considerations
for choosing probiotic supplements
There are hundreds of probiotic supplements available on the
market. Many of these products have no claim to any supporting studies. As probiotics are considered dietary supplements
and not medications, they do not require certification from
the Federal Department of Agriculture (FDA). There are great
variations in the strains of bacteria they contain. It is best to
buy products that are backed by clinical research. The wise
consumer will examine the labels of the product to be certain
that it contains the particular research-backed strains he or she
desires. If one hopes for a particular cure or health benefit, the
supplement one chooses should contain strains shown to be
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Table 1

Condition

Probiotic Bacterial Species

Population*

antibiotic-associated diarrhea

Lactobacillus rhamnosus, L. casei, Saccharomyces people younger than 65 years
boulardii [cerevisiae]

infectious diarrhea caused by shigella, E. Lactic acid bacteria species, Saccharomyces
coli, and salmonella
boulardii

adults and children

irritable bowel syndrome (IBS)

Bifidobacterium infantis 35624

adults

promoting bowel movements and
better nutrition intake

Lactobacillus planturum, L. paracasei, L. bulgaris, L.
acidophilus, Bifidobacterium breve, B.longum, B.
infantis, Streptococcus thermophiles

individuals of 65 years and older

fever and diarrhea (prophylactic treatment)

Bifidobacterium lactis (BB-12), Lactobacillus
reuteri 55730

infants

constipation

Bifidobacterium lactis DN-173 010,VSL#3®
adults
formula (a probiotic mix), Bifidobacterium lactis
BB-12, Lactobacillus casei Shirota, Bifidobacterium
longum

necrotizing enterocolitis

Bifidobacteria infantis, Streptococcus thermophilus, Bifidobacteria bifidus

infants

hepatic encephalopathy
(prophylactic treatment)

Bifidobacterium breve, B. longum, B. infantis, Lactobacillus acidophilus, L. plantarum, L. paracasei, L.
bulgaricus, Streptococcus thermophilus

cirrhosis patients

*These particular populations were studied. Effects on other populations are not included unless indicated.

Table 2

Yogurt Brands

Bacteria Strains

Yoplait

Lactobacillus bulgaricus
Streptococcus thermophilus
sometimes: Lactobacillus acidophilus

Chobani

Lactobacillus acidophilus
Bifidobacterium bifidum
Lactobacillus casei

Stonyfield Farms

Lactobacillus bulgaricus
Streptococcus thermophilus
Lactobacillus acidophilus
Bifidobacterium bifidum
sometimes Lactobacillus rhamnosus

Yakult

Lactobacillus casei Shirota

Dannon

Lactobacillus bulgaricus
Streptococcus thermophilus
sometimes: Lactobacillus acidophilus
Bifidobacterium lactis DN-173 010 in Activia®
Lactobacillus casei DN-114- 001 in DanActive®

La Yogurt

Lactobacillus bulgaricus
Streptococcus thermophilus
Lactobacillus acidophilus
Bifidobacterium bifidum
Lactobacillus casei
Bifidobacterium animalis BB12
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beneficial to that end. Table 1 summarizes researched bacterial
strains and the conditions they benefit.

Probiotic Yogurt
Many yogurt products claim to be probiotic. Again, these claims
are not backed by the FDA. Some bacterial strains in yogurt
have more scientific support than others. According to the
Dairy Reporter (August 2, 2013), Dannon, Yoplait, Chobani, and
Stonyfield rank among the most popular brands in the United
States. Table 2 lists the strains included in commonly available
yogurts.

Starter bacteria
Most of the brands use Lactobacillus bulgaricus and
Streptococcus thermophilus as yogurt culture starters to turn
milk into yogurt. The only researched health benefits of these two
species is that they boost the immune system in anorexia patients
(Nova E et al 2006) and help lactose absorption those who are
lactose-intolerant (Riskalla SW et al 2000).

Other added strains
Bifidobacterium animalis lactis BB-12 (LaYogurt)
The precise bacteria combination found in La Yogurt hasn’t been
scientifically researched. However, there have been many trials
using the strain Bifidobacterium animalis lactis BB-12, which all
La Yogurt probiotic products contain (*personal communication).
Studies have shown BB-12 reduces incidences of fever and need
for antibiotic treatment in infants (Weitzman Z et al 2005). Also,
it has been demonstrated that negative immune-related effects of
non-breastfed infants can be significantly reduced by including B.
animalis lactis BB-12 in their diet (Holscher HD et al 2012).

Bifidobacterium lactis DN-173 010 (Activia®)
On the yogurt ingredient panel this strain is known as Bifidus
regularis. This strain is well suited to treating intestinal inflammations such as colitis (Veiga P et al 2010). Studies showed that it
can reduce symptoms of irritable bowel syndrome (Agrawal A et
al 2009) and improve digestive comfort and symptom experience
of adults from the general population (Guyonnet D et al 2009)
and well as help improve constipation in children (Tabbers MM
et al 2009).

Lactobacillus casei DN-114 001 (DanActive®)
L. casei DN-114 001, also known as L. casei immunitas, used in
DanActive®, has great study results. Daily consumption of a product containing Lactobacillus casei DN-114 00 has been shown to
reduce the risk of gastrointestinal and respiratory common infectious diseases in shift workers (Guillemard E et al 2010).

Lactobacillus casei Shirota (Yakult)
The yogurt drink Yakult’s live Lactobacillus casei Shirota has been
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tested for effect on constipation with excellent results. Chronic
constipation patients experienced a sharp reduction in symptoms
after only two weeks of drinking Yakult (Koebnick C et al 2003)
(Cassani E et al 2011).

Yogurt Certification
In the USA, a ‘Live Active Culture Seal’ (image 1) was introduced
by the National Yogurt Association to identify refrigerated or frozen yoghurt products which contained at least 108 or 107 viable
bacteria per gram at the time of manufacture (AboutYogurt.com).
In heat-treated yogurt, a process done to prolong shelf life or decrease yogurt’s natural tartness, these cultures are killed during
heating after fermentation.
However, because these counts do not differentiate between
true scientifically proven probiotic strains and mere starter cultures, the National Yoghurt Association’s certification emblem is
still not reflective of true probiotic value (Senok AC et al 2005).
One must also check that the strains inside the yogurt are the
well-researched bacteria discussed above.

Conclusions
While it is true that many strains of bacteria confer positive
health benefits when taken orally, these bacterial strains demonstrate great specificity. Precise subspecies and strains have been
shown to cure certain ailments but not others, to benefit only a
particular age group, and to provide these advantages only when
taken on a regular basis. The research in this paper is important
because it shows the specific ways in which probiotic bacteria
are effective. The widely spread beliefs about benefits of probiotic products are not ensured by any governing body. Research
indicates that the functions and mechanisms of gut bacteria
are very complex and therefore there is no reason to assume
that random “probiotic” bacteria will offer any health benefit.
In addition, considerations for form and storage of probiotics
were discussed: namely that alginate coating may aid in probiotic
colonization and that probiotic supplements should be stored at
or below 4°C. Consumers should note that the positive results
in the studies were generally observed after 2-4 weeks or more
of daily probiotic consumption. Additionally, suggestions for
future studies utilizing gut bacteria unique to non-modernized
traditional societies have been made. This paper aids the general population by providing the necessary knowledge needed in
order to be an educated consumer of probiotic products.
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Abstract
Ulcerative colitis (UC), a subdivision of inflammatory bowel disease, is a chronic disease of the large intestines. Ulcerative
Colitis is normally a lifelong chronic illness with times of intense flairs and remission. During a flare, the lining of the
colon becomes inflamed, and develops small ulcers causing patients to experience rectal bleeding, vomiting, anemia and
diarrhea.The treatment options available to treat colitis are very small, causing many patients to need a total colectomy
with in the first five years of their diagnosis. However, recent advancement in bio-technology has led to the development of a large array of new therapeutic agents intended to target the exact site in the multifaceted cascade of cytokine
and chemokine effector molecules involved in UC pathogenesis. This article discusses the introduction of the chimeric
monoclonal antibody to TNFa that has deeply affected the clinical treatment of moderate to severe ulcerative colitis,
opening the door to a new era in the treatment of this disease. Studies discussed in this paper prove the effectiveness
of both Remicade and Humira, two different biologics, given to patients with an active state of this disease.
Introduction
Acronyms: UC-ulcerative colitis IBD-inflamitory bowel disease
Ulcerative colitis (UC), a subdivision of inflammatory bowel
disease (IBD), affects 1 to 2 million people in the United
States each year. The reason for ulcerative colitis is not quite
understood. However, the condition appears to be related to
a combination of genetic and environmental factors. Minor
symptoms include unformed stools, abdominal cramping, and
diarrhea (Lichteger et al.,1994). As the severity of the disease
increases, patients experience fatigue, loss of appetite, weight
loss mucus present in the stool, intense rectal bleeding in
addition to fever and anemia. UC can ensue at any time yet it is
usually diagnosed in a person’s teenage years. Roughly around
20% of people with UC have a close relative with IBD. (CCFA.
org, 2015).
UC is normally a lifelong chronic illness with times of intense
flairs and remission. A severe attack which can be a potentially fatal condition, is sometimes the first manifestation and is
observed in about 15% of the patients with this disease. The
introduction of corticosteroids sharply reduced the death rate.
Corticosteroids remain as a pillar in the treatment of a severe
attack of ulcerative colitis. The importance of achieving remission is undermined by the fact that the long-term colectomy
rate in patients with a severe attack who achieve clinical and
endoscopic remission after steroids is similar to those with a
moderately severe or mild attack. The dependence on corticosteroid is a continuous problem. Steroid dependent patients
may develop osteoporosis as they get older, in addition to dealing with weight gain, moon face, increase in appetite, as well as,
acne and joint pain. Furthermore, the likelihood of a colectomy
within the first five years from diagnosis ranges from 9% in patients with distal colitis to 35% in patients with complete colitis,
normally because of unsuccessful medical therapy. The risk of
recurring inflammatory bowel disease in the form of pouchitis
ranges from 15.5% 1 year after the procedure to 45.5% 10 years
after the procedure. Accordingly, new treatments for ulcerative
colitis are needed (CCFA.org, 2015).

92

In recent years biological therapy has been the new method of
treatment for those who are steroid dependent and or failing
to respond to other treatments.Tumor necrosis factor α (TNFα) is a key pro-inflammatory cytokine in patients with Crohn’s
disease, but is also found in amplified amounts in the intestinal
tissue, stools, blood and urine of patients with ulcerative colitis. Infliximab, also known as Remicade, is an IgG1 monoclonal
antibody that binds with intense strength to TNF-α, neutralizing
its biologic activity (Simmons & Jewell, 2002). The question now
becomes; will biological therapy be the answer to help induce
clinical remission in those suffering from UC?

Material and methods
In order to answer the question proposed above, many research articles with relation to this topic have been read. Touro
College’s library database, the national website of Pubmed and
Google Scholar were all used to obtain information for this
paper. All of the articles and information that was accumulated
through this research have been used in an attempt to conclusively determine if biological therapy will induce a remission in
patients living with active state of ulcerative colitis.

Different types of ulcerative colitis
The symptoms present for a person with ulcerative colitis will
vary based on the amount and severity of inflammation present
and the site of the disease in the large intestines. Ulcerative
proctitis, the mildest form of ulcerative colitis, is limited to the
rectum (about 6 inches or less). Proctosigmoiditis is colitis that
affects the rectum and sigmoid colon-which is located superior
to the rectum. Proctosigmoiditis can be determined sometimes
by the symptom of tenesmus (straining to have a bowel movement.) In addition, moderate pain on the lower left side of
the abdomen may occur while the disease is present. The third
version of colitis is known as left sided colitis. This presents as
continuous inflammation that begins at the rectum and goes
up as far as the splenic flexure (a bend in the colon near the
spleen in the upper left abdomen). Symptoms for left side colitis
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include severe pain on the left side of the abdomen, in addition
to loss of appetite. Lastly, the most severe form of ulcerative
colitis is pancolitis. Pancolitis affects the entire colon causing
terrible abdominal pain, weight loss and complete loss of appetite (CCFA.org, 2015).

ongoing inflammation. Immunomodulators are mostly used in
people who have failed to respond to the 5-ASA and steroids
have not been effective or have been minimally effective in
controlling the disease. Furthermore, immunosuppressants are
geared to allow people who are steroid dependent to eliminate
the use of them (Sood et al., 2002).

Climbing the medical ladder
Today, there are very effective treatments on the market to help
control the disease with the goal of putting it into remission. The
main aim of the different treatments is designed to decrease inflammation. This not only allows the colon to heal, but also relieves the symptoms of diarrhea, rectal bleeding and abdominal
pain accompanied by the flare. Unfortunately, there is no “one size
fits all” treatment plan for everyone suffering with this disease.
One person may do just fine with the most minor suppository
and live fine the rest of his life, while another may require more
invasive treatment or need a complete colectomy. Therefore, the
approach must be customized for each individual person because
each person’s disease is different.With the correct medical treatment, a patient can achieve remission with the hope of the state
of remission lasting for months or even years. Nonetheless, ulcerative colitis may ﬂare up at times from the reappearance of
inﬂammation or from a specific trigger. Reoccurrence of a flare
usually indicates the need to change the medication regimen for
the patient. The choice of drugs to treat a patient is dependent
upon the severity of the disease. The most commonly prescribed
drugs fall into three basic categories:
Aminosalicylates: This class of drugs encompass 5-aminosalicylic acid commonly known as the 5-ASA . This class of drug
is available in an oral form in addition to a suppository or an
enema. The goal of the 5-ASA is to line the GI tract with the
hope to decrease inflammation. In addition, Aminosalicylates are
beneficial as a maintenance treatment in order to prevent a relapse of the disease (Colombel et al., 2010).
Corticosteroids: The job of steroids is to prevent the body
from launching an inflammatory cascade. Additionally, corticosteroids work to keep the immune system properly balanced.
Steroids are effective for short-term control of flare-ups. This
class of drugs is known to help “put out the fire”. Yet, corticosteroids are not recommended for long term use or as a
maintenance drug for UC because of their tremendous amount
of side effects. The goal of steroids is to buy the patient time,
not fix the problem. A person who is unable to come off steroids without experiencing a relapse of the disease will then be
prescribed a higher class of drugs to help manage the disease
(Colombel et al., 2010).
Immunomodulators: Immunosuppressants work to control the body’s immune system response in order to prevent

Though these three possibilities of treatments have been shown
to be effective, there are always patients who fail to respond to
the three treatment options. These patients were left with no
choice but to have surgery to rid them of the disease leaving
them without a colon and remaining with a pouch for the rest
of their lives. It had become evident that there was a need to
help prevent patients from undergoing a complete colectomy.

TNF-a and inflammation
All humans have a large gastrointestinal mucosal surface that
is continually being exposed to billions of potentially harmful
antigens from our food, bacteria and the environment. However,
the mucosal surface of the GI tract possesses an immune system that strongly controls the balance between immunogenic
responsiveness and non-responsiveness-tolerance. Response to
luminal antigens provokes “controlled” inflammation that is rapidly down regulated after eradication of the pathogen. However,
this is not the case for someone with ulcerative colitis. In this
disease this state of equilibrium is disturbed resulting in a state
of chronic inflammation. During the start of the inflammation,
antigen presenting cells, such as macrophages, cause the activation of T lymphocytes. T lymphocyte cells divide into two T
helper T1 and T2 cells.T1 cells secrete interferon gamma (IFNy)
which then enables macrophages to produces TNFa (Simmons
& Jewell, 2002).
TNFa is an inflammatory mechanism that has been shown to
play a vital role in the pathogenesis of IBD. The transcribing of
the TNFa gene in stimulated macrophages, platelets, monocytes, adipocytes and T cells results in the secretion of TNFa.
Circulating TNFa binds to 2 TNFa receptors facilitating numerous biological effects including activation of other macrophages,
further expansion of the T cell response, and initiation of granuloma formation. TNFa also lengthens inflammation by triggering
NF-kB dependent pathways, which contribute to ulceration and
degradation of the mucosa through the release of MMP (matrix
metalloproteins). TNFa triggers other inflammatory mediators,
such as, IL6 therefore strengthening the early sequence of the
inflammatory cascade. Increased TNFa production and NFKb
have been shown to be abundant in lamina propria mononuclear cells derived from UC patients with ulcerative colitis through
stool, urine and blood tests (Hassan et al., 2007).
Recent advancement in bio-technology have thankfully led to
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the development of a large array of new therapeutic agents
intended to target the exact site in the multifaceted cascade
of cytokine and chemokine effector molecules involved in UC
pathogenesis. In particular, the introduction of the chimeric
monoclonal antibody to TNFa has deeply affected the clinical
treatment of moderate to severe ulcerative colitis, opening the
door to a new era in the treatment of this disease.

Infliximab
Infliximab is the first and most widely studied biological agent
for ulcerative colitis. As of 2006, Infliximab has been approved
by the FDA for the treatment of ulcerative colitis. “This biologic is a chimeric monoclonal antibody to TNFa composed
of a “human” IgGI constant region (75%) and murine-derived
antigen binding variable region (25%)” (Sands & Kaplan, 2007
). Infliximab is able to bind powerfully to both soluble and
membrane-bound TNFa receptors. The actual mechanism of
Infliximab is not completely understood, direct neutralization
of TNFa does not entirely explain its effect. Infliximab has
been found to apply a proapoptotic effect on monocytes and
T cells in the lamina propria of the gut. The proapoptotic effect in infliximab may be exerted, preventing the production of
granulocyte macrophage colony-stimulating factor, which is a
growth factor that stimulates granulocyte growth and differentiation and activates neutrophils with greater adhesion (Sands
& Kaplan, 2007).
Patients were eager to try this treatment option hoping to get
their disease under control. A study was conducted in March
2002 testing the safety and efficacy of Infliximab. This study
consisted of two large double-blind, placebo controlled trials
known as the Active Ulcerative Colitis Trials 1 and 2 (ACT 1
and ACT 2). Both trails were done on 364 patients with moderate to severe ulcerative colitis. All participants in ACT 1 who
were considered eligible were screened for a confirmed diagnosis of ulcerative colitis via biopsy and endoscopies. Eligible
patients had active colitis with a Mayo score of 6 to 12 points
(scores range from 0-12 with higher scores indicating more
severe disease activity). Additionally, eligible patients also had
active disease on the sigmoidoscopy exam results (despite simultaneous treatment with steroids alone or in combination
with immunosuppressant’s, aza or 6mp). ACT 2 allowed study
participants who had only failed 5 ASA’s to participate. Patients
formerly exposed to infliximab or any other anti-TNF agents
were omitted. Patients who were eligible were randomly assigned to be administered intravenous infusions or infliximab
at a dose of 5mg or 10mg per kilogram of weight or a placebo
at weeks 0, 2, and 6 and then every 8 weeks. Patients were
monitored through week 54 in ACT 1 and week 30 in ACT 2
(Rutgeerts et al., 2005).
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The main end point was a clinical response at week 8. Secondary
end points included a clinical response or remission with stoppage of corticosteroids at week 30 in both studies and at week
54 in ACT 1.
Of the 364 patients in ACT 1, 121 were given a placebo, 121
received 5 mg of infliximab, and 122 to received 10 mg of infliximab.Treatment was stopped early by 74 patients in the placebo
group, 45 patients in the group receiving 5 mg of infliximab, and
49 patients in the group getting 10 mg. Of the 364 patients in
ACT 2, 123 were given a placebo, 121 received 5 mg of infliximab, and 120 were administered 10 mg. At week 8, in ACT 1,
clinical remission was achieved in 69.4% of patients receiving 5
mg of infliximab and 61.5 % of patients in the group receiving
10 mg of infliximab. However, in the placebo group only 37.2
percent of patients achieved clinical response. In ACT 2, at week
8, 64.5 % of the patients in the group receiving 5 mg of infliximab
and 69.2 % of patients receiving 10 mg of infliximab exhibited
a clinical response, in comparison to the 29.3 % of patients in
the placebo group. Additionally, at the end of weeks 54 and 30
significantly higher percentage of patients receiving Infliximab
as opposed to the placebo went into complete remission and
were able to discontinue the use of steroids (Rutgeers et al.,
2005).

Antibodies against Infliximab
A common concern when starting biologics is the possibility
of a buildup of antibodies towards the drug. One study tested
serum samples from participants to check for a buildup of antibodies to the drug. At week 54, 229 patients in ACT 1 had serum
samples available for testing of antibody build up to Infliximab. Only
14 patients had a positive test after the first infusion, 36 presented
negative tests and 179 patients had inconclusive tests. In ACT 2
from the 188 patients who had serum samples available for testing,
12 presented a positive test for antibodies, 34 negative, and 142 inconclusive. Furthermore, in ACT 2 a clinical response still occurred
in 11 patients who tested positive for antibodies.
The study further tested the safety of this drug. In both studies,
the proportions of patients with adverse events were similar in
the placebo group and the two Infliximab groups. In ACT 1, serious
adverse events occurred in 25.6% of patients in the placebo group,
21.5% of patients receiving 5 mg of Infliximab, and 23.8% percent
of patients receiving 10 mg of infliximab. In ACT 2, the percentages of serious adverse events were 19.5% in the placebo group,
10.7% in the 5mg group, and 9.2% in the 10mg group. Based on
these numbers, it was concluded that adverse events were more
common in the placebo group showing that the medication was
effective. Serious adverse events were most commonly related to
the gastrointestinal system.
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Among adverse events in ACT 1, basal-cell carcinoma developed in
one patient treated with 10 mg of infliximab. In ACT 2, basal-cell
carcinoma developed in one patient who received placebo, and
rectal adenocarcinoma developed in one patient treated with 5
mg of infliximab.Three neurologic events occurred only in patients
treated with infliximab. One patient in ACT 2 (receiving 5mg of
infliximab) presented a lupus-like reaction (Rutgeers et al.,2005).
The incidence of infections was similar among the groups in
both studies. In ACT 1, infections occurred in five patients in
the placebo group, three patients in the group receiving 5 mg
of infliximab, and eight patients in the group receiving 10 mg of
infliximab. In ACT 2, severe infections occurred in one patient
in the placebo group, two patients in the group receiving 5 mg
of infliximab, and three patients in the group receiving 10 mg
of Infliximab. In ACT 1, tuberculosis developed in one patient
treated with 10 mg of infliximab (Rutgeers et al., 2005).
This study proves that Infliximab is twice as likely two induce
clinical remission in patients with moderate to severe ulcerative
colitis in comparison to a placebo. Because the results of the
study proved to be positive for adult patients put on Infliximab
doctors wanted to use this drug to treat young children failing
to respond to other medical therapy as well. Consequently, a
study was done to test the safety and efficacy of the use of
Remicade in pediatric patients with a moderate to severe form
of the disease. A total of 60 pediatric patients ranging from ages
6-17 years old who had active ulcerative colitis and had not responded to or tolerated other treatment options like immunosuppressants, steroids or 5ASA, were given 5 mg/ of infliximab
at weeks 0, 2, and 6. The primary end point was response at
week 8. At week 8, those whose responded well to the drug
were randomly assigned to groups given Infliximab every 8 or
12 weeks and were monitored through week 54 (Hyams et al.,
2012).

Results
The study done proved Remicade to be highly effective in
treating children with moderate to severe form of the disease.
At week 8, Infliximab induced a response in 73.3% of patients.
Additionally, 68.3% of patients achieved mucosal healing at week
8. Those who achieved remission at week 8, were randomly assigned to receive Infliximab, 5mg every 8 weeks through week
46 or every 12 weeks through week 42. At week 54, twice as
many patients in the group that received Remicade every 8
weeks achieved remission compared with the group that received Remicade every 12 weeks. Serious unfortunate events
and infusion reactions occurred in comparable quantities in the
8 and 12 week groups. No deaths, cancers, serious infections,
or tuberculosis were reported in either group given Remicade.
Infliximab was safe and effective, inducing a response at week

8 in 73.3% of pediatric patients with moderate to severely active ulcerative colitis who did not respond to other medical
intervention. Those given the every 8 week infusion ended up
with a higher clinical remission rate than those who were given
infusion every 12 weeks (Hyams., 2012) .
Today, Remicade is approved for children and adults. It is known
to be one of the most effective methods of treatment for those
suffering with an active state of the disease. Remicade is known
to save people form undergoing a complete colectomy in addition to giving them a new lease on life. The studies above help
strengthen this point showing how effective this biologic can be.

Adalimumab
Another biologic on the rise is known as Humira has been approved by the FDA in 2012. Humira is a treatment method
for moderate to severe active ulcerative colitis in adult patients
who have failed to respond to conventional therapy. Humira
is a fully humanized monoclonal antibody against TNFa. Unlike
Remicade, Humira is administered subcutaneously. Because
Adalimumab is fairly new on the market it is still being tested today. The main studies that assessed the effectiveness of
Adalimumab in UC are the induction and maintenance trials,
known as ULTRA 1 and ULTRA 2 (Ammuzi et al., 2013).
ULTRA 1 was an 8 week randomized, double-blind, placebo
controlled trial studying the use of Humira as an induction
therapy in patients with moderate- severe UC despite the
use of conventional therapy. In the ULTRA 1 trial 576 patients
were randomly selected to receive either placebo or one of
two different regimens of Adalimumab. The first regimen was
160/80mg. patients were given 160mg at week 0 followed by
80mg at week 2 and 40mg at weeks 4 and 6.The second regimen
was 80/40mg. 80mg were given at week 0, 40mg were given at
week 2, 4, 6. At the same time patients were still receiving stable
treatment with oral corticoid steroids or immunosuppressants
(Sandborn et al., 2013).
The primary endpoint of the trail was clinical remission at week
8. The patients who participated had moderately to severely
active UC, with a Mayo score of 6–12 and simultaneous treatment with at least oral corticosteroids, mercaptopurine/AZA
or did not respond or could not endure prior corticosteroids
or immunomodulators.
The primary endpoint of clinical remission was achieved with
the higher dose of Adalimumab 160/80mg showing results of
18.5% percent response and 9.2% placebo. The amount of patients who achieved clinical remission at week 8 in the placebo
group compared to the group receiving Humira at a regimen
of 80/40mgand 80/40mg was a difference of point .6%. These
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results show that Humira is much more effective when given
to patients at a higher regimen. Additionally, Adalimumab treatment was tolerated well at both doses. The safety profile was
comparable to that of placebo. Ulcerative colitis was the most
common adverse event which led to discontinuation of 4% of
the placebo group, 3.8% of the 80/40mg group and 3.6% of the
160/80mg group (Sandborn et al., 2013).
ULTRA 2 was a 52 week study evaluating the efficacy of
Humira as a maintenance therapy in UC patients. The ULTRA
2 trial included 494 patients displaying moderate-severe ulcerative colitis and failed to respond to conventional treatment.
ULTRA 2 evaluated patients through week 52 but did not have
an open-label phase after induction like in ULTRA 1.ULTRA
2 included two treatment possibilities: 248 patients received
Adalimumab 160/80mg (160 mg at week 0, 80 mg at week 2,
and 40 mg every other week starting at week 4) and a placebo
group consisting of 246 patients. Participants were randomly
assigned to treatment groups. The two primary endpoints were
remission at week 8 and 52 (Sandborn et al., 2013).
Overall, clinical remission at week 8 was achieved in 16.5% of
patients on Humira compared to 9.3% on placebo. The results
for week 52 for the Adalimumab and placebo groups were
17.3% and 8.5%. Secondary endpoints encompassed clinical
response and mucosal healing. The differences between adalimumab and placebo were substantial at weeks 8 and 52 in favor
of adalimumab (Ammuzi et al., 2013).
A subclass analysis of ULTRA 2 evaluated the one-year maintenance outcomes in patients who responded to therapy with
Adalimumab. Patients who attained clinical response at week 8
were evaluated at week 52 to determine if they achieved several
outcomes such as clinical remission, clinical response and mucosal healing. At week 8, approximately half of the Humira treated
patients achieved clinical response. Of those, 30.9% from the
placebo, 49.6% for the 160/80mg and 43.1% for the 80/40mg
achieved clinical remission, clinical response and mucosal healing
at week 52. Furthermore, of the week 8 responders who were
dependent on corticosteroids, 21.1% achieved steroid-free remission and 37.8% were able to discontinue steroids at week
52 (Sandborn et al., 2013).
Aside from the ULTRA trials, there is further clinical experience
on the use of Adalimumab for UC. Data from a study on a small
group of 30 patients from Spain validated that Adalimumab induction and maintenance therapy was effective in patients who
previously failed other therapies including infliximab. At weeks
4 and 12, clinical response was achieved in 16 (53%) and 18
(60%) of patients, and clinical remission was achieved in 3(10%)
and 8 (27%) of the patients. Adalimumab was continued in 50%
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of the patients after the 48week follow-up. Total colectomy was
necessary in six (20%) of patients. Nevertheless, patients who
reached clinical response at week 12 evaded colectomy over
the long term (Denese et al., 2013).

Adalimumab vs. Infliximab
Real-life data on the use of anti-TNF agents in UC was obtained
from a Canadian group. This was a forthcoming study with a longterm follow-up of 53 patients treated with either Remicade or
Humira. Effectiveness was evaluated using physician’s worldwide
assessment focusing on stabilization of bowel frequency, nonappearance of blood with defecation and tapering of corticosteroids
until it can be discontinued. Responses to induction therapy were
96.4% for infliximab and 80% for Adalimumab. Responses to maintenance therapy were similar: infliximab 77.8% and Adalimumab
70.0% (Denses et al.,2013).
Based on research present above, Remicade tends to produce better results when given to patients with active disease.There haven’t
been any studies found showing that Remicade does not induce
remission to those experiencing moderate to severe ulcerative
colitis.

Administering biologics
However, due to the way the two biologics are administered may
be enough of a reason for a patient to prefer one over the other.
Remicade is administered as a 2-hour IV infusion so that it goes
right into the bloodstream and starts to work. Doctors will normally give a patient 5mg per infusion. Some adult patients who at
first respond to treatment or completely fail to respond to 5mg/kg
may do well if their dose is increased to 10mg/kg. Remicade is first
given at weeks 0, 2, and 6. Patients will then stay on maintenance
therapy, which is every 8 weeks, which could be as few as 6times
per year (REMICADE.com, 2014).
Humira, on the other hand, is given via self-injection under the
skin, typically every other week (after the initial starting doses).
Humira needs to be kept in a refrigerator in its original bottle and
protected from light until it’s ready to be used.The recommended
dose regimen for adult patients taking Humira is 160 mg initially on
Day 1 (given as four 40 mg injections in one day or as two 40 mg
injections per day for two sequential days), followed by 80 mg two
weeks later. When this is completed patients continue two weeks
later with a dose of 40 mg every other week (HUMIRA.com, 2013).

Possible side effects
As always, all drugs come along with side effects. The usual side
effects of biologics are nausea, headaches and fatigue. However,
with time these side effects usually subside. More serious side effects have been experienced by patients especially those 65 years
and older. Patients have had serious infections caused by viruses,
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fungi or bacteria that have spread all through the body, including
tuberculosis (TB) and histoplasmosis. Some of these infections
have been deadly. Rare cancers have been reported in children and
teenage patients taking TNF-blocker medicines.T-cell lymphoma, an
uncommon form of deadly lymphoma, has transpired typically in
teenage or young adult males with ulcerative colitis who were taking Remicade or Humira. (REMICADE.com, 2014; HUMIRA.com,
2013).To help prevent serious side effects, patients are required to
go for blood work initially every other week and then monthly in
order to monitor their blood count. Though the side effects listed
above are scary, a patient needs to weigh the benefits and the risks
together. Prolonged, untreated inflammation is the number one
cause of colon cancer a number one leading death in the United
States today.

Immunosuppressants + Biologics
Seeing the results biologics produce on their own, doctors questioned if combining immunosuppressants with biologics to treat
patients would have an even greater outcome than just using biologics alone. Their thought process was as follows; the job of immunosuppressants is to stop the production of white blood cells
by interfering with transcribing DNA and preventing the division
and multiplying of many more white blood cells. Biologics on the
other hand, are geared to stop an inflammatory response by binding with TNFa. Therefore, it was thought by combining these two
drugs the likelihood of the patient achieving a remission is two
times more likely than just treating them with one drug.
Initial data is available from a UC study that had a similar design to SONIC (which was a study designed to test the same
combination in Crohn’s patients) (Colombel et al., 2012). The
study included 239 patients with moderate-severe UC who
were unexperienced to biologics, were failing corticosteroids
and were either unexperienced to AZA or had stopped AZA
three months before entering the study. Patients were randomly
assigned to receive AZA 2.5 mg/kg, infliximab 5 mg/kg or infliximab 5 mg/kg plus AZA 2.5 mg/kg for 16 weeks. The primary
endpoint was steroid-free remission at week 16 and secondary
endpoints included response and mucosal healing both at week
16. Preliminary results showed that the primary endpoint was
achieved in the infliximab plus AZA group compared with the
AZA alone. Additionally, infliximab plus AZA was greater to
AZA or infliximab monotherapy in inducing steroid-free remission in patients. Patients treated with an infliximab plan of action
were more likely to achieve response and mucosal healing than
those treated with AZA monotherapy. What does this study
mean for anti-TNF therapy moving forward? It is tough to make
any precise conclusions and more data is needed. Nonetheless,
the limited data (only from infliximab experience) point that anti-TNF therapy in combination with immunosuppressants may
be more effective in early UC compared with monotherapy at

16 weeks. Though remission is achieved in a greater percentage
when the two classes of drugs are combined, it is not recommended to combine the two because of increased risk of side
effects (Denese et al., 2013).

Conclusion
Recent advancement in bio-technology have thankfully led to
the development of a large array of new therapeutic agents
intended to target the exact site in the multifaceted cascade
of cytokine and chemokine effector molecules involved in UC
pathogenesis. In particular, the introduction of the chimeric
monoclonal antibody to TNFa has deeply affected the clinical
treatment of moderate to severe ulcerative colitis, opening the
door to a new era in the treatment of this disease. Studies discussed in this paper show the effectiveness of both Remicade
and Humira given to patients with an active state of this disease. Additionally, doctors tested the possibility of combining
a biologic with an immunosupressent. Though remission nearly
doubled, side effects were likely to double as well. Therefore,
doctors are not pushing the combination of the two drugs unless there is no other option.
With the recent introduction to biologics, patients suffering
with ulcerative colitis in an unmanageable state are able to
try a new treatment option with the hope of avoiding surgery.
Remicade and Humira have both been proven to put patients
with an active state of the disease into full remission.
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Abstract
Ever since the mid 1980’s when Autism Spectrum Disorder (ASD) started to become increasingly prevalent, researchers
have been trying to find a possible cause for it. Autism Spectrum Disorder is a developmental disorder that manifests
itself in children who are between 18-30 months old. People with autism have reduced social skills, and they have a
difficult time communicating verbally and non-verbally. Autism is diagnosed through a questionnaire and other instruments that allow psychologists, psychiatrists, speech therapists, neurologists and many other doctors to determine if a
child has a form of ASD. There are many theories about what causes autism. It has been widely believed that vaccines,
specifically the MMR vaccine causes autism, but that theory has been disproven. Another possibility is the role genetics
plays in ASD. Many studies have been done to determine which genes might cause autism. Because of the heterogeneity
of the symptoms and behaviors of people with autism and general genetic complexity it has been hard to find a specific
genetic cause of autism.While a confirmed gene has not been determined to cause autism many studies have been done,
some using whole-exome sequencing (WES) to see if mutations in parent’s genes caused their children to have autism.
It is also possible that autism can be caused by hereditary or parental factors. There have also been theories that
environmental factors play a role in autism such as exposure to tobacco, pollutants, and metals, and including maternal
conditions that could affect the fetus. While many of the studies were inconclusive, and a confirmed cause of autism
has not been found, the studies do show that genetics does play a major role in ASD, though more studies will have to
be done to determine how and which genes cause it.
Introduction
Autism Spectrum Disorder (ASD) is a neurological impairment
where the child has a problem interacting with others, has trouble communicating verbally and non-verbally, and exhibits odd
behaviors such as repeating certain actions over and over again
and acting out if something does not go according to routine
(Block et. al., 2006). A child with ASD will have trouble making
eye contact with those interacting with him and will be unable
to understand what others are thinking or feeling because they
have trouble picking up on social cues (“What is Autism”, 2009)
ASD is predicted to occur in three to six children for every
1000 who are born. It is 5 times more likely for a male to get
autism than a female, however if a female does have autism her
symptoms are more severe. Autism Spectrum Disorder is categorized as a pervasive developmental disorder because there
are many different symptoms and behaviors for people with
autism. Someone who has severe symptoms of autism can be
placed on one end of the spectrum, while someone with a milder case can be on the opposite end of the spectrum. Different
forms of ASD include Rett’s disorder, childhood disintegrative
disorder, and Asperger’s syndrome. (Block et. al., 2006).

Methods
The information that was collected for this research paper was
obtained through Proquest, Ebsco, Pubmed, and the NIH website. These resources were provided from the Touro College
Library. Key words included autism, ASD, vaccinations, genetics,
and environmental factors.

Discussion: Diagnosing Autism
There is no specific test done to determine if a child has ASD
because the symptoms and behaviors are so broad and can vary

significantly between each child. Although children can start
showing symptoms between 15-18 months of age, the average age of diagnosing is four to five years old. Diagnosis for
ASD should be done by gathering developmental history of
the child, and by direct observation of the behaviors of the
child. There should be a team of different professionals who
can assess symptoms and behaviors of the child. The team
should include a pediatrician, a child psychiatrist, and a speech
and language therapist, and a child psychologist. Behavior of
the child should be observed in different settings such as in
his home and in his school. The team should be looking for
different behaviors that are prevalent in children with ASD.
Prognosis of each case is done on an individual basis because
the behaviors of the child can vary greatly, and the behaviors
can even change over time. Some people with autism can lead
productive lives, such as those with high functioning Asperger’s
syndrome, while others will need assistance all through their
lives (Yates et. al., 2013).

MMR Vaccine and Autism
There has been much talk over the years about a possible
link between the Mumps, Measles and Rubella (MMR) vaccine
and autism. The supposed link caused major panic because
vaccines are needed to prevent, in this case, mumps measles
and rubella from spreading. Vaccines were a vital discovery
which prevented many infectious diseases from recurring over
and over again around the world.
The link between the vaccine and autism was introduced by
Andrew Wakefield in 1998 (cited in Richards, 2011), when
he conducted an experiment using twelve children to prove
the link. It came out later, while his experiment was under
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investigation, that he altered many of the details of the children’s previous symptoms and behaviors. Therefore his study
had no scientific basis to prove a link. Many studies have been
done since then to disprove the supposed link between the
MMR vaccine and autism (Richards, 2011).
One reason why people may think there is a link between
the MMR vaccine and ASD is because children start showing signs of autism right around the time that they get the
vaccine. The explanation for this is that the vaccine is given
to children only after they are a year old, which is when
children start showing symptoms and unusual behavior. Just
because these events happen around the same time does not
mean that there is any basis for a connection. Many studies
were done to try to prove a link between the vaccine and
autism but none of them have been successful (‘Autism and
the MMR Vaccine’, 2001).

Investigations done to disprove the link
In 2000, the Institute of Medicine at the National Academy of
Science, under the request of the CDC and NIH conducted
a review of all the evidence linking the MMR vaccine to ASD.
They took under consideration all the studies and concluded that the evidence did not support an association between
the vaccine and autism. Furthermore in 2000, the American
Academy of Pediatrics held a conference to review the information and found no evidence in support of a linkage (‘Autism
and the MMR Vaccine’, 2001).
In 1999, Taylor and colleagues published a study to determine
a connection between the MMR vaccine and autism (‘Autism
and the MMR Vaccine’, 2001). He took all the known cases of
ASD in children living in certain districts in London who were
born in 1979 or later and matched the ASD patients with an
independent registry of vaccinations. His results were: 1. the
number of ASD cases had increased steadily since 1979 but
there was no steep incline in cases after doctors started using
the MMR vaccine. 2. Children showed symptoms and were
diagnosed with ASD all at around the same age, regardless if
they got the vaccine before or after 18 months of age. This
is important because if the children were vaccinated they
would have shown signs of ASD earlier than those children
who were not vaccinated. 3. Lastly, by age two the number
of children who got the vaccine and showed signs for ASD
was almost the same amount as children who got the vaccine
but did not show any symptoms. If there was a connection
between the MMR vaccine and autism more children should
have shown symptoms for ASD (NICHD, 2001). Although the
MMR vaccine was a popular theory concerning the causes of
autism, many later studies failed to show a connection. This
still remains controversial and continues to be studied.
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Genetic factors that may cause ASD
possible genetic mutations that cause autism
Another possible cause of autism is genetic mutations in the
genome of the affected person. Mutations in genes that are
responsible for encoding proteins which are involved in molecular machinery regulating synaptic protein synthesis is strongly
connected to autism. Autism possibly can be caused due to
mutations known as Fragile X Syndrome and tuberous sclerosis
(TS). Both of these syndromes are caused by abnormal mRNA
translation, resulting in excess protein synthesis.
Fragile X Syndrome (FXS) is caused by an unstable expansion of
the CGG repeat in the FMR1 gene. The prevalence of autism in
the FXS mutation is 30%. This gene mutation causes abnormal
methylation production, FMR1 transcription silencing, and decreased FMRP protein levels in the brain. ASD in FXS is mainly
characterized by deficits in peer interaction. Tuberous sclerosis
is an autosomal dominant disease that is caused by a mutation on
either the TSC1 or TSC2 gene. Clinical manifestations of tuberous
sclerosis included epilepsy, learning difficulties, and behavioral problems. There are a variety of mutations that cause tuberous sclerosis including nonsense, missense, insertion, and deletion mutations.
Autism is significantly more frequent among TS patients than in the
general population. Because there is a large phenotypic variability
in FXS and TS with patients who have autism, research is being
done to make a clear correlation (Perisco et. al., 2013).

Using Whole-Exome Sequencing (WES) to
determine possible genetic links to ASD
Whole-Exome Sequencing (WES) is a technique which captures
and sequences the exons in the genome to reveal all de novo
and low frequenting alleles that contribute to genetic risk for disease. This method is cheaper than Whole-Genome Sequencing,
because instead of searching through the entire genome, it only
goes through the exons in the genome, which only takes up 2-3%
of the genome. This technique is better than the previously used
technique of Genome Wide Association Studies (GWAS) because GWAS only reveals risk factors that are common in the
population (Icahn School of Medicine, 2012). WES is particularly
good for finding the cause of ASD because ASD can be caused
from different genes in many different locations with a weak genotype and phenotype correlation (Perisco et. al., 2013).
A study was done applying WES on families where the spouses
were related and on families where cousins shared the same
disease. This way it is easier to identify specific mutations that
cause ASD. The mutations that were identified on the genes
were hypomorphic mutations, meaning that the altered gene
product has a reduced level of activity, which can explain the
wide spectrum of ASD. This analysis was done on three families.
In this paper the first family will be discussed.

Causes for Autism Spectrum Disorder

The first family had three children with ASD and two unaffected
children. The parents were first cousins. WES was performed
and it showed a single linkage peak in a large homozygous interval, and suggested a 900:1 likelihood that the responsible mutation was found in this homozygous interval. Then WES was
performed on one of the affected children. The linked interval
showed only a single rare change that was absent in the known
databases and population matched controls.

patients with ASD show significant reductions in the temporal
lobe blood flow. The study was done in fuller depth where an
fMRI (functional MRI) was done on adults with ASD that showed
significantly less amygdala activation during a mentalizing task
called “Judging the Mind in the Eye” task. In this experiment, six
people with autism were matched for mean age, handedness, IQ,
socioeconomic status and educational level with twelve people
in the normal group.

This mutation was on a gene that is responsible for the production of the enzyme AMT, aminomethyltransferase. This enzyme
is needed for the breakdown of glycine. Sanger Validation confirmed that the mutation was heterozygous in both parents, homozygous in the affected children, and absent or heterozygous in
the unaffected children.

In the fMRI scanner a blocked periodic ABA design was used.
There were two tasks. The first task, Task A, was supposed to
induce periodic MR signal changes, with signal maximum in brain
regions relatively specialized from gender recognition from facial stimuli. In this task, the subjects were visually presented
with pictures of eyes and were asked to indicate by right button
pressing if the picture was a male or female.

Mutations in AMT cause nonketotic hyperglycemia (NKH), which
is a neonatal syndrome that causes lethargy, hypotonia, several
seizures and death within the first year. Rarer, atypical forms of
NKH have been described in association with hypomorphic missense AMT mutations. This manifests at a later age and causes
delay in expressive language, behavioral problems and seizures.
While individually non diagnostic, when all three children were
tested they exhibited a range of neurological symptoms that
were strongly suggestive of NKH (Yu et. al., 2013).

The amygdala theory of autism
There is a network of neural regions that comprise the “social
brain”: the orbit-frontal cortex, the superior frontal sulcus, and
the amygdala. This region of the brain is responsible for social
intelligence, a quality which ASD patients are known to be lacking. The Neuroscience and Behavioral Reviews has come up
with The Amygdala Theory of Autism, where they hypothesize
that patients with ASD have an amygdala deficit which causes
the deficit in social skills.
An experiment was done on rhesus monkeys which showed
that ibotenic acid lesions of the amygdala affect the social behavior of the monkeys and they also became socially isolated.
When the amygdala-lesioned monkeys were sent into the wild,
they were unresponsive to group members, failed to display appropriate social signals and they withdrew from other animals.
When another study was done, where lesions were made to the
monkeys’ anterior temporal lobe, which included the amygdala,
the monkeys showed specific symptoms, for example they had a
tendency to overreact to all objects, they were hyperemotional,
they had a loss of fear, and they started to investigate objects
with their mouth instead of their hands.
Then a study conducted with humans was done. They used
single photon emission computed tomography that showed that

The second task, Task B, was checking the periodic MR signal
change with signal maximum in brain regions relatively specialized in mental state recognition from facial stimuli. In this task, a
response involved choosing between two words that described
the mental state of the photographed person.
The key difference between the two tasks was seeing the subject’s judgement between the two pictures. Social intelligence is
about picking up social cues, such as the expression of people’s
faces to understand what the person is thinking.
The subjects who had ASD had a hard time doing task B. The
fMRI data was analyzed in two stages. First, generic brain activation maps were constructed separately for the control
and autistic groups. By doing so, they were able to determine
which voxels were activated in each group by each of the two
tasks. Secondly, ANOVA was used to determine the voxels that
demonstrated a significant difference between groups in mean
power of response to each task.
The autistic group activated the frontal components less extensively than the control group, and they did not activate the
amygdala at all. The control group demonstrated significantly
greater power of response in their bilateral superior temporal
gyrus. The autistic group seems not to use the amygdala for the
task, and compensated by using a greater processing load on
temporal lobe structures, which specializes in verbally labeling
complex visual stimuli. This may be because of compensation
for an amygdala abnormality (Baron-Cohen et. al., 2000).

Maternal diabetes and autism
A study was done to investigate if Gestational Diabetes Mellitus
(GDM) in the mother may result in the child having ASD.
Specifically, researchers were determining if the timing of when
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the mother developed GDM had any significance whether the
child would develop ASD.
This study included children who were born at 28-44 weeks
gestation. Women who had type 1 diabetes and congenital
anomalies were excluded from the study. The primary variable
was maternal type 2 diabetes or maternal GDM during pregnancy. Exposures were broken up into three categories- 1. No
exposure to maternal diabetes, 2. Exposure to maternal type 2
diabetes, and 3. Exposure to maternal GDM. Other variables
that were included were maternal age at delivery, education,
self-reported maternal race/ethnicity, and the gender of the
child. For the GDM exposed group, the different methods that
were used to diagnose were also recorded. The gestational
weeks were also split up into three categories- 1. Diagnosed
26 weeks or earlier, 2. Diagnosed after 26 weeks but before 30
weeks, 3. Diagnosed at 30 weeks or later.
The primary data analysis was collected from 322,323 children. The children were checked up on approximately five
and a half years after birth. During this time, 3,388 children
were diagnosed with ASD. A large amount of mothers who
got GDM during the first 26 weeks of pregnancy gave birth
to a child with ASD. It is also interesting to note that among
the children who had ASD, 121 of them had older siblings who
also had ASD.
To summarize, mothers with pre-existing type 2 diabetes were
not significantly associated with risk of ASD, but mothers who
got GDM earlier than 26 weeks of pregnancy were significantly
associated with risk of ASD (Xiang et. al., 2015).

De Novo Mutations
De novo mutation is an alteration of a gene that was present for
the first time in one family member as a result of a mutation in a
germ cell (egg or sperm) of one of the parents or in the fertilized
egg itself (Genetics Home Reference, 2015). De novo mutations
are important in finding the cause of ASD.
Studies show that the majority of de novo mutations do not
cause the disease, they only increase the risk of getting the disease. There may be several genes in which a high risk of de novo
mutations can occur from. Through these studies many de novo
mutations were found that predicted that these mutations would
disrupt the gene function in a child with ASD, however these mutation are not necessarily what causes the disease. Two studies
also found that de novo mutations are caused from the paternal
side and are age dependent. There is a detectable increase in autism risk with children who were born to older fathers (Perisco
et. al., 2013).

Advancing parental age and autism
There are a number of studies which are trying to determine if
the age at which the parents conceived the child increases the
risk of the child being born with ASD. Whole-Exome Sequencing
links older fathers to de novo mutations and increased risk of
having a child with ASD. The linkage of older mothers having a
child with ASD follows different pathways.
Prevalence of ASD has increased from 5 cases per 10,000 people in the 1980’s to the latest CDC’s estimate of 1 case in every
68 people. This may be due to a variety of reasons, including
changes in diagnostic practice, heightened awareness, or even
an actual increase in the disorder. One factor that might cause
ASD is parental age, since there is a tendency in recent years for
people to become parents later in life. In Spain and England the
proportion of mothers who had children after 35 years old in
1980 was 14% and 25% respectively. In 2007, the proportion of
mothers who had children after 35 years old increased to 25%
and 40% respectively.
There are more than forty studies being done trying to link age
of parents when they had kids to ASD. While individual studies
are not consistent with their findings, this can be because of a
number of factors. The discrepancies can be caused by inconsistent sample sizes and characteristics, or missing data. The
studies did conclude an increased risk of ASD from both older
parents, an older father but not older mother, and older mother
but not older father, and neither an old mother or old father.
Inconsistencies could have also been affected by the fact that
these studies did not take into account socioeconomic status
of the families or co-parental age.
The general consensus is that advancing paternal age (APA) and
advancing maternal age (AMA) are independent factors that can
increase the risk of having children with ASD.
In 2012 meta-analysis focused on advancing maternal age and a
link to autism, using data from over 25,000 ASD patients, and
eight million controls aggregated from 10 studies. The results
were that mothers who were 35 years or older when they had
the child had a 1.5 fold increased likelihood of having a child with
ASD compared to mothers who had children at 25-29 years of
age. In 2010, a study was done to test the theory of advancing
paternal age and its link to autism. Meta-analysis was done on
eleven studies and found that fathers who were 40-49 years old
when they had children, had a 1.8 fold increased likelihood of
having a child with ASD, compared to fathers who were 29 years
old or younger.

APA effects on ASD
At this point the question is how APA and AMA are associated
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with a child being born with ASD. One possibility of why age
affects ASD is age- related mutagenesis in the male germ cell.
While a female germ cell undergoes 22 mitotic cell divisions in
utero, male germ cells undergo 30 mitotic cell divisions in embryogenesis, and then divide every 16 days from puberty and on.
Because the male germ cell undergoes many more cell divisions
during his reproductive age, there is more of a possibility of gene
copying errors, which can lead to de novo mutations in the male’s
child, which can cause ASD.
Multiple studies that are using Whole-Exome or Genome
Sequencing found that higher numbers of de novo loss-offunction single nucleotide variants are seen in fathers of increasing age. While it is fine for a new born to have between
30-100 de novo point mutations, there is an increase of about
one to two mutations for each increasing year of a father’s
age. If the mother is also older, it increases the likelihood of
more de novo mutations, because AMA and APA can be linked
together.
Two studies were conducted to disentangle APA effects from
AMA effects on the child. The studies used multiple regression
which was adjusted so that both parental ages were entered
as predicators. It was found that APA remained a significant
predicator in de novo mutations while AMA effects were negligible. Two thousand, five hundred families who had one child
with ASD were analyzed and found that a majority of the de
novo mutations originated from the father. It should be pointed out that although de novo mutations can affect any biological system, there is reason to believe that de novo mutations
differentially impact brain development because the brain may
have fewer redundancy mechanisms that are needed to inhibit
mutations (Lee et. al., 2015).
They hypothesized that if mutations in germ cells result in a
slightly faster rate of cell division, then cells with these mutations will expand within the testes and logically they will
contribute to the larger proportion of sperm. This process is
known as “selfish spermatogonial selection”. This mechanism
can favor the propagation of germ cells which are carrying mutations that prefer to impact certain cellular signal pathways.
(Lee et. al., 2015).

AMA effects on ASD
One possible correlation between AMA and ASD would be
assisted reproductive technologies which are used by couples
more commonly with increasing age. A Swedish study was
done which involved 2.5 million infants. The results were that
in vitro fertilization procedures had no association with risk
of ASD, while a specific procedure called “Intracytoplasmic
Sperm Injection (ICSI)” has a slightly increased risk of having

children with ASD. ICSI is done when there is paternal infertility. The reason why ICSI can increase risk of ASD is because
the injection process can damage the egg which can increase
the risk of adverse outcomes.
Another possible correlation can be the fact that a person
accumulates more and more environmental toxins with increasing age. Environmental factors such as pesticides, heavy
metal, and organic pollutions have been linked with increased
risk of ASD. Human brain samples were examined and found
that exposure to polychlorinated biphenyl 95 strongly predicted maternal 15q11-q13 duplication, which is one of the most
common CNV findings in ASD cases (Lee et. al., 2015).

Other factors that effect advancing parental age
and autism
A study was done using 1,251 ASD cases occurring in over
250,000 births throughout the United States. This study found
a connection between parental age and birth order with increasing risk of ASD. Younger parents (mother younger than
35, father younger than 40), on their first birth, had a 1.7 fold
increased odds of having a child with ASD compared to other
young parents on their third birth and later. Regardless of the
age of the parents, the risk of ASD is increased in first born
children. Older parents (mother older than 35, father older
than 40) on their third child or later had a 1.8 fold increase
on the likelihood of having a child with ASD. Older parents on
their first child had a 3.1 fold increase on the odds of having a
child with ASD. To conclude, the effect of parental age on ASD
is amplified if it is their first birth (Lee et. al., 2015).

Environmental chemical exposures and autism
spectrum disorder
Autism can be caused by a mixture of genetic and environmental influences, and studies are being done to understand
the interplay of both contributions. These contributions can
be different from one person to the next. A study in Sweden
was done which included 14,000 children with autism. The
study showed that heritability contributed to 50% of a possible cause of autism while environmental factors contributed
an equally strong role. Genetic and environmental factors may
work together to disrupt the normal process of nervous system development, interfering with neuron formation and migration, synapse formation, or neurological connectivity which
can cause ASD.
In this study, the chemical exposures that were included are
ones that can be reduced in exposure, which opens up possibility for prevention of autism. Of course it can only be reduced
because not all exposure can be controlled, such as air pollution
and any toxic chemical that are unknown to the patients.
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Maternal smoking in pregnancy and ASD
diagnosis
Seven studies were included which were done in the United
States, Canada, Sweden, Norway, Finland, and England/Whales.
These studies showed no association between maternal smoking during pregnancy and ASD diagnosis. Some of the studies
focused on the spectrum of autism. There was an elevation in
two of the studies between maternal smoking during pregnancy and higher functioning autism, such as Asperger’s syndrome,
compared to lower functioning autism. Overall, there is no
conclusive evidence that maternal smoking or tobacco exposure to a fetus has any effect on a child being born with autism
(Kalkbrenner et. al., 2014).

Regulated and traffic related air pollutants
exposure and ASD
Air pollutants include hundreds of chemicals which can be
categorized into three categories: 1. Point pollutants arising
from spatially separated large buildings, for example factories
and power plants. 2. Area pollutants associated with population density, for example gas stations and dry cleaners. 3.
Mobile pollutants associated with vehicles. In this paper we
will be discussing the third category. When these pollutants
enter the atmosphere they undergo reactions that create new
pollutants. Specific chemicals that arise from traffic that will
be discussed here are particulate matter (PM), NO2; nitrogen
dioxide, and O3; ozone.
Air pollutants enter the body through inhalation and direct
transportation from the nose to the brain via the olfactory
bulb. Some chemical pollutants are known to induce oxidative stress and cause a systemic inflammatory reaction, which
can alter normal neurodevelopment. Fetuses itself can come
in contact with chemicals from air pollutants or they can be
exposed to them from the elevated levels of inflammatory cytokines in the maternal circulation.
Seven studies were done in the United States with adequate
sample sizes ranging from 284 to 7,594 children with autism.
The studies also had controls under consideration such as maternal age and the parent’s level of education. Season of birth
is also important to take under consideration because occurrence of autism varies by season of conception for unknown
reasons. It is also important because certain air pollutants
have a stronger concentration in some seasons over other
season, such as influenza infection and vitamin D levels.
Results for this study concluded that exposure to pollutants
such as PM2.5, PM10, and NO2, were associated with the risk
of getting autism. For almost every pollutant in every study, associations were stronger for exposures in the third trimester
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of pregnancy and the first year of life compared to earlier
on in the pregnancy. All of these studies estimated exposure
to outside levels of these air pollutants using historical data
that could be related geographically to the home residence
of the pregnant woman or infant, because retroactive direct
person-based air sampling was not possible (Kalkbrenner et
al 2014).

Metal (Ethylmercury) from vaccinations
and ASD
Connecting this discussion back to vaccinations, thimerosal
was thought to be a toxic compound that increased the risk
of autism. Thimerosal is a vaccine preservative that contains
ethylmercury which is considered a less toxic form of mercury
compared to methylmercury.
Although the Institute of Medicine already stated that there
is no concrete evidence that the MMR vaccine causes autism,
people are still skeptical. No one suspected thimerosal to be
toxic, seeing as it was found in such small doses in vaccines.
In the 1970’s it was known that large doses of mercury were
harmful. It was only in the late 1990’s that scientists suggested
that even relatively low exposure to organic mercury could be
dangerous to fetuses and young infants (Baker, 2008). The U.S.
Food and Drug Administration suggested removing thimerosal
from vaccines in 2001, because of the biological plausibility that
thimerosal may pose as a neurotoxic harm. However, trace
amounts of thimerosal are present in influenza vaccines which
infants and pregnant women may be exposed to. Six studies
were included, testing for a link between thimerosal-containing
vaccines and autism. The results of the studies suggested that
there is no connection between thimerosal and increased risk
of autism (Kalkbrenner et. al., 2014).

Conclusion
The causes of autism are still vague. Because it is characterized
as a spectrum disorder there can be many different variables
that can play a role in causing different levels of it. The theory that vaccinations cause autism has become a popular idea,
therefore much research has been done to make a correct conclusion. Until the causes of autism are confirmed research is
still being done to see what role vaccinations have on autism,
however the research that has been done until now has concluded that vaccinations do not have a link to ASD. Another
highly researched cause of autism is a genetic cause, be it a
genetic mutation or a number of other different genetic variables. In this paper the idea that different genetic mutations
that can cause autism has been discussed, and while some studies have brought optimistic results, further studies have to be
conducted. Other genetic factors that have been discussed are
the effect of maternal diabetes on the fetus, and parental age
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when the child was conceived. While further research is needed to confirm these factors, the studies that have been done
have given additional insight into what causes autism. Another
possible cause for ASD that was discussed was a mixture of
genetic and environmental factors that the child was exposed
to either as a fetus or as an infant. While some environmental
factors that have been tested had no correlation to ASD, other
environmental factors did show a correlation, although more
research is required.
Many studies are constantly being done, and researchers are
discovering more factors that might be a cause for ASD. The
closer they come to finding a cause, the closer they get to trying
to find a way to prevent autism from becoming more prevalent,
and maybe even closer to finding a possible cure for Autism
Spectrum Disorder.
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Abstract
The brain is so complex that it is almost impossible to select one variable as the reason for a specific observation. This
paper will discuss the neurological basis of hypnosis, and how hypnosis has made unique contributions to the refinement
and development of cognitive neuroscience. In addition, hypnosis has been proven to cure many psychological and
neurologically based diseases. Due to in-depth study of the neurological underpinnings of hypnosis, much advancement
has been made in elucidating the relationship between the complex neural circuitry of the brain, its direct correlation
to consciousness, and both the efferent and afferent neurological systems. New neuroimaging techniques, such as fMRI
and other brain scanning methods such as Electroencephalography (EEG) and positron emission tomography (PET),
have made it possible to localize task related regionally specific brain activity and cognitive mental state, which allows researchers to scientifically examine and construe the many obscure theories surrounding the phenomenon of hypnosis.
Introduction
Modern views on the experience of hypnosis are largely dominated by the belief that the ‘‘hypnotist’’ possesses the ability to
generate a ‘‘sleep-like state’’ within the individual being hypnotized. It is then presumed that the hypnotist possesses a supernatural control over the person’s mind, causing him to behave in
an irrational manner. In actuality, hypnosis is a highly complicated
component of neuroscience related to the intrinsic workings of
the human brain. Neurobiologically, the induction of a hypnotic
trance can be viewed as an alternate state of consciousness due
to the modulation of brain activity critically related to areas in the
brain that oversee the regulation of the conscious state of being
(Kihlstrom, 2013). Hypnosis is also characterized as an increase
in mental relaxation and mental absorption mainly related to
changes in the anterior cingulate cortex (ACC), various areas of
the prefrontal cortex and frontal lobes, cortical and sub-cortical
areas, the ponto-mesencephalic brainstem, and changes of regional cerebral blood flow (rCBF) in these areas (Rainville et al., 2002).
Contemporary scientific theories of hypnosis emphasize changes
in the engagement or disengagement of specific neurocognitive
processes, and their effect on performance and psychophysiological activity such as executive control and attention. Additionally,
there are individual psychological characteristics, partially relating to genetic brain structure, predicting hypnotic susceptibility.
Moreover, scientific experiments have proven that hypnosis can
be effective as an analgesic. Hypnosis can reduce acute pain associated with invasive medical procedures, burn care pain, labor
pain, as well as reduce chemotherapy side affects. Hypnosis can
also decrease chronic pain such headaches, backaches, and fibromyalgia. The study of hypnosis and its clinical applications is an
ever-evolving field that can greatly advance the understanding of
the conscious versus the subconscious mind and the complex
structure of the human brain.

bodies. Mesmer called this idea the “animal magnetism” effect.
He practiced his healing through animal magnetism, capturing
the “magnetic fluid” through pieces of iron and conductive metals that he fixed upon the diseased areas on the patients´ bodies.
He concluded that one could attain “magnetic” effects through
the laying of hands, or even simply by speaking to the patient.
His teaching became known as mesmerism. This theory was accepted until the mid-1800’s. James Braid disproved this idea of
mesmerism in 1840 (Gauld, 1992). Braid demonstrated, through
various experiments, that hypnosis was nothing more than a
fixation of attention rather than an occult shadow of mesmerism. Braid concluded that there is a biological and physical basis
to what was previously known as “mesmerism”, and coined the
term “hypnosis”, which comes from the Greek word “Hypnos”,
which means sleep (due to the trance-like state of the subject). Subsequently, many famous psychologists such as Milton
Erickson, who introduced the Neuro-Linguistic Programming
via hypnosis, used hypnosis to cure clients of psychological ailments (Gauld, 1992). The trance-like state of hypnosis is now
known to be a reflection of biological circuitry and a form of
focused attention as proposed by Braid. The future of hypnosis
will be to uncover fully all the underlying neurological components of hypnosis and discover its many clinical applications.

Materials and Methods
In researching the neurological underpinnings of hypnosis and
its clinical advantages, many articles and journals were compiled
to properly explore and present this topic. References were
obtained through PubMed, and Touro College’s Database, in addition to Google scholar and EBSCO multisearch. Key words,
such as; hypnosis, hypnotic susceptibility, clinical benefits of
hypnosis, and hypnotic analgesia were used to find pertaining
articles that are cited throughout this paper.

History of Hypnosis

Contemporary rendition of hypnosis

In the 1770’s Anton Mesmer wrote his doctoral thesis titled: ‘De
influxu planetarum in corpus humanum’ (On the Influence of the
Planets on the Human Body), in which he revisited the ancient
belief that the solar system emits invisible rays that affect our

Succeeding the Braidian definition of hypnosis, researchers argued regarding the exact definition of hypnosis and its
causes. Hypnosis refers to a change in mental activity following an induction, which usually results in increased attention,
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dissociation, and an increased absorption in pertaining stimuli
(Spiegel, 2007). Typical hypnosis includes alterations in sensory
experiences, motor control, and even amnesia. During a hypnotic induction, specific neural synaptic circuits are activated to
express one’s character, and personality in relation with his/her
character traits specifically portrayed during hypnosis. Herbert
Spiegel (2007), an American psychiatrist who popularized hypnosis as a treatment for pain and other disorders, identified
three characteristics of hypnotized individuals:
1. Dissociation is the conscious versus unconscious separation
of memory, perception, and motor response from one’s main
awareness. The capacity to dissociate is biologically determined and is reflected in the Eye Roll (ER) movements controlled by the external ocular muscles (as explained below).
2. Absorption is the decrease in peripheral awareness to facilitate greater focal attention. The intensity and duration of this
absorption is influenced by bio-psychological components
of intelligence and motivation. Absorption is diminished by
attention deficit disorders, impaired concentration, and some
medications.
3. Suggestibility is characterized by how prone an individual is
to accept new information as fact with a relative suspension
of critical judgment.
Rainville et al. (2002) described hypnosis as a state of mental
relaxation and mental absorption, which are both associated
with the instructions used to induce a hypnotic state. Hypnotic
relaxation results from the direct instruction to relax prior
to a hypnotic induction, which leads to positive bodily feeling,
drowsiness and mental ease. Mental absorption, otherwise
known as fixed attention, as “total attention that fully engages
one’s representational resources and results in imperviousness
to distracting events” (Rainville et al., 2002).
Individuals who were hypnotized reported having been in an altered state of consciousness, describing this state as an increase
in mental relaxation, automatic response, slight disorientation
of time, increased imagery, focused attention, dissociation of irrelevant stimuli, and a disorientation toward their sense of self
(Oakley and Halligan, 2009).

Hypnosis susceptibility
Hypnotic susceptibility is unique to each individual. Some people are easily hypnotizable while others are virtually unaffected
by hypnotic induction. Hypnotic suggestibility scales are the primary way to measure hypnotic susceptibility. Two such scales
include the Stanford Hypnotic Susceptibility Scale (SHSS) and
the Harvard Group Scale of Hypnotic Susceptibility (HGSHS).

These tests are constructed for standardized group administration and are scored by self-report. They consist of a recorded verbatim hypnotic induction, which is scored according to
how similar the subjects responses are in relation to previously
measured highly susceptible individuals. There are many other
ways to measure hypnotic susceptibility, but these two scales
are most commonly used in scientific experiments.
Hypnosis is thought to be a state of fixed attention and absorption. It can therefore be postulated that that the individuals who
have the highest score in hypnotic susceptibility are more able
to focus intently on one specific stimulus, disregarding other
competing “noise”(Galbraith et al., 1970). There is much controversy as to whether or not hypnotic susceptibility depends
on the individual’s ability to selectively attend to the hypnotist’s
instructions, or whether it has to do with the ability to shut off
distracting stimuli, creating a mental state where the subject is
more able to capture the hypnotist’s commands. A study was
done to measure hypnotic susceptibility via an electroencephalogram (EEG). Subjects were asked to focus intently on a dim
light. The EEG showed that those who scored highest on hypnotic susceptibility were more able to fix their attention on the
dim light, which directly led to their ability to ignore all other
stimuli (Galbraith et al., 1970).This discovery discounts the findings that hypnosis is an inhibitory response and lends credence
to the fact that hypnosis is a result of fixed attention.
To further research this phenomenon, a case study was done
to determine the differences in cortical activity in “high” and
“low” individuals (in regard to hypnotic susceptibility). The EEG
showed greater theta activity (4-8 Hz) in highly susceptible individuals in the anterior frontal cortex, as well as in the occipital
cortices. Theta waves in the frontal lobes and occipital cortices
are associated with vivid visualizations, and great imagination.
This shows a pattern of EEG dimensionality more consistent
with imagery processes, which are controlled by various parts
of the frontal, occipital and parietal regions of the brain. Low
susceptible individuals exhibited a pattern more consistent with
cognitive activity such as mental math (Blai et al., 1998). This
study was done in conjunction with another study involving
neuropsychological tests.These tests were administered to both
“high” and “low” individuals.The tests were selected to examine
potential differences in tasks using the prefrontal cortex, as well
as verbal and visual-spatial modalities. The WCST (Wisconsin
Card Sort Test) tests the ability to detect relevant information
by dissociating the irrelevant. Overall, a faster performance was
observed in the highly susceptible individuals, which indicated
that highly suggestive participants are more flexible in their ability to shift cognitive sets, which is consistent with the results of
the EEG (shifting cognitive sets more easily insinuates a greater
imaginative ability) (Blai et al., 1998).
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In 1992, Herbert Spiegel presented three different personality
styles based on the way an individual related to the self and to
the world. Those who score high on hypnotic ability tend to
be more trusting, have a higher degree of malleability, and an
extreme propensity to dissociate.This lends to total absorption
with a complete abandonment of peripheral awareness. Those
who are not susceptible tend to place logic at highest priority
and have a limited experience of dissociation, having constant
peripheral awareness. Those in midrange exhibit trends toward
oscillating between relative periods of action and inaction. They
tend to fluctuate between feeling and thinking and have a moderate ability to express dissociation.
In a study conducted by Herbert Spiegel in 2006, the measure
of what was referred to the “eye roll” determined hypnotic susceptibility. This proved that there was a discernable biological
component in the ability to experience a hypnotic state.The eye
roll is the distance between the lower eyelid and the bottom
of the cornea. Spiegel hypothesized that hypnotic susceptibility
was based on the amount of sclera seen in the eye while hypnotized. Consequently, experiments showed that his hypothesis
was correct. When he asked his patients to look up during the
induction phase of hypnosis, he found that if the eye roll was
so high that nothing but the sclera was showing, that individual
has a higher neurological capacity for dissociation and focused
attention, thereby having the potential to be highly hypnotizable.
This is attributed to the basic biological circuitry of the brain
unique to each individual. This complex circuitry involves spinal
cord pathways, the trigeminal nerve that includes the ocular
motor muscles (which explains the ER phenomena), as well as
the vagus complex and many other nuclei and neural circuits.
Conversely, if little sclera is seen between the lower lid and
the cornea, that individual has a lower biological dissociative
ability and is therefore only capable of low hypnotic capacity.
This study was further proven in conjunction with the Hypnotic
induction profile, which provides an assessment for mental concentration, the ability to internalize new ideas, disassociation,
and the capacity to experience sensory alteration. This proves
that the ER can be regarded as a surface indicator of underlying
synaptic circuitry.
To enable those who have low hypnotic susceptibility to benefit from hypnotherapy, studies have been done to determine
whether hypnotic susceptibility can be increased. A study
done by Kinny and Sachs (1974) demonstrated that hypnotic
susceptibility could indeed be increased in some individuals.
Additionally, this experiment determined whether the permutation in hypnotic susceptibility is attributed to actual cognitive and perceptual changes or to a response alteration due to
expected behaviors. The experiment included training that was
found to improve hypnotic susceptibility in past experiments.
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Participants were taught how to imagine certain sensations so
acutely until the perception of the sensory explanation was
perceived as being genuine. The goal of this learning process
was to teach participants how to feel the sensation that was
imagined, in addition to blocking out other competing variables.
Therefore, it can be inferred that the more imaginative a person
is, the more susceptible they are to hypnosis. The SHSS was
given after each training session to measure the progress of
the participants. The result of this experiment proved to be
exceedingly intriguing. Overall there was an increase in hypnotic
susceptibility among most of the subjects. Researchers postulate that the reason for this change can be attributed to three
variables: learning, attitude and motivation. This can essentially
be positively correlated to the learning process of all other skills.
Subjects practiced attending to specific sensations and blocking
out others. Moreover, subjects were allowed to advance at their
own pace to ensure optimal results. There were also changes
in the attitude previously attributed to hypnosis. Many subjects
were originally skeptical regarding the legitimacy of hypnosis.
Once they accepted the fact, for example, that their hand could
be lowered involuntarily, they were more willing to capitulate to
the hypnotic induction. Subjects then reported that they were
better able to concentrate, and believed that they had greater
autonomy over their actions during hypnosis. The subjects who
originally portrayed controlling, rigid and/or fearful personalities
failed to show large improvements in their ability to be hypnotized. They were afraid of losing control and were concerned
that their mind would betray them during the hypnotic stage
(Kinny and Sachs, 1974). Furthermore, hypnotic susceptibility
has been shown to be a stable trait due to studies that tested
the hypnotic susceptibility of the same individuals at different
ages. Therefore, it can be deduced that hypnotic susceptibility
can be attributed to personality traits that are inherent in each
individual, which also control their ability to imagine, focus attention, and absorb internal stimuli.

Neurological underpinnings of hypnosis
There is much controversy regarding the neurological basis of
hypnosis. This is attributed to the fact that much remains unknown regarding the various structures and networks present in
the brain. Although many studies show conflicting results, there
are some conclusions that can be deduced from the many studies
that examined this topic.The following comprehensive study was
done by Rainville et al. in 1999 and was later repeated in 2002,
attaining similar results. Therefore, it can be assumed that the information presented in these studies can be considered rather
factual, as opposed too purely theoretical.The effects of hypnosis
on regional cerebral blood flow (rCBF) were measured using
positron emission tomography (PET), which gauges the rCBF in
the brain. “Pure” hypnosis (hypnosis without suggestion) was
accompanied by a considerable increase in rCBF in the following
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regions: the occipital region, the right anterior cingulate cortex,
and bilaterally in the inferior frontal gyri. Decreases in rCBF were
found in the right inferior parietal lobe, the posterior cingulate
gyrus, and the left precuneus. Hypnosis with suggestion showed
additional increases in rCBF in the frontal cortices, chiefly in
the left side of the brain (Rainville et al., 1999). This is attributed
to the fact that the proposal for an altered perception reflects
the verbal arbitration of suggestion and top-down processing
involved in the reinterpretation of the perceptual experience
(Kihlstrom, 2013).An increase in delta rhythms shown in the EEG
performed along with the PET, supports the theory that hypnosis
reflects an altered state of consciousness which is associated with
decreased arousal. Moreover, findings show a great increase in
occipital rCBF, which supports the theory that hypnosis facilitates
visual imagery.

of the network of the neural correlates of self-consciousness
and self-related mental representation (Cavanna and Trimble,
2006). A reduction in rCBF was observed in the left posterior
cingulate gyrus, which has been proven to become deactivated
during effortless mind wandering, while controlled awareness
corresponded to activation in the posterior cingulate (Garrison
et al., 2013), the left medial superior frontal gyrus, which is involved in self -awareness in conjunction with sensory system,
and left posterior middle temporal gyrus, whose function remains unknown (Rainville et al., 1999).

rCBF differences in suggestion related hypnosis
Increases in rCBF were seen predominantly within the medial
superior and left dorsolateral regions of the frontal lobes, in

Figure 1

rCBF differences in “pure” hypnosis
Hypnotic induced relaxation showed a wide-spread increase in
rCBF bilaterally in the occipital lobes (Figure 1). Interestingly,
comparable effects have been reported during visual imagery.
In this study, subjects were not encouraged to engage in imaginative thinking, but spontaneous visual imagery was reported
in many subjects. This phenomenon could be attributed to the
establishment of deep relaxation, which has been proven to
facilitate visual imagery processes (Brann et al., 2012). Other
areas associated with an increase in rCBF included: the inferior frontal gyri, which are associated with prepotent responses, and the right anterior cingulate cortex (ACC), as seen in
Figure 1. The ACC is an area in the brain that is connected to
functions related to conscious experiences and the emotional
interpretation of pain. Greater rCBF in the ACC was present
in more emotionally aware females (Lane et al., 1998). Many
studies have found that the ACC is involved in functions such as
anticipation tasks, attention, and motivation (Bush et al., 1999).
Moreover, focus of attention is associated with the anterior cingulate gyrus, which is consistent with the definition of hypnosis
as being a state of focal attention and increased concentration.
Decreases in rCBF were associated with the inferior parietal
lobule, which involves language and mathematical operations. It
is remarkable to note that individuals with low hypnotic susceptibility tend to exhibit a greater preference to cognitive activities such as mental math (as aforementioned). Specific parts
of the posterior parietal cortex also showed a significant decrease in rCBF (Figure 1). The posterior parietal cortex attends
to processes involving spatial attention, orientation to external
stimuli, and self-representation. A decrease in rCBF in this area
reflects the decreased orientation to extrapersonal and somatic stimuli observed in individuals under hypnotic influence.
Additional decreases in rCBF were found in the medial precuneus, which is involved in self-processing operations, and is part

Statistical (t) maps of hypnosis-related increases in rCBF, across
stimulation conditions, in occipital (A), right anterior cingulate
(B), left frontal (arrow in C), right frontal and right temporal
cortices (arrows in E). Decreases in blood flow were found in right
lateral and medial posterior parietal cortices (D).When analyzed
separately in each stimulation condition, the hypnosis-related
increase in occipital rCBF was observed mainly in the neutral
stimulation condition, as shown in F. (Rainville et al., 1999).
addition to the right dorsolateral frontal lobule (Figure 2). This
can reflect the verbal mediation of hypnotic suggestions, working memory processing, and top-down mechanisms involved in
the reinterpretation of the sensory experience sometimes used
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in the induction of hypnosis. Similar effects have been found in
subjects who were asked to listen and list words that include
verbal lexical-sematic processing (Oakley and Halligan, 2009).

Figure 2

Statistical (t) maps of suggestion-related changes in rCBF show
increases in medial (A) and dorsolateral frontal cortices (C, D, and
E), and in medial and lateral posterior parietal cortices (arrows in
B). Arrow in D shows significant subcortical increase in left nucleus
accumbens. (Rainville et al., 1999).
Therefore, it was postulated that the left anterior lobes are
largely involved in the internally generated reinterpretation of
stimuli, which can lead to an alteration in perception known to
affect hypnotized individuals (Rainville et al., 2002). Significant
increases were also seen in the left medial parietal and bilateral
posterior parietal cortices (Figure 2). This can be attributed to
the specific content of the suggestion, which may cause specific
somatic interpretation of perception. Decreases were found in
the right uncus, bilateral in posterior orbitofrontal regions, and
the left lateral cerebellum (Rainville et al., 1999).

Hypnotically induced changes in neural
oscillations as measured by EEG
When searching for neurological changes in the brain due to
hypnosis, Electroencephalography (EEG) can directly measure the
electrical activation of the various parts of the brain. An EEG records the frequency (measured in Hz) and amplitude (measured
in microvolts) of waves produced by electrical brain activity. Four
simple periodic rhythms are recorded in the EEG: alpha, beta, delta,
and theta. These rhythms are associated with the frequency of the
waves. Alpha waves are typically 8-13 Hz. Alpha rhythms are usually
prominent in adults who are awake, but in a very relaxed state
(e.g. eyes closed). These alpha waves diminish when subjects tune
into external stimuli and are usually observed to be of the greatest
amplitude in the parietal and occipital regions of the cerebral cortex. In contrast, Beta rhythms (13-30 Hz) occur in individuals who
are attentive to external stimuli, or who exhibit specific mental
stimulation. In essence, Beta waves represent the arousal of the
cerebral cortex to higher degrees of alertness and attention. Delta
waves (1-5 Hz) are generated in deep meditation, and suspend external awareness. It has been proven that healing and regeneration
occur in this state as well.Theta waves (4-8 Hz) are low-frequency
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rhythms that are dominant in deep meditative sleep. Senses in this
state ignore external stimuli and focus on the subconscious. Vivid
imagination beyond normal conscious awareness is present in this
stage as well (Lee et al., 2007). Not surprisingly, these rhythms directly correspond to the EEG brain waves associated with different
stages in hypnosis.
A case study was done to determine whether an EEG during
“pure” hypnosis (hypnosis without suggestion) would differ from
a normal non-hypnotic EEG. Pure hypnosis can be categorized
as a state of heightened attention and increased alertness, reflected in neuronal activation (Rainville et al., 1999). These neural
changes account for the susceptibility to suggestion after a hypnotic induction. This study concluded that hypnosis affected all
of the EEG electrodes. Occipital and frontal EEG channels were
most affected by hypnosis. There was up to an 89% increase in
Spectral Pattern (SP) from baseline to hypnotic state in the frontal
lobes. Right parietal and mid-frontal EEG channels increased 11%.
Comparative analysis demonstrated that hypnotic conditions
caused a large increase in delta, beta, and theta rhythmic segments
in various areas of the brain when compared to the non-hypnotic state EEG. Although all EEG channels were affected by hypnosis, the prefrontal cortex (Fp1 and Fp2 electrodes) and the
right occipital electrode (O2) showed the greatest percentage
increase (Fingelkurtz et al., 2007). This data is consistent with the
knowledge that many neural changes in these areas occur during
hypnosis. Hypnosis increased beta activity and decreased delta
activity in the frontal lobes.This is an interesting phenomenon, for
delta rhythms should increase during hypnosis while beta rhythms
should technically decrease when measured in accordance to the
mental states that they represent. However, it can be inferred
that the EEG measured hypnotic state after induction, which can
account for the increase in beta waves due to heightened attention, while an increase in delta waves may have been observed
during the induction, but decreased thereafter. A majority of beta
rhythmic conditions appeared in the EEG only after the induction
of hypnosis. This unique composition in brain oscillation in the
prefrontal cortex during hypnosis reinforces the premise that this
area is of major import in the hypnotic state (Fingelkurts et al.,
2007). In addition, these findings disprove previous views that
hypnosis constitutes a sleep-like state. This study further demonstrates that in actuality, hypnosis is a state of increased alertness
and heightened attention to internal stimuli, as proven by the
increase in beta waves. Moreover, this confirms the theory that
the frontal lobes are extensively involved in attention networks.
To further elucidate the notion that suggestion for specific perception under hypnotic induction facilitates the same response
in cortical activity as reality, a study was done by Kosslyn et al.
(2000) in which color perception in the brain was recorded. A
grey-scale image was shown to hypnotically induce participants
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with a suggestion to perceive a colored image. There was modulation of activity in the fusiform gyrus that is responsible for color
processing in the brain, thereby proving that when hypnotically
induced, the brain interprets perception as authenticity.

Hypnotic Analgesia
The mechanism through which hypnosis reduces pain is still
quite obscure; however, there is a plethora of scientific evidence
proving the effectiveness of pain amelioration via hypnosis. Pain
is a spinal nociceptive reflex. Once the nociceptive signal reaches
the brain, a sensory and affective discriminative neural network
acts to facilitate the conscious perception of pain (Perl, 2011).
Structures in the brain that compromise these networks include
the primary and secondary somatosensory cortices (S1 and S2),
thalamus, insula, and the ACC (Rainville, 1998). Hypnotic analgesia is thought to be attention based in that incoming stimuli are
inhibited while awareness is simultaneously deployed elsewhere
(Eimer, 2000). The inhibition of afferent nociceptors can be attributed to the decrease in thalmic activity when hypnotically
induced (Faymonville et al., 2003). Miron, Ducanan, and Bushnell
(1989) conducted a study in which subjects were instructed to
attend to a painful stimulus or divide their attention between
the painful stimulus and a visual stimulus. Pain reduction was
reported in subjects who were asked to divide their attention
between two simultaneous stimuli. These results support the
hypothesis that when faced with competing processes, attention
is directed to other processes, thereby inhibiting the conscious
perception of pain. This process depends on a supervisory attention control system that operates to relocate thalamocortical activities. Incoming painful stimuli are suppressed at cortical
levels and do not enter conscious awareness, thereby reducing
the degree of perceived pain by invoking physiological inhibitory
processes of the brain (Faymonville et al., 2003).
Although most studies attribute the reduction in pain to cortical activity, a study was conducted to monitor nociception
at the spinal cord level and how it is affected by hypnosis. A
study done in 1998 demonstrated that a suggestion for analgesia directly correlates with the spinal nociceptive (R-III) reflex.
Subjects showed strong inhibition of the R-III reflex at the spinal
cord level in response to hypnotic induction (Danziger et al.,
1998). These results are rather intriguing because they introduce a new aspect of hypnosis, independent of the cognitive
model. There is no recorded scientific basis for these findings,
but they do insinuate that there may be mechanisms in the peripheral nervous system that are directly influenced by hypnosis.
There has been much research as to whether hypnotic analgesia
affects the sensory or affective processing of pain. Researchers
speculated that hypnosis has a greater affect on the affective
system because that system has a greater cognitive evaluation,

while the sensory system is modulated by nociceptive inputs
from the peripheral nervous system. Studies have shown that
both are affected by hypnosis. Hypnotic analgesia produces
both a modulation of pain effect by producing changes in the
anterior cingulate cortex, and inhibition of afferent nociceptive
signals arriving at the somatosensory cortex. Hypnotic suggestion for altering pain unpleasantness affected rCBF flow to
the ACC, but not to the S1 Cortex, proving the role of the
ACC in pain affect. Suggestion for modulating pain intensity
affected rCBF mainly in the S1 and S2 cortices and had little
affect on the ACC. These results are consistent with the role
of the somatosensory cortex in the sensory dimensions of pain.
Interestingly, the context of the suggestion that facilitated the
analgesia determined to what degree the affective and sensory
systems were affected (Rainville, 1998).
Researchers at the University of Iowa conducted a case study
in 2004 to determine the difference in pain perception in hypnotically induced individuals. fMRI (functional magnetic resonance imaging) was used to measure brain activity. A painful
thermal stimulus was applied to the participants’ left hand. The
subjects were then hypnotized, and their brain activity was
recorded by the fMRI. The hypnotic state was then broken
and the procedure was repeated. Hypnosis was successful in
reducing perceived pain in all of the individuals. Participants
reported a significant pain reduction or feeling no pain. The
fMRI reported decreased activity in the primary sensory cortex,
which is involved in pain perception. Increased activation was
seen in the basal ganglia and the anterior cingulate cortex. The
increase in brain activity in these two regions could be attributed to their involvement in the inhibition pathway that blocks
pain signals from reaching higher cortical areas responsible for
pain perception (Schulz‐Stübner et al., 2004).
The induction of hypnotic analgesia, simply known as the reduction of pain via hypnosis, can offer amelioration of pain intensity
and offer an alternative to drugs that have various negative side
effects. By utilizing direct suggestion such as suggesting numbness (glove anesthesia), direct suggestion for turning down pain,
physical dissociation from painful areas of the body, pain relief
imagery, or cognitive reframing while in an hypnotic state, pain
reduction is possible (Eimer, 2000).
A study was conducted to ascertain whether pain modulation
requires a hypnotic suggestion for pain reduction, or if pure
hypnosis affects the ratings for pain unpleasantness. Participants
were expected to submerge their left hand in painfully hot
water (470C) during pure hypnosis and then again in response
to a suggestion for pain reduction while hypnotized. The relationship between pain effect and cerebral activity was recorded
via PET. An increase in rCBF was seen in the insular cortex,
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where a person imagines pain while looking at painful images
and feels sensation of pain and its intensity. Increases were also
found in the ACC, which mediates affective response to noxious
stimuli, and the primary and secondary somatosensory cortical
areas (S1 and S2), which are believed to involve the sensory
discriminating processing of pain. Comparing hypnosis related
changes in rCBF in neutral and painful stimuli conditions tested
the effect of hypnotism on pain reduction. A strong lateralization increase in rCBF in the right ACC has been shown in
conjunction with the experimental painful stimuli. Furthermore,
although pain and hypnosis related ACC sites were anatomically
close within broadmann area 24 (which is part of the cingulate
gyrus), the pain related peak was medial along the cingulate
gyrus and the hypnosis related peak was more lateralized in the
cingulate sulcus. Occipital rCBF was less when a pain modulatin
suggestion was proposed in relation to occipital rCBF without
suggestion. Additionally the amount of pain reduction and pain
unpleasantness was directly correlated with the participant’s
level of hypnotic susceptibility (Rainville et al., 1999).

Hypnosis in treating acute pain
Acute pain is defined as pain that gradually resolves as the injured tissue heals. Many studies have been done to uncover
the effects of hypnosis on the reduction of acute pain. A study
was performed in 1991 to determine the effects of hypnosis
in treating invasive medical procedure pain. This study compared participants who received pre-surgery hypnosis prior to
angioplasty surgery with participants who received standard
care. The hypnotically induced patients showed a 25% increase
in the amount of time they allowed the cardiologist to keep the
balloon catheter inflated, and showed a substantial reduction
in opioid analgesics that are vital during the procedure. The
hypnotically induced group also showed a significant decrease
in catecholamine blood levels relative to the control group
(Weinstein and Au, 1991). Another study done in 1996 produced similar results. Sixteen patients received hypnosis with a
suggestion for relaxation and pain relief imagery while fourteen
patients were treated with the standard procedure. Hypnotized
patients reported less pain, used less pain medication, and
showed more physiological stability during the diagnostic arteriogram procedure. No statistically significant differences in
heart rate or blood pressure were recorded (Lang et al., 2000).
Bone marrow transplant patients often receive supralethal
doses of chemotherapy prior to the procedure. This treatment
often results in severe nausea, pain from oral mucositis, and
vomiting. Patients were hypnotically induced and were given
suggestion for pain control and relaxation. Most patients reported a significant reduction in pain; however, no significant
differences emerged regarding nausea and vomiting (Syrjala et
al., 1992). Burn care patients who were treated with hypnosis
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reported a reduction in burn-related pain and even facilitated
wound healing (Patterson et al., 2003). Additionally, burn patients who received hypnosis used significantly less analgesic
drugs than the control group (Wakeman and Kaplan, 1978).
Labor pain is also a good candidate for hypnosis. There have
been many clinical benefits recorded in using hypnosis to reduce
labor pains. Women who were given sessions of posthypnotic
suggestions for pain relief and relaxation during labor showed
shorter stage 1 labor and reported less labor pain (Davidson,
1962). Freeman et al. (1986) conducted another study in which
women received hypnosis before labor. Hypnosis involved
suggestion for pain relief and for transferring anesthesia from
the hand to the abdomen. No differences were reported in
pain relief during labor; however, highly susceptible individuals
reported that hypnosis helped reduce their anxiety during labor,
thereby helping them cope effectively with the pain.

Hypnosis in treating chronic pain
Chronic pain is defined as pain that persists beyond the healing
time needed for a specific injury. Many psychological factors,
such as patient coping responses, patient cognition, and environmental factors play an important role in the expression and
experience of chronic pain, while acute pain is directly related
to the injury itself. Therefore, different techniques in hypnosis
must be used in the treatment of chronic pain as opposed to
acute pain. The difficulty in treating chronic pain with hypnosis
can be maintaining reduced pain awareness for an extended period of time (Patterson et al., 2003). Many studies have been
performed to determine the effectiveness of hypnosis on headaches, fibromyalgia, and back pain. Other etiologies of chronic
pain have not been extensively researched. Hypnosis treatment
was given to 47 subjects suffering from migraine headaches. The
control groups consisted of participants who were not given
any treatment as well as subjects who were given prochlorperazine. Suggestion was given for visual imagery techniques,
pain reduction, and for the aversion to migraine headaches. The
patients who received hypnotherapy reported fewer headaches
per month, a higher frequency for remission, and fewer Grade
4 headaches (Anderson et al., 1975). Hypnosis was also proven to be more effective than physical therapy in the treatment
of fibromyalgia. Muscle pain, fatigue, and sleep disturbances
caused by fibromyalgia were improved via hypnosis (Haanan et
al., 1991). Back pain was also shown to improve when treated
with hypnosis. A study done among 22 patients suffering from
spinal cord injury related pain showed an 86% decrease in pain
following a hypnotic induction (Jensen et al., 2001).

Conclusion
Although there is still much obscurity surrounding the intriguing
phenomena of hypnosis, much research has been done to elucidate the underlying mechanisms and benefits of this remarkable
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phenomenon. Hypnosis has matured to become both a worthwhile treatment option for many medical conditions as well as
a significant research tool in the quest to understand human
cognition. The actual benefits of hypnosis can be seen through
various experiments, both cognitively and clinically, disputing researchers who term hypnosis as being one giant placebo effect.
The clinical applications of hypnosis are numerous, and more
study is being done to discover viable hypnotic treatments for
various illnesses. By understanding of the neurophysiological
mechanisms underlying the hypnotic modulation of conscious
experience, and its specific patterns of cerebral activation, one
can appreciate, and potentially benefit, from the many advantages of hypnosis both in research and in practice.

References
Anderson, J. A., M. A. Basker, and R. Dalton. “Migraine and hypnotherapy.” International Journal of Clinical and Experimental
Hypnosis 23 (1975): 48-58. Print.
Blai, A., W. Ray, D. Aikins, J. Coyle, and E. Bjick (1998):
Understanding hypnosis and hypnotic susceptibility from a
Psychophysiological perspective. On-line Proceedings of the
5th Internet World Congress on Biomedical Sciences ’98 at
McMaster University, Canada.
Brann, Les, Jacky Owens, and Ann Williamson. The Handbook
of Contemporary Clinical Hypnosis: Theory and Practice. N.p.:
John Wiley & Sons, 2012. Print.
Bush, G., P. Luu, and M. I. Posner. “Cognitive and emotional
influences in anterior cingulate cortex.” Trends in Cognitive
Neuroscience 4 (2000): 215-22. Print.
Cavanna, Andrea E., and Michael R. Trimble. “The precuneus:
a review of its functional anatomy and behavioural correlates.”Brain: A Journal of Neurology 129 (2006): 564-583.
Web. 22 June 2015.
Danziger, N, E. Fourier, D. Bouhassira, D Michaud, and T De
Broucker. “Different strategies of modulation can be operative
during hypnotic analgesia: A neurological study.” Pain 75 (1998):
85-92. Print.

Faymonville, M. E., Roediger, L., Fiore, G. D., Delgueldre, C.,
Phillips, C., Lamy, M., Luxen, A., Maquet, P., Laureys, S. “Increased
cerebral functional connectivity underlying the antinociceptive
effects of hypnosis.” Cognitive Brain Research 17 (2003):
255-262.
Fingelkurts, Alexander A., Andrew A. Fingelkurts, Sakari
Kallio, and Antti Revonsuo. “Hypnosis Induces a Changed
Composition of Brain Oscillations in EEG: A Case Study.”
Contemporary Hypnosis 24 (2007): 3-18. Print.
Freeman, R. M., A. J. Macaulay, L. Eve, G.V. Chaimberlain, and A.V.
Bhat. “Randomized trial of self-hypnosis for analgesia in labour.”
British Medical Journal (Clinical Research Ed.) 292 (1986):
657-58. Print.
Galbraith, Gary C., Perry London, Morris p. Leibovitz, Leslie M.
Cooper, and Joseph T. Hart. “EEG and Hypnotic Susceptibility.”
Journal of Comparative and Physiological Psychology 72.1
(1970): 125-31. Print.
Garrison, K. A., J. F. Santoyo, J. H. Davis, T A. Thornhill, and C. E.
Kerr. “Effortless awareness; using realtime neuro-feedback to
investigate correlates of posterior cingulate cortex activity in
mediator;s self report.” Frontiers in Human Neuroscience 7
(2013): 440. Print.
Gauld, Alan. A History of Hypnotism. New York: Cambridge
University Press, 1992. Print.
Haanen, H. C., H. T. Hoenderdos, L. K.Van Romunde, W. C.
Hop, and C. Mallee. “Controlled trail of hypnotherapy in the
treatment of refractory fibromyalgia.” Journal of Rheumatology
18 (1991): 72-75. Print.
Jensen, M., J. Barber, R. Avery-Willaims, L. Flores, and M. Brown.
“The effect of hypnosis suggestion on spinal cord injury pain.”
Journal of Back and Musculoskeletal Rehabilitation 14 (2001):
3-10. Print.
Kihlstrom, John F. “Neuro-hypnostism: Prospects for hypnosis
and neuroscience.” Cortex 49 (2013): 365-74. Print.

Davidson, J. “An Assessment of the Value of Hypnosis in
Pregnancy and Labor.” British Medical Journal 2 (1962): 951-52.
Print.

Kinney, Jill M., and Lewis B. Sachs. “Increasing Hypnotic
Susceptibility.” Journal of Abnormal Psychology 83 (1974):
145-50. Print.

Eimer, Bruce N. “Clinical Applications of Hypnosis for Brief and
Efficient Pain Management Psychotherapy.” American Journal of
Clinical Hypnosis 43 (2000): 17-40. Print.

Kosslyn, S. M., Thompson W., Costantini-Ferrando M., Alpert N.,
Spiegel D. “Hypnotic visual illusion alters color processing in
the brain.” American Journal of Psychiatry 157 (2000): 1279-84.
Print.

113

Raizy Leizerowski

Lane, R D., E. M. Reiman, B Axelrod, G. E. Schwartz, and A
Holmes. “Neural correlates of levels of emotional awareness.
Evidence of an interaction between emotion and attention
in the anterior cingulate Cortex.” Journal of Cognitive
Neuroscience 10 (1998): 525-35. Print.
Lang, E.V., Benotsch, E. G., Fick, L. J., Lutgendorf, S., Berbaum,
M. L., Berbaum, K. S., Logan, H., Spiegel, D. (2000). Adjunctive
non-pharmacological analgesia for invasive medical procedures:
a randomised trial. The Lancet, 355, 1486-1490.
Lee, J-S, D Spiegel, S. B. Kim, and B. H.Yang. “Fractal analysis
of EEG in hypnosis and its relationship with hypnotizability.”
Journal of Clinical and Experimental Hypnosis 55 (2007): 14-31.
Print.
Miron, D, G H. Ducanan, and M C. Bushnell. “Effects of attention on the intensity and unpleasantness of thermal Pain.” Pain
39 (1989): 345-352. Print.
Oakley, David A., and Peter W. Halligan. “Hypnotic suggestion and cognitive neuroscience.” Trends in Cognitive
Neuroscience” 13 (2009): 264-270. Web. 22 June 2015.
Patterson, David R., and Mark P. Jensen. “Hypnosis and Clinical
Pain.” Psychological Bulletin 129 (2003): 495-521. Print.
Perl, Edward R. “Pain Mechanisms: A commentary on concepts
and Issues.” Prog Neurobiol. 94 (2011): 20-38. Print.
Rainville, Pierre. “Brain Imaging Studies of the Hypnotic
Modulation of Pain Sensation and Pain Affect” (1998): Online Proceedings of the 5th Internet World Congress on
Biomedical Sciences ’98 at McMaster University, Canada.
Rainville, Pierre, Robert K. Hofbauer, Gary H. Duncan,
Catherine M. Bushnell, and Donald D. Price. “Cerebral
Mechanisms of Hypnotic Induction and Suggestion.” Journal of
Cognitive Neuroscience 11 (1999): 110-25. Print.
Rainville, Pierre, Robert K. Houfbauer, Catherine Bushnell,
Gary H. Duncan, and Donald d. Price. “Hypnosis Modulates
Activity in Brain Structures Involved in the Regulation of
Consciousness.” Journal of Cognitive Neuroscience 14 (2002):
887-901. Print.
Spiegel, Herbert. “The Neural Trance: A New Look at
Hypnosis.” Intl. Journal of Clinical and Experimental Hypnosis
55 (2007): 387-410. Print.

114

Spiegel, Herbert. “An eye-roll test for hypnotic susceptibility.”
The American Journal of Clinical Hypnosis 15 (2006): 25-29.
Print.
Syrjala, K. L., C. Cummings, and G. W. Donaldson. “Hypnosis
or cognitive behavioral training for the reduction of pain and
nausea during cancer treatment.” Pain 48 (1992): 137-46. Print.
Schulz-Stübner, Sebastian, Timo Krings, Ingo Meister, Stefen
Rex, and Armin Thron. “Clinical Hypnosis Modulates Functional
Magnetic Resonance Imaging Signal Intensities and Pain
Perception in a Thermal Stimulation Paradigm.”Regional
Anesthesia & Pain Medicine 29 (2004): 549-56. Print.
Wakeman, J R., and J. Z. Kaplan. “An experimental study of
hypnosis in pain burns.” Americal Journal of Clinical Hypnosis
21 (1978): 3-12. Print.
Weinstein, E. J., and P. k. Au. “Use of hypnosis before and after
angioplasty.” American Journal of Clinical Hypnosis 34 (1991):
29-37. Print.

Epigenetics as a Cure for Cancer
By Sara Rivka Margolis
Sara Margolis graduated June 2015 with a BS Honors degree in Biology.

Abstract
Epigenetics is an emerging research topic that is being tested as a potential cure for cancer. Epigenetics is a non-genetic
influence that shapes the phenotype. Epigenetics effects gene expression, but does not cause any changes in the DNA.
DNA methylation patterns is one such epigenetic change in the cell that has huge potential for cancer treatment.
Scientists have observed that many cancerous genes express signs of either hypermethylation or hypomethylation. The
key for the treatment is that epigenetic changes are reversible, which opens the door to potential drugs to cure cancer
and other diseases.
Introduction

Materials and Methods

Epigenetics literally means “above” the gene and is a new
study of research in biology that explains how environmental
factors impact one’s biology. Epigenetic mechanism explains
how there are over 220 different cell types in an adult organism even though they all have the same DNA. All cells in each
organism contains the same DNA, but their cell function differs in different cells, based on “qualitative and quantitative
differences in gene expression.” (Gibney, Nolan, 2010). Bone
cells, skin cells, heart cells, all have the same DNA, but their
functions are completely different. This cell differentiation is
a specific pattern of gene expression where certain parts
of the DNA are turned on or off in each type of cell. This
specific pattern of gene expression is passed down from
cell to cell. Epigenetics is defined as “the study of mitotically
(and potentially meiotically) heritable alterations in gene expression that are not caused by changes in DNA sequence
(Gibney, Nolan, 2010). One researcher compares genes and
epigenetics to a computer, where genes are the hardware and
epigenetics is the software telling the hardware how to function. There is a certain balance of epigenetics that is normal
and healthy for the cell, but when these balances are changed
and the epigenetic mechanisms become unregulated there
may be alterations in gene expression, and can ultimately
lead to cell transformation and malignant outgrowths. There
are three major types of epigenetic changes; DNA methylation, Covalent Posttranslational Histone Modification, and
Small Inhibitory RNA-mediated signaling Pathways. Mainly,
Epigenetic processes, including DNA methylation and histone
modification, influence gene expression at the transcription
level.

In order to understand how epigenetics can be a potential cure
for cancer, many journals and articles were retrieved from Touro
College’s library database. Those articles and the references
they listed formed the basis for exploring this topic.

DNA methylation is the most studied epigenetic factor and
that is what will be discussed in this paper. DNA methylation occurs through the covalent addition of a methyl group
(CH3) to the 5 position of a cytosine generating 5-methylcytosine (Stein, Davis, 2012). Methyl groups protrude into
the major groove of DNA and change the biophysical characteristics of the DNA. Cells can methylate and demethylate
DNA, which effects specific gene expression. These epigenetic changes can experience multigenerational inheritance; not
only does it change the phenotype of the first individual, but
the methylation can pass onto further generations.

Correlation between DNA methylation and gene
silencing
An experiment with mice and coat color phenotype and body
weight measurement exposed the correlation between methyl
groups and silencing of gene expression. A group of pregnant
mice that were genetically identical were assembled, half the
group were fed a diet rich in methyl groups (here soy), and the
control half their regular diet. All these mice had the agouti
gene, which when expressed gives the mouse a yellow color
and causes obesity.The offspring of the mice that had the methyl
rich diet were thin and brown, whereas the offspring of the
mice that did not eat the methyl groups remained yellow and
fat. They both have the agouti gene, but the brown mice had a
methyl group attached to the agouti gene which shut it down.
Bisulfite sequencing methylation analysis of CpG sites in the
promoter region of the agouti gene (Avy IAP) showed a statistical increased average percentage of cells methylated of the mice
given the methyl rich diet. This was a simple experiment to see
how DNA methylation affects gene expression because it was
easy to see when the gene was on and off based on the phenotype color switch and body measurement. Also, this epigenetic
tag was passed down to the offspring’s of these mice, and continued until they ate a diet without enough methyl groups. Soy
has an active ingredient that methylates DNA.This research may
explain why there is a lower incidence of cancer among Asians
compared to Westerners, because Asians eat diets rich in soy
and may explain why Asians who emigrate to America are more
likely to develop cancer than their family back home. (Dolinoy,
et. al. 2006)

DNA methylation causes gene silencing
Although a correlation was noted between gene activation and
methylation, the authors wanted to prove conclusively that
DNA methylation is the cause of the gene silencing. They were
not positive yet which was the cause and which was the effect,
they though that it might be possible for the gene inactivation
to cause the DNA methylation. An experiment was carried
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out that proved that DNA methylation caused gene inactivation. The experiment was conducted on the E2a region of Ad2
DNA. The region was cloned, and then half of the gene was
methylated in vitro with HpaII DNA methyltransferase and then
microinjected into the nuclei of X. laevis oocytes.The key is that
the scientists ensured that the methylated DNA only remained
methylated for 24 hours after microinjection.There was no synthesis of Ad2 specific RNA in the methylated DNA cells until 24
hours after injection. The control did however readily express
the Ad2 specific RNA.The experiment results demonstrate that
methylation plays an actual role in causing genome inactivation
because at the end of the 24 hour period, there is no genome
expression, yet that does not cause the methylation to continue, which proves that methylation is not a consequence of a
lack of gene expression. The gene expression inactivation only
occurred in the narrow window that the Gene was methylated
(Doerfler, 1981).

How it causes gene silencing
Cytosine methylation inhibits the transcription of genes. When
there is an extra methyl group on the DNA, it becomes inaccessible for protein binding for gene expression. The methyl group
interferes with the binding of the protein to its specific DNA
to transcribe it.

Cancer
Typically, it was believed that cancer was caused by genetic defects such as, mutations, amplifications, deletions and translocations, which affected the cancer cell and provided it with the
advantage to survive and metastasize. However, today, it is clear
that there is another system of equal importance that is liable in
causing cancer, and that is epigenetic marks.Today cancer is considered a genetic and epigenetic disease. This epigenetic alterations which can cause cancer have been termed epimutations.
This is extremely important because damage to a cell’s DNA
is permanent, whereas epigenetic change is reversible. (Stein,
Davis, 2012).

Proof that epigenetic changes can cause cancer
Take arsenic which is known to cause cancer of the skin, liver, lung,
and bladder, but actually does not cause DNA mutations, as demonstrated in standard mutagenic assays. However in 2010, researchers
found that arsenic caused cancer by epigenetic mechanisms. This
was a groundbreaking epigenetic mechanism that cause cancer,
and that is a major breakthrough in terms of finding a cure. One
group of researchers studied CpG islands of over 14000 genes
in people who were exposed to high levels of arsenic, verified by
their urinary arsenic levels. It was found that these genes were
epigenetically modified from the arsenic exposure, and researchers
found that a tumor suppressor gene was silenced. This is called
a “tumor suppresorome,” which is a group of 17 confirmed or
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recognized tumor suppressor genes that are silenced in human
cancers, most of these through abnormal methylation patterns.
(Stein, Davis, 2012)

Two ways that DNA Methylation can have an
impact on carcinogenesis
One is by hypomethylation and one is by hypermethylation.
Hypomethylation is a decrease in the normal amount of methylation on DNA. Hypomethylation usually occurs at repetitive
chromosomal sequences where DNA is normally methylated.
Researchers found that four out of five cancer patients had
significant hypomethylation in their cancer cells as compared
to their neighboring cancer free cells. Hypomethylation, in
decreasing the normal amount of methylation of the gene,
decreases the normal amount of gene silencing, i.e. increases
gene expression. This can result in an activation of genes with
growth and tumor promoting functions (Lund, Lohuizen, 2004).
Additionally, hypermethylation, or the increase in the amount
of DNA methylation can cause a negative impact on the cells,
and can lead to carcinogenesis. This hypermethylation is found
at CpG islands, which are most likely found in the 5’ regulatory
region of the gene, which are not methylated. Here the extra
methylation causes gene silencing, and tumor suppressor genes
are being silenced (Feinberg, 2001). In one experiment, it was
revealed that the mRNA for RL7NX3, a tumor suppressor gene
involved in several cancers, is suppressed in primary cutaneous
melanoma and in metastatic tumors. CpG Island, which are usually not methylated and transcriptionally active, have been found
to be abnormally hypermethylated during the development of
cancer, particularly in tumor suppressor genes. Genes involved
in cell cycle regulation, DNA repair, (to name two) are very
epigenetically susceptible (Stein, Davis, 2012).

Hypermethylation of GSTP1 and prostate cancer
Methylation of GSTP1 is the most common epigenetic alteration
described in several tumors, such as prostate cancer, endometrial
cancers, and breast cancers. GSTP1 catalyzes the s conjugation
of GSH, which protects the cell from cytoxic and carcinogenic
agents. Methylation of GTSP1 gene occurred in 90% of prostate
cancer tissue from surgical specimens. In this experiment, the
tissue samples from 144 patients who were having a prostate
biopsy were examined. Forty two out of the 144 patients were
diagnosed with prostate cancer. Additionally, there was hypermethylation of the GTSP1 gene in 31 out of those 42 patients,
and only in 2 out of the 102 patients who did not have cancer.
Since epigenetics is a cause of carcinogenesis, and, therefore, cells
will exhibit hypermethylation at the onset of the cancer, there is
potential for using hypermethylation as a biomarker to detect
the cancer.These genes, and other genes that exhibit hypermethylation in the early onset of cancer, may eventually be useful as
a biomarker to detect prostate cancer. However, methylation of

Epigenetics as a Cure for Cancer

Epigenetics and age correlation

Table 1 shows a list of that when hypermethylated become
cancerous.This means that it may be possible to use
hypermethylation as a biomarker to detect cancer early on.
the GTSP1 gene may indicate another cancer, and does not indicate prostate cancer, specifically. However there is potential for
mapping out hypermethylation of other genes and using a multi
gene profile to improve specificity for cancers. Azacytidine has
been found to reverse the hypermethylation of the GTSP1 gene,
and reactivate transcription (Miano et. al. 2007).

Epigenetic tests on identical twins
The best way to study epigenetics is on monozygotic twins
because they have the same genetic material, but still have difference in cell expression and their phenotype. There is a high
discordance rate between identical twins for many diseases,
even those thought to be genetic. Epigenetic changes through
environmental variances can be the answer to the phenotypic
differences of identical twins. Researchers in Madrid studied 80
identical twins in a range of 3 to 74 years old. Thirty five percent of the twin pairs had significantly different methylcytosine
genomic content. Researchers observed that the difference in the
methylcytosine pattern for the twins increased with the age of
the twins. The youngest twin pair had their epigenetic pattern
the most similar, whereas the oldest pair’s epigenetic pattern was
very different. Also, they found that twins who had not grown up
together had the greatest difference of 5’ methyl cytosine levels.
These differences in methylation of their cells is what causes the
gene expression and phenotype of monozygotic twins to differ.
This study indicates that methylation patterns are one reason
why twins with the same DNA may have different phenotypes.
Additionally, the fact that the epigenetic differences were more
distinct in twins who spent less of their lives together indicates
that major role the environment plays into translating a general
genotype into different phenotypes detectable. External factors
play a great role in gene expression by changing the pattern of
epigenetic modifications (Fraga, et. al. 2005).

For every cell division there is a potential for epigenetic damage.
As a person ages, their cells are forced to divide again and again
to replenish any tissue damage that may have occurred. Each time
this happens there is a chance for epigenetic damage through an
altering of the normal methylation pattern of the cell. Scientists
can take tissues from an older person and can estimate by looking
at the epigenetic patterns of the DNA in a particular tissue how
old the person is, because these epigenetic changes accumulate as
a person ages. For a cell, aging is counted by how many times the
cell has divided. The more damage a cell has, the more times it is
forced to divide and replenish, and the more chances that there
is going to be an abnormal pattern of methylation in this cell. For
example, smoking and sun exposure can cause skin tissue injury.
When a person’s skin peels from a sunburn its cells repair that
damage by dividing and replenishing those cells. In these cases,
the sun and cigarette exposure can cause actual DNA damage,
but they also just damage the tissue which leads to cellular repair
of that injury through cell division, and leads to a gradual accumulation of epigenetic damage. Lungs of heavy smokers can look
20 times older than nonsmokers. This can explain why there is a
higher incidence of cancer among older individuals. With age, the
amount of exposure he or she has had to environmental toxins
increases, which can ultimately lead to an abnormal methylation
pattern (Nova, 2007).

Epigenetic therapy
Epigenetic therapy works to repair the normal methylation pattern of the cell.This is done through DNA methylation inhibition.
5’Azacytidine and 5-aza-2’-deozycytidine (Decitabine/DAC), the
two most advanced drugs for epigenetic therapies for cancer.
Both are in clinical use (Silverman, et. al. 2006). They are DNA
methyltransferase inhibitors and work by trapping DNA methyl transferases thereby inhibiting methylation, and restoring the
gene’s normal expression. DNA methyl transferases, known as
DMTAs, are the enzymes that are responsible for DNA methylation. DAC incorporates into DNA and forces the methyl
transferases to form irreversible covalent bonds to DNA. These
methyl transferases are then targeted for deletion in the proteasome. Then, cells divide, without DMTA and there is now DNA
hypomethylation and reactivation of genes that were silenced
from the extra methyl groups. However, DAC can also cause cytotoxicity when given in high doses, and therefore dosage must
be monitored. A positive side to epigenetic therapy of cancer is
the minimal side effects which is due to the fact that scientist can
give low doses of the medication with successful results.Whereas
for cancer drugs scientist have to give the highest dose possible
of the medication to kill all the harmful cells, epigenetic therapy,
does not necessitate high doses of the drug because it is not
aiming to kill all the cells, but rather just to change the abnormal
methylation patterns of the cancer cells. DAC was not tested
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on young children or on pregnant women. The drug does not
target normal methyl tags for two reasons. Firstly, drugs target
the area of the most cellular divisions, and in this case, they are
going to target the cancer cells and leave the normal cells alone.
Additionally, modification of epigenetic patterns has a large effect on cancer cells but will hardly have any long term effect on
the behavior of normal cells. When the drug was stopped the
normal cells returned to their normal epigenetic pattern, while
the cancer cells, now healthy cells with normal methylation patterns, did not revert to tumorigenesis. There is potential for all
other cancers that have an epigenetic origin. Myelodysplastic syndrome, also known as MDS, and Acute Myelogenous Leukemia,
also known as ALS are easier targets for these drugs because the
cancer cells are in the blood and have easy access to drugs. (Issa,
2013) These drugs do not work with solid tumors yet. A reason
that is likely is because it is much harder to incorporate the drugs
into these cells, which are multiplying much more slowly than
hematological cancers. Right now, these drugs are being tested
with solid state tumors and the results have been promising. In
the laboratory the scientists have been able to adjust the abnormal epigenetic pattern of the solid state tumor with these drugs,
and are working to mimic these results in the body. The catch is
that these drugs that prevent methylation can reactivate expression of multiple silenced genes, even genes that we want silenced,
like oncogenes, which are genes that have the potential to cause
cancer. Therefore, the demethylation can be harmful as well as
helpful. For example, oncogene NT5E is transcriptionally silenced
by methylation in breast cancer. Therefore hypomethylating that
area would activate that oncogene and not be helpful.This is why
in the future it is important to have some sort of epigonomic
profiling- to identify potentially deleterious silenced genes before
using epigenetic therapy to pharmacologically reverse resistance
(Hatzmichael, Crook, 2013).

MDS, AML and other lymphomas
Myelodysplastic syndrome, or MDS, and Acute Myelogenous
Leukemia, are cancers of the bone marrow. MDSs are hematological disorders that usually progresses into AML. Years ago,
patients diagnosed with MDS were basically given a death sentence, there was no cure, and no hope for any remission. It was
soon realized that MDS was epigenetic in origin. Researchers
thought to study the epigenetic pattern in patients with MDS
because of the fact that the patients with the disease have an
average age of 70. Diseases that target older individuals likely
have an epigenetic component in it. MDS patients have aberrant
methylation of their CpG loci and silencing of multiple genes.
MDS was therefore an ideal candidate for epigenetic therapy,
and indeed results were positive. Decitabine was given to over
100 patients for Acute Myelogenous Leukemia. In fifty percent
of the patients the disease disappeared fully. Twenty five percent
achieved some improvements. However, another 25% did not
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respond to the drug, or the drug worked for a short amount of
time but then stopped working (Nova, 2007).

Conclusion
All in all, the discovery that many cancers have an epigenetic
origin, has opened a new path for potential cures for cancer.This
was possible because epigenetic abnormalities are reversible. It
is integral to realize that everything one does affects his or her
health, and the health of future generations. One’s diet and what
one is exposed to can affect his epigenome and subsequently his
future generation’s phenotype. We are not just the product of
our biology, we are also its cause.
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Abstract
Laron syndrome is a congenital autosomal recessive disorder that is caused by a mutation in the growth hormone
receptor. People with this syndrome have an insensitivity to growth hormone. Insulin-like growth factor 1 is produced
by the liver in response to GH stimulus. It is responsible for systemic GH activities. If there is something wrong with the
growth hormone receptor there will be decreased levels of IGF-1. Low IGF-1 levels cause physical deformities notable
short stature. Additionally, people with low levels of IGF-1 have a natural resistance to cancer. This article discusses the
ways that the decreased levels of IGF-1 in Laron subjects protect the body from cancer.
Introduction
Laron Syndrome, eponymously named after the scientist Zvi
Laron who first discovered the syndrome, is a growth hormone
insensitivity syndrome. People with Laron Syndrome have a genetic mutation in the growth hormone receptor. These patients
have a normal level of growth hormone but a reduced level of
Insulin-like Growth Factor 1 (IGF-1) and are characterized by
dwarfism and other physical deformities. Remarkably, patients
with this condition have been proven to be immune to cancer.
Through research on Laron Syndrome scientist have found a
link between a key growth hormone and resistance to cancer.

Methods and Materials
Information was compiled from various articles that were obtained through Touro College’s library database and Pubmed.
The information was narrowed down to those directly related
to the topic. The information extracted and synthesized was
used to hypothesize why Laron Syndrome patients are immune
to cancer.

Background information
Data shows that Laron Syndrome (LS) patients have normal levels of, and a normal, GH molecule, but a defect in the Growth
Hormone Receptor gene (GHR). Patients with LS have either a
gene deletion or a point mutation in this gene (Wood & Savage,
1996).

this syndrome. One hundred and forty eight are known to have
Semitic origin. One third of the people with this syndrome live
in Loja, Ecuador which is where most of the genetic studies take
place. The people in Loja, Ecuador are said to have ancestors
who converted to Christianity during the Spanish Inquisition
(Wood & Savage, 1996).
Laron syndrome is a congenital autosomal recessive disorder.The
parents of an individual with Laron syndrome must each have a
copy of the mutated gene while displaying no signs of the syndrome. People with Laron Syndrome have postnatal growth failure; it begins with “subnormal birth length, retarded brain growth,
acromicria, also of the facial bone, defective and crowded teeth,
sparse hair, small gonads and genitalia, obesity, retarded skeletal
maturation, delayed puberty, hypoglycemia. As these patients get
older they have obesity, muscle underdevelopment and weakness, osteoporosis, hypercholesterolemia, hyperinsulinemia, and
various degrees of glucose intolerance (Yamamoto et al, 2007).”
There is wide phenotypic variability among patients with this
syndrome. With that said, there is uncanny similarity between
patients with LS even with variability in genotype and even if they
are from different places. In the image below of two men with

Mutations in the growth hormone receptor interrupts the JAKSTAT signaling pathway which stimulates the production of
IGF-1. The JAK-STAT signaling pathway brings information from
chemical signals outside the cell, through the cell membrane,
and into the cell where gene promoters on the DNA in the cell
nucleus can causes DNA transcription and activity in the cell.
The mutation in the Growth Hormone Receptor, leads to an
inability of the extracellular domain to bind growth hormone
and stimulate the production of IGF-1 (Gastier et al., 2000).
Cited from Rosenbloom and Guevara-Aguirre that in 1966,
Laron, Pertzelan and Mannheimer did research on the high
levels of growth hormones in patients with clinical and laboratory signs of growth hormone deficiency (Rosenbloom and
Guevare-Aguirre, 1998). There are ~251 reported people with
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Laron Syndrome, it is evident that there is a similarity in physical
features.

deficiency is the main determinant of a reduced birth size.
(Puche & Castille-Cortazar, 2012).

The man in figure A and C is 21 years old with a height of 126.6
cm. The man in B and D is 28 years old and has a height of 115
cm. Analysis of the faces indicate different craniofacial phenotype, but still both men with Laron Syndrome have an uncanny
resemblance (Rosenbloom and Guevare-Aguirre, 1998).

Research done on the effects of GH to stimulate skeletal
growth has proven that GH directly stimulates bone growth.
Additionally, GH stimulates the production of IGF-1 which
will then promote bone growth. This proves, along with
other findings, that IGF-1 and GH work independently and
synergistically to promote postnatal body growth (Puche &
Castille-Cortazar, 2012).

Patients with LS have extremely low levels of insulin-like growth
factors, below the 0.1st percentile for age, such as IGF-I which
is the major hormone responsible for growth and it is under the
control of GH. Patients with GHD also have a low level of IGF-I
but those patients responded well to exogenously administered
GH, whereas patients with LS did not which is a characteristic
of LS. This is the primary difference between GHD and GHRD.
LS patients also have extremely low levels of Insulin-like growth
factor binding proteins (IGFBPs). Specifically, IGFBP-3 levels are
decreased in LS patients (Wood & Savage, 1996).

Insulin-like growth factor 1 (IGF-1)
IGF-1 is a 70 amino acid polypeptide hormone involved in endocrine, paracrine, and autocrine functions. An original name for
this hormone was somatomedin C because it was under the
control and mediates the effect of the growth hormone. The
name was changed to Insulin-like because it shared a similarity
to proinsulin. Also, it mimics insulin activity such as stimulating
glucose uptake in the cells. Additionally, IGF-1 has mitogenic capabilities (Puche & Castille-Cortazar, 2012).

Synthesis and Circulation
Growth hormone is secreted by the pituitary gland and it stimulates the production of IGF-1 by acting on the liver where
it is made. The pituitary gland releases GH and it works
together with the liver in a negative feedback mechanism to
stimulate the secretion of IGF-1; increased levels of IGF-1
cause a decrease in production of GH which stimulates the
production of less IGF-1 (Puche & Castille-Cortazar, 2012).
Recent research by Puche and Castille-Cortazar is uncovering IGF-1 as an independent and self-sufficient peptide,
separate from GH. IGF-1 is produced mainly by the liver
in response to the endocrine GH stimulus, but it is also
secreted by multiple tissues for autocrine and paracrine
purposes. In tissues throughout the body it is evident that
IGF-1 expression is regulated and stimulated by other factors besides GH, such as estrogen in the uterus (Puche &
Castille-Cortazar, 2012).
The stimulatory role of IGF-1 on intrauterine growth is
GH-independent. Regardless of the levels of GH, IGF-1
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Central nervous system development
IGF-1 binds to IGF-1R a cell surface receptor. When IGF-1
binds to the receptor intracellular signaling is initiated. The
AKT signaling pathway, which is a stimulator of cell growth
and proliferation, and a potent inhibitor of programmed cell
death, is activated.
IGF-1 production coincides with periods of neuron progenitor
proliferation and differentiation. The role of IGF-1 in the brain
is not only neuronal produced IGF-1. Systemic IGFs (mainly
produced by the liver) can cross the blood-brain-barrier and
are also involved in these processes. Labeled IGFs were placed
in the carotid arteries of rats and were later on detected in
the choroid plexus, median eminence, brain arterioles, and
parenchyma. This coincides with the data that confirmed the
presence of IGF-1 receptors in the brain capillary endothelial
cells which constitutes the BBB, and the role in internalizing
IGFs from circulation to the CNS. There is evidence that
growth factors, GH, basic fibroblast growth factor; nutrition;
and injury influence and regulate IGF-1 expression in the brain.
All of the growth abnormalities that are attributed to LS patients (see above), indicate that IGF-1 plays a critical role on
brain development and function.

Current therapeutic options and limitations
In 1980, Recombinant Human IGF-1 (rhIGF-1), Mecasermin
became available for experimental therapy for people with severe primary IGF-1 deficiency. An average of 8.5 cm in height
was grown the first year. Besides for an increase in height, patients with rhIGF-1 treatment had an increase in testosterone
levels, testicular size and stretched penile length. This shows
the effect of IGF-1 on sex hormones and organs in male patients (Puche & Castile-Cortazar, 2012).
Another treatment that the FDA approved was a combination
of IGF-1 and IGFBP-3, Mecasermin Rinfabate. This was thought
to have been a smarter alternative to Recombinant human
insulin growth factor 1 (rhigf-1) because it was supposed to
extend the duration of IGF-1 in the body. Interestingly enough,
when the combination of IGF-1 and IGFBP-3 were used to
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treat patients compared to a control group who only were
treated with IGF-1, those treated with IGF-1 alone had better
results (Puche & Castile-Cortazar, 2012).

Prevalence of malignancy in the surveyed subjects

Dosing guidelines for rhIGF-1 are still being debated. The international Congress of Endocrinology has stated that both
one and two injections of rhIGF-1 is safe and efficient. One
or two injections regimen have the same growth velocity. By
carefully monitoring the IGF-1 serum levels the negative side effects can be avoided. Long-term rhIGF-1 has reported negative
side effects. These side-effects, namely tachycardia were easily
managed without treatment discontinuation (Puche & CastileCortazar, 2012).
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A novel and efficient method for hormone replacement therapy
is being developed using Sertoli cells. Sertoli cells are originally from the male testis, and they can ameliorate development
and survival and function of different cell types. In the “Laron
mouse” it was successfully reported that pre-pubertal sertoli
cells in microcapsules can successfully promote growth. There
was a significant increase in body weight and body length compared with the control “Laron mouse” treated with empty capsules. IGF-1 serum levels were noticeably increased in mice
treated with Sertoli cells microcapsules. The reduction in side
effects, the increase in growth, and the fact that sertoli cells
do not require intramuscular daily injections are all reasons
that sertoli cell treatment is preferred over rhigf-1 treatment
(Kinam Park, 2012).
Puche and Castille-Cortazar cite a study done by Steuerman R,
Shevah O, Laron Z. on the prevalence of cancer in people with
Laron Syndrome compared to their family members. This study
proved that IGF-1 deficiency provides protection against cancer.
Interestingly, this study reported that Laron Syndrome patients
are protected against future cancer development, even when
treated with rhIGF-1. (Puche & Castile-Cortazar, 2012).
The positive results of exogenously administered IGF-1 in subjects without IGF-1 deficiency, to use its anti-inflammatory,
hematopoietic, antioxidant, metabolic or anabolic properties, is
not clearly determined (Puche & Castile-Cortazar, 2012).

Discussion
Studies have shown that patients with overexpression of IGF-I
are more susceptible to tumors. Laron set out to determine
if patients with IGF-I deficiency (LS) are less likely to develop
cancer. Two hundred and twenty eight patients with IGF-1 deficiency and 338 of first and second degree family members were
surveyed. Cancer was not a cause of death in GHRD patients of
any age.Ten to twenty four percent of the family members had a
history of malignancies. Only one GHRD subject monitored had
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(Laron & Shevah, 2006)
cancer, papillary serous epithelial tumor in the ovary. The table
below shows the prevalence of the malignancies in patients and
family members. Because of the results of this and further studies, IGF-I receptor blockers are being developed as drugs for
cancer therapy (Shevah & Laron, 2006)

What is the link between GH and cancer?
Data suggest that the GH/IGF-1 axis shows an important role
in cancer.
Growth Hormone does not have the ability to induce cancer,
but it has cancer-enhancing properties. There are many different factors that influence the different effects of the IGF-1. The
powerful effects of IGF-1 on the stages of cancer development
and behavior include “cellular proliferation and apoptosis, angiogenesis and metastasis…” Additionally, IGF-1 is a powerful
antiapoptotic agent. These opposing effects relate strongly to
cancer. Firstly, there is increased proliferation causing epithelial cell turnover within tissues. Secondly, there is an imbalance
in the control between proliferation and cell death because of
the anti-apoptotic effects which leads to hyperproliferation.
This is the first stage of development of many cancers. Thirdly,
this imbalance between cell proliferation and cell death causes
the favoring of cell survival even in damaged cells. This could
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accelerate carcinogenesis. Both the second and third point are
ways that cancer is accelerated not initiated (Puche & CastileCortazar, 2012).
Research in epidemiological studies have shown a correlation
between the role of GH and carcinogenesis. People with more
growth hormone are naturally taller. The Boyd-Orr study
showed an SD of 1 inch height to be linked with a 42% higher
risk of cancer later in life in boys. High birth weight, high stature
at 14, low body mass index, and peak growth at early age were
independent risk factors for breast cancer. (Jenkins et. al., 2005)
Epidemiological date found a correlation between adult height
and cancer. An increase in breast cancer by 22 % was noted with
increased height. These studies suggest that the GH/IGF-1 axis
plays an important role in cancer development and behavior
(Jenkins et. al., 2005). Many pharmaceutical companies are creating drugs that inhibit the IGF-1 signaling to inhibit breast cancer
proliferation and block the mitogenic effects of exogenous IGF1.They are also experimenting with Inhibitors of the IGF-IR as a
chemotherapeutic (Jenkins et. al., 2005).
Studies on mice were done to provide evidence to this relationship. Transgenic mice with human GH and agonist for the
IGF-1 receptor have increased incidence of breast tumor development. On the other hand, mice with a non-functioning GH
receptor (serum GH/IGH-1 levels of ten percent the normal),
showed inhibition of growth of transplanted breast cancer cells.
Even the serum was less mitogenic to breast cancer cells in
vitro than a control serum, this changed once IGF-1 was added
to the serum. Recent studies have shown that mice transfected
with growth hormone receptor antagonists have less incidences
of carcinogenesis (Guevara-Aguirre et. al., 2011).
Another study done on mice was used to prove the influential effects IGF-1 exerts on the metastatic power of cancers
(Guevara-Aguirre et. al., 2011). This is an extremely important
aspect of cancer as the metastatic spread of cancer is usually
what causes mortality. A cell from the LCC6 metastatic breast
cancer cell line was transfected with a truncated IGF-1 receptor
that silenced the expression of IGF-1 receptor and inhibited
IGF-1 signaling. These cells were transplanted into mice and the
metastatic spread was measured. Mice that were transplanted
with wild type cells had multiple pulmonary metastases, but the
mice transplanted with the transfected cells were completely
absent of any metastases (Guevara-Aguirre et. al., 2011).
Another reason how the GH/IGF-1 axis can cause cancer is
by promoting an increased DNA damage. Experiments on
Saccharomyces cerevisiae yeast indicate that mammalian growth
signaling pathway genes promote an increase in DNA mutations by elevating superoxide production and increasing DNA
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damage. This is particularly important because it hypothesizes
that, in addition to the possibility that the GH/IGF-1 axis may
promote cancer by preventing apoptosis of the damaged cells,
it can increase DNA damage in cells that can ultimately lead
to cancer. To test this hypothesis, human mammary epithelial
cells (HMECs) were placed in a medium that contained 15%
serum from either Laron syndrome subjects or their relatives.
The cells were then treated with H2O2 followed by comet analysis to detect DNA strand breaks. The comet analysis indicated
that cells incubated in serum from GHRD patients had fewer
DNA breaks after treatment in comparison to cells incubated in
serum from relatives. This teaches that serum from GHRD subjects can protect against oxidative DNA damage independently
of cell division. It was determined that that IGF-1 signaling was
responsible for the sensitization of cells to oxidative damage via
analysis of DNA damage in MEF cells lacking the IGF-R or overexpressing the human IGF-1R cell (R+ cells). R+ cells had more
DNA damage than did R-cells. (Guevara-Aguirre et. al., 2011).
A study done by Wang and colleagues on rats explains that
down-regulation of GH signaling could block carcinogenesis in
rats. Human prostate cancer cell lines express GH receptors
at levels greater than normal. A rat that does not have GH
because of a mutation was crossed with the Probasin/Tag rat,
a rat which develops prostate carcinomas at 100% incidence
rate. The rats that were homozygous for the GH deficiency had
prostrate tumor incidence and tumor latency reduced relative
to wild type rats. At 25 weeks of age, the rats with no GHR
resulted in a 20% and 80% decrease of carcinoma in the dorsal
and lateral lobes, respectively. At 52 weeks of age, invasive prostate adenocarcinomas were observed in all Probasin/ Tag rats
positive for the Growth Hormone. Conversely, majority of the
Tag rats with the mutation that makes them GH deficient did
not develop invasive tumors (Wang et. al. 2008).
The potent antiapoptotic and mitogenic properties of IGF-1
is linked to an increased risk in developing cancer. It is documented that IGF-1 can promote carcinogenesis at the cellular

(Svensson et. al., 2012)
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level, but evidence is accumulating that circulating IGF-1 can
also promote carcinogenesis. For example, reduction of IGF-1
by dietary restriction slows tumor progression and increase
apoptosis in tumor cells of animal models. And when these
models were treated with recombinant IGF-1 the effects were
reversed. Additionally, IGF-1 gene deletion in mice is linked to
a 75% decrease in circulating IGF-1 levels. Tumor growth and
development was much higher in the control group than transgenic mice.

Biological interactions among insulin, IGF-1 and
IGFPBS
As stated above there are many clinical studies that suggest that
high serum IGF-1 levels associate with increased risk of cancer.
Increasing clinical evidence suggests that low IGF-1 levels are associated with cancer mortality in older men. In numerous studies, the association between circulating IGF-1 levels and cancer
mortality was U-shaped with increased levels of mortality at
both the low and high serum IGF-1 levels.
Serum IGF-1 was extracted from the blood of a large cohort of
elderly men from Sweden. The measurements of serum IGF-1
levels were obtained.The reason for mortality was documented
on the death certificate of the subjects and then used in the
study. Cox proportional hazards was used to analyze the association between serum IGF-1 levels and mortality by cancer. Cox
regression analysis showed that both low and high serum IGF-1
concentration was associated with increased cancer mortality.
The patients with a history of cancer were excluding from the
analysis (Svensson et al, 2012).

IGF-1R Inhibitors as an Anti-Cancer
Because of the role that IGF signaling plays in the promotion
of cell growth and inhibition of apoptosis, IGF blocking is being
developed as a therapeutic potential to protect against cancer.
Currently there are many clinical studies targeting and inhibiting the IGF pathway to promote anti-tumor activities. There
are three main classes of IGF/IGF-1R inhibitor antibodies being
studied in clinical trials; each class inhibits IGF-1R signaling
but through different mechanisms. There has been some small
success in treating patients with select tumor types, but many
trials have been unsuccessful. Researchers are trying to identify
patient selection markers to attain future success in IGF-1R inhibitor development (Chen & Sharon, 2013).
IGF blocking is also being used to overcome chemotherapy
sensitivity. Resistance to chemotherapy is common nowadays.
IGF is implicated in chemotherapy resistance because it promotes proliferation and inhibits apoptosis. Researchers have
tested this hypothesis and have found that IGF-1R inhibitors
have caused significant tumor growth inhibition. Currently,

researchers are testing the combined effect of IGF-1R inhibitors
with a chemotherapeutic (Weroha & Haluska, 2008).

Conclusion
Laron Syndrome subjects participate in groundbreaking genetic
studies to explore the relationship between the deficiency in
the growth hormone receptor and immunity to cancer. This
syndrome is providing insight to, and revolutionizing, the way
cancer is treated and prevented. Because Laron Syndrome subjects have decreased levels of IGF-1 they are protected against
numerous and potentially harmful effects of IGF-1 including cellular proliferation, apoptosis, angiogenesis, and metastasis. The
increased proliferation and decreased apoptosis causes survival
of damaged cells that then spread easily throughout the body,
which could lead to the development of cancer. Because Laron
Syndrome subjects have decreased levels of IGF-1 they are
immune to cancer. The implications of IGF/IGF-1R in cancer
development, maintenance, and progression, is what led to replicating the IGF-1 levels of LS patients to use as an anti-cancer
target. IGF-1 has been successfully inhibited in animal models to
prevent cancer cell growth. Now researchers are beginning to
use IGF-1 reducing agents and blockers as a chemotherapeutic
to prevent cancer.

Abbreviations
IGF-1
LS
GH
GHR
GHD
GHRD
CNS
rhIGF-1
IGFBP
HMEC

Insulin Growth Factor 1
Laron Syndrome
Growth Hormone
Growth Hormone Receptor
Growth Hormone Deficiency
Growth Hormone Receptor Deficiency
Central Nervous System
Recombinant Human Insulin Growth Factor 1
Insulin Growth Factor Binding Proteins
Human Mammary Epithelial Cells
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